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Abstract 
Fatty liver disease is a collective phrase for a spectrum of diseases characterised by 
increased liver fat content. It ranges from fatty infiltration of the liver to an 
inflammatory condition, steatohepatitis, which may lead onto cirrhosis. Although not 
associated with alcohol consumption, nonalcoholic steatohepatitis (NASH) has strong 
associations with obesity, diabetes and dyslipidaemia. Overlapping pathological 
mechanisms may be involved. The course of the disease will remain unpredictable, 
and specific treatment will only be able to be instituted once the pathogenesis is fully 
understood. 
This thesis reviews current understanding of the pathogenesis and explores the 
suitability of a recently defined obese diabetic mouse model for its value as a model 
in the heterozygous and homozygous states. 
Observations revealed that the dblwt phenotype has a larger mass than the wtlwt 
and responds with hyperglycaemia. Lipid accumulation occurs in this model when 
alcohol is administered and lipid peroxidation occurs but histological changes of 
steatosis and steatohepatitis do not occur. The db/db model is phenotypically 
distinguished by a large amount of fat storage, diabetes and macrovesicular steatosis 
that has more lipid peroxidation but no steatohepatitis even when alcohol further 
increases lipid peroxidation. 
The model, as explored, did not reveal steatohepatitis either alone, or with alcohol as 
a single additional stressor, but both the db/wt and db/db mouse model could be 
further investigated to explore whether additional stressors could induce 
steaotohepatitis in this model. 
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Chapter 1; Overview of Nonalcoholic Fatty Liver Disease 
1.1 Introduction 
Hepatic steatosis or fatty liver was previously regarded as a benign condition, but this 
impression has changed since Ludwig et al., (1980) first coined the term nonalcoholic 
steatohepatitis (NASH) when encountering a group of non-drinkers whose liver 
biopsies were revealed to be histologically indistinguishable from alcoholic hepatitis. 
Similarities between nonalcoholic liver disease and alcoholic hepatitis had already 
been recognised (Miller et al., 1979) but it was not until Ludwig et al., (1980) 
announced the mimicking of the poorly defined condition that the disease gained true 
recognition. 
The groundbreaking study (Ludwig et al., 1980) was conducted using 20 patients 
who denied excessive alcohol intake (averaged one drink per week). The liver biopsy 
specimens were examined and all patients exhibited lobular inflammation and 
moderate to severe macrovesicular fatty changes which predominantly occurred in 
central hepatic zones. Alcohol is not the causative factor in the development of these 
fatty livers, but patient profiles implicated obesity and diabetes as predisposing 
conditions for NASH. 
However, NASH has a prevalence of approximately 2-3% in the general population 
and is often considered under the denomination of nonalcoholic fatty liver disease 
(NAFLD) (Yu and Keefe, 2002). This term encompasses a wider range of liver 
disorders that are beginning to be recognised more frequently in affluent individuals 
(Haque et al., 2002) with the spectrum ranging from fatty liver alone to cirrhosis and 
possibly even development of hepatocellular carcinoma (Nanji, 2004). NAFLD is 
present in approximately 20% of the USA making it the most common form of liver 
disease within that country (Yu and Keefe, 2002). 
NAFLD comprises the complete spectrum of liver degeneration; beginning as fatty 
liver alone, advancing to steatosis, then steatohepatitis (NASH) before progressing to 
fibrosis and resulting in cirrhosis which is the final end-point of an inflammatory 
response in the liver (Alba and Lindor, 2003). The pathology presented by this 
sequenced chain of events closely resembles that of alcohol-induced liver injury, 
even though NAFLD patients are exempt from extensive alcohol consumption 
(Matteoni et al., 1999). 
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The grouping together of all these mulitfactorial diseases under the term NAFLD has 
resulted in a wide range of pathologic and clinical entities. Despite NASH being 
regarded as potentially the most severe form in this arrangement of diseases, most 
patients are asymptomatic and a liver biopsy may be needed to determine certain 
distinguishing features that correlate with the stage of the disease (Fernandez-
Rodriguez et a/., 2003). As a result, Brunt et a/., (1999) devised a grading and 
staging system which reflects the unique pathological features present in this range 
of diseases (see below for histologic classification). A NASH patient would typically 
display type 3 or 4 characteristics and therefore only represents a percentage of the 
NAFLD assemblage. 
Type 1: Steatosis 
Type 2: Steatosis plus lobular inflammation 
Type 3: Steatosis plus lobular inflammation and degenerative ballooning 
Type 4: Steatosis plus degenerative ballooning, Mallory bodies ± fibrosis 
Matteoni et a/., (1999) also created a scoring system based on fat content, 
necroinflammation and progression to fibrosis within the spectrum of NAFLD. A study 
undertaken by Matteoni et a/., (1999) examined liver biopsy specimens of 132 NASH 
patients with complete clinical records and established that approximately 29% were 
suspected of disease progression to cirrhosis. The occurrence of cirrhotic livers 
results from structural changes along with fibrosis. These changes may be described 
as a decline in regular lobular architecture and the emergence of fibrous tissue bands 
formed by regenerative nodules of hepatocytes (Diehl et al., 1988). Brunt et al., 
(1999), developed a staging system for assessing the extent of liver injury incurred 
by fibrosis/cirrhosis in NASH patients and is displayed below. Cirrhosis is not 
reversible and signals the loss of regulatory hepatic function. 
Stage 1: Zone 3 perisinusoidal and pericellular fibrosis, focal or extensive 
Stage 2: Zone 3 perisinusoidal fibrosis, focal or extensive periportal fibrosis 
Stage 3: Perisinusoidal and portal fibrosis, bridging fibrosis 
Stage 4: Cirrhosis, with or without perisinusoidal fibrosis 
A combination of both of these methods was adapted for the purpose of grading in 
this study. Fatty cysts, glycogenated nuclei and lipogranulomas can appear at 
histological examination, but these were not deemed reliable in making a correct 
prognosis (Brunt, 2002). It is worth noting that a diagnosis usually results from a 
variation of microscope findings as opposed to the exposure of a single pathological 
feature. Additional clinical traits which can be used for identification purposes include 
hepatomegaly, the most common physical sign and evaluation of serum 
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aminotransferase levelso No specific diagnostic test is currently available (Fernandez-
Rodriguez et at, 2003)0 
Liver biopsies are used for histological assessment of NAFLD patients to determine 
the extent of hepatocyte injury, inflammation and fibrosis. Haematoxylin and eosin 
(H&E) stains assess hepatic injury and cell disruption, whereas sirius red (SR) 
preparations can gauge the extent of fibrosis (Brunt, 2002). Periodic-acid Schiff after 
diastase digestion (D/PAS) is used for evaluation of debris-containing Kupffer cells 
(Brunt, 2001). 
Factors which can promote or cause fatty liver (other than alcohol), include obesity, 
diabetes, insulin resistance, hyperlipidaemia, rapid weight loss or, more commonly, a 
combination of these (Fong et alo, 2000)0 Additionally, hepatoxic drugs, jejunoileal 
bypass operations, hepatitis C and Wilson's disease are also acknowledged 
facilitators of fatty liver development (Fong et al., 2000). Rarely, fatty liver is 
encountered in disorders of lipoprotein assembly: either MTP deficiency or 
homozygous hypo~lipoproteinaemia. 
The occurrence of steatosis is biochemically described as an accumulation of lipids 
in the liver exceeding 5% of the liver weight (Cairns and Peters, 1983), altho~gh this 
is not universally agreedo Steatosis in I\lAFLD patients is generally identified to 
consist of macrovesicular fat (large single lipid droplets) within hepatocyte cytoplasm 
displacing the nucleus, although mixed steatosis is also recognised to occur, in which 
microvesicular fat (multiple, small lipid droplets) are additionally present (Brunt and 
Tiniakos, 2002). Abnormalities in the metabolism and synthesis of lipid and 
consequent accumulation of triglycerides is believed to result in macrovesicular fat 
whereas the presence of microvesicular fat is indicative of further progressed liver 
disease characterised by a diminution of ~-oxidation of fatty acids (Brunt and 
Tiniakos, 2002). The favourable location of fatty injury is located in acinar zone 3 
despite the varying severity from patient to patient and is reversible. The potential of 
ballooning and Mallory bodies being located is dependent on stage of development 
(Brunt, 2001)0 
The occurrence and progression of the inflammatory response is coupled with 
steatosis and is frequently associated in NASH patients, as can be deduced by 
involvement in the scoring systems for assessment of disease status. The 
inflammation is mainly lobular and a key feature is the existence of 
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polymorphonuclear leukocytes (PMN) (Takahashi et al., 1987) which are closely 
located to ballooned hepatocytes in further advanced cases of NASH (Brunt, 2001). 
The ensuing inflammation can be either acute or chronic, but caution is advised when 
examining biopsy samples as steatosis and hepatic inflammation occur under many 
other circumstances. 
The manifestation of hepatocyte injury primarily occurs as degenerative ballooning 
and is characterised by swelling of the cytoplasm of affected cells (Brunt, 2001), 
however, whether presence of ballooning degeneration is necessary for diagnostic 
evaluation of NASH is controversial. The additional appearance of lVIaliory bodies 
(dense intra-cytoplasmic inclusions in hepatocytes) provides evidence of further liver 
deterioration and can be verified by histochemical stains (Brunt, 2001). 
Megamitochondria are recognized as intracellular structures which display 
ultrastructural abnormalities and can also be observed in NASH patients as markers 
of progression to fibrosis, although association with extensive alcohol abuse is more 
frequent (Caldwell, 2002). 
The progression to fibrosis in NASH is not universal as some patients experience a 
relatively benign pattern of the disease and do not require therapeutic treatment 
(James and Day, 1998). When fibrosis does develop, it is initially encountered in the 
centrilobular region zone 3, characterised by pericellular distribution and is referred to 
as 'chicken-wire' fibrosis that is often seen in alcohol-induced steatohepatitis (Brunt, 
2001). Progression of the disease results in fibrosis becoming 'bridged' as a 
consequence of additional collagen deposition from hepatic stellate cells (HSC), the 
increased activity of which coincides with steatosis grading advancement (Reeves et 
aI., 1996). 
Patients with NAFLD and NASH are predominantly asymptomatic and are usually 
diagnosed accidentally during alternative investigations. A liver biopsy is usually 
requested on the grounds of patient history or unexplained clinical findings to clearly 
determine the presence of disease, although ultrasound and computerised 
tomography (CT) have also been used in detection with modest results (Yu and 
Keefe, 2002). Therefore prevalence of NAFLD and NASH is difficult to accurately 
measure as there will be a speculative number of unreported cases. Observations 
from various studies have been collated in an attempt at estimating the incidence of 
NAFLD. Harrison et aI., (2002), established a 14% frequency of NAFLD in Japenese 
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trials whereas Yu and Keefe (2002) approximated the value to be nearer 20% in the 
USA population. 
1.2 Associated Risk Factors 
Research performed by Angula et al., (1999), established a link between fibrosis 
severity and steatohepatitis by examining particular features of patient profiles. The 
findings implied that body mass index (BMI), older age, diabetes and ratio of liver 
enzymes aspartate aminotranferase (AST) I alanine aminotransferase (AL T) lower 
than 1 were helpful markers in providing information for NAFLD or NASH 
identification. Further studies carried by Chitturi et aI., (2002) and more recently by 
Sorrentino et aI., (2004) confirmed that female gender may also be a risk factor to 
consider when assessing this group of diseases. The additional risk and surrounding 
complications posed by these menacing factors in relation to NAFLD progression will 
be discussed individually. 
1.2.1 Age 
The detection of NAFLD in children has been clearly documented over the years, 
especially in obese, pubertal adolescence (Baldridge et al., 1995). However, before a 
correct diagnosis can be established, malnutrition, short gut syndrome and drug and 
alcohol abuse, especially in older children, must be disproved before the condition 
can be attributed to NAFLD (Rashid and Roberts, 2000). Despite the prevalence of 
NAFLD in patients of all ages, individuals between 40-60 years of age seem to be at 
a higher risk independent of other factors involved (Reid 2001). 
1.2.2 Obesity 
Obesity is strongly associated with NAFLD patients, but the exact role of obesity 
within this arrangement of diseases remains undefined as non-obese individuals are 
also affected, comprising a small proportion of reported cases. Many studies have 
identified obesity as a possible predictor of NAFLD (Powell et al., 1990; Angulo et aI., 
1999; Garcia-Monzon et aI., 2000) with values as high as 90% in a study undertaken 
by (Ludwig et al., 1980). In contradiction to this consistent observation, Bacon et aI., 
(1994) reported the prevalence of NAFLD in non-obese patients to be higher than 
50%. The majority of established NAFLD cases in children is highly associated with 
obesity (Baldridge et al., 1994). 
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1.2.3 Type 2 Diabetes Mellitus (T2DM) 
Another factor seen to be closely linked with the occurrence of NAFLD is T2DM, 
though the range of association widely varies from 2-55% (James and Day, 1998). 
An assortment of studies has found hepatic fibrosis to be more common in obese 
patients with diabetes (Matteoni et a/., 1999; Dixon et a/., 2001). One study in 
particular revealed a 2.6-fold increase risk of progressing to NASH if T2DM was 
present (Wanless and Lentz, 1990). The added metabolic complications arising from 
diabetes may contribute to increased oxidative stress and may perpetuate 
hepatocyte degeneration. (Evan et aI., 2002). 
1.2.4 Insulin Resistance (lR) 
The presence of insulin resistance comes as no surprise since obesity, dyslipidaemia 
and type 2 diabetes are linked to decreased sensitivity to insulin (Marchesini et a/., 
1999). The precise role of IR is unclear. Apart from a greater flux of fatty acids from 
adipose tissue to the liver, IR may aid in activation of tumour necrosis factor-a (TNF-
a). Sustained production of this cytokine has been shown to promote the progressive 
pathogenesis of the disease (Koteish and Diehl, 2002). As a result of the close 
association between NAFLD and IR, many rodent models such as ob/ob (leptin 
deficient) and db/db (Ieptin receptor deficient) rodents are being employed or 
modified to exhibit the characteristics of obesity, diabetes and insulin resistance in an 
attempt to gain a better understanding of the pathogenesis of these diseases. 
1.2.5 Gender 
The recent inclusion of gender as a risk factor in NAFLD development and 
progression has received some criticism due to some conflicting evidence. Initial 
studies performed by Ludwig et a/., (1980) displayed that an obese, middle-aged 
female would be a prime candidate for progressive NAFLD. Additional work by 
Angulo et a/., (1999) and Chitturi et aI., (2002) corroborated these findings. However, 
a study of 580 obese patients carried out by Marceau et aI., (1999) did not find that 
gender was an indicator of fibrosis or cirrhosis, though it was statistically significant at 
predicting inflammation. The debate was continued by the finding, by Bacon et a/., 
(1994), of NASH in young, non-obese males. 
As previously mentioned, utilisation of rodent models is becoming more frequent in 
the exploration of NAFLD causes. A point of interest is the recent development of an 
animal model that exhibits a relationship between gender and the degree of hepatic 
injury (Kirsch et a/., 2003). 
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1.2.6 ASTIALT ratio> 1 
Aspartate aminotranferase (AST) and alanine aminotransferase (AL T) are liver 
specific enzymes. The release of aminotransferases indicates the presence of 
hepatocyte damage (Teitz, 1987). The enzyme activity of plasma has a strong 
correlation with the gradation of steatosis (Marceau et aI., 1999). The ratio of 
AST/AL T is advantageous to the physician as a good predictor of NAFLD 
development and can also guide the decision to perform a liver biopsy. 
1.2.7 Genetics 
The postulate that certain genes or groups of genes may assume responsibility for 
inherited conditions which could promote the onset of NAFLD and NASH and their 
outcome is not yet adequately researched (Day, 2002). 
The P450 enzymes present themselves as candidate genes for NASH development. 
Cytochrome P450 2E 1 (CYP2E 1) in particular, is capable of producing free radicals 
which could affect the rate of fatty acid oxidation and thus could contribute to the 
progressive nature of NASH (Day, 2002). The increased expression of CYP2E1 in a 
rodent dietary model of steatohepatitis adds further evidence of involvement in 
complications of NASH (Weltman et al., 1998). 
Copper/zinc dismutase and aldehyde oxidase are genes responsible for regulation of 
mitochondrial manganese superoxide dismutase (MnSOD) which aids the body in 
combating oxidative stress by activation of uncoupling protein 2 (UCP-2) (Shimoda-
Matsubayashi et aI., 1996). Alteration of these genes could lead to unregulated UCP-
2 activity which could effect lipid metabolism and may itself lead to hepatic damage 
and necrosis (Pessayre et al., 2001). 
Cytokine genes have also been implicated in the pathogenesis of NAFLD and NASH, 
in particular tumour necrosis factor - a (TNF-a). Kupffer cells are the primary site of 
TNF-a generation, which, upon release in excess, impedes the normal action of 
insulin and contributes to oxidative stress through enhanced production of reactive 
oxygen species (ROS) (Peraldi and Spiegelman, 1998). A study conducted by Hui et 
aI., (2004) confirmed activation of TI\IF-a in NAFLD patients that correlated with 
severity of steatosis and fibrosis. 
Peroxisome proliferator activator receptors - a and y (PPAR-a) and (PPAR-y) are 
genes which modulate fatty acid oxidation and insulin sensitivity respectively (Day, 
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2002). PPAR-a is abundantly produced in the liver. Disruption of its function may 
cause uncontrolled fatty acid accumulation, whereas PPAR-y has been shown to 
aggravate steatosis by activating lipogenic enzymes (Tanaka et al., 2005). Recent 
evidence from rodent and human studies suggests that agonists of PPARs display 
the ability to reduce triglycerides and lipid peroxidation and are therefore being 
introduced as a new approach for NAFLD treatment (Reifel-Miller et al., 2005; 
Kersten, 2002). 
Additional candidate genes include: 1113 hydroxysteroid dehydrogenase-1 (11I3HSD-
1) which contributes to the magnitude and pattern of obesity (Masuzaki et aI., 2001) 
and Apolipoprotein E, that helps regulate lipid storage and export (Day, 2002). Many 
classes of genes have gained recognition for NAFLD association. Unless a strong 
monogenic component is responsible for fatty liver, the modulatory genes linked with 
NAFLD could hamper the detection of a single causative gene that may unravel the 
unknown. 
Although contributing features have been identified in NAFLD and NASH patients, a 
solitary, causal factor remains elusive. Additional triggers such as drug abuse, jejuno-
illeal bypass operation (JIB), and rapid weight loss are also at fault, but encompass a 
smaller proportion of patients. 
1.3 Diagnosis 
NAFLD and NASH patients are typically asymptomatic. Many cases are discovered 
accidentally or are not even reported. Initial symptoms include; fatigue, lethargy, 
discomfort in the right-upper-quadrant of the abdomen and slight elevations of 
aminotransferase levels (Kumar and Malet, 2000). The presence of hepatomegaly 
and splenomegaly can be seen upon physical examination and provide additional 
indicators for patient evaluation (Reid, 2001). 
The ASTIAL T ratio is a good marker of hepatic injury as are the associated risk 
factors, but the true extent of liver damage remains unresolved until a liver biopsy. 
This remains the definitive means by which an accurate diagnosis and possible 
method of treatment can be evaluated (Brunt 2001). A physician will not immediately 
recommend a liver biopsy as an intervention in lifestyle may bring about a marked 
improvement in obesity related symptoms. 
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1.4 Therapy 
The management of fatty liver is currently non-specific and involves general health 
measures with good nutrition and obtaining an ideal body mass, along with 
avoidance of factors that may promote or cause fatty liver. Healthy eating and 
exercise continues to be the cheap, safe option of therapy for weight reduction which 
should subsequently result in an improvement of insulin sensitivity and lowering of 
liver enzyme levels. Precautionary measures must be adhered to when subjects 
undertake severely restricted mass reduction diets as rapid weight loss can also 
induce hepatic injury (Capron et aI., 1982). A liver biopsy would be indicated if this 
therapeutic approach was not successful, and risk factors proceeded to accumulate 
or the risk of cirrhosis was presented. 
Further approaches to weight reduction have included administration of the drug 
orlistat, but this has produced mixed results. It may be hepatoxic, thus affecting the 
risk / benefit ratio adversely (Lau et aI., 2002). More extreme measures of losing 
weight are advertised as gastric banding and jejuno-ileal bypass (JIB) and if patient 
care is well maintained, the effects of steatosis are lessened and even reversed, 
although the reoccurrence and worsening of the conditions remains a high possibility 
(Holzbach, 1977). 
Administration of vitamin C has been shown to be beneficial in the alleviation the 
progress of NAFLD (Oliveria et al., 2003). This antioxidant drug has displayed 
significant inhibition of steatosis, presumably by reducing oxidative stress levels 
which are thought to playa key role in facilitating the development and progression of 
NAFLD. 
Additional drugs that have been prescribed as therapeutic agents involve a group of 
agents known as PPAR-a and PPAR-y agonists (Desvergne and Wahli, 1999). As 
previously stated, these agonists posses the ability to modulate lipid transport and 
oxidation and enhance the actions of insulin, resulting in augmented fatty acid 
breakdown and control of inflammation. Research undertaken by Ip et aI., (2003), 
exposed Wy-14,643 as a further agonist that shows the capacity to avert hepatic lipid 
accumulation and should be considered in future use as a preventative treatment. 
The insulin-sensitizing thiazolidine-dione (PPAR-y agonist), troglitazone has been 
investigated in NASH. Despite reasonable success in reducing AL T levels to within 
normal limits, post-treatment liver biopsies revealed NASH still to be present. The 
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drug later proved to be hepatoxic and was withdrawn from the market (Chitturi and 
George, 2002). 
Metformin is a biguanide, an anti~diabetic drug which has been used to treat T2DM 
for many years and is especially favoured in obese diabetics. The benefits arise from 
lowering fasting glucose and subsequent control of lipid production in diabetics. A 
study performed by Lin et a/., (2000), used a diabetic mouse model (ob/ob) , to 
examine the effects of metforrnin and successfully displayed a notable retraction in 
steatosis development and a normalizing trend of liver function tests, paving the way 
for future trials. 
Clofibrate, a PPAR-a agonist, is an additional consideration for NAFLD management 
The action of this drug reduces hepatic triglyceride as opposed to enhancing the 
effects of insulin (Laurin et al., 1996). It has been surpassed by newer fibric acid 
derivatives. 
Colchicine is an anti-inflammatory and anti-fibrotic drug which can be administered to 
lessen the effects of cirrhosis in alcoholic and nonalcoholic patients but results to 
date have been inconsistent. Colchicine is a plant alkaloid that possesses the ability 
to inhibit the migration of granulocytes into the injured area, thereby inhibiting the 
metabolic and phagocytic activity of granulocytes (Rambaldi and Gluud, 2005). 
Furthermore, colchicine has been shown to impede the mediated transport of 
procollagen (Ehrlich and Bornstein, 1972), improve collagenase activity (Harris and 
Krane, 1971) and decrease liver fibrosis in rats (Rojkind and Kershenobich, 1975). 
A recent review comprised of 1714 patients, randomised in 15 trials, was undertaken 
to examine the beneficial and harmful effects of colchicine in patients with alcoholic 
or nonalcoholic fibrosis or cirrhosis (Rambaldi and Gluud, 2005). In the majority of 
trials, the dosage received was 1 mg colchicine, five days a week, although some 
trials did administer the same dose for 6 and 7 day periods. The median duration of 
the 15 trials was 18 months. The findings from the assemblage of trials revealed that 
colchicine had no significant effect on mortality, liver complications, liver biochemistry 
and liver histology. Colchicine was found to exhibit a positive effect on two serum 
markers of fibrotic activity (7S collagen and prolidase), however, the levels of 
collagen-peptidase were unaffected. 
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Another study investigating the effects of colchicine was carried out by Gong et aI., 
(2004) which examined the outcome in patients being treated for primary biliary 
cirrhosis. Colchicine is administered to patients with primary biliary cirrhosis because 
it can delay progression of the disease (Kaplan, 1997) and enhance liver biochemical 
tests and immunoglobin levels (Warnes et aI., 1987). The study concluded that 
treatment with colchicine did not significantly improve biochemical or histological 
parameters such as total cholesterol, AL T, AST, fibrosis, parenchymal inflammation 
or parenchymal necrosis in comparison to the placebo group which had no 
intervention. The findings from this study, combined with the data generated by 
Rambaldi and Gluud, (2005) do not provide any significant evidence that treatment 
with colchicine successfully ameliorates the effects on liver fibrosis or cirrhosis. 
Colchicine should only be used in further randomised trials once the detrimental 
effects and benefits, if any, are clearly defined. 
Ursodeoxycholic acid (UDCA) treatment displays membrane-stabilising effects and 
has few drug interactions. It could playa defensive role in protecting the liver from 
oxidative stress and the progression of liver disease. The advantage of UDCA 
administration is the background history of the drug which provides strong evidence 
for the safe use in the milieu of fatty liver disease (Angulo, 2002). 
The development of NAFLD is regarded as a fairly new concept in medical practice 
and has spurred the development of new and upcoming drugs to combat the 
outcomes. 
Adiponectin is newly established as a possible al/eviator of NAFLD. Adiponectin is 
secreted from adipose tissue and is diminished in obese patients. It is believed to 
decrease steatosis by increasing insulin sensitivity (Berg et a/., 2002). This peptide 
also exhibits anti-inflammatory effects. It has been cited as a partial activator of TNF-
a (Hui et al, 2004). In addition, low levels of adiponectin correlate with higher grades 
of hepatic steatosis and necroinflammatory and may prove to be an important 
therapeutic tool (Hui et a/., 2004). It is not clear whether low adiponectin 
concentration merely reflects adipocyte dysfunction or is directly implicated in NASH. 
Some therapeutic drug administration is clearly beneficial in treating NAFLD and 
certain treatments even reverse the outcome of steatosis, although 'knock-on' effects 
constantly persist and therefore considerate care in management is advised. The 
influx of experimental rodent work which covers the full range of consequences in 
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NAFLD is proving to be invaluable and needs to be sustained to gain a full 
understanding and to achieve effective medical therapies. The pathogenic 
mechanisms involved in the development and progression of NAFLD require to be 
clearly defined to establish advantageous treatment options and will be discussed in 
detail in the proceeding chapter. 
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Chapter 2; Pathogenesis of Fatty Liver Disease 
2_ 1 Introducing the Pathogenesis of NAFLDINASH 
The pathogenesis of NAFLD and subsequent progression to NASH remains poorly 
understood, but information gained from studying animal models of hepatic steatosis 
has been invaluable and has established that the underlying mechanisms of NAFLD 
and NASH are multifactorial (Koteish and Diehl, 2002). 
Steatosis is believed to be a benign condition but its presence facilitates susceptibility 
to further injury in the liver which has led to the 'two-hit' hypothesis. Normal liver, 
which has no steatosis, has a better ability to withstand the insults of oxidative stress, 
lipid peroxidation, abnormal cytokine production and insulin resistance and generally 
does not result in the development of hepatitis (Day and James, 1998). The 
presence of steatosis represents the 'first-hit' which is the initial insult but apparently 
benign to the liver and merely causes the hepatocytes to become fatty. It is 
suggested that a 'fatty' liver faces greater difficulty in dealing with the complications 
of a 'second-hit' that results in amplified damage and progressive NAFLD to I\lASH 
(Day and James, 1998). The 'two-hit' model is depicted below (Figure 2.1.1). 
The second 
'hits' 
Figure 2.1.1; The 'two-hit' hypothesis of NASH involves the common occurrence of hepatic steatosis as 
the initial ofience (i.e. 1irst-hit') and following development 01 steatosis. the liver becomes vulnerable to 
additional injury (i.e. 'second-hits'). These further insults are induced by oxidative stress and other 
strained situations resulting in progression to steatohepatitis and liver cell death (Day and James 1998). 
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2.2 Insulin Resistance (lR) 
A trademark characteristic of NAFLD is the presence of insulin resistance (IR). The 
manifestation of obesity, dyslipidaemia and type II diabetes is closely linked to 
decreased sensitivity to insulin and as sometimes referred to as the 'insulin 
syndrome' with IR being the common factor, (Marchesini et aI., 1999). Recent reports 
have demonstrated that the majority of NAFLD patients display signs of impaired 
insulin activity (Pagano et al., 2002; Chitturi et aI., 2002) and the close association 
between IR and the resultant metabolic changes has been a central theme to 
research. 
The association of lowered sensitivity to insulin and obesity is a frequent occurrence. 
Obese patients display elevated levels of TNF-a expression and activity which 
coincides with rises in body mass index (BMI) (Kern et al., 1995). The generation of 
TNF-a rivals the normal functioning of insulin activity and assists in exacerbating 
insulin sensitivity by facilitating increased reactive oxygen species (ROS) production 
and oxidative stress (Peraldi and Spiegelman, 1998). This creates further insult and 
stress to the already vulnerable liver and promotes disease progression. 
Additionally, the increased TNF-a also augments the performance of NF-KB that will 
amplify TNF-a. The implementation of this loop cycle is detrimental to the patient as 
NF-KB, an important transcription factor responsible for contributing to the regulation 
of inflammation, will promote inflammation. Continuous generation of these two 
cytokines propagates the activity of other pro-inflammatory cytokines such as 
interleukin-2 and 8, (IL-2) and (IL-8) which will also incite hepatocyte inflammation 
(Barnes and Karin, 1997). Studies performed in mice by Uysal et al., (1997) and 
more recently by Li et al., (2003) have shown that induced mutations of TNF-a 
receptors Significantly improve the sensitisation towards insulin. This in turn, 
contributes to alleviating the development of fat accumulation leading to severe 
steatosis and confirms the role of TNF-a as a mediator of the 'second-hit' that 
worsens NAFLD. 
The effects of IR on free fatty acid (FFA) metabolism are also believed to significantly 
contribute to the development of hepatic steatosis and progression to steatohepatitis. 
In an insulin-resistant individual, there is a greater flux of FFAs to the liver, causing 
strain on normal liver function. The increase in lipopolytic activity in the adipocytes is 
part of insulin resistance (Roden et al., 1996). The increased presence of FFA in the 
hepatocytes inhibits the metabolism in the Krebs cycle, and facilitates fatty acid 
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oxidation, which endorses oxidative stress in the liver. Elevated hepatic glucose 
levels coincide with impairment of the Krebs cycle and the resulting sustained 
stimulation of gluconeogenesis and prolonged inhibition of glycolysis contribute to the 
accumulation of glucose. An increased production of glucose is met with raised 
concentrations of insulin in an attempt to improve clearance rates. The capacity of 
the pancreas to maintain demand for insulin is eventually exhausted and initiates the 
development of diabetes (Bergman, 1997). 
Glucose uptake for cellular function is crucially dependent on insulin. Transporters of 
glucose (GLUT) gather on cell surfaces in higher numbers allowing glucose-6-
phoshate (G-6-P) to accumulate as glycogen, which can be retransformed back to 
glucose when required for later use (Anthon sen et a/., 1998). This reconversion 
process is modulated by glycogen synthetase and protein phosphatase (Newgard et 
al., 2000). The phosphorylation status of these enzymes is regulated by protein 
kinase A (PKA) which becomes inhibited when insulin circulates in high 
concentrations. Therefore, insulin enhances cellular import and storage of glucose by 
stimulating glycogen formation and also protects against potential degenerative 
hepatic glucose accumulation through inhibition of glycogenolysis and 
gluconeogenesis. 
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Figure 2.2.1; Top; Mechanism of fatty acid-induced insulin resistance in skeletal muscle. An increase in 
fatty acid concentration results in an elevation of the intramitochondrial acetyl GoA/GoA and 
NADH/NAD+ ratios, with subsequent inactivation of pyruvate dehydrogenase. This in turn causes citrate 
concentration to increase, leading to inhibition of phosphofructokinase. Subsequent increases in 
intracellular glucose-6-phosphatase concentration would inhibit hexokinase II activity, which would result 
in an increase in intracellular glucose concentration and a decrease in muscle glucose uptake. Bottom; 
Proposed alternative mechanism for fatty-acid induced insulin resistance in human skeletal muscle. An 
increase in delivery of fatty acids to muscle or a decrease in intracellular metabolism of fatty acids leads 
to an increase in intracellular metabolites such as diacyl-glycerol, fatty acyl GoA and ceramides. These 
metabolites activate a serine/threonine kinase cascade (possibly initiated by protein kinase G8) leading 
to phosphorylation of serine/threonine sites on insulin receptor substrates (IRS-1 and IRS-2), which in 
turn reduces the ability of the insulin receptor substrates to activate PI 3-kinase. As a consequence, 
glucose transport activity and other events downstream of insulin receptor signalling and diminished 
hexokinase II (HK), phosphofructokinase (PFK), pyruvate dehydrogenase (PDH) and protein kinase G8 
(PKG8) (Schulmann et al. , 2000). 
A recent study performed by Yesilova et a/., (2005), examined the role of acylation 
stimulating protein (ASP) which is second in abundance behind insulin in adipocytes 
and partially responsible for triglyceride synthesis. ASP stimulates the uptake of 
glucose in adipocytes. Mice previously administered ASP were shown to display 
improved clearance rates of FFA and TG (Saleh, 2001). Diacylglycerol 
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acyltransferase is an important rate-limiting enzyme involved in TG synthesis and its 
activity is increased as a direct result of ASP induced glucose uptake, the 
consequence of which is increased stimulation of FFA re-esterfication into 
triacylglycerol and reduction of FFA endogenous production (Germinario et al., 1993; 
Faraj et aI., 2004). 
The work undertaken by Yesilova et al., (2005), could not fully establish a correlation 
between plasma ASP levels and lipid accumulation in NAFLD patients but did further 
outline the significance of ASP as a regulatory mediator of FFA uptake and TG 
synthesis. The dysregulation of the ASP pathway appears to increase the influx of 
FFAs to the liver which in turn results in hypertriglyceridaemia and a host of 
additional metabolic changes associated with obesity, and predisposing to coronary 
heart disease and diabetes (Sniderman et al., 2000; Weyer and Pratley, 1999; 
Cianflone et aI., 1997; Koistinen et al., 2001). ASP and insulin are key factors which 
determine the rapidity of TG synthesis in the adipocyte, thus playing an important 
role in controlling FFA plasma concentration and transport and may have noteworthy 
implications in the metabolic complications of NAFLD and NASH (Sniderman et aI., 
1998). 
A reduction in metabolic clearance is a resulting key feature of NASH patients who 
fail to successfully dispose of excess glucose. This lessened metabolic capacity of 
the liver, coupled with impaired lipolysis in adipocytes or disposal from hepatocytes, 
is a consequence of IR enhancing free fatty acid production. Hepatic steatosis occurs 
when hepatocytes lose the ability to balance synthesis and exportation of FFA, 
ultimately resulting in fat accumulation. The additional progression of the disease 
may depend on the presence or severity of further hits which will include P450, TNF-
a and lipid peroxidation (Sanyal, 2005). 
2.3 Free Fatty Acid (FFA) 
The physiological pathways of FFA are illustrated in figure 2.3.1, but components in 
this scheme will be discussed and illustrated separately in this section. Free fatty 
acids (FFA) are the principal metabolic product of adipocytes, and under normal 
circumstances will not accumulate as triglycerides within hepatocytes (Saleh et al., 
1999). FFA synthesis and recycling of FFA and triglycerides to the liver provide for 
the export of energy from the liver as VLDL. Fatty acids also serve other functions: 
intracellular signalling, regulation of gene transcription and act as a source of 
immediate energy when oxidised. 
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The normal regulation of FFA results in their l3-oxidation within mitochondria and 
peroxisomes, whilst oxidation may also occur within the cytochrome P450 system 
which responds to increasing demand. FFA may also be re-esterified to triglycerides 
or may be used for synthesis of other lipids (Fong et al., 2000). The two central 
mechanisms operated by the liver for providing FFA for cell function are lipogenesis 
(from acetyl CoA) and recruitment from the circulation by FAT protein (C036). The 
FFA are primarily esterified into triglycerides (TG) which are the chief components of 
fat in the fatty liver (Wanless et al., 1989). Triglycerides accumulate as fat droplets in 
the cytosol of hepatocytes. For export they are moved by MTP to apolipoproteins 
B48 in the enterocyte or B 100 in the hepatocytes to be secreted as chylomicrons and 
very low density lipoproteins (VLOL) respectively. These triglyceride-rich lipoproteins 
are transported in the blood to release FFA under the catalytic influence of lipoprotein 
lipase, chiefly at muscle and adipose tissue. The remnant particles of chylomicrons 
and VLOL return to the liver for redistribution within the cell as discussed above. A 
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Figure 2.3.1; Diagram illustrating the interrelationship of fatty acid and glucose metabolism (Kersten, 
2002). 
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The hepatocytes adjust to an excess influx of FFA through adaptive modifications 
whereby secretion of VLDL is increased and the flux of free fatty acids towards 13-
oxidation is increased. Under normal conditions only a small amount of TG is stored 
in the liver. Hepatic TG accumulation reflects a discrepancy in triglyceride synthesis 
and/or fatty acid disposal which may be a result of increased FFA production, 
reduced capacity of l3-oxidation or impairment of VLDL secretion (Fong et aI., 2000). 
These factors all contribute to the production of oxidative stress, accumulation of 
hepatic fat and the pathogenesis of fatty liver. The consequence of this 
compensatory system becoming overloaded or being defective is an increase in TG 
content. The compensatory response and/or the increased TG may contribute to 
hepatic damage. 
2.4 fJ-Oxidation of Fatty Acids 
As mentioned earlier, l3-oxidation is a fate of FA which occurs primarily in the 
mitochondrial inner membrane. Before FA arrive for l3-oxidation, they are first 
transported through the cytoplasm in a combined complex with fatty acid binding 
proteins (FABP) which delivers the FA to the outer membrane of the mitochondria. 
Once they arrive at binding sites of the outer mitochondrial membrane, they are 
transformed into acetyl CoA and the converted derivatives of FA are transported from 
the outer membrane to inner membrane by carnitine palmitoyltransferase 1 (CPT1) 
and CPT2 respectively. The consequent l3-oxidation of FA derived acetyl CoA 
generates a high energy yield and has proven to be a very useful pathway for an 
energy source cleaved from non-esterified FA. 
The complexity of the development and progression of fatty liver in I\JAFLD and 
NASH remains incomplete but the involvement of l3-oxidation is well documented. A 
very recent study carried out by Nakamuta et al., (2005) investigated the expression 
of various genes known to be involved in l3-oxidation of fatty acid metabolism in 
NAFLD. Target genes included acetyl-CoA carboxylase (ACC) 1, ACC2, fatty acid 
synthase (FAS), carnitine palmitoyltransferase 1 a (CPT1 a) and long chain acyl-CoA 
dehydrogenase (LCAD). The study revealed an increased expression of ACC1 and 
ACC2 but not FAS using liver biopsies from 12 NAFLD patients. Further findings 
included a diminished expression of CPT1 a which is a rate-limiting enzyme involved 
in l3-oxidation. As a result, l3-oxidation is reduced. This provides evidence that 
dysfunctional l3-oxidation maybe partly why there is an accumulation of fat in 
hepatocytes of patients with NAFLD. 
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A great deal of attention has been focused on the role of FA in NAFLD and recent 
research undertaken by Drover et al., (2005) was concentrated on CD36 which is 
known to be the gene responsible for mediating the transfer of FA across plasma 
membranes and is therefore regarded as having a very important role in regulating 
FA metabolism. Impairment of gene CD36 in mice was previously shown to result in 
irregular uptake of FA and in addition, circulating levels of triacylglycerol (TAG) were 
increased (Coburn et al., 2000; Febbraio et al., 1999). Conversely, over-expression 
of the CD36 gene has demonstrated a link to hypertriglyceridaemia, insulin 
resistance and elevated levels of FA in hypertensive rats (Aitman et al., 1999). In 
humans, abnormal plasma lipid levels are also often associated with dysfunctional 
expression of the CD36 gene. 
CD36 is referred to as a multi-ligand scavenger receptor and expression favours 
tissues with a high influx of free fatty acids (Coburn et al., 2000). Drover et aI., (2005) 
investigated the role of CD36 using CD36-null mice and monitoring their responses 
to acute and chronic feeding in relation to FA utilization and secretion of lipoproteins. 
The study confirmed the necessity for the CD36 gene through comparing levels of 
circulating TAG between knockout CD36 mice and their respective wild-type 
littermates after high fat feeding. The levels of TAG recovered in the knockout mice 
were 23% which was significantly lower than the 67% of the controls. Furthermore, 
deficiency of CD36 also resulted in a reduced clearance of lipoproteins and defective 
lipoprotein lipopolysis which enhances the case that an aberration in gene CD36 
function could contribute to facilitating fatty liver development and progression. 
2.5 Peroxisome proliferator activated receptors - (PPAR) 
FFA is required by hepatocytes to maintain cell function. Because FFA supply may 
exceed the demand, protective pathways are required to prevent stress and liver 
injury. One mechanism by which the possible cytotoxic effects of FFA have been 
restrained involves the peroxisome proliferator activated receptors (PPARs). These 
hormone receptors have gained significant interest due to their orchestrative role of 
FFA metabolism and their activation in response to a variety of drugs used in 
treatment of obesity and T2DM (Kersten et aI., 2002; Bocher et al., 2002). 
Peroxisome proliferator activated receptors (PPARs) display a common structure 
comprising a central DNA-binding domain structure containing two zinc-fingers (for 
interaction with DNA) and a large C-terminal domain that binds ligands (Aranda and 
Pascual, 2001). PPARs are key ligand-activated transcription factors consisting of 
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isotypes a, ~ and y and the different distinguishable forms each permit the liver cells 
to deal with alternate biological processes (Kersten et al., 2002). 
PPAR-a is responsible for regulating fatty acid oxidation, gluconeogenesis, amino 
acid metabolism and is predominantly operative in the liver (Kersten et aI., 2002). A 
group of ligands which enhances the binding affinity of these receptors is referred to 
as fibrates and have been in use for the treatment of hypertriglyceridaemia since the 
1960s (Kersten et al., 2002). Clofibrate and gemfibrozil are further lipid-lowering 
drugs that have had limited success in combating the complications of NASH. A 
further therapeutic approach has included the administration of atorvastatin which 
has resulted in significant improvements in serum lipid concentrations which 
correlated with less severe hepatic inflammation and ballooning (Horlander et al., 
2001 ). 
PPAR-a is employed by the liver as sensor apparatus to detect elevated levels of 
FFA. When hepatocytes experience an influx of free fatty acids, PPAR-a relays 
signals for the expression of acyl CoA oxidase, a key enzyme required for 
inducement of ~-oxidation. This presents a preventative measure against fatty acid 
cytotoxicity (Kersten et al., 2002). However, despite the rewarding benefits of PPAR-
a activation, continuous stimulation by FFA overload may generate ROS and 
participate in the role of carcinogenesis (Bocher et al., 2002). The role of PPAR-a in 
regulating nutrient metabolism is shown below; (Figure 2.5.1). 
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Figure 2.5.1; PPAR-Q regulation of nutrient metabolism occurring in hepatocytes. The positive 
regulatory role PPAR-a in fatty acid metabolism and gluconeogenesis is displayed aswell as the 
negative metabolism of amino acids (Kersten, 2002). 
PPAR-o contributes to the control of lipid metabolism, the running of which is also 
altered by the presence of excess alcohol and products of the inflammatory 
response. Dysfunctional lipid metabolism may be central in ALD and in NASH as 
well, explaining the similarities of the two diseases (Kotesih and Diehl, 2002). 
Nakajima et al., (2004), investigated the role of PPAR-o in alcoholic liver disease 
using PPAR-o null mice fed a 4% ethanol diet and assessed for liver injury. The mice 
administered ethanol displayed hepatic irregularities that included inflammation, 
mitochondrial swelling and fibrosis, which corresponds with injuries found in 
alcoholics. Additionally, ethanol-fed PPAR-o null mice were subjected to higher levels 
of oxidative stress and had markedly increased lipid peroxides after 6 months in 
comparison to the controls. There was also a reduction of liver mRNA proteins 
encoding for growth factors (HGF-o, TGF-o and TGF~ 1) involved in hepatic 
proliferation in wild-type mice whose PPAR-o expression was decreased by 60%. 
This implicates PPAR-o in the pathogenesis of fatty liver as its deficiency can result 
in altered signalling and stimulation of hepatic cell growth in the presence ethanol. It 
should strongly be considered that PPAR-o is an important target gene for the 
modulation of ALD, at least in rodents. PPAR-a is not expressed as highly in humans 
in comparison to rodents, resulting in the hypothesis that humans may possibly be 
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more vulnerable to the effects excess alcohol as PPAR-a appears to have a 
defensive role in ALD. 
The knowledge of PPAR-~ remains relatively small but previous studies have 
proposed a partial role in lipid metabolism of nerve cells (Basu-Modak et aI., 1999). 
PPAR-~ may also be implicated in adipogenesis, suggesting a link to obesity (Bastie 
ef aI., 2000), and hence fatty liver. 
In contrast, PPAR-y has been more extensively studied. It is located in plentiful 
quantities in white adipose tissue and macrophages (Braissant et al., 1996), although 
the amounts expressed in the liver are relatively low in comparison (Nanji et al., 
2004). Owing to its role in adipocyte differentiation, PPAR-y is regarded as having a 
strong connection with obesity (Kersten et aI., 2002). Mice that do not exhibit 
sufficient levels of PPAR-y become fat intolerant, develop hyperlipidaemia and 
become insulin resistant (Clarke, 2001). This evidence is suggestive of PPAR-y 
being a crucial regulator of triglyceride homeostasis and a potential contributor 
towards hepatic steatosis development (Gavrilova ef aI., 2003). 
Not only is PPAR-y central in differentiation of preadipocytes into mature fat cells, a 
process called adipogenesis, but it is also believed to occupy a regulatory role in 
lipogenesis (Kubota et aI., 1999). PPAR-y and sterol regulatory element-binding 
protein-1 (SREBP-1) are thought to be involved in a continuous loop whereby they 
possess the ability of upregulating each other, thus encouraging lipogenesis in 
adipose tissue (Kersten et aI., 2002). SREBP-1 is a transcription factor responsible 
for stimulating expression of various genes fundamental in lipogenesis such as 
acetyl-CoA carboxylase, fatty acid synthase and ATP-citrate lyase. A study carried 
out by Way et aI., (1999) used a PPAR-y agonist known as GW1929 in Zucker fatty 
rats and displayed an increased expression of SREBP-1 and genes involved in fatty 
acid oxidation and confirmed PPAR-y participation in lipogenesis although it is not yet 
understood whether it is direct or secondary to up-regulation of SREBP-1. 
PPARs have been extensively examined in rodent models and recent work 
undertaken by Wargent et al., (2005), has implicated the possible involvement of 
PPAR activation in response to conjugated linoleic acid (CLA). The findings indicated 
that CLA increased insulin sensitivity in lepob/lepob mice and that the subsequent 
activation of PPAR-a and y may contribute to the improvement of insulin sensitivity in 
these genetically obese female mice. It is clearly evident that the action of PPARs is 
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central in controlling fat accumulation and other overlapping pathogenic mechanisms 
such as lipogenesis, l3-oxidation and insulin sensitivity and should remain at the fore 
for future research into fatty liver development and other surrounding complications. 
2.6 Cytochrome P450 Enzymes 
The cytochrome P450 proteins (CYP450) are recognized as a group of closely 
related isoenzymes which are encoded by separate genes and classified according 
to their molecular structure (Gonzalez, 1990; Nebert et a/., 1989). These enzymes 
perform numerous functions and are located in most human tissue, although the liver 
has the highest content, in mitochondria and the endoplasmic reticulum. Induction of 
the CYP450 system is usually in response to drugs, including barbiturates, and toxins 
such as alcohol and tobacco smoke (Okey, 1989). Once induced, the P450 
cytochromes increase the degradation of drugs and toxins. Relentless and 
unremitting induction may, however, lead to increased generation of oxidative stress 
and reactive oxygen species (ROS), thus providing an initiating step for liver injury 
(Lieber, 1997). 
CYP2E1 is the most abundant enzyme in the P450 family and is central in the 
metabolism of alcohol. CYP2E1 is activated as an adaptive response to high blood 
ethanol levels and catalyses the following reaction (see below). 
Although the induction of CYP2E1 accelerates the metabolism of ethanol, this 
reaction is also closely associated with the release of free radicals whose nature can 
facilitate lipid peroxidation, mitochondrial damage and oxidative stress which all 
contribute to liver damage (Lieber, 2004). Furthermore, acetaldehyde (ethanol) 
production is increased. Ethanal is highly reactive and toxic, adding to the cumulative 
pathogenic effects (Lieber et aI., 1986). 
CYP2E1 activity is also exacerbated in response to nutritional states including 
fasting, diabetes and obesity. This explains the presence of increased CYP2E1 in 
NASH despite the lack of excess alcohol consumption (Robertson et aI., 2001). 
However, CYP2E1 is not the only factor contributing to the development of fatty liver 
as products of the inflammatory response and fibrogenesis also combine to the 
resultant oxidative stress. The many possibilities of CYP2E1 interactions are 
depicted below in figure 2.6.1 (Lieber, 2004). 
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Figure 2.6.1; This diagram displays the many compounds which act as potential substrates for induction 
of cytochrome P450 CYP2E1 activity that results in detrimental and beneficial effects (Lieber, 2004). 
CYP2E1 has been described as a "leaky" enzyme as it is capable of "futile cycling" 
whereby detrimental oxygen species and hydroxyl radicals are formed in the absence 
of substrates causing NADPH-dependent lipid peroxidation and cellular damage 
(Robertson et aI., 2001). It is believed that for NASH to occur and progress, 
additional oxidative stress is necessary as a 'second-hit' to establish a certain degree 
of lipid peroxidation that surmounts regular cell defences resulting in 
necroinflammation (Day and James, 1998). Common characteristics of NASH such 
as obesity and diabetes are regarded as mediators of CYP2E1 induction and 
therefore must be also regarded as 'second-hit' candidates capable of causing 
oxidative stress and hence hepatic damage. 
IR is already established as a common characteristic in NAFLD and I\lASH patients. 
A further complication of IR is the ability to induce the operation of the cytochrome 
P450 system CYP2E1. This can also lead to the production of ROS as a result of 
intra-hepatic metabolic abnormalities which mimics the conditions experienced in 
alcoholic liver disease (ALD) (Albano et aI., 1996). A study performed by Weltman et 
aI., (1998) investigated the presence of hepatic CYP2E1 in a group of 31 patients 
with NASH that comprised 23% diabetes and 45% obese, both being aetiologic 
factors closely linked to relative insulin deficiency. The findings revealed that 
concentrations of CYP2E1 in patients with NASH was increased in comparison to the 
controls and also very similar to levels identified in patients with alcoholic 
steatohepatitis. Furthermore the acinar distribution of CYP2E 1 seen in NASH 
patients closely resembles the distribution displayed in early alcoholic liver injury and 
coincides with the extent of steatosis through acinar zones 3 to 1 as with ALD. 
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A further source of induction of the CYP2E 1 pathway is an elevated concentration of 
FFA which can occur via peroxisomal ~-oxidation providing a supplementary source 
of oxidative stress. A reduced sensitivity to insulin can also lessen the suppression of 
HSC and thus cause adipocytes to increase FFA delivery to the hepatocytes, 
resulting in yet another potential source of liver cell damage (Sniderman et al., 1998). 
In addition to CYP2E1, a further P450 cytochrome subfamily, CYP4A, can serve as 
an alternative microsomal lipid oxidase for catalysing ethanol. The ROS and 
additional oxidative stress may thus come from other avenues of formation of 
superoxides and H20 2 (Robertson et aI., 2001). 
Overall, hepatic steatosis is regarded as a benign condition which results when the 
hepatic triglyceride pool expands as a result of limiting oxidation or export capacity. 
The development of steatohepatitis requires an additional 'second-hit' in the form of 
oxidative stress from an array of hepatic pathways such as CYP2E 1 that elicits the 
progressive nature of the disease, thus providing a framework for treatment and 
disease prevention (Day and James, 1998). 
2.7 Leptin 
Leptin resistance is yet another potential causative factor in the pathogenesis of the 
fatty liver diseases. Leptin is a 17 kilodalton protein product derived from adipocytes 
and is involved in several key biological functions that include the regulation of food 
intake and energy expenditure (Zang et al., 1994). Furthermore, leptin is known to 
influence enzymes of fatty acid oxidation and control store levels of body fat thus 
permitting fluctuations in appetite and metabolism (Zhou et aI., 1997). 
Leptin is genetically deficient in ob/ob mice. This strain of mouse exhibits several 
characteristics of humans with I\lAFLD such as obesity, diabetes and development of 
steatosis. It has become a valuable model for studying the disease mechanisms 
involved (Unger, 2000). A study by Campfield et aI., (1995) revealed that the 
administration of recombinant leptin suppressed the appetite and consequently 
reduced the food intake in ob/ob mice and had a protective effect. Conversely, when 
excess caloric intake does occur, leptin aids in stimulating the confinement of extra 
calories to adipocytes, therefore deflecting potential steatotic damage away from 
non-adipocytes and exhibiting a defensive role against obesity (Unger, 2002). 
Page 27 
In spite of this, when steatotic liver damage is incurred by a NASH patient, 
dysfunctional leptin expression and signalling is a probable outcome. Leptin is 
responsible for aiding the regulation of several cytokine receptors but the balance of 
the leptin effects promotes the initiation of fibrosis. It is known that leptin stimulates 
the production of the potent profibrotic cytokine transforming growth factor-~1 (TGF-
131) (Bissell et al., 2001). Additional proposed profibrotic effects of leptin are that the 
receptors may activate STAT-3 through ligand-binding, thus increasing collagen gene 
production and CYP2E1 expression is partly reliant on leptin activity and therefore 
has the ability to enhance oxidative stress by means of CYP2E 1 induction (Saxena et 
aI., 2002; Enriquez et al., 1999). Excess lipids or 'lipotoxicity' due to increased 
amounts of free fatty acids is also a very common occurrence in NASH and may be 
attributed to the dysfunctional production of leptin that aims to modulate insulin 
sensitivity to correct for insulin resistance (Chitturi et al., 2002). 
It is not only leptin that has been implicated as a contributing factor in fatty liver 
development but also leptin receptors. Zucker fa/fa rats are diabetic and have leptin 
resistance as a result of a substitution mutation in the leptin receptor (Ob-R) with an 
ensuing loss of function (Unger, 2002). After approximately 5 weeks of age, these 
rats exhibit elevation in FFA plasma levels as well as an accumulation of triglycerides 
in various organs. Furthermore, Unger (2000) showed that an intravenous injection of 
cDNA of wild-type OB-Rb consequently restores normal expression of leptin 
receptors in the falfa rat, resulting in a regression of hepatic triglyceride levels. 
Recent research by Cohen et al., (2005) also examined the leptin receptor (Ob-R) 
and established that the liver unexpectedly contained Ob-R mRNA and therefore 
could augment circulating levels of leptin when negative energy balance is endured. 
Numerous other studies have investigated the role of leptin in genetic rodent models 
of obesity such as leptin-deficient ob/ob mice and Zucker diabetic fa/fa rats. This will 
be discussed later in the NAFLD/NASH animal models chapter. However, it must be 
noted that increased leptin gene expression has been observed in humans in 
addition to leptin plasma concentrations and suggests the occurrence of obesity in 
humans may owe itself to dysfunctional leptin receptors as opposed to leptin itself 
(Hamilton et aI., 1995). 
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2.8 Type 2 Diabetes Mellitus 
It is estimated that 250 million people distributed worldwide will be affected by type 2 
diabetes mellitus within 15-20 years as a result of insulin resistance (O'Rahilly, 
1997). 
A recent advance in the prevention of diabetes and hepatic injury has examined the 
effects of dehydroepiandrosterone (DHEA) and its sulphate ester (DHEA-S) (Aoki et 
al., 2003). These adrenal steroids circulate in great numbers in humans and have 
shown beneficial effects in the treatment of inflammation. The study performed by 
Aoki et al., (2003) treated diabetic db/db mice with DHEA and resulted in reduced 
TNF-a concentration, inhibition of inflammatory cytokines, an increase in insulin 
sensitivity and consequently a diminished degree of hepatic injury. A one-year 
treatment programme with DHEA in post- menopausal women revealed a 30% 
restoration of insulin sensitivity, but a definitive role of DHEA remains unresolved 
(Ishizawa et al., 2001). 
2.9 Obesity 
Although the progression of NAFLD can occur in the lean individual, the presence of 
obesity is almost a prerequisite. It is now estimated that nearly 1000 people a week 
are dieing prematurely in the United Kingdom alone as a direct effect of obesity 
(Small and Bloom, 2005). Recent research has been directed at drug-inducing 
appetite suppression which leads to a lower food intake and the loss of weight. The 
ingestion of food stimulates the immediate release of numerous gut peptides such as 
glucagon-like peptide-1 (GLP-1) and -2 (GLP-2), cholecystokinin (CCK) and peptide 
YY (PYY) (Baggio et al., 2004). These peptides amongst others possess the ability to 
stimulate ascending neural pathways or directly enter the central nervous system 
(CNS) to signal the termination of food consumption (Korner and Leibel, 2003). They 
are therefore believed to act as sensitive modulators of feeding behaviour by 
communicating with CNS satiety centres which govern control of gut motility and 
glucose homeostasis (8aggio et al., 2004). 
Oxyntomodulin (OXM) is a natural digestive hormone consisting of a 37 -amino acid 
peptide which contains the entire sequence of glucagon and is cosecreted with GLP-
1 (Dakin et al., 2001). GLP-1 is known to lower blood glucose and to reduce food 
intake in obese diabetic patients (Drucker, 2002; Zander et al., 2002) whereas GLP-2 
is implicated in the ihhibition of gastric motility and acid secretion (Drucker, 2001). 
Less is understood about OXM. Investigative work has examined this peptide and 
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highlighted a strong association with gastric emptying and stimulation of intestinal 
glucose uptake in rodents (Jarrousse et a/., 1993; Collie et a/., 1997). Furthermore, 
OXM has also displayed capabilities of inhibiting food intake and lowering weight 
gain in rats and more recently in humans (Dakin et a/., 2002; Cohen et a/., 2003). 
The latest development in oxyntomodulin research is a 4-week trial (Bloom - Argus, 
2005), conducted in 26 overweight or obese patients. They received three injections 
a day, each administered 30 minutes before eating. The results revealed an average 
weight loss of 2.3 kg from treatment with OXM in comparison to a placebo group 
which lost approximately 0.5 kg during the same period. 
The exact mechanisms by which OXM inhibits food intake in rodents and humans is 
unclear but it is hoped that the drug will be available on the market as a therapeutic 
approach for obesity within the next 5 years. Despite OXM being primarily developed 
as a means of weight reduction, the drug could also have a significant impact in 
halting the progression of NAFLD. 
Rimonabant is an anti-obesity drug which is under current investigation as it is 
believed to increase satiety and promote weight reduction (Bays, 2004). Cannabinoid 
(CB) receptors are the molecular targets for the active ingredient in cannabis; !:J.9_ 
tetrahydrocannabinol, which are triggered by a small family of endogenous lipids 
(Giuffrida et al., 2001). Cannabis smokers may experience an enhanced appetite 
when this reaction occurs which has led to rimonabant being examined. Rimonabant 
is a CB antagonist and functions by blocking the CB-1 receptor (Bays, 2004). It is 
therefore hypothesised, that inhibition of the receptor responsible for regulating 
appetite would reduce caloric intake and consequently lower body mass. 
Rimonabant, at present, is being studied in clinical trials of over 6000 patients, 
including those with type II diabetes (SPG Media Limited). Initial findings are 
encouraging, revealing advantageous effects on lipids such as triglycerides and high-
density lipoprotein-cholesterol levels (Anthenelli and Despres, 2004). 
The epidemic of obesity is still relatively new, but despite public health education 
highlighting the surrounding complications, it is estimated that over 1 billion adults 
worldwide are overweight (Bays, 2004). Studies in weight-reducing drugs like 
rimonabant are still in early development and it remains unclear whether a single 
treatment target or a multiple of treatment targets provides the most effective 
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approach. Further research is required to find a suitable treatment that will effectively 
modulate fatty liver by limiting or preventing obesity. 
2.10 Hepatic Fibrosis 
Fibrosis is not always present in NAFLD patients but is regarded as the key 
pathological feature of liver damage in NASH. The fibrotic process in steatohepatitis 
is believed to be nearly identical to other modes of chronic liver damage such as ALD 
(Friedman, 2000). The common trait of fibrosis in steatohepatitis is often referred to 
as pericellular 'chicken-wire' fibrosis due to its histological appearance within 
hepatocytes and is initially located in acinar zone 3 as with ALD (Brunt and Tiniakos, 
2002). The progression to fibrosis has been attributed to various underlying factors 
including oxidative stress, lipid peroxidation, insulin resistance, and upregulation of 
cytokines which are all potentially able to be the 'second-hit' after the metabolic 
stress. The adaptive responses of the liver to further injury help explain the 
underlying pathogenesis of NASH and contribute to the knowledge of fibrogenic 
mechanisms. Although the risk factors for fibrosis development and progression in 
NASH remain unclear, the morphological changes that occur are clearly defined and 
are outlined below (Figure 2.10.1). 
NormaJ liver Liver injury 
Figure 2.10.1; Changes in cellular structure during fibrotic liver injury; In a normal functioning liver, the 
hepatocytes possess microvilli and endothelial fenestrae are still present. During liver damage, HSC 
proliferate and are consequently surrounded by fibrillar matrix whilst hepatocyte microvilli and 
endothelial fenestrae are lost resulting in fibrosis (Friedman, 2003). 
Fibrosis is generally regarded as a defensive repair mechanism in response to cell 
injury. Fibrogenesis mechanisms can be activated without cell death or inflammation. 
The trademark characteristic of hepatic fibrosis is the deposition of extracellular 
matrix (ECM) proteins within the space of Disse (Geerts, 2001). In the normal 
functioning liver, the ECM provides support for cellular structure, permits growth-
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factor transport and is also relied upon for transmitting signals to surrounding cells in 
order to maintain their differentiated functions (Friedman, 2003). Conversely, an 
injured liver exhibits scarred tissue with amassing ECM which encompasses 
macromolecules from three main families: collagens, glycoproteins and 
proteoglycans. As the liver develops fibrosis, changes in the arrangement of the ECM 
occur due to an influx of fibril forming collagens (types I and III), fibronectin and 
laminin (Friedman, 2000; Shuppan et aI., 2001). Furthermore, the expression of 
matrix metallproteinases (MMP) and their inhibitors appear to be in an imbalance, 
causing disorder in hepatic compartments because excessive matrix deposition is not 
being compensated by increased degradation (Friedman, 2000; Shuppan et aI., 
2001 ). 
Hepatic stellate cells (HSC), among other major cell types including Kupffer cells and 
endothelial cells are activated in the fibrotic liver. HSC in particular have been viewed 
as a causative factor for enhancing ECM production during fibrogenesis (Eng et aI., 
2000). HSC are present in both normal and damaged livers, and can be 
distinguished by their vitamin A content and location. HSC are located beneath 
endothelial cells in the space of Disse and in normal functioning liver they connect 
with other stellate cells via gap junctions (Eng et aI., 2000). However, during injury, 
HSC are converted into myofibroblast-like cells that now contain little vitamin A and 
facilitate collagen assemblage (Friedman, 2000; Eng et aI., 2000). The 'activation' of 
HSC at the onset of injury is therefore regarded as being a central event in the 
detrimental progressive nature of hepatic fibrosis which entails the conversion of 
quiescent vitamin-A storing cells into proliferative, fibrogenic and contractile 
myofibroblasts (Friedman, 2003) (see figure 2.10.2). 
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Figure 2.10.2; HSC activation is a response to liver injury by a two-step process of initiation and 
perpetuation. Resolution of fibrosis may occur by reduction of HSC number by apoptosis and reversal of 
activated HSC to quiescent phenotype (Friedman, 2003). 
The potential disadvantage arising from HSC activation include alterations in ECM 
components, and the loss of vitamin A. The cells enlarge and continued injury will 
exacerbate the fibrosis with activation being propagated by increased expression of 
cytokines such as platelet-derived growth factor (PDGF), epidermal growth factor 
(EGF) and transforming growth factor-~1 (TGF-~1) (Maher, 2000). Transcription 
factors that include nuclear factor-KB (NF-KB), activator protein-1 (AP-1) and signal 
transducer and activator of transcription-1 (STAT -1) also play a supporting role in 
activating HSC which coincides in synchrony with accumulation of ECM, remodelling 
of the matrix and modification of fibrotic activity. 
Studies which are primarily concerned with the fibrotic response in NASH patients 
are limited. A study undertaken by Baldridge et al., (1995) discovered that 14 children 
with NASH all displayed signs of portal fibrosis and postulated that fibrosis may be 
more prominent in children than adults. Additional research has also proposed that 
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old age, obesity, female gender and diabetes mellitus are further independent 
determinants of fibrosis (Wanless et al., 1990; Angula et al., 1999). 
A clear, singular, causative factor for generating fibrotic stimuli in NAFLD and NASH 
remains elusive. Several inter-related discrepancies in lipid metabolism, inflammatory 
response, resistance to insulin or a combination playa role. Further work must be 
aimed at gaining a better understanding of the processes involved in a liver 
becoming fibrotic in order to channel resources towards identifying possible 
therapeutic targets for treatment purposes of these at highest risk for serious 
complications of fatty liver, especially cirrhosis. 
2.11 Cirrhosis 
Although liver cirrhosis is not evident in every patient with progressive fatty liver 
disease, clinical studies reveal that approximately 20% of patients with NASH 
proceed in developing a cirrhotic liver (Diehl et aI., 1988; Matteoni et al., 1999). 
Whether a patient is developing a cirrhotic liver or not is difficult to determine 
clinically and biochemically and has resulted in the endorsed use of needle biopsy as 
the 'gold standard' for correct diagnosis (Brunt, 2001). When cirrhosis is fully 
established in the liver, the regular lobular structure is completely lost and is replaced 
by regenerative nodules that vary significantly in size, and is bounded by bands of 
fibrous tissue (Diehl et al., 1998). Cirrhosis can be classified as micronodular, 
macronodular or more commonly a combination of both. Micronodular cirrhosis 
consists of small uniform nodules and is frequently associated with alcoholics. It often 
results in yellow coloration of the liver due to severe fatty change. Macronodular 
cirrhosis is often revealed after cessation of heavy drinking and comprises large 
protuberant nodules separated by fibrous bands. 
The rate at which cirrhosis proceeds is dependent on the extent of injury incurred by 
the individual and factors that trigger cell-death, fibrosis and regeneration. A toxin 
such as alcohol will effect concentration-dependent cell death and damage. Cirrhosis 
greatly enhances the likelihood of developing hepatocellular carcinoma (HCC), 
cirrhosis may also result in the loss of liver function and often portal hypertension 
arises due to the increased resistance to flow. Research carried out long ago by 
Heston and Vlhakis, (1962) indicated that ageing mice develop hepatic tumours but it 
remains unclear whether the occurrence of hepatocellular carcinoma is a genuine 
event in the advancement of NASH. Increases in oxidative stress and lipid 
peroxidation have been reported in numerous studies involving NASH patients 
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(Weltman et aI., 1996; Esterbauer et al., 1992) suggesting a possible link to arising 
hepatocarci nogenesis. 
A study conducted by Seki et al., (2002) investigated the hepatic expression of 4-
hydroxy-2'-nonenal (HNE) and 8-hydroxydeoxyguanosine (8-0HdG) as HNE is a 
reliable marker of lipid peroxidation and 8-0HdG is regarded as a target of free 
radicals in cellular DNA that demonstrates signs of oxidative DNA damage. The 
findings revealed that expression of HNE and 8-0HdG were markedly increased in 
NAFLD patients in correlation with the stage of fibrosis when compared to patients 
with normal liver. HNE is a strong chemical attractant for neutrophils and oxidative 
stress-induced NF-KB activation (Schaur et al., 1994; Jaeschke et al., 1996). It may 
therefore contribute towards initiating the activation of HSC which are a primary 
source of ECM proteins central to the progression of fibrogenesis (Friedman, 1993). 
In addition, the accumulation of 8-0HdG in cellular DNA of NAFLD patients resulted 
in mispairing and provides evidence that this oxidative modification is mutagenic and 
carcinogencic (Kasai et al., 1991). The probability that oxidative DNA damage or 
increased levels of oxidative stress is involved in developing HCC is high, but more 
studies need to be undertaken to confirm the hypothesis. Further mechanisms which 
have been proposed for facilitating the development of hepatic carcinogenesis 
include alterations in fatty acid metabolism (Ockner et al., 1993), activation of PPAR-
a (Gonzalez et a/., 1998), insulin stimulation of TNF-a (Bertrand et a/., 1998) and 
overexpression of insulin growth factor-2 (IGF-2) (Rogier et 81., 1994). Other tumour-
forming pathways exist but whether cirrhosis is a prerequisite for HCC to transpire 
remains ambiguous. 
The pathogenesis of NAFLD remains unclear despite the advances which have been 
made in understanding the progressive nature of the disease and the complexity of 
the process. The 'two-hit' model described by Day and James (1998) summarises 
the process of events that occurs in this multifactorial disease. The 'first-hit' results in 
the development of steatosis as a consequence of several metabolic features that 
include insulin resistance and altered lipid metabolism leading to an increase in 
esterified fatty acid in the liver. The 'second-hit' occurs as a follow-up to the 
development of steatosis whereby the liver is more susceptible to disease through 
confrontation with detrimental factors such as increased lipid peroxidation, P450 CYP 
activity, insulin, leptin and the inflammatory infiltrate which all significantly contribute 
to the escalation of the disease. 
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The important causative features of NAFLD and NASH which facilitate the 
development and progression of the disease are predominantly researched in rodent 
models that lends itself to specific manipulation action and the evaluation of the liver 
biochemically, genetically and histologically. Work undertaken in this thesis aims at 
investigating whether the (db/db) strain is suitable for additional research and 
describes some biochemical changes along with the histology of the liver. 
2.12 Similarities with Alcoholic Liver Disease (ALD) 
The occurrence of NAFLD and the subsequent progression from simple fatty liver to 
fibrotic liver and cirrhosis is similar to the pathogenesis arising in alcoholic liver 
disease (ALD). A major difference between the two disorders is that NAFLD patients 
do not consume what is considered to be an excess amount of alcohol whereas the 
consumption of the ALD patients is significant to cause an effect which results in the 
same extent of liver injury. The proposed doses of alcohol required to facilitate ALD 
is 40-80 g/day for males and 20-40 g/day for females over a 10-12 year period 
(Becker et al., 1996; Grant et al., 1988). However, Ludwig et al., (1980) carried out a 
study and found patients who denied any alcohol intake or averaged one drink per 
week still exhibited comparable liver damage as revealed in ALD patients. This 
contrasting data suggests that a safe alcohol intake limit cannot really be applied in 
forecasting whether an individual develops fatty liver as some people are more 
sensitive to the effects, although a low intake coupled with a healthy diet and 
exercise would certainly decrease the possibility. 
Potential pathways by which fatty liver can develop and progress include fatty acid 
oxidation, increased ROS production by the cytochrome P450 system and effects of 
IR on oxidative stress (Haque and Sanyal, 2002). The fact that complete abstinence 
from alcohol does not guarantee avoidance of fatty liver development suggests that 
certain biochemical pathways involved in metabolizing alcohol and generating fatty 
liver in ALD must also be operational in NAFLD. 
The metabolism of alcohol primarily occurs by alcohol dehydrogenases (ADH), 
although CYP2E1 and catalases are also regarded as having important roles (Arteel 
et al., 2003). CYP2E1 is believed to be of significant importance as it is localized in 
hepatic lobules when liver injury is endured from excess alcohol intake. In addition, 
CYP2E1 induction has the potential to be a source of oxidative stress but the 
mechanisms involved remain unclear (Arteel et al., 2003). Possible mechanisms by 
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which alcohol consumption may lead to liver injury are depicted below (Figure 
2.12.1 ). 
Alcohol Metabolism 
i Acetaldehyde production 
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Figure 2.12.1; Mechanisms by which ethanol consumption may lead to liver damage. Ethanol causes a 
number of physiological and biochemical changes to liver that may lead to initiation and progression of 
alcoholic liver disease (ALO). These include the following; alcohol metabolism, via the formation of toxic 
byproducts (e.g. CYP2E1). Inflammation coupled with priming of these immune cells and an increase in 
proinflammatory cytokines and chemokines. Sensitisation of hepatic cells, via alteration of intracellular 
signaling, depletion of energy reserves and an increased response to external stimuli (e.g. 
cytokines/chemokines) alters/enhances the response of the cells during the course of alcohol 
administration. Reactive oxygen species I reactive nitrogen species (ROS/RNS) formation, via electron 
leakage from enzyme systems (e.g. mitochondria and CYP2E1), inflammatory cells and by decreased 
degradation of oxidatively-modified proteins is proposed to playa key role in mediating the effects of 
ethanol. These events are not mutually exclusive and ten to enhance the effects of the other pathways. 
The net result is a vicious cycle of damage and progression in the disease. Polymorphisms in key genes 
involved in these events are also thought to cause the sensitivity of some individuals to chronic alcohol 
abuse (Arteel et al., 2003). 
There are several animal models that are employed to study the effects of alcohol 
such as the Sardinian alcohol-preferring (sP) rat line which has been purposely bred 
for over 20 years for high alcohol consumption (Colombo et aI., 1997) and the 
Indiana University alcohol-preferring (P) and high-alcohol-drinking (HAD) lines (Li et 
al., 1993). However research undertaken in these model poses limitation problems 
as sucrose must be added to concentrations (>6%) to create a 'sweet taste' 
otherwise the rodents will behave adversively towards the solution. This sugar 
supplement consequently decreases the rate of alcohol intake. 
Further problems arising from working with rodent models is creating an accurate 
representation of the conditions that humans endure in developing fatty liver through 
excess alcohol consumption. The majority of people whose alcohol intake is in 
excess of 60 g/day will develop fatty liver whilst those who have a severe mixed 
micro/macrovesicular pattern are more likely to develop fibrosis and resultantly 
cirrhosis (Teli et al., 1995). However, due to the difference in body mass between 
humans and rodents, it is difficult to gauge a concentration of alcohol that would 
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correspond accurately. A study undertaken by Yin et aI., (1999) subjected wild-type 
TNF-R1 knockout mice to ethanol concentrations of 28 g/kg·1/day-1 to induce fatty 
liver. The treatment lasted 4 weeks and also included an acclimatization period in 
which the initial dose was 16 g/kg-1/day-1 and incremented until the desired dosage 
was reached. It takes approximately 10-12 years of alcohol abuse to develop fatty 
liver in humans (Becker et al., 1996; Grant et al., 1988) whereas the wild-type Tf'IIF-
R1 mice showed significant steatosis and inflammation after only 4 weeks. 
Additionally, many rodent models do not live beyond 2 years and further confirms the 
difficulty in trying to bridge the gap between rodent and human data. Research in 
animal models remains the best option to successfully manage and possibly 
eliminate the conditions arising in ALD and similarly in NAFLD. Additional work 
should possibly be aimed at determining the overlapping pathways involved in 
provoking a fatty liver in ALD and NAFLD and therefore establish why this type of 
liver injury occurs in NAFLD patients despite alcohol not being an applicable factor. 
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Chapter 3; Animal Models of NASH and NAFLD 
3.1 Introduction 
This chapter illustrates the extensive assortment of rodent models that are employed 
to investigate the pathogenesis and surrounding complications of NAFLD and NASH. 
From hepatic steatosis being originally regarded as a benign condition, there are now 
several animal models which have been specifically modified to induce key features 
considered to be risk factors in development and progression of fatty liver. NAFLD is 
an asymptomatic disease and detection by liver biopsy remains an invasive, yet the 
most effective technique by which correct diagnosis can be reached. Obesity, insulin 
resistance, type 2 diabetes mellitus and dyslipidaemia are almost a prerequisite for 
facilitation of the disease in human patients (Koteish and Diehl, 2002) and it is these 
characteristics which are purposely activated in rodent models to replicate the 
conditions observed in a 'typical' human profile. 
The findings generated from animal models of steatosis and steatohepatitis have 
been invaluable and greatly improved our understanding of the pathogeneisis of 
NAFLD and NASH. Additional studies in animal models will hopefully identify a 
causative factor of these disorders, therefore allowing successful treatment and even 
amelioration of the disease. Although, care must be taken when interpreting the 
results as no animal model to date has been shown to exactly mirror the biochemical 
and metabolic pathways known to exist in humans with fatty liver. 
3.2 (Ob/ob) Mouse Model 
A number of animal models has been used in recent years to help advance the 
understanding of NAFLD. The ob/ob mouse has been widely studied as this 
particular model of genetic leptin deficiency owing to a mutation in the ob gene, 
manifests key traits seen in the human clinical profile of NAFLD. These 
characteristics include obesity, hyperinsulinaemia, insulin resistance, type II diabetes 
and hepatic steatosis (Lin et aI., 2000). 
Many different approaches have been employed to combat the development and 
progression of NAFLD in the ob/ob mouse model with no real success. One study 
investigated aminosterol 1436, which is a spermine-cholesterol metabolite originally 
isolated from dog shark and has been found to repress appetite and resultantly 
reduce weight (Ahima et aI., 2002). The action of 1436 suppresses SREBP1 and its 
target genes (GPAT and SCD-1), which are involved in hepatic lipid metabolism, and 
subsequently ameliorates the development of fatty liver (Yahagi et al, 2002). A 
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study undertaken by Takahashi et aI., (2004), examined the effects of 1436, in an 
attempt to decrease body weight and resultantly defuse surrounding complications in 
LepOblOb mice. 
LepOblOb mice treated with aminosterol 1436 displayed significantly reduced daily food 
intake and consequent weight loss in comparison to the non-treated animals. 
Triglyceride, cholesterol and AL T concentrations were also significantly reduced in 
association with decreased insulin levels. Although further studies are required to 
establish if 1436 can also reverse other abnormalities of NAFLD such as necrosis 
and fibrosis, aminosterol 1436 still serves as an effective treatment for insulin 
resistance and hepatic steatosis by decreasing hepatic lipid synthesis. 
Another approach used to examine the abnormalities of NAFLD was to investigate 
the formation of reactive oxygen species (ROS). ROS are produced in liver 
mitochondria and there are multiple mechanisms that can promote their generation in 
NAFLD. The production of ROS may be a result of increased fatty acid oxidation, 
elevated cytochrome P450 activity or a metabolic consequence of insulin resistance 
to name a few, all of which typically occur in a NAFLD patient (Haque et al., 2002). 
Research performed by Yang et al., (1999) documented an increased expression of 
mitochondrial uncoupling protein-2 (UCP-2) in fat laden hepatocytes of ob/ob mice. 
The raised activity of UCP-2 is believed to increase the risk of collapse of membrane 
structure by partially depolarising the inner mitochondrial cell walls and may explain 
the vulnerability of fatty hepatocytes to necrosis. 
A further study carried out by Yang et al., (2000) used the ob/ob model again to 
establish whether increased production of ROS and the resultant oxidative stress 
contributed to the development of fatty hepatocytes and promotion of necrosis 
through mediation of UCP-2. The study demonstrated a significant increase in the 
release of H20 2 from mitochondria of fatty liver and confirms an increased production 
of reactive oxygen species compared to the controls. In addition, the mitochondria 
from fatty livers displayed an elevated rate of O2 consumption or production which 
conforms with the idea that mitochondria from ob/ob mice may contain more UCP-2 
when compared to the lean wild-type littermates. The increase of UCP-2 and ROS 
mayor may not directly result in necrosis, but in concert with several dispositional 
factors within fatty livers may promote necrosis that does not occur in normal livers. 
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Another strategy for identifying the underlying factors involved in the pathogenesis of 
NAFLD proposes that impaired regeneration in fatty liver may promote progression of 
the disease. Additional work undertaken by Yang et al., (2001) was aimed at 
recognizing the altered mechanisms which may contribute to impaired regenerative 
responses of a fatty liver in NAFLD. Obese (ob/ob) mice and normal wild-type 
controls were subjected to a 70% partial hepatectomy (PH), after which the animals 
were allowed to recover. The regenerative responses of both groups of animals were 
recorded. Within the first 36 hours after the PH procedure 7/25 ob/ob mice with fatty 
livers died in comparison to 0/26 lean controls, instantly suggesting an abnormality in 
the hepatic compensation and/or regeneration ability of obese mice. Further findings 
revealed substantial decreases of hepatocyte proliferation in surviving ob/ob mice by 
monitoring induction of proliferating cell nuclear antigen (peNA), the action of which 
is typically increased as hepatocytes leave the pre-replicatve phase of the cell cycle 
(Michalopolous et a/' J 1997). Oxidant-sensitive, growth regulatory protein kinase 
cascade systems are believed to help regulate hepatocyte proliferation in response 
to liver injury. Jun N-terminal kinases (Jnks) and extracellular regulated kinases 
(Erks) are two such systems which are normally activated by cytokines and growth 
factors (Westwick et a/., 1995). However, signalling pathways become altered in fatty 
livers as an outcome of sustained oxidative stress and result in abnormal function of 
these systems, hence the poor proliferative response to liver damage in obese 
animals. 
Although a single causative factor of NAFLD remains unidentified, the observations 
from the study confirmed that fatty livers of ob/ob mice had less efficient regenerative 
responses when compared to normal livers of wild type controls. Zucker fa/fa rats 
have also been shown to display inhibited liver regenerative responses (Selzner et 
a/., 2000) adding further speculation that impaired regeneration may assist in the 
progressive nature of the disease by inhibiting hepatic proliferation and increasing 
liver injury. 
Obesity and diabetes are fully established risk factors implicated in the development 
and progression of NAFLD. The exact mechanisms involved in the disease process 
remain unclear, but as these components appear to be central in amplification of 
NAFLD, their roles are becoming more scrutinized in the search for a true cause and 
a possible treatment. Glucocorticoids have been closely examined of late as they 
are believed to play a significant role in the manifestation of obesity and insulin 
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resistance and may therefore contribute to the materialisation of the adverse 
outcomes of the disease (8jorntop et a/., 2000). 
A study performed by Liu et a/., (2003) attempted to determine the role of 
glucocorticoids through measuring the activity of 11 ~-hydroxysteroid dehydrogenase 
type 1 (11 ~-HSD1). The synthesis of corticosterone is predominantly regulated by 
liver-specific 11 ~-HSD1 and is an essential reaction in facilitating further generation 
of active glucocorticoids (Voice et aI., 1996). Female ob/ob mice were treated with 
leptin and compared to non-treated ob/ob animals. Fatty livers of leptin-treated mice 
revealed significantly elevated 11 ~-HSD1 activity and increased levels of 
corticosterone. In addition, body weight was significantly reduced (27.6%) when 
compared to the untreated obese mice. However, despite the leptin-linked 
improvements, 11 ~-HSD1 activity, corticosterone levels and body weight never 
returned to normal levels as indicated by the lean littermate controls. The findings 
implicate increased insulin sensitivity in response to leptin treatment and that the 
obese nature of ob/ob animals is associated with the impaired activity of 11 ~-HSD1. 
The altered hepatic activity of 11 ~-HSD1 in fatty liver may therefore become a very 
useful tool in understanding the development of obesity and diabetes. 
Clearly, much time and resources have been directed at unravelling the 
pathogenesis of fatty liver of the ob/ob mouse model. The characteristics of this 
particular model closely resemble the conditions seen in humans with NAFLD and it 
is therefore hoped that a better understanding of ob/ob mice will serve as guide for 
treatment and the ob/ob model remains a fundamental component for future 
research. 
3.3 Tumour Necrosis Factor-a (TNF-a) Knockout Mouse Model and Human 
Studies of TNF-a 
Increased levels of TNF-a are already well-documented to mediate liver damage 
(Diehl, 2000). Patients suffering from NAFLD and other complications of fatty liver 
continuously display elevated TNF-a in plasma (Winkler et a/., 1998), hence the great 
interest surrounding this cytokine. A study performed by Ji et aI., (2004) investigated 
the role of TNF-a in ethanol-induced liver injury using TNFR1 knockout mice. TNF-a 
is judged to permit the incidence of steatosis occurring in part by impeding normal 
insulin signalling pathways, thus acting with proinfiammatory effects (Crespo et aI., 
2001). The mice lacking the receptor for Tf\IF-a expression displayed minor 
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reductions in triglyceride levels and grading of steatosis. Furthermore, AL T and 
necroinflammatory foci were lowered by 50% in comparison but no significant 
changes were noted in endoplasmic reticulum (ER) stress. These observations 
implicate the involvement of TNF-a in ethanol-induced liver damage. 
Yin et al., (1999) also used TNFR1 knockout mice to establish a role of TNF-a in 
alcohol- induced liver injury. The mice were exposed to a high-fat ethanol diet for 4 
weeks to induce fatty livers before being subsequently terminated. The study showed 
liver/body weight ratios to be affected by ethanol feeding in comparison to the control 
diet, as expected. But this finding was not replicated when comparing TI\lFR 1 
animals. However, assessment of steatosis, inflammation, necrosis and AL T levels 
after ethanol feeding revealed all parameters to be significantly increased in the 
presence of TNF-a. The biochemical and pathological differences arising from 
evaluation of TNFR1 knockout mice and those capable of expressing TNF-a confirm 
that TNF-a plays a role in alcohol-induced liver injury. 
There is further speculation that TNF-a acts as a second hit in the already discussed 
"two-hit" hypothesis (Day, 2002). TNF-a is accepted as a 'second-hit' as it is one of 
the predominant cytokines produced in response to increased reactive oxygen 
species (ROS) (Yang et aI., 2000) and has a major influence in progressive NAFLD. 
One method by which TNF-a is believed to promote hepatic oxidative stress is 
through inhibitor kappa beta kinase beta (IKK~) (Yuan et aI., 2001). IKK~ is partly 
responsible for the inactivation of nuclear factor kappa beta (NF-kB) which initiates 
the transcription of TNF-a. However, because TNF-a is also responsible for 
stimulation of I KK~, a positive feedback loop is generated that results in insulin 
resistance, further production of TNF-a and a chronic inflammatory state (Yuan et al., 
2001 ). 
Work undertaken by Hui et al., examined TNF-a activity in NASH and NAFLD 
patients and attempted to establish markers for differentiating histology. There were 
109 subjects with varying degrees of liver damage in the study, standardised in order 
to eliminate confounding factors of age, sex and body weight. Hypoadiponectinemia 
and TNF-a activation were associated with NASH which was coupled with higher 
grades of steatosis and necroinflammation. Adiponectin has been shown to inhibit 
the activity of NF-kB (Ouchi et al., 2000) which consequently reduced the self-
reinforcing flow of TNF-a and effectively lowered hepatic inflammation. Thus 
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adiponectin may have a potential therapeutic application for alcohol and nonalcohol 
liver disease" 
As illustrated above, TNF-a is implicated in NAFLD and alcohol induced fatty liver 
damage and the histopathological similarities which exist between the different 
diseases reinforces the idea that mutual pathways must be involved (Ludwig et ar, 
1980) 
3.4 Sprague-Dawley Rat Model 
A study carried out by Lieber (2004) fed male Sprague-Dawley rats a high-fat, liquid 
diet in an attempt to produce a suitable experimental model which replicates all the 
key characteristics seen in human patients with NASH. The high-fat diet consisted of 
71 % of fat-derived energy compared to 35% in the standard diet fed to the control 
animals. Both diets were fed ad libitum. 
After 3 weeks, pan lobular steatosis and inflammation were evident in the high-fat diet 
fed rats" This was coupled with elevated plasma lipid concentrations and increased 
levels of hepatic TNF-a in comparison to the control group. Furthermore, increased 
plasma insulin was indicative of insulin resistance and CYP2E1 induction was also 
documented to add to oxidative stress. 
However, the rats fed the high-fat diet did not become obese and comparison of the 
mean body weights against the standard diet fed animals revealed no statistical 
significance. Restriction of the high-fat diet substantially reduced the hepatic changes 
observed in these animals, but the undesirable development of mild steatosis still 
occurred" This provides evidence that restricted, food components can playa strong 
role in deranging liver function. 
Despite the increasing knowledge of NASH and associated liver diseases, an exact 
model remains elusive as all models to date lack one or more pathogenic factors" 
The subsequent non-development of obesity in Sprague Dawley rats raises doubt on 
the suitability of this model for studying NASH, although targeting food components is 
still regarded as a possible strategy for studying the disease process and modulation 
of its outcome. 
3.5 Peroxisome Proliferator-Activated Receptors (PPAR) Mouse Model 
PPARs comprise a superfamily of nuclear hormone receptors which are capable of 
facilitating the effects of fatty acids and oxidised phospholipids on DNA (Kersten, 
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2002). Three subtypes of PPARs exist (denoted a j p and y) and each has a distinct 
tissue distribution pattern (Braissant et al., 1996). PPAR-a is mainly present in liver, 
PPAR-P is ubiquitously expressed and PPAR-y is predominantly located in adipose 
tissue (Memon et aI., 2000). 
PPAR-a is believed to be central in the homeostasis of lipid metabolism and is thus 
likely to participate in the pathogenesis of fatty liver (Desvergne et aI., 2004). The 
altered expression or function of PPAR-a may result in abnormal lipid accumulation 
and ROS which are key mediators of fatty liver disease. Cytochromes CYP2E1 and 
CYP4A are possible hepatic sources of ROS (Weltman et al., 1996) as their crucial 
role in fatty acid production pathways may potentiate the development of 
steatohepatitis if PPAR-a regulation becomes augmented. 
Ip et al., (2003) investigated the role of PPAR-a activation by analysing ROS and lipid 
peroxidation parameters. Fatty livers were induced by administration of the MCD diet 
for 5 weeks in PPAR-a deficient mice and compared against animals fed a control 
diet. Wy-14,643 is an agonist specific for PPAR-a and was administered in addition 
to the MCD to a further group of animals in an attempt to resolve the function of 
PPAR-a in steatohepatitis development. 
The MCD diet induced significant weight loss as was expected from previous 
findings, but was not normalised by the Wy-14,643 agonist. Administration of the 
MCD diet also induced macrovesicular steatosis which was more severe in PPAR-a 
deficient animals. However, Wy-14,643 administration prevented the onset of 
steatohepatitis development in wild-type MCD diet-fed mice through cessation of 
hepatic triglyceride accumulation and even lowered the concentration to levels below 
those observed in control-diet mice. Thus, activation of PPAR-a significantly reduces 
hepatic triglyceride levels by stimulating hepatic fatty acid disposal which 
consequently exhausts the liver of potential material capable of facilitating lipid 
peroxidation reactions. Additionally, CYP2E1 and CYP4A activity was not increased 
in MCD diet-fed PPAR-a deficient mice, whereas MCD diet-fed animals treated with 
Wy-14,643 displayed a huge increase of CYP4A activity despite the absence of 
steatohepatitis. This information suggests that CYP proteins are unlikely to be a main 
source of oxidative stress as originally postulated before the commencement of the 
study. 
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The activation of pathways involved for hepatic fatty acid turnover are regulated in 
part by PPAR-a expression which increases fatty acid uptake and ~-oxidation and is 
therefore regarded as an important trigger in provoking the development of steatosis 
(Fan et al., 1996). However, PPAR-a hepatic expression in humans is significantly 
reduced in comparison to rodents (Hertz et aI., 1998), proposing the possibility of 
alternative mechanisms being in force for control of lipid accumulation and fatty acid 
oxidation. 
Recent work performed by Reifel-Miller et aI., (2005), examined LSN862, an agonist 
of PPAR-a and PPAR-y. Rodent models known to exhibit type II diabetes were 
administered with LSN862 which resulted in a noteworthy reduction of glucose and 
triglyceride levels. The lowering of triglycerides confirms the earlier work of Ip et aI., 
(2003), while the decrease in glucose displayed an improvement in antidiabetic 
efficiency and provides strong evidence for using this dual agonist in future 
therapeutic treatment. 
A further study concentrating on the role of PPAR-a was carried out by Crabb et aI., 
(2004). Here the focus was whether PPAR-a mediated responses are altered in the 
presence of sustained ethanol metabolism. C57BLl6J mice were administered an 
ethanol-rich diet for 4 weeks and sacrificed. The livers were removed and examined 
for fatty oxidation, lipid content and DNA binding of PPAR-a/RXR-a complexes in 
comparison to untreated animals. The findings revealed that ethanol-feeding had 
induced fatty livers coupled with a 4-fold increase in triglycerides. Ethanol had no 
effect on PPAR-a mRNA, although RXR-a mRNA displayed a 20% reduction, 
possibly resulting from increased LPS levels (Uesugi et aI., 2002). Ethanol-fed mice 
also experienced a reduction in expression of genes influenced by PPAR-a, including 
long chain acyl-CoA and acyl-CoA dehydrogenase and mirrors the fact that ~­
oxidation of fatty acids was not induced in these animals. 
The PPAR-a agonist Wy-14,643 was administered to an additional group of ethanol-
fed mice and again proved to lessen the accumulation of fat. The animals receiving 
Wy-14,643 also displayed a significant increase in free fatty acid oxidation and this 
coincided with a massive 50% elevation of PPAR-a expression, despite RXR-a levels 
being unaffected. Overall, functioning of PPAR-a appears to be central in facilitating 
the development of fatty liver enduring the strain of alcohol. Treatment with Wy-
14,643 unblocked the ethanol-induced restriction of PPAR-a which stimulated fatty 
acid removal and consequently averted fatty liver. In conclusion, Wy-14,643 
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promotion of PPAR-a activities should be considered as a possible approach for 
alleviation of liver injury or fibrosis. 
The resultant success achieved from work done with PPARs and relevant agonists in 
rodent models has proved to be critical in identifying components important to fatty 
liver disease development. However, this success has not been repeated in human 
studies and further work is required in adapting the findings in rodents to a positive 
outcome in human treatment (Kersten et a/., 2002). 
3.6 Methionine and Choline Deficient (MCD) Dietary Model 
This section of the thesis has previously examined specialised mouse and rat types 
that have been specifically generated for studying NAFLD and the associated 
outcomes. Information generated from these models has played a significant role in 
understanding the mechanisms involved with the development and progression of 
the disease. However, several groups have been investigating the pathogenesis of 
NAFLD via the effects of a particular diet as opposed to a certain rodent model. 
The MCD diet is deficient of methionine and choline and has been administered to a 
wide variation of animal models to induce the characteristics seen in humans with 
NAFLD. Previous studies fed animals with diets deficient in only choline which had 
partial success as steatosis did develop (Lombardi et aI., 1968) but without the key 
features of inflammation and fibrosis regularly seen in NAFLD. A study carried out by 
Leclercq et a/., (2000), displayed that MCD diet fed animals developed fibrosing 
steatohepatitis, and therefore set the trend for further work. 
Methionine is an amino acid that is also involved in the transfer of methyl groups, 
including the formation of phospholipids. Choline is the trimethyl polar moiety of 
phosphatidylcholine. The synthesis of phosphatidylcholine is extremely important in 
the liver (Nanji, 2004) not only for membrane properties but also for export of 
lipoproteins and has potential to be adversely effected by MCDD. 
Work undertaken by George et a/., (2003) was aimed at studying the cell types and 
products of lipid peroxidation in high-fat, MCD diet-fed rats that acquire 
steatohepatitis and fibrosis. Male Sprague-dawley rats were fed the MCD diet ad 
libitum for up to 17 weeks and compared against a control, supplemented diet. The 
MCD rats displayed a 32% loss in body weight in comparison to the untreated 
animals. Livers from rats administered the MCD diet displayed signs of steatosis by 
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week 2, and by week 12, hepatic fibrosis had developed, prominently in zone 3 
hepatocytes Furthermore, glutathione (GSH) levels were significantly reduced and 
correlated with an increase in TSARS (47-fold by week 17), when compared to the 
control animals. 
The histological features that appear in humans with NAFLD were replicated in the 
MCD diet-fed rats. In addition, the occurrence of lipid peroxidation in hepatocytes 
coupled with the development of liver injury and subsequent fibrosis is consistent 
with the chain of events in humans. This further enhances the theory that lipid 
peroxidation may be a primary stimulator of the liver damage and fibrosis or at least 
could be a strong marker for the process. 
As previously stated, the formation of reactive oxygen species (ROS) is thought to be 
closely connected to the underlying mechanisms of NAFLD development by 
facilitating lipid peroxidation and consequently fibrosis (Yang et a/., 2000). Vitamins C 
and E are antioxidant drugs which are known to react with ROS, intercepting their 
detrimental effects and therefore reduce the levels of oxidative stress and lipid 
peroxidation occurring in the liver. 
A study performed by Oliveria et a/., (2003), investigated the role of these antioxidant 
vitamins with regards to prevention of NAFLD. Wistar rats were administered the 
MCD diet for 4 weeks to induce fatty livers and subjected to daily doses of either 
vitamin C, vitamin E or the vehicle for control animals. The findings from the study 
revealed slight increases of AST and triglyceride levels which were comparable 
across all groups. In addition, the induction of macro- and microvesicular fat was 
noted in rats treated with the vehicle and vitamin E whereas vitamin C treated 
animals did not develop liver steatosis. It is therefore reasonable to claim that vitamin 
C may reduce oxidative stress, thus preventing the development of steatosis and 
associated outcomes. Interestingly, vitamin C is a watersoluble anti-oxidant that is 
involved in the recycling of tocopherol that can protect lipids against oxidation. 
The effect of vitamin C supports the theory of antioxidants being able to defuse the 
outcomes normally brought about by ROS. However, vitamin E did not prevent the 
onset of steatosis, possibly owing to the inability to diminish oxidative stress, 
presumed to occur primarily in an aqueous environment. Further research must be 
undertaken in to evaluate whether anti-oxidant drugs can be therapeutic agents in 
combating the disease. 
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Drug-induced reversal of NAFLD is a further approach which has been taken in an 
attempt at treating the disease. Pentoxifylline (PTX) is regularly used for peripheral 
vascular disease but also displays antioxidant characteristics by reducing ROS (Bhat 
et al., 2001). PTX has also previously shown to decrease TNF-a expression after 
being treated with LPS (Streiter et al., 1988) and to reduce mortality in patients with 
alcoholic hepatitis (Akriviardis et al., 2000). Tumour necrosis factor - a (TNF-a) is 
already established as a major instigator of hepatocyte injury in NAFLD (Kugel mas et 
al., 2003), as are ROS and increased products of lipid peroxidation. 
A study carried out by Koppe et al., (2004) investigated the effects of PTX in mice fed 
the MCD diet to determine whether PTX administration reduced the progression of 
steatohepatitis. Fatty livers were induced in C57BLl6J mice by administrating the 
MCD diet for 2 weeks. The treated animals were subjected to 5mg/ml PTX, 
administered i.p. at a dose of 1 00 1-1 gIg tid, compared to untreated animals receiving 
the vehicle. The observations confirmed the anti-inflammatory effects of PTX as 
serum AL T levels were significantly decreased, as were TNF-a levels, and 
inflammation was less severe in animals treated with PTX compared to untreated. 
However, the PTX treated mice illustrated a higher concentration of hepatic 
triglycerides in accordance with a higher degree of steatosis in comparison to the 
vehicle group. No specific explanation is available but it is possible that sparing FA 
from peroxidation could make more available for esterification to TG. In addition, PTX 
treatment did not make any difference to the weight loss induced by the MCD diet. 
PTX demonstrated its usefulness by impeding the development of steatohepatitis in 
MCD diet-fed mice. An increased level of triglycerides normally results with an 
increase in inflammation, which did not occur in this study and was unexpected. 
Although, a single causative factor could not be identified for development and 
progression of NAFLD, consideration should be given to the use of PTX as a future 
therapeutic agent. Further work is required in assessing the pathogenesis applicable 
to lipid metabolism and the effects of administering PTX in the context of a fatty liver. 
Another factor that is highly regarded as a major contributor in the disease process of 
NAFLD is insulin. The presence of insulin resistance is a common trait in NAFLD and 
is considered a fundamental metabolic abnormality. Despite the exact functions of 
insulin remaining unknown, they are presumed to be considerably influenced by 
TNF-a and free fatty acids (FFA) (Hotamisligi et al., 1999). Research performed by 
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Rinella et al., (2004), attempted to uncover the role of insulin in steatohepatitis, 
induced by the MCD diet. 
Male FVB/NJ mice were fed the MCD diet for 10 days and 28 days in addition to a 
control group administered a methionine and choline supplemented diet. 
Steatohepatitis and elevated AL T levels were brought about by MCD diet 
administration regardless of the duration of feeding. Insulin sensitivity was assessed 
by insulin tolerance testing (ITT) and glucose tolerance testing (GTT) and revealed 
that MCD diet-fed mice displayed no indication of insulin resistance and was 
comparable with the controls. 
Although evidence exists for a strong association between NAFLD and insulin 
resistance, a definitive relationship has yet to be proven. The experiment conducted 
by Rinella et al., (2004) indicates that insulin resistance does not appear to feature in 
animals developing NAFLD when fed the MCD diet. Insulin resistance may not be as 
critical to NAFLD development as previously thought but the role of insulin resistance 
in the complex pathogenesis of the disease may be to provide a metabolic stress. 
A further probable contributor to NAFLD development may be cytochrome P450 2E 1 
(CYP2E1), which is believed to initiate lipid peroxidation through the production of 
oxidative stress (Ueber et aI., 1997). A study embarked on by Leclercq et aI., (2000), 
was aimed at ascertaining the role of hepatic CYP2E1 in the development of 
steatohepatitis. Female C57BL6/J mice were fed the MCD diet for 10 weeks to 
induce hepatic steatosis and were compared to animals receiving the control diet for 
the same period. The purpose of this was firstly to determine if CYP2E1 expression 
was affected by administration of the MCD diet and secondly to confirm lipid 
peroxidation in MCD diet- induced steatohepatitis. In addition to significant body 
weight loss and increased AL T levels, as was expected in MCD diet-fed mice, the 
findings indicated an increase in CYP2E1 enzyme activity when compared to the 
control group. Furthermore, lipid peroxidation was immensely enhanced in MCD diet-
fed animals as verified by the rise in TBARs and 100-fold increase in lipid peroxides. 
These results imply that increased CYP2E1 activity may assist in the accumulation of 
lipid peroxidation products. With this hypothesis, the next logical step was to feed the 
MCD diet to CYP2E1 deficient mice and their non-deficient heterozygous littermates 
as a comparison. Hepatic steatosis and necroinflammation were induced by the MCD 
diet in both sets of mice as expected, but, the CYP2E1 deficient animals displayed a 
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larger degree of fat accumulation which corresponded to elevated AL T levels and a 
major increase of lipid peroxides in comparison to the control group. 
The data provided presents strong evidence that the enzymatic action of CYP2E1 is 
involved in the development of NAFLD. This enzyme is not crucial for the instigation 
of NAFLD but may influence the course of the disease by modulating the flux of TG 
and permitting increases in lipid peroxidation. It is concluded that further work is 
necessary to define the exact properties of CYP2E1 within the MCD model aswell as 
the mechanisms promoting the development and progression of NAFLD and the 
associated outcomes. 
The role of osteopontin (OPN) as a mediator of steatohepatitis development has also 
been investigated. OPN is a Th1 cytokine which is believed to be involved in the 
inflammatory process of fibrotic diseases such as atherosclerosis (Chiba et al., 
2002). The synthesis and secretion of this cytokine occurs in numerous immune cells 
and is considered to play an important role in the recruitment of macrophages during 
inflammation (Mazzali et al., 2002). The definitive role of OPN in liver diseases is yet 
to be established, but a study performed by Sahai et al., (2004) attempted to identify 
the function of this cytokine from an NAFLD perspective. Female AlJ mice were used 
out of a selection of 8 different strains as these were found to be more sensitive to 
the effects of the MCD diet. The diet was administered for up to 12 weeks to induce 
steatohepatitis and other complications surrounding the disease before comparing 
these animals to that receiving a control diet. The histological examination results 
revealed the presence of macrovesicular steatosis and progressive hepatic portal 
inflammation in MCD diet-fed mice. The biochemical analysis confirmed these 
findings which revealed an increase in CYP2E 1 enzyme activity and AL T levels as 
previously confirmed. Additionally, the concentrations of triglycerides and TSARS 
were also significantly enhanced, as was TNF-a, in comparison to the controls up to 
12 weeks. The elevated level of CYP2E1 is a probable cause of increased lipid 
peroxidation but consideration should be given to the increase in TSARS merely 
reflecting an increase in TG. 
These results are again suggestive of elevated CYP2E1 activity being implicated in 
the production of lipid peroxidation and oxidative stress. With the liver histology and 
biochemistry results further outlining the effects of the MCD diet, the subsequent part 
of the study was to examine the effects of OPN within the MCD diet framework. OPN 
knockout mice were fed the MCD diet and compared to the wild type littermates who 
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were also administered the diet. The animals deficient in OPN displayed a decrease 
in liver damage and fibrosis. Furthermore, TNF-a expression was also lower in mice 
lacking the Th1 cytokine and lipid peroxidation and oxidative stress were reduced as 
well. OPN expression or at least macrophage activation, must not be ignored in 
defining the underlying mechanisms of NAFLD as it is regarded as an important 
signal messenger in the development of steatohepatitis. 
Despite the relevance of findings generated from administration of the MCD diet, this 
approach stili receives much criticism as it induces significant weight loss and does 
not involve insulin resistance in contrast to humans who gain mass and develop 
insulin resistance. Nevertheless many important revelations have appeared from 
using the MCD diet and it may remain a useful tool to evaluate the development or 
treatment of NAFLD. 
3.7 Lip 0 dystrophic Mouse Model 
Lipodystrophic mice strains have genetic defects that affect the development and/or 
function of adipose tissue, leading to lipoatrophy or adipose tissue excess. Since 
adipose tissue is primarily responsible for leptin production some of these models are 
leptin-deficient or deficient for leptin receptors (Koteish and Diehl, 2002). Phenotypic 
characteristics displayed in the leptin-deficient ob/ob mouse model such as insulin 
resistance, elevated TNF-a levels and the occurrence of fatty liver disease are 
concordant with human NAFLD (Reitman et al., 1999). 
Lipodystrophic model complication of lipoatrophy is the over-expression of sterol 
regulatory element binding protein-1 (SREBP-1) (Shimano ef al., 1996). 
Hydroxymethyl glutaryl coenzyme A (HMG CoA), low density lipoprotein (LDL)-
receptor and acetyl CoA carboxylase are genes heavily involved in fatty acid and 
cholesterol synthesis and are controlled by the important transcriptional regulator 
SREBP-1 (Koteish and Diehl, 2002). Resultantly, the enhanced expression of 
SREBP-1 can facilitate hepatic steatosis and increased AL T levels (Reitman ef al., 
1999). 
The means by which lipid metabolism is disrupted and cytokine functioning is altered 
in this model remain to be clearly defined, but it is hypothesised that they are very 
similar to the pathogenic mechanisms in ab/ab mice which are also leptin-deficient. 
However, an important feature of the lipoatrophic mouse model is that the 
complication of obesity does not arise. The fact that progressive NAFLD and NASH 
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occur in lean individuals is truly reflected by the presence of fatty liver disease in 
these non-obese mice and stresses the importance of these models in understanding 
the pathogenic factors involved. 
3.8 Leptin Deficient Mouse Model 
The existence of leptin, first discovered in 1994, created a wealth of investigative 
work to identify the key processes of energy metabolism (Zhang et al., 1994). Leptin 
is a hormone product of white adipose tissue and appears primarily responsible for 
suppression of appetite and raised expenditure of energy (Campfield et aI., 1996). 
Leptin is deficient in ob/ob mice, aptly named because of a genetic deficiency in the 
ob gene which results in these rodents becoming hyperphagic and severely obese. 
Most importantly, these rodents develop fatty livers (Nanji et aI., 2004). Leptin has a 
significant role in controlling weight levels, and acts in a preventative measure 
against obesity. Recent research has also shown that leptin plays a crucial role in 
alterations of appetite and the relaying of information on fat reserves by orchestrating 
the storage of body fat in adipocytes (Unger, 2002). 
Ogus et al., (2003) examined leptin-related functions in recently developed 
transgenic mice (LepTg). The genetic nature of LepTg mice prompts the over 
production of leptin resulting in these animals becoming hyperleptinaemic. The 
animals were administered a high-fat diet for 20 weeks to induce obesity and to 
determine if over-expressed leptin aided the responses of the liver to combat the 
onset of steatohepatitis. The findings from the study established that lean littermates 
remain in their morphologic state because of an increased production of leptin on a 
normal control diet. However, the subjection of the LepTg model to a high-fat diet 
resulted in near immediate development of obesity and suggests that exposure to 
high fat diets facilitates profuse production of adipose tissue which becomes 
differentiated causing accumulation of hepatic fat in the organism, including the 
adipose tissue and liver. 
Hyperleptinaemia or partial lipodystrophy is an unusual condition characterised by an 
insufficiency of adipose tissue and a concerning inadequate supply of leptin 
(Peterson et aI., 2002). As a result, the liver becomes fatty and develops NASH 
through accumulation of triglycerides. Javor et al., (2005) explored the possibility of 
reversing the progressive nature of fatty liver in lipodystrophic patients by leptin 
replacement therapy. The study contained 26 patients with known lipodystrophy but 
only 10 met the criteria for treatment. The patients received twice daily injections of 
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recombinant methionyl human leptin (r-metHuLeptin) for a mean duration of 6.6 
months. Liver biopsies were obtained before and after intervention to evaluate the 
effects of therapy. Considerable reductions in transaminases, triglyceride levels and 
glucose concentrations were noted as well as lowered fat content. Leptin treatment 
thus ameliorated NASH. Despite the encouraging results with r-metHuLeptin, raised 
AL T and AST levels were not found in all test subjects and it is not known if the group 
of patients suffering from lipodystrophy are truly representative of NASH patients. 
The true action of leptin is not yet fully understood and additional work is required to 
investigate pathways relevant to fatty liver development, although Lee et aI., (2002) 
has shown leptin to increase PPAR-a expression which has already been described 
as a possible modulator of fat accumulation. 
Angiopoietin-like protein 3 (ANGPTL3) is a liver-specific secretory product. It was 
recently reported to considerably enhance plasma triglyceride concentrations as a 
result of inhibiting free fatty acid (FFA) and lipoprotein lipase (LPL) in humans and 
mice (Koishi et al., 2002). In an attempt to further investigate leptin function, a study 
undertaken by Shimamura et aI., (2004) was aimed at trying to identify leptin as a 
responsible regulator of (ANGPTL3). Obese, leptin-deficient (ob/ob) mice were 
analysed and were found to exhibit increased values of ANGPTL3 in comparison to 
the control group. The elevations in ANGPL T3 were accompanied with rises in 
triglycerides and FFA. Additionally, in vitro, leptin and insulin presented the ability to 
decrease ANGPL T3 expression in hepatocytes. These findings indicate that obesity 
is correlated with a deficiency in leptin and elevated triglyceride levels and 
corroborate previous work of Unger et aI., (2002). Leptin does not appear solely 
responsible for regulation of ANGPTL3 as insulin also clearly displays an effect. 
Variability of ANGPTL3 mRNA expression may influence lipid metabolism and thus 
contribute to the pathogenesis of the disease. 
A study performed by Angulo et al., (2004), examined the effects of leptin in relation 
to liver fibrosis in human NAFLD. A total of 88 patients with liver biopsy proven 
NAFLD were enrolled in the study to determine the relationship between levels of 
leptin and (progression to) fibrosis of the liver. The experimental liver samples were 
graded for fibrosis. The advance of fibrosis was significantly correlated with increases 
in leptin concentration. However, patients with more severe fibrosis were also shown 
to be older, more insulin resistant and more commonly diabetic. Once these 
variabilities were accounted for, no direct relationship could be formed with leptin 
concentration and degree of fibrosis. It is therefore likely that increases in leptin 
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levels are representative of other confounding factors such as age, diabetic state and 
insulin resistance as opposed to stage of fibrosis, although additional work is 
required to fully define the role of leptin. 
The evidence to date is suggestive of leptin being an enhancement factor for 
progression of fatty liver disease. TNF-a is also believed to be a causative agent in 
NASH patients and recent work performed by Shen et a/., (2005) hypothesised that a 
further function of leptin was to increase TNF-a production. Observations in male 
zucker (fa/fa) rats revealed that leptin increases TNF-a in isolated kupffer cells in a 
dose-dependent manner, but only in the presence of lipopolysaacharide (LPS). 
Kupffer cells are the primary source of hepatic TNF-a when under LPS inducement 
(Ulevitch and Tobias, 1995) and because leptin administration boosts the production, 
it is resultantly regarded as a potential aggravator of the inflammatory response. 
3.9 Fatty Liver Shionogi (FLS) Mouse Model 
The FLS model is currently also employed to study fatty liver disease. FLS mice have 
been derived from inbreeding and develop spontaneous fatty liver without obesity, 
diabetes or hyperphagia (Soga et a/., 1999). At birth, this particular model exhibits an 
abnormal elevation of triglyceride levels and by the age of 15 weeks, macrovesicular 
fat (large lipid droplets) occupy the hepatocytes, which is accompanied by hepatic 
cell disorder (Soga et a/., 2003). Further evidence of liver injury was confirmed by 
elevated serum alanine aminotransferase (AL T) levels. 
From their fatty livers, the FLS mice develop steatohepatitis and a high incidence of 
these animals (especially males) progress to develop tumours, including 
hepatocellular adenoma (HCA) and carcinoma (HCC). Hepatocarcinogenesis was 
not detected in the non-obese sister strain dd Shionogi (OS) and supports the theory 
that the tumours observed in the FLS mice are a consequence of chronic fatty liver 
(Soga et a/., 2003). 
Although obesity is normally a major factor contributing to the occurrence of NASH in 
humans, fatty liver also appears in non-obese individuals as with the FLS mice. 
The FLS model could prove to be beneficial in improving our understanding the 
occurrence of hepatocarcinogenesis and NASH, although the exact mechanisms 
involved are unclear at present. Further studies are required in the pathogenesis of 
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this model as despite the appearance of liver tumours, liver cirrhosis was not evident 
in any of the animals and is normally a key finding in a NASH patient. 
3.10 Zucker (fa/fa) Rat Models 
Zucker fa/fa rats are similar to several other models being examined for NAFLD as 
they also possess the characteristics of obesity, leptin receptor deficiency, type II 
diabetes, hyperinsulinaemia and hepatic steatosis (Chua et a/., 1996). A study 
performed by Nagao (2004) used the Zucker fa/fa rats as a dietary model by feeding 
them conjugated linoleic acid (CLA) for 8 weeks compared with control fed rats. CLA 
is a mixture of positional and geometric isomers of linoleic acid and is believed to 
alleviate liver injury through increased production of adiponectin (Nagao et a/., 2004). 
Adiponectin is present in abundance in adipose tissue in rodents and humans. Its 
release under the influence of CLA has been shown to improve insulin action in vitro 
and in vivo, therefore indicating that adiponectin may playa protective role against 
insulin resistance which is one of the first pathological processes in the development 
of NAFLD (Yamauchi et aI., 2001). 
The findings in the study carried out by Nagao (2004) revealed that hepatic 
triglyceride (TG) levels and hepatic injury markers AL T and AST were significantly 
reduced in the CLA-fed animals in comparison with the controls. Furthermore, the 
mRNA expression of TNF-a (an inflammatory cytokine) was also suppressed when 
compared to the control group. It is therefore proposed that enhanced production of 
adiponectin may alleviate the development and progression of NAFLD in CLA-fed 
Zucker fa/fa rats. 
Another study that was carried out using Zucker fa/fa rats was undertaken by Yang 
(1997) who proposed that the process of steatohepatitis development is accelerated 
when tile animals are exposed to low doses of lipopolysaccharide (LPS). The release 
of several cytokines, (including IL-10, IL-12 and IFNy), from macrophages and 
Kupffer cells is promoted by LPS stimulation (Tracey et aI., 1993). Once unleashed, 
the cytokines proceed to stimulate the biological activity of TNF-a which has a 
significant influence on endotoxin liver injury. The observations from the study 
revealed obese fa/fa rats had a marked accumulation of liver injury markers AST and 
AL T in contrast to their lean littermates when subjected to LPS exposure. In addition, 
histological examination revealed all surviving obese fa/fa rats to have significantly 
developed steatohepatitis in comparison to the non-obese controls (Yang et a/., 
1997). This evidence displays that LPS and/or TNF-a stimulated endotoxins may play 
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a vital role in contributing to progressive liver damage in obese individuals which 
could have important clinical consequences. 
An additional strain of fa/fa Zucker rats currently used to study metabolic disorders is 
the stroke-prone spontaneously hypertensive rat (SHRSP). SHRSP fatty (fa/fa) rats 
are derived by crossing a segment of the mutant leptin receptor gene from Zucker 
fatty (fa/fa) rats with the genetic background of SHRSP/lzm rats (Yamamoto et aI., 
2004). The new animal model develops obesity and hypertension simultaneously as 
well as displaying significantly elevated levels of total cholesterol, triglycerides, 
glucose and insulin in comparison with the SHRSP/lzm control rats. SHRSP fatty 
(fa/fa) rats are distinct as they are not only associated with metabolic abnormalities 
but also encounter cardiovascular disease. 
Overall, the fa/fa model along with the subsequent strains, exhibit several key 
characteristics relevant for studying NAFLD and other associated conditions. 
However further work is required to determine the pathological processes linking 
obesity and liver disease. 
3.11 Acyl-CoA Oxidase (AOX) Mouse Model 
The AOX mouse model is deficient of acyl-CoA oxidase (AOX) and was generated by 
inactivation of the AOX encoding gene. In the normal liver, fatty acids are oxidised by 
mitochondria and peroxisomes via j3-oxidation after activation to acyl-CoA The acyl-
CoA that remain unmetabolised in the absence of AOX may serve as a trigger for 
uncontrolled peroxisome propagation (Hashimoto et aI., 1999) as these appear to be 
powerful agonists for the peroxisomal proliferator activator receptor x. 
A study performed by Fan (1998), investigated the AOX mouse model and produced 
some interesting observations. The livers of mice deficient of AOX displayed severe 
microvesicular steatosis in liver parenchymal cells and by the age of 15 months, 
hepatic carcinomas had appeared. Acyl-CoA enzymes, which are abnormally 
regulated in AOX deficient mice, are believed to sustain proliferation of peroxisomes 
by acting as ligands for peroxisome proliferator-activated receptors (PPARs). The 
continued induction of these receptors by acyl-CoA enzymes may be partially 
responsible for the resultant tumour development (Fan et al., 1998). 
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The findings provide sufficient evidence to suggest that AOX plays a significant role 
in hepatic lipid metabolism and may contribute to developing fatty liver, although 
further studies are required to establish the true pathogenesis. 
3.12 Human Studies 
As discussed, many animal models have been tried and tested in order to generate a 
model suitable for studying NAFLD. The various experimental strains being 
investigated are susceptible to disease development because genetic factors and 
expression genes are purposely manipulated to manifest the adverse outcomes of 
NAFLD (Koteish et al., 2002). Although the arising pathology in rodent models is near 
identical to that in humans, caution should be taken when interpreting the findings 
because of the species difference which may result in alternative biological pathways 
being engaged. 
Since research is ultimately directed at amelioration therapy or complete elimination 
of NAFLD in humans, the models discussed above must therefore serve as ideal test 
models. Additional complications arise in humans, including variation between 
patients and the practicality problems of sampling; this explains the efforts consumed 
in animal model experimentation. Many different components have been recognized 
in work carried out in animal models which has been invaluable in understanding 
development and progression of liver disease. However, various human studies have 
also been undertaken in an attempt to eliminate species variability and identify an 
ever elusive single causative factor. 
Obesity is a significant feature being constantly associated with fatty liver due to links 
with surrounding complications such as diabetes, dyslipidaemia and hypertension 
(Kissebah et aI., 1994). Appearance of obesity and the consequent escalation of 
these correlated outcomes have been collectively labelled as metabolic syndrome X 
in the context of a fatty liver. 
Work orchestrated by Marceau et al., (1999), examined metabolic syndrome X using 
580 patients over a 9 year period. Despite the varied range of disease-associated 
complications within the group, severe obesity remained a central feature. The study 
including males and females presented a mean age of 36 years, 95% had endured 
routine liver biopsies and no patient had any history of hepatitis, nor was it clinically 
suspected. 
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The study revealed a significant association between the degree of fat present in liver 
samples and the components of metabolic syndrome X; fat distribution, impaired 
glucose tolerance, hypertension and dislipidaemia. The results indicated a close link 
between elevated AST and AL T levels and the existence of steatosis, which was 
present in 86% of patients. In addition, the presence of diabetes was recorded as the 
statistically strongest predictor of cirrhosis (P<0.001), although the occurrence and 
subsequent progression of steatosis was also a reliable indicator. Furthermore, a 
strong correlation existed between fasting blood sugar, steatosis and the 
development of fibrosis. Unfortunately, a significant relationship was not established 
between any of the variables (including steatosis and fibrosis) and the presence of 
inflammation. It is therefore hypothesised that steatosis resulting from metabolic 
syndrome X related obesity is a separate assemblage of reactions to that taking 
place in non-alcoholic steatohepatitis (Bacon et al., 1994). 
The pathogenesis of obesity and the surrounding associated effects are difficult to 
separate from the outcomes of fatty liver. The exact involvement of insulin, target 
cytokines and leptin are unclear, but overlapping pathways must exist due to major 
similarities. The variables of metabolic syndrome X contribute independently as 
predictors of fatty liver mechanisms, but their collective label of metabolic syndrome 
X allows the effects of fatty liver disease to be investigated by outlining the risk 
factors involved. 
In addition to obesity, alcohol is a further extension to the growing list of reasons to 
which fatty liver can be attributed. Further investigative work carried out by 
Bellentani et a/. , (2000) examined the prevalence of obesity, alcohol and other risk 
factors involved in developing hepatic steatosis. Two hundred and fifty-seven people, 
19-70 years of age, from Northern Italy partook in the study which comprised 4 
different groups; controls, obese, heavy-drinkers and obese heavy-drinkers. 
Steatosis was present in 58.3% of the cohort with raised levels of AL T, y-
glutamyltransferase and plasma triglycerides acting as positive indicators. Also 
detected by comparison with the controls, steatosis was found to be 2.8-fold more 
common in heavy drinkers whereas a 4.6-fold increase of development was 
discovered in the obese group. The group consisting of overweight heavy drinkers 
had a 5.8-fold increase when compared to the controls. Thus, steatosis appears to 
be more closely associated with obesity than excess alcohol intake, but obese 
heavy-drinkers are almost guaranteed to develop some form of steatosis. An 
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immediate reduction in caloric and alcohol intake is recommended in over-weight, 
high-alcohol consumption patients to decrease the chance of fibrosis and to lessen 
the effects of fatty liver. 
There are many complications surrounding fatty liver disease and they are due to the 
multi-factorial pathways including steps acting as initiators and modulators of 
progression. Markers that can detect the extent of liver malfunction are of vital 
importance in determining if a patient has a fatty liver. Sorrentino et aI., (2004) 
studied the liver enzymatic activity in plasma from 58 patients known to exhibit 
varying degrees of NASH and compared these to a control group known to display 
abnormal liver enzymes. The observations of the study revealed the severity of 
steatosis to be similar between NASH patients and those with irregular metabolism 
but hepatic mallory ballooning and glycogenated-nuclei were more prominent in 
patients presented with NASH. Although, age, presence of diabetes and period of 
being obese were typically linked with fatty liver development and was subsequently 
shown to significantly enhance the severity of liver damage independent of abnormal 
enzymatic activity. Despite the inability of liver enzymes to act in the capacity as a 
marker of NASH detection, the presence of ballooning degeneration may be 
essential to progression of fibrosis. 
Additional human work undertaken by Seki et al., (2002) is of particular interest as it 
describes lipid peroxidation and oxidative DNA damage in NAFLD patients. 4-
hydroxy-2'-nonenal (HNE) is a key metabolite involved in lipid peroxidation and is 
also regarded as a very reliable marker for this process (Esterbauer et al., 1992). 8-
hydroxydeoxyguanosine (8-0HdG) is also believed to be a reliable marker (Kasai et 
a/., 1997), but in the context of oxidative stress as this compound is predominantly 
produced by free radicals (Shibutani et al., 1991). The research that was carried out 
concentrated on the hepatic expression of these biomarkers to determine lipid 
peroxidation and oxidative damage. 
The study was conducted using fatty liver samples from 40 patients. Non-alcoholic 
fatty liver disease (NAFLD) was present in 23 patients whereas non-alcohol 
steatohepatitis (NASH) had developed in the remaining 17 patients. The criteria for 
inclusion in the study were macrovesicular steatosis without necro-inflammation in 
the first group of 23 patients and the presence of macrovesicular steatosis without 
hepatocyte necrosis for the remainder. Samples from 7 histologically normal livers 
were used as a control group. 
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The study revealed a high expression of HNE adducts in hepatocyte cytoplasm in 
both sets of patients with fatty livers, although slightly higher levels were detected in 
the NASH group by comparison. Despite the differences, these elevated levels are 
still strongly indicative of lipid peroxidation. In addition, HNE may also provide a 
source capable of activating hepatic stellate celis (HSC), these are deemed 
precursors for collagen type 1 production and could therefore have another 
significant part in developing fibrogenesis of the liver (Friedman, 1993). 
Another interesting observation of the study revealed 8-0HdG expression in only 
2/23 NAFLD patients whereas 11/17 patients with NASH were found to exhibit 8-
OHdG activity, mainly in hepatocytes. The expression of 8-0HdG is representative 
of oxidative DNA damage as it causes mispairing which can result in the occurrence 
of mutagenic and carcinogenic oxidative modification (Kasai et al., 1991). Although 
hepatocarcinogenesis has been reported in human NASH (Welltman et al., 1998), no 
defining link has been established between oxidative stress and hepatocellular 
carcinoma although the possibility still exists. 
To concur, lipid peroxidation and oxidative damage are again closely associated with 
the clinical outcomes of fatty liver disease, but the varied pathological pathways 
involved in NASH and NAFLD still need to be accurately identified. 
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3.13 Overview of Various Rodent Models In NAFLD Research 
3.13.1 Introduction 
As stated previously, research undertaken in a wide array of rodent models has been 
invaluable in gaining a better understanding of the pathogenesis of NAFLD and the 
surrounding complications. The employment of rodent models to investigate the 
effects of NAFLD is not always ideal as it is widely documented that this disease is 
multifactorial and therefore many of the biological systems involved are not identical 
to those exhibited in humans. As a result, the facilitation and development of fatty 
liver and fibrosis in humans may be induced by alternative pathway in rodents and 
vice versa. For example, PPAR-a is present in large quantities in rodents but levels 
are considerably lower in humans who also do not experience peroxisome 
proliferation in response to treatment with fibrates (Crabb et a/., (2004). Nonetheless, 
the information gained from rodent work remains the key at attempts to manage and 
ameliorate the wide spectrum of effects of NAFLD and NASH. 
The data presented in the following tables further illustrates the importance of 
information acquired from studying various rodent models in the context of NAFLD 
and NASH. Some of the findings have already been discussed, but the additional 
information allows a more detailed comparison between the different models. The 
tables display many fields of omitted data which are parameters that were not 
recorded for the respective studies. The omissions reveal that too many different 
potential factors are involved in development and progression of the disease and as 
a result not all these parameters can be investigated in every study. The lack of a 
collective research protocol and difficulty in cross-referencing study data confirms the 
complexity of the disease and problem in finding a single causative factor. 
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3.13.2 (Ob/ob) Mouse Model 
Takahashietal, (2004) (Ob/ob) Mice 




Duration of Treatment at 4 day 
intervals 
Sex Female Female 
------.--.------.------10-------- -.~-----
Age 12 wks 12 wks 12 wks 
--.--~~-~"~--.--~~-~~~.~~~------~~-.-.----- --~-~-t-'-------l 
No, of Animals 4 4 4 
;--------- .. ------------- --~--
LepOb/Db 
FR 





Terminal Body Mass (g) 22.8 ± 0.2 21.0 ± 0.2" 21.8 ± 0.1" 
Liver Mass (g) 
---~__I-----~-.~. .-" .--.-----~~- -f---.------.-........ --.j----.. --.--------.-
Liver Mass I Body Mass x 
3.6 ± 0.2 3.3 ± 0.3 3.3 ± 0.1" 
100% .......... -.---.... -.~-.. ---....... -.. -.----.. -----~~--- .-----.--\---.-.-... --+--..... -.--.-.--.------1 
Conjugated Dienes 
___________ (1J_Q29.Hg, Ii~er)_. __ _ 
LOOH 
__ (rlm ~~'=-Q9Hi~: liv~EL __ . ________ +_~ _____ _!_-------.+ 
TTBARS (nmol/g,liver) 
. ..-- .. -----.~.--.. --... ----------.--I----.. ---- ... -
Cholesterol BO.5 ± 2* 137 ± 5$ 82.3 ± 1 * 125 ± 5$ 
____ .. ___ .. ____ (1!'9[d IL_ ...... ___ ._ _ __ .... _.____ _ __ ~ .. ____ .~. ___ ~--_.------+- .............. ~-... ----_-I 
Triglycerides 78.2 ± 4* 155 ± 6$ 
._ .. ____LI"D9!fL_U'!~rJ.___ _ _____ _ 95.4 ± 7* 
. ____ ~_:~~ei~~~~)~t~tion __ . __ ~_3_ ± 6* . 3~2_= 22$ __ ~_:!_=_~_~ ____ ...... __ .~~_~_=_~_~_ .. 
CYP2E1 Conc. 
__ ___ ~. __ @i.~Ltr:~ry_~~!~l ____ . ___ ------- t-.-.-------.--j-.---.. -------~f-..... ------.---.. -j 
AST 
___ . ___ .{l!!}l_. ___ +_. ____ . ____ _ 
ALT 
13.2 ± 1* 87.5 ± 4$ 12.B ± 1* 
~.... ~~~~~~L.~ ____ 1.1 ± 0.2* 24.3 ± 5$ 1.82 ± 0.2* 1B.4 ± 2$ 
Histology I Additional Observations; 
Arninosterol 1436 administration resulted in decreased bwt, inhibited food intake, 
lowered circulatory lipids, reversed hepatic steatosis, decreased glucose and 
normalized ALT. Adiponectin and insulin levels were also elevated in response to 
• 1436 which resulted in inhibition of TG synthesis and increased fatty acid 
• oxidation. Treatment of 1436 is recommended to increase insulin sensitivity and 
lI!'ClY.~\I~reverse steatosis to a cert.9j!!..~)(!t:nt \Allt~ll()QQ care a!!..<LI!'_C!D_~_~.I!'_I3_r:!t:.__ 
"P<O.01 vs. vehicle. FR = Food Restricted 
'P<O.001 vs. vehicle treated LepOblOb mice. $P<O.001 vs. wild-type. FR = Food Restricted 
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3.13.2 (Ob/ob) Mouse Model (continued) 
Memon et al., (2000) (Ob/ob) Mice 
-----.. ------.-.. ~ .. + .. -..... ---.~~ --------·-------,··--····---··-----i 
(ob/wt) (ob/wt) 
Control Tro 




Duration of Treatment 10 days 10 days 10 days 10 days 
Sex Male Male Male Male 
Age 5-10 wks 5-10 wks 5-10 wks 5-10 wks 
No. of Animals 
Terminal Body Mass (g) 
Liver Mass (g) 















1 ___ . __ ~((I~_moll/g~.J_liv. __ e~r) _____ + _______ _+------_+-___ _+--- .... --.--




Cholesterol 1_96 i 0.1 1.99 ± 0.1 4.45 ± 0.2 4.12 ± 0.2 
** (mg/dl) 
1·-- -.-.--.---.--'---"'----'---... --.. - .. ----+--.----.-.-.----- ·-······-----·i---·-------i-·---------···-
Triglycerides 1.2 i 0.06 0.1 i 0.02 1.5 i 0.06 0.7 ± 0.03 
(mg/g. liver) * /I ** 
f--- --............. -............. ---.---.----. . ....... - .. -.---.---r----~- ------·-·1··-·--·----·-------1 
Glucose Concentration 8.04 i 0.3 7.77 i 0.4 20.6 i 1.4 11.0 ± 0.9 
(mg/dl) /I ** 
--.-... ---.• -----.. -----.--.• ----. -.--f.-------... --- ·---------f--·----------····f···------·---j 
CYP2E1 Conc. 
_______ .@rbi:tr§l!Y.J:l!li~ ______ .---~---- -----~---.. -+---.-----.-----i---.--.-----------1 
AST 36.3 i 4.3 34.1 i 3.8 88.0 ± 8.9 74.8 i 9.4 
(U/I) ** 
f------------.-.----------t------.-- --.. --.-- .. -
ALT 
(Uti) 
44_8 ± 3.1 36.4 i 2.7 99.9 i 8.0 101.4 ± 9.9 
** 
--·---·--·-·-c==~·:_-----+-- -------j------·-···---·-I--~~-_:-==-t-__=_=__·__:__:···:~-I 
se~:o~iA 1.2 i 0.07 1.2 i 0.05 1.7 i/\ 0.07 1.0 :*0.05 
__ ._. ____ . __ . __ {r ___ L_~ ___ L__.. ____ • __ • _____ • ____ ~ _____ •.. _ •..•.. ~. 
Histology I Additional Observations; 
Troglitazone (Tro) is ligand for activating PPAR-a and -v. 
TG and FFA were lowered following Tro admin but had no effect on ALT and 
AST levels in both lean and obese mice. PPAR-y activators (stimulated by 
Tro) induced expression of aP2, FAT/CD36 and UCP2 which is believed to 
have contributed to the significant decrease of total hepatic content in ob/ob 
mice. PPAR activation therefore improves lipid utilization in obese diabetic 
_!1lJ.c;~_a.r'I(:tR.r_~vides mechanism wherel2Y_~ru_I'!1_lipid leve~c;_~r:!_~~gecreased. 
*P<O.01 relative to tile control 
**P<O.001 relative to the control, AP<O.001 relative to ob/ob, (Tro) = Troglitazone, 
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3.13.3 TNFMR1 Knockout Mouse Model 
Yin et al., (1999) TNF-R1 (knockout) Mice 
._----_. __ ._--_._. __ .... _---_._- .. _-_ .. _---- --_._--_ . ,-----,------
Treatment / Phenotype 







Control ------- --_ .... __ ._.--/-------





--.-.. ---.------.. --------- -----.. --.-.- .----.. --.-- .------f---.. ---.--.-... 
Sex Male Male Male Male 
Age 
.---------t------- .... -----.--- .. -
1\10. of Animals 6·7 6-7 6-7 6·7 
----_.+-----1 .. _-_._ .... _._-
Terminal Body Mass (g) 27.5 ± 0.2 26.8 ± 0.3 26.0 ± 1.5 24.7 ± 0.5 
_ .._ ... _-_._. __ ._-----_._-_.-._--_._ .. _._ .. - -_ .. - ..... _ .. _ ... _._--- _._._-----_._--_ ..• ---'--'-'-'" 
Liver Mass (g) 
-_._-----------_ .. - --"-'-'-"'-'-' ._._._ .. _---_ .. _----_.- ._-_ ..... _-_ .. _ .. _--
Liver Mass / Body Mass x 
100% 
5.5 ± 0.2 8.3 ± 0.8* 5.0 ± 0.7 6.7 ± 0.3 
.... - .. _ .... _ .. _--_._----_._----_._.- --_._--- ._. __ .. _---_.- -_._-_._--_ .. _-------._._. 
Conjugated Dienes 
(I..lmol/g.liver) - - - -_ .. _ ... __ ._---_._ ... _------- -"- ... _._ ...... __ .. -_._-_ ... _._----_ .. _-- ----_ .. __ .. __ .. _ .. 
LOOH 
_____ ._0_r:!1~!J_:QQ_~j.9Ji~e..!l. ____ . ___ .. _._._ .. _ _ ___________ .... _____ . 
TTBARS (nmol/g.liver) 
_ .._- _ ..__ ._ ... _ ...... _ .... _ .. _ .. - ._ ... _._---- -----_._---- ._---------_._._----_._-
Cholesterol 
(mg/dl) 
._._-_ .. _._. __ ... _ .. _._ .... _-_ .... _-_._._-----_._j-- ._--_.- _ .. _- .-.. _----- ------ --_._-_._-_. 
Triglycerides 
__________ J mg~9,--· _Iiv_e....,r)'--__ . ._._._ .. __ . __ .... _ ... _. ___ ._._-----j-_____ . ____ _ 
Glucose Concentration 
.. _. _______ .J.r!1g/dl) --- ._----- .. ---... - .. --- --------- -------_ .. _ ... 
CYP2E1 Conc. 
__ ... ___ ~r:.~11r~.l:l.1] it~) _____ -_._ .... _~ .-.- .. -.. - .... _ .. _ ..... _._._ ... _1--__ . __ ._ .. _ _ .. _._ .......... __ 
AST 
(U/I) 
-~---.-~-.--~--.-------.-----.---- .----- .--.-----. f-----.-.--.-. ---.-.. ------
ALT 30 ± 4 90 ± 6* 42 ± 10 38 ± 9 
(U/I) .--- ----.. -... -- -----------1----_.+-----_._-_ .. __ .... 
Pathology Score 0.0 ± 0.0 0.0 ± 0.0 5.5 ± 0.6 0.8 ± 0.4* 
______ . ___ .. ..L.. ___ .___ ._ .. __ . ______ _ 
Histology / Additional Findings; 
No fatty accumulation was present in control mice, wtlwt or TNF-R1 but 4 
weeks of ethanol administration caused steatosis in 13% of midzonal area in 
wtlwt animals but TNF-R1 displayed less steatosis (3.9%; p < 0.001). 
TNF-a is proinflammatory cytokine and its absence in knockout mice results in 
only moderate fatty accumulation with no inflammation or necrosis after ethanol 
exposure whereas the wt/wt which had micro- and macrovesicular steatosis 
.. I?r_~.~~.rlt ______ .. ____ __ . __________ . . ---._----
·P<O.05 vs. mice of the same genetic background fed a control diet 
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3.13.4 Sprague Dawley Rats 
Lieber et aI., (2004) Sprague Dawley Rats 
Treatment / Phenotype 










No. of Animals 22 22 
Terminal Body Mass (g) 311 ± 9.8 306 ± 5.8 
Liver Mass (g) 11.8 ± 0.51 12.1 ± 0.38 
Liver Mass / Body Mass 
x 100% 
Conjugated Dienes 
3.79 ± 0.09 
______ {E~()1~9·1i~~O __ ____ ~ ___ "___ ___ _ 
LOOH 
(nmol LOOH/g.liver) 
3.94 ± 0.07 
----~-~---~--~-.. --.-,-.--.. - .. --~.-.-- .. ----.-.- - ._-- -,.- -_.---- --~---~----
TTBARS (nmol/g.liver) 
Cholesterol 
~ __ ~" __ ~_( mg_/_~JL. ~_~_ 
Trig Iycerides 
._ ___Jm9/dIL~ _____ ._ 
Glucose Concentration 
(mg/dl) 
-------_._---_._._ .. _---_._-------------------_ .. __ .. -- - ----- -- ---~--
CYP2E1 Conc. 0.80 ± 0.07 1.31 ± 0.08 
_ __~ ~~~i!r:.Clry_~!li~~)_______ _______ . _ .. ___ ~ ___ ~~:__ __ _ 
AST 
____ ~~ __ ~_(ld!I_) ___ ._._._ ... ~. ___ . _______ ._________ _ ______ .~ 
ALT 
___~~~ ___ (U[Jl __________ ._ ________ _ _________________________ _ 
Tumour Development 
Histology / Additional Observations; 
Control; displayed minimal fat accumulation and few 
inflammatory cells. 
High-Fat Diet; showed pronounced hepatic steatosis 
and abundant mononuclear inflammatory cells, also 
revealed abnormal mitochondria with degenerative 
__ c,:b_C:J.Il_g~·____ ____ __ _ _________________ ______ ~~ ___ ~ __ ~ ________ _ 
Significantly different from the Control; *P<O.05, **P<O.01, 
P<0001 
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3.13.5 (Db/db) Mouse Model 
Sahai et al., (2004) 
Treatment / Phenotype 
Duration of Treatment 
Sex 
Age 
No. of Animals 
Terminal Body Mass (g) 
Liver Mass (g) 
































.. --- ------------_.- ---.. ~. -------~-- ----... --.---~- ._----
24.7 ± 1.0 15.1 ± 0.1 49.6 ± 3.0 42.4 ± 2.0 
* 
1.16 ± 0.1 1.17 ± 0.1 2.10 ± 0.1 3.0 ± 0.1 
46.7 ± 0.1 7.75±1.0 4.16±0.3 7.16±0.2 
* * * 





. _ __ Jr11~~1 L _____ ~__________. _._ __ __ ____ ~_. 
Triglycerides 30 ± 6 
____ l~g/g ~.li\lt:!.rL ______ . ___ .. _ 
Glucose Concentration 
(mg/dl) 
121 ± 7 
* 
.- - ------- ~-------~-.--.~~--~-- ----- ---- -----._--".- .----~-'" ------------
46 ± 3 91 ± 7 
* 
3.89 ± 0.3 6.73 ± 0.2 18.9 ± 1.0 52.7 ± 3.0 CYP2E1 Conc. 
(arbitrary units) * * 
--- _. -,,----.-.~.--.-~-~-.--
AST 
. __ .__ ..... .cLJII} 
ALT 
. . ___ .. _._. _ ~.CLJ{ll_. ____ _ 
Insulin 
(mg/dl) 
25 ± 5 154 ± 15 260 ± 20 
* 
Histology / Additional Observations; 
Histology revealed hepatic steatosis and lobular inflammation in animal being 
fed MCD diet. The levels of TNF-a were also raised which corresponded with 
elevated AL T and worsening steatosis. The MCD exhibited stimulated 
expression of OB-Ra (Ieptin receptor) and enhanced signaling which may 
contribute to the increase in hepatic fibrosis. Levels of osteopontin (OPN) were 
also raised and are thought to play an important role in the pathogenesis of 
f'J~§JtJhECJ.LJ_g~_il~_p_a~r:!J Q.J Q.~r~.c!~!r19_Qf:3:-.R§_~xpr~~~ig !1_c:l.IlSUt:!2t!l1~i9!:lC3 ~ i1l9· . 
Significantly different frDm the Control, *P<O.01 
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3.13.6 PPAR-a Mouse Model 
Ip et aI., (2003) PPAR-a Mice 
T t t / Wt Wt Wt PPAR -/- PPAR -1- PPARa-
l
-
rea men MCDfWy- a a MCDfWy-
Phenotype Control MCD 14,643 Control MCD 14,643 
L om.I__ L om.I,_ ~ .•. 1__ ~ .~.!__ ~ ... 1 __ i UUI C::IlIUfl UI I rt:!C::IHfIt:!f1l I ~ WK.~ 
I 
~ WK.S ~ WK.::> 
I 
~ WK5 l ~ WKS 
! i I 
I 
I 
I I I Sex Male ! Male Male Male Male Male-I I I I 
I I I I I I Age I 8-10 wks ! 8-10 wks 8-10 wks 
I 
8-10 wks 8-10 wks 8-10 wks 
I I I I I 
I I i I I I 
1\10. or I-\nlmal5 .q 0 
Mass Change (%) + 21 - 34 - 39 + 23 - 35 - 34 




I ! I I Liver Mass f Body 
8.0 ± 1.4* 3.7 ± 0.5 I 5.5±1.1 I 5.8 ± 1.4 
I 
I 4.0 ± 0.8 4.1±0.1 I I I Mass x 100% I 
Conjugated Dienes I I 
I 
I -I - - -- -(I..lmol/g.liver) I 
LOOH I - I - - -- -(nmol LOOH/g.liver) I I 
I i TTBARS (I..lmol/g.liver) 0.10 ± 0.1 5.3 ± 1.8** 0.31 ± 0.1 0.60 ± 0.2 6.4 ± 3.1*** 4.1 ± 2.3 
I 
*P<O.05 relative to same genotype fed the MeO diet. $P<O.05 relative to same genotype fed the control diet 
**P<O.01 relative to same genotype fed the MeO diet, ¥P<O.01 relative to same genotype fed the control diet 


















3.13.6 PPAR-a Mouse Model (continued) 
Cholesterol ~ $ $ 
Plasma; (mmol/l) 2.05 ± 0.55 0.70 ± 0.16 2.53 ± 0.90 2.92 ± 1.07 0.85 ± 0.34 0.87 ± 0.21 








tu~~ 20 ± 4 720 ± 100t 175 ± 83*** I 310 ± 200 790 ± 50¥ 890 ± 225 
Steatosis Grading + s ¥ I z + 
(scale = 0-3) I 0.5 - 1.0 2.3 ± 0.3 0.0 ± 0.0 I 2.1 ± 1.5 I 3.0 ± 0.0 [ 3.0 - 0.0 I 
I Administration of MCD diet caused weight loss as expected and the addition of Wy-14,643 I 
I (PPAR-a agonist) did not modify weight loss in either group. 
I The wild-type mice fed MCD diet developed moderate steatohepatitis and macrovesicular 
. . . i steatosis with neutrophil polymorphs. Administration of Wy-14,643 almost completely 
Histology I Additional I prevented accumulation of lipid TSARS although slight elevations in CYP4a10 and 14 were 
Observations I noted. 
I Wy-14,643 did not affect liver histology in PPARa-l. mice and serum AL T and lipid levels 
were unchanged compared with PPARa-l- mice fed the MCD diet alone confirming 
requirement for PPARa to provoke these effects. 
*P<O.05 relative to same genotype fed the MeO diet, $P<O.05 relative to same genotype fed the control diet 
**P<O.01 relative to same genotype fed the MeO diet, ¥P<O.01 relative to same genotype fed the control diet 
***P<O.001 relative to same genotype fed the MeO diet, tp<O.001 relative to same genotype fed the control diet 
zP<O.05 compared to wt mice fed the same diet 
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3.13.7 LepTg Mouse Model 
Ogus et al., (2004) LepTg Mice 
Treatment I Phenotype 
Duration of Treatment wks 20 wks 
Sex Male Male 
Age 9 wks 9 wks 9wks 
No. of Animals 1 10 10 10 
Terminal Body Mass (g) 
Liver Mass (g) 
.................. - ................. - .... --.... ----------1----...... - ......... --.-1-------·-,-.. ----------1-.. ------·· .. ···-1 







± 0.3 3.9 ± 









________ ._..lI}~I)_ .. ------f----.-.. - ... - .. - ...... -f .. -- .. --.. --.. - .... + .. - ... 
Tumour Development 
I Additional Observations; 
± 0.05 0.4 ± 
fed LepTg mice adipocytes 76% smaller than normal mice. Chow 
cause fatty liver. Alterations in insulin levels were also noted Oel[WE!e 
fed and high fat fed diets; 2.2~fold increase in normal mice and 1 
n,.. ... o"",,,o. in LepTg mice. In addition, LepTg mice fed a high fat diet had 
In('r""~I~O in bwt gain 1.6-fold faster than lean littermates in same group. 
small adipose quantities in LepTg mice may be caused by 
of and accumulation of -------.. ------.. ~~~---........ ---.. ~ 
Significantly different from tfle Control; *P<O.05, **P<O.01, P<O.001 
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3.13.8 Fatty Liver Shionogi (FLS) Mouse Model 
Soga et al., (2004) 
Treatment / Phenotype 
Duration of Treatment 
Sex Male Female Female 
Age 13-16 mths 13-16 mths 20-24 mths 
----_ .. _ .. _---_. --_.- ---_._- -.-.-----
No. of Animals 54 36 42 
Terminal Body Mass (g) 
Liver Mass (g) 
Liver Mass / Body Mass x 100% 
------.---------. ··--·----·------·--·----·r------------··------·-·-
Conjugated Dienes (~mol/g.liver) 
LOOH 






.. -.-- --·-------·l----·-----· 
_._ .. _(f!lg~qI1 _____________________________________________ _ 
Glucose Concentration (mg/dl) 
'"- --------~------~----~-------------~---
CYP2E 1 Conc. 
_. _________ tCl!bit~~~~~n i~~t____ __ _ 
AST 
. ______ . ___ . _____ (~J/D_____________ __ _ 
ALT 
(U/I) 
-_. ~---~--.------- ----.- --- ---'- ----- ~---- ----
Tumour Development 
Histology / Additional Observations; 
HCA = 10 
HCC = 12 
HCA= 0 
HCC = 0 
HCA= 7 
HCC =4 
None of these mice exhibit hyperphagia nor obesity but develop abnormal 
TG from birth and develop hepatic steatosis. 
After 2-4 months, mononuclear cell infiltration and clusters of foamy cells 
appear in addition to fatty liver and corresponds with raised AL T levels. 
These mice develop tumours following steatohepatitis but unclear whether 
lbis_L~defir1Jtiv~_i~uJ_~ fOIJ'J~!?t:I P9ti_~I1t§~___ _____________ ____ _ 
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3.13.9 Zucker (fa/fa) Rats 
Yang et al., (1997) Zucker (fa/fa) Rats 
Treatment / Phenotype (fa/wt) 
--_._._-----_._-_._----_.-.- _ ... _---_. 
Duration of Treatment 
Sex 
Age 
No. of Animals 
Terminal Body Mass (g) 
Liver Mass (g) 




304 ± 55 
9.9 ± 1.6 
3.26 ± 0.3 
(fa/fa) 
6-18 
496 ± 89* 
15.2 ± 2.6* 
3.17 ± 0.4 
_ ... ___ CH.!!,ol/g -1i~~~L_ .. ___ .. __ . __ . ______ . _____ . ____ ._. 
LOOH 




70 ± 26 140 ± 10** 
Triglycerides 104 ± 19 287 ± 17** 




185 ± 10 259 ± 26* 
_. ___ (~r~itra!y"lJ.Dits 1_.____ _. __ . _____ ... ___ .. ________ _ 
AST 
(UlI) 72 ± 2 74 ± 4 
.~'-----------------.----.-. 
ALT 
... _ .... _____ .. _iY.lIl _____ . __ 56 ± 2 86 ± 6* 
Tumour Development 
Histology / Additional Observations; 
(fa/wt); livers appeared normal, hepatic steatosis was 
not observed. 
(fa/fa); grade 3-4 macro- & microvesicular steatosis in 
addition to hepatocyte apoptosis was evident in all 
animals. 
Significantly different from the Control; 'P<O.05, *'P<O.01, P<O.001 
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3.13.9 Zucker (fa/fa) Rats (continued) 
et a/., 
Treatment / Phenotype 
Duration of Treatment 
Sex 
Age 
No. of Animals 
Terminal Body Mass (g) 
Liver Mass (g) 














IS{CIIOCIV I Additional Observations; 
Zucker (fa/fa) Rats 
(falfa) 
251 ± 3 428 ± 6** 472 ± 4** 
7.7±0.1 12.2 ± 0.8** 0.9 ± 
71 ± 3 98 ± 6** 102 ± 2*" 
55 ± 3 296 ± 24**" 93 ± 11** 
98 ± 1 155±14** 148 ± 7** 
leptin levels in SHRSP/(falfa) and (fa/fa) rats elevated 70- and 50-
than SHRSPllzm rats which explains noted abnormalities in metabolism. 
(fa/fa) rats also display obesity, hypertension and hyperinsulaemia 
beneficial for fatty liver development, strain more concerned 
Significantly different from the Control; ·P<O.05, **P<O.01, P<O.001 
1\ ::: P<O.05 compared with Zucker (fa/fa) rats. 
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3.13.9 Zucker (fa/fa) Rats (continued) 
Tomita et aI., (2004) Zucker (fa/fa) Rats 












.---.--.-----.. -.--------.---- -.---.---.------ .. ---.-----t--
Sex Male Male Male Male 
Age 4wks 4wks 4wks 4wks 
No. of Animals 10 10 10 10 
Terminal Body Mass (g) 
Liver Mass (g) 
Liver Mass I Body Mass x 
100% 
2.3 ± 0.1 2.4 ± 0.1 3.0 ± 0.2 4.0 ± 0.3 
Conjugated Dienes 
(!.Jmol/g .liver) 
--- ~--------~.- .. -~--.--.---~-------- ------_. -----,~----
LOOH 
_______ (!l_~()L LqQl:i/g:!~yer). __ . __ ._. __ . ___ . ___ . 
TTBARS (nmol/g.liver) 
Cholesterol 






15 ± 3 40 ± 9 
** 






50 ± 8 60 ± 10 
. -------_.--_. __ ._------- -------.-~---
Histology I Additional Observations; 
** * 
60 ± 10 125 ± 15 
* 
105 ± 12 495 ± 65 
** * 
-'--.----~----.----. 
Alcohol-fed mice in both groups were shown to have increased plasma FFA 
and increased fat accumulation with moderate inflammation. Furthermore, the 
genetic disposition of leptin deficiency in theses rats suppresses hepatic 
metallothionein (MT-1) and increases TNF-a which both enhance sensitivity 
to steatohepatitis. The data suggests that leptin deficiency causes a worse, 
_~ore s~ver~ st~atob.~titis fQ!!owin9ncJ1ro!lic e!.b_anoL~xposu~.: ____ ~ 
·P<0.05 VS. the other groups, *·P<0_05 VS. the control groups 
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3.13.9 Zucker (fa/fa) Rats (continued) 
Nagao et aI., (2004) Zucker (fa/fa) Rats 
Treatment / Phenotype 
Duration of Treatment 
Sex 
Age 
No. of Animals 













_________ JiJL __________ .. _._. ________________ _ 
Liver Mass (g) 
Liver Mass / Body 
Mass x 100% 
4_74 ± 0.36 
".~.-~,,~--- ---~---.,~---.--- -~-.-----"--.~~-
Conjugated Dienes 
_____ Jll_~nol/g .li.YerL_______ ________ _ 
LOOH 




3.50 ± 0.1r 
Triglycerides 
Plasma; (mmol/I) 
2.08 ± 0.15 5.40 ± 0.31 * 
--------._ .. _---------------- -_. --------- -- ---
Glucose Concentration 
(mg/dl) 




66 ± 13 24 ± 2* 
-------~'"--.--------------. ~--------,----- -------~,,-
ALT 
19 ± 2* ~I) 48 ± 7 
~~~n~EJI-~;:;mt~in)-_~~~I1.~~ ~~~-.~ 0 _~~~- ± 0~~5: __ 
Histology J Additional Observations; 
Administration of CLA (conjugated linoleic acid) was 
shown to protect against hepatic injury through raising 
levels of adiponectin production. 
CLA also improved insulin sensitivity and suppressed 
expres_sion~U"'!E:__a_. ______________ ._. __________ _ 
Significantly different from the Control; *P<O.05, uP<O.01, P<O.001 
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3.13.10 AlJ Mouse Model 
,~-~. --.-.~ -~.---~--.-- .. " 
Sahai et al_, (2004) NJ Mice 
"---.--~-.----~---~--.--~---
Treatment I Phenotype 
NJ Mice AlJ Mice 
Control MCD 
.--~ 1----.----.-
Duration of Treatment 12 wks 12 wks 
"-
Sex Female Female 
--------~----.-~------~- ----_. 
Age 7-8 wks 7-8 wks 
---~--.. ---~ 
No. of Animals 3-5 3-5 
.---------.~---.+--~---,--
Terminal Body Mass (g) - -
.~---.--- ---.--.-,-~~~ 
Liver Mass (g) - -
.,,--_. .-------~.-- .. ------ ----, 










TTBARS (nmol/g.liver) 0,67 ± 0,08 1.20 ± 0,08* 
---,-~."~-~-~--.. ~-, r---' 
Cholesterol -(mg/dl) 
. __ . ---------~---- ,,-
Triglycerides 
10 ± 2.5 78 ± 8.0* 
(mg/dl) 
--~-~,,-~--~--------,--.--~-.-.. -.-------.-------~- 1-----_. 
Glucose Concentration 
" " 
____ ,,~/dl) ___ ,_ 
"'--~,,-----,,---r----~-'---' .~.---.-- ,,, ..... -
CYP2E 1 Cone. 
1.00 ± 0.10 2.55 ± 0_18* 




----,----~ ._--_ .. _._---_._-'" 
ALT 
27 ± 5.2 250 ± 14* (UlI) 
.-~------ .... ~-.- -,--------
Tumour Development - -
,~,~~--.-. 
Histology I Additional Observatio, 
Macrovesicular steatosis in zones 2 and 3 after only 1 
wk of the MCD diet with portal inflammation resulting 
after 4 wks. OPN expression was elevated early in 
development of NASH and preceded increases in TNF-
a and oxidative stress. 
Significantly different from the Control, *P<O,01 
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3.13.11 C57BI61J Mouse Model 
Leclercq et ai., (2000) C57BI6/J Mice 





Duration of Treatment 10 wks 10 wks 
Sex Female Female 
Age 8-10 wks 8-10 wks 
No. of Animals 4 4 
Terminal Body Mass (g) 
24 ± 1.1 
Liver Mass (g) 
1.01 ± 0.08 
Liver Mass I Body Mass 4.22 ± 0.16 
x 100% 
Conjugated Dienes 
12 ± 0.1 
** 
0.5 ± 0.01 
*** 
4.14 ± 0.05 
...~~jE~()!/£..~V~!L~_.~_ ... ~~ ___ ... .. _ ....... ~_~_. ~ ____ .~~. 
LOOH 56 ± 8 100 ± 19 
.~_Jf!~~I~gq 1j~~Ji.v. e r).~ _~ ___ ._._~_._ .~~ 
TTBARS (nmol/g.liver) 
Cholesterol 
. ___ .~_~ __ .~{1"!19{~~ L_.. ___ ~ .. ___ .~ ... ~_ ...... _ ...... +- .~_ ~._~ ......... ~ .. _~ .. _. 
Triglycerides 24 ± 9 79 ± 6 
.~( rll.9/ g..~~Ui\l~.rL * 
Glucose Concentration 
__ ~ __ .... (l12g/dIL~~._~_. 
CYP2E1 Conc. 57 ± 18 167 ± 16 
.. _~_.~(arbi!r-.ClIL~ni~s.L ~ ...... ~ .... ~_~~_~ .~_ ~._.~~~ __ :.:~._ ... ~ 
AST 
._ .... _ .. ~~ .. (Ul-'1_ .. 
ALT 
... (~I!IL __ 
Serum FFA 
22 ± 3 
.~ ... LIll.r11.9111). _ .. 
Histology I Additional Observations; 
637 ± 128 
.* 
Control mice displayed no fat accumulation whereas 
the MCD diet induced steatosis mainly in zone 2 with 
large areas of inflammatory infiltrate. Collagen fibre 
deposits were also noted and confirmed pericellular 
fibrosis. 
Significantly different from the Control: *P<O.05, **P<O.01, P<O.001 
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3.13.12 Acyl CoA Oxidase Deficiency (AOX) Mouse Model 
Unfortunately, results generated from work undertaken by Hashimoto et aI., (1999) 
are presented in such a manner that many fields of data are not applicable to the 
parameters being examined and contrasted in the other studies. This further 
illustrates the difficulty in comparing findings from different research papers. 
However, the data generated from the study conducted by Hashimoto et al., (1999) 
was deemed relevant to the parameters being examined in this thesis and therefore 
has been included despite the alternative mode of presentation. 
The work carried out by Hashimoto et al., (1999) used PPARa·I., AOX·I., and PPARa· l . 
lAOX-' mouse genotypes in an attempt to demonstrate the role of PPARa and fatty 
acid oxidation in the pathogenesis of fatty liver. The schematic representation 
depicted below (figure 3.13.12.1) reveals the different extent of liver injury exerted on 
each model and the different steps involved in getting hepatic damage. 
Decreased constitutive 
mitochondrial ~-oxidation 
Fatty liver (mild large 
droplet, centrilobular) 
Increased VLCFAs, related 
















Fatty liver (severe 
microvesicular, pan lobular) 
PPARa'/'/AOX/' 
Increased VLCFAs, related 




No induction of CYP4A 
w-oxidation 
1 
DCA levels constituitive 
1 
Absent peroxisomal 
~-oxidation of DCAs 
1 
Minimal DCA toxicity 
1 
Fatty liver (mild, 
microvesicular, periportal) 
Figure 3.13.12.1 PPARa·i., AOX', and PPARa"'/AOX" represent the mouse genotypes. In PPARa' 
mice, constitutive mitochondrial [3-oxidation is reduced and leads to slow progression of large droplet 
centrilobular steatosis in liver. The constitutive extra-mitochondrial fatty acid metabolism (peroxisomal 
and CYP4A metabolism of LCFAs and VLCFAs) is not adversely unaffected in the absence of PPARa. 
In AOX'" mice, the sustained hyperactivity of PPARa because of ligands that are not metabolized 
because of AOX deficiency results in overexpression of CYP4A enzymes and the LCFAs and VLCFAs 
not metabolised by peroxisomal [3-oxidation because of lack of AOX are converted to DCAs by CYP4A 
w-oxidation. Extensive microvesicular steatosis is considered a reflection of DCA induced inhibition of 
mitochondrial [3-oxidation. In mice nullizygous for both PPARa and AOX, the absence of PPARa and 
lack of CYP4A induction resulted in the blunting of microvesicular steatosis (Hashimoto et al., 1999). 
In conclusion, alterations in PPARa and AOX can effect lipid homeostasis and it is 
proposed that VLC and LC Acyl CoAs may play an important role in provoking 
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spontaneous peroxisomal proliferation by functioning as PPARa ligands in the 
facilitation of microvesicular steatosis. Considering all the results from this study, it is 
proposed that both PPARa and AOX are considerable factors in hepatic lipid 
metabolism and in the pathogenesis of fatty liver development and progression. 
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Chapter 4; Methods and Materials 
4.1 Introduction 
The research being performed in this thesis is of dual nature as the livers were 
examined for histology and biochemistry, spanning 2 different laboratories. The 
different aspects being investigated are from separate scientific backgrounds, but it 
was hoped that the biochemistry data would correlate with the histology findings. 
Despite significant biochemistry data being strongly indicative of hepatic damage in 
several instances, histology findings often failed to reveal the extensive injury that 
was anticipated. Therefore, histology and biochemistry methods and results have 
been described separately for clarity. 
4.2 Histology 
4.2.1 Tissue Processing 
Immediately after sacrifice, fresh liver slices were obtained from the left lobe of the 
liver and stored in 10% formalin at room temperature until they could be processed. 
The processing begins with washing the tissue in 70% alcohol, before immersion in 
two changes of 10% neutral formalin for 2h and 1 h respectively. The tissue was then 
dehydrated in two changes of 96% ethanol (10 mins each), followed by four changes 
of 100% ethanol (15 mins each). Once dehydrated, the tissue was immersed in two 
changes of xylol (15 mins each). Finally, the tissue was subjected to four changes of 
embedding wax (two changes at 20 mins each and two changes at 30 mins each) 
before being embedded in paraffin wax. 
4.2.2 Stains / Light Microscopy 
Sections were cut 4-6~m thick with a micrometer and stains were performed by 
standard laboratory techniques before being viewed under a light microscope. 
These included; 
(1) (H&E) - haematoxylin and eosin stain. This is the most widely used stain as it 
clearly illustrates a wide variety of different cell and tissue structures, is cost effective 
and not time-consuming. Haematoxylin stains the cell nuclei a blue-black colour and 
provides good, clearly visible intra-nuclear detail whereas the eosin component 
stains the cell cytoplasm and connective tissue fibres in shades of pink, orange and 
red (Bancroft and Stevens, 1990). This stain is used for overall assessment of 
hepatic injury and cell disruption. 
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(2) (SR) sirius red stain. This stain uses the cotton dye Sirius red F3B for the 
detection of amyloid. This is used to gauge the extent of fibrosis and is dependent on 
the linearity of the dye molecule and ~-pleated sheet configuration (Bancroft and 
Stevens, 1990). 
(3) (D/PAS) periodic-acid Schiff after diastase digestion stain. This reaction is useful 
for detecting tissue carbohydrates, specifically for glycogen when a diastase 
digestion stage is incorporated into the stain (Bancroft and Stevens, 1990). Periodic 
acid promotes an oxidative cleavage of carbon-to-carbon bonds or amino derivatives 
to form dialdehydes which react with fuschin-sulphurous acid and forms a magenta 
colour upon binding with paraosaniline (Stoward, 1967). This stain is of particular use 
in evaluation of debris-containing Kupffer cells. 
4.3 Biochemistry 
4.3.1 Lipid Extraction 
The original method for extracting lipids described by Folch (1957) is now commonly 
referred to as the Folch technique. There were however, practicality problems with 
the original process as it was time consuming and used large volumes of solvent 
making it in-appropriate for lipid peroxidation studies. An improved modification to the 
Folch technique was made by Bligh and Dyer (1959) making the method simpler, 
less time consuming and as a result is well adapted for routine lipid analyses. 
The essential concept underlying the technique is that homogenised tissue in a 
mixture of chloroform and methanol creates a monophasic solution which then 
separates into a biphasic solution when diluted with chloroform and an aqueous 
solvent The lipid fraction remains in the chloroform layer (non-aqueous phase) while 
the non-lipid impurities are contained in the methanol and water layer (aqueous 
phase). Chloroform, being the denser liquid is below the aqueous phase. 
Freshly frozen liver samples were thawed on ice and approximately 70mg of each 
liver sample was homogenised in 2ml chilled SEAP (0.15M NaCI, 0.02M NaH2P04 , 
0.01g % NaN3 , 0.001 M EDTA) using a Virtis Handishear®. The resulting solution was 
sonicated with twenty 1 sec bursts at an output power of 4-6 watts using a Virtis 
Virsonic®. Sonication was carried out to completely obliterate any remaining 
subcellular structure. The homogenate from each liver sample was aliquoted (0.8ml 
per tube) and utilised for measurement of lipid peroxidation. The remaining 
homogenate of each sample (1.2ml) was stored at -80°C. 
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To 0.8ml chilled homogenised liver, 1 ml chilled chloroform and 2ml chilled methanol 
were added and vortexed for ten seconds. The solution was then centrifuged at 3000 
rpm for 15 mins at 4°C in a Beckman GS-6R centrifuge. The resulting supernatent 
was then transferred to a clean tube on ice. The remaining pellet was washed by 
addition of 1 ml chloroform, 2ml methanol, 0.8ml SEAP and vortexed for ten seconds 
The solution was subjected to further centrifugation as described above. To remove 
non-lipid impurities from the collected supernatant, a phase split was necessary and 
was achieved by addition of 2ml chloroform, 2ml SEAP, vortexing for ten seconds 
and then centrifugation at 3000 rpm for 10 mins at 4°C. The upper aqueous phase, 
containing the impurities, was removed by suction, leaving the lower non-aqueous 
phase that contains the lipids. The lower phase was dried in a Pierce Reacti-therm 
module under nitrogen gas at room temperature. The resultant dried extract was then 
re-suspended in 200IJI chloroform and 20IJI aliquots were placed in microreaction 
vials (eppendorf tubes). The eppendorf tubes were then placed in the Pierce Reacti-
therm module as described above, to completely dry the solvent. The dried lipid 
extractions were stored in the dark at -80°C freezer until required for biochemical 
assessment. 
Owing to small sample volumes, plasma lipid studies were not practicable. The 
plasma was used where possible for glucose and alcohol, as well as transaminase 
alterations. 
4.3.2 Conjugated Dienes (CD) 
Conjugated dienes manifest in unsaturated fatty acids as an early indicator of lipid 
peroxidation reactions (Vasankari et aI., 1995). Their appearance is due to a 
rearrangement of double bonds following free radical attack (Recknagel and Glende, 
1984). The molecules containing CD are characterized by an intense absorption (K 
band) which may range from 215 to 250 nm, depending on the presence of nearby 
substituent groups (Recknagel and Glende, 1984). The spectra of lipids that contain 
CD are characterised by an intense K band near 233 nm with a lesser secondary 
absorption in the region of 260-280 nm due to ketone dienes. 
Conjugated dienes were measured using a GBC UVNIS 916 spectrophotometer. 
The baseline was established using distilled water and the absorbance of a 
cyclohexane blank was measured to verify purity. At 234 nm, unoxidised 
cyclohexane has an optical density of 0.049. 
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The CD content of each sample was measured by adding 1 ml cyclohexane to the 
20~1 dried lipid extract and vortexing for ten seconds. The mixture containing 
cyclohexane and the experimental lipid sample were transferred to a quartz cuvette 
for reading in the spectrophotometer. The absorbance of each sample (in duplicate) 
was read at 234 nm immediately after mixing. The concentration of conjugated 
dienes from each sample was calculated using a molar extinction coefficient (l:) of 
2.95x104 M-1 cm-1 . 
4.3.3 Lipid Hydroperoxides (LOOH) 
Lipid peroxidation reactions are complex and involve alterations of biosynthetic 
unsaturated fatty acids. These reactions yield conjugated dienes as previously 
described, lipid hydroperoxides (LOOH) and other fragmentation products including 
aldehydes and carboxylic acids. Jiang et al. (1991) modified a method, initially 
described by Gupta (1973) which resultantly measures the LOOH indirectly through 
the oxidation of Fe2+ ---; Fe3+ by peroxides. This occurs in the presence of a ferric-
complexing dye, xylenol orange, which has maximal absorption at 560 nm. The 
method will detect Fe3+, H20 and lipid hydroperoxides but lipid extracts will by 
definition only contain lipid hydroperoxides. The determination of these lipid 
hydroperoxides will assist in the evaluation of the oxidative stress occurring in the 
liver (Jiang et al., 1991). 
To measure the LOOH concentration, several reaction components were added to 
the dried lipid extract. Firstly, addition of 1 OO~I chloroform and vortexing for ten 
seconds was necessary to re-dissolve the lipid. Secondly, 350~1 of methanol was 
added and vortexed for ten seconds to generate a monophase. The aqueous 
component of the assay is subsequently added, 50~1 "nanopure" H20, and vortexed 
for ten seconds. Finally, 600~1 of FOX 2 Mix* was added and vortexed for ten 
seconds. Standard reactions were prepared as described above, except 50~1 of the 
relevant standard was used as a replacement for nanopure H20. The tubes were left 
at room temperature for 20 mins for the reaction to occur and the absorbance was 
read immediately after at 560 nm. The concentration of lipid hydroperoxides in each 
experimental sample (in duplicate) was determined from a non-linear regression 
curve of the t-butyl hydroperoxide (t-BHP) standards. The reliability of the assay was 
assessed by the calculating the ratio of t-BHP to FeCb at an absorbance of 1.00. The 
recorded value was 6.79 ± 0.23. 
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'Fox 2 Mix: 1 part FOX 2A (2.5mM ferrous ammonium sulphate, 2mM Xylenol Orange in O.25mM 
H2S04) 
4.5 part FOX 2B (O.BBmM BHT in methanol), always prepared fresh. 
FeCI3 Standards _________________ , ____ ,_, ____ _ 
FeCb [4mM] Volume of Water (iJl) Concentration of 
_'{\Iorking Solution [mM] 
Quantity of Ferric 
_y h I<:>rJ~EJJb~()JL __ _ 
_____ °._1 _____ -+ ___ , ______ --"-__ , _______ -1 
~------~~--------,4_---------~=~----_+------0~.2~---~----~=-______ ~ 
___ S~,<::.i<_ So~lu=tio=-:.n'-'(=iJl:L) -r-------:-::-----
25 975 
100 900 0.4 20 --j--------,--::-----------r-------------
200 800 
_=,~====~Q-O --~==-----_f----------===-=-=--~-~-----_~_-___ :==~====~-=~=====~===:=====--=--=--8''-'0'--------'---_==_-.,-1 
~----------------::_:::::----------_1----------5-00-------+--___________ .:':.::_. __ , ______ -+-_____ 10_0 ____ _ 
800 200 160 
,,~t:..:-B:;.:H.:.:P-=S;.::.:ta:.:.:n:.::::d.=:ar~d~s __ ,____------------ ________________ _ ____________ -, 
t BHP [0696mM) Concentration of Quantity of Butylated --. Volume of Water (iJl) 
f ______ S ___t,_o __ c __ k ___ S ___ o_1 u_tio __ n--'L-' ___ ,"-1 _______ , ________________ ~2~!<!!:1R.§~~utionll"!!.~L --'::!Y.<:l ro peroxi<!EJ~J n M_()!l. 
__________ -=-, _____ -J-_____ 99_5_____ __, __ -=-0=.0-=-04~2=__ _ _+_---------,-=,c=:---
__ ",, ______ JQ____ _ ____ ~~Q.. ___ , __ _______ .<1.9_07§.. __ -+ ______ 0._35 ____ ,_, __ _ 
20 980 0.015 0.75 
~--~--~---------.-----.-.----------.--~----- ------------~------- ---"----------
40 960 --------------- _____________ , ________ ,, ___ --jf ___ , __ , ______ =,'-c __ c __________ + ________ -'-'-=-_________ --1 
_________ 20_0 _______ + _____ . ____ -=c_=-= _____________ + __________ ------=.:..:-=-.-----------1----,------'--------1 
400 600 0.28 14 -------80-0-----t------200----- -------0.56-----+-----------_______________________________________________________ .L ___________ '-'-'--_______ , 
4.3.4 Thiobarbituric Acid Reactive Substances (TBARS) 
TSARS are intermediate to late products in the process of lipid peroxidation damage. 
The process by which TSARS produce a secondary product red dye, after reaction 
with malondialdehyde (MOA) has been widely used as a sensitive assay method for 
lipid peroxidation in animal tissues (Ohkawa et al., 1978)_ The assay measures the 
red chromogen, formed as a result of MDA reacting with two molecules of 
thiobarbituric acid and was carried out according to the method of Asakawa and 
Matasushita (1979), with slight modifications. 
To determine the concentrations of TBARS from experimental samples, 501-11 
chloroform was initially added to each dried extract and vortexed for ten seconds to 
re-dissolve the lipid. This was transferred to a tube, to which 501-11 0.27% FeCb was 
added and also vortexed for ten seconds. The next step was to add either 1001-11 
ethanol for measurement of "total" TBARS (i.e. the amount present at time of death 
and those generated during tissue handling) or 1001-11 0.22% butylated 
hydroxy toluene (BHT), an antioxidant for measurement of "free" TBARS (Le. the 
amount of TSARS present in the sample at time of death) and vortexed for ten 
seconds. These may be lost in the process of extraction. To all tubes, 7501-11 glycine 
buffer, pH 3.6 (0.2M glycine HCI) was added and vortexed for ten seconds, after 
which 7501-11 TSA reagent (0.5% thiobarbituric acid, 0.3% SOS) was added and 
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vortexed again. Chloroform and water blanks were prepared by the same method, 
except that 50~1 chloroform and 50~1 were added in place of the re-suspended dried 
extract respectively. A glass bead was inserted to each tube, which was then capped 
by marbles and boiled at 100°C on a Techne® DS-3A dri-block. After 20 mins, the 
tubes were removed and allowed to cool to room temperature. 
After cooling, 250~1 of the pink aqueous phase from each experimental lipid sample 
was transferred to a microtitre plate. The absorbance of each sample (in duplicate) 
was read at 540 nm. The concentration of total TSARS and free TSARS was 
calculated using a molar extinction coefficient (£) of 1.09x1 05 M-1 cm-1. 
Free TSARS can be measured but were not viewed as significant in extracts 
because of potential losses of volatile compounds and were therefore not analysed in 
the studies presented in this thesis. 
4.3.5 Total Cholesterol (TC) 
Total cholesterol concentration was measured using a commercial kit (KATTM) (No. 
AD704CH). The enzymatic method used in the kit is derived from the procedure 
described by Allain et aI., (1974). Cholesterol esters are hydrolysed using cholesterol 
esterase as a catalyst to produce cholesterol and fatty acids. The resultant 
cholesterol is oxidised with cholesterol oxidase and forms cholestene-3-one and 
hydrogen peroxide. Under the catalytic influence of peroxidase and phenol, the 
hydrogen peroxide reacts with 4-aminoantipyrine to produce the chromogenic red 
indicator quinoneimine (see below). 
Cholesterol ester + H20 
Cholesterol + O2 







Cholesterol + Fatty Acids 
Cholestene-3-one + H20 2 
Quinoneimine + 4H 20 
The supplied commercial standard was not used as more accurate standard curves 
were being produced from the supply of cholesterol in the laboratory. However, the 
provided enzyme reagent was still used for TC determination. 
A series of standards were prepared by dissolving cholesterol (1IJg/~I) in measured 
volumes of ethanol and mixing, as described in table (4.3.5.1). The standards were 
dried in the fume cupboard after mixing. To the dried cholesterol standards, 50~1 
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ethanol, 15~1 1 % Triton X-1 00 and 500~1 0.9% NaCI were added and vortexed for ten 
seconds after each. Experimental samples were prepared by adding 50~1 ethanol, 
15~1 1 % Triton X-1 00 and 500~1 0.9% NaCI to 20~1 dried extract and vortexing for ten 
seconds after each. From the prepared standards and sample mixtures, 125~1 was 
transferred to a microtitre plate, to which 125~1 of the provided enzyme reagent was 
added and mixed. The plate was then left at room temperature for 30 mins for the 
reaction to occur. The absorbance was read at 500nm with the quantity [~g] of TC of 
each sample (in duplicate) being calculated from a linear regression curve of the 
standards. 
Weigllt of Cholesterol (~g) Volume of Ethanol (~I) Cholesterol Content (~g) 
7.5 

















Precinorm® U, a commercially provided standard with a TG range of 111-153 mgdf 1 was 
used as a cali/)ratol. 
4.3.6 Hepatic Trig/ycerides (TG) 
Hepatic triglyceride concentration was measured using a commercial kit (KA TTM) 
(No. AD801T). The method derived from Werner (1981), Triglycerides are hydrolysed 
using lipases to produce glycerol and fatty acids. The resultant glycerol is 
phosphorylated with the assistance of glycerol kinase (GK) and consequent 
oxidisation with glycerol-3-phosphate oxidase (GPO) forms dihydroxyacetone 
phosphate and hydrogen peroxide. Under the catalytic influence of peroxidase 
(POD), the hydrogen peroxide reacts with 4-aminoantipyrine and 4-chlorophenol to 
produce the chromogenic indicator red quinone (see below). 
Lipase 
Triglycerides + H20 Glycerol + Fatty ACids 
GK 
Glycerol + ATP Glycerol-3-phosphate + H202 
GPO 
Glycerol-3·phosphate +02 Dihydroxyacetone phosphate + H202 
POD 
2H 20 + 4-Chlorophenol + 4-aminoantipyrine . .., Red quinone + 4 H20 
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A series of standards was prepared, using the supplied commercial standard, by 
mixing measured volumes with 0.9% NaCI, as described in table (4.3.6.1). The 
standards were then mixed with 501-11 ethanol and 151-11 1 % Triton X-100. 
Experimental samples were prepared by adding 501-11 ethanol, 151-11 1 % Triton X-100 
and 5001-11 0.9% NaCI to 201-11 dried extract and vortexing for ten seconds after each. 
From the prepared standards and sample mixtures, 1251-11 was transferred to a 
microtitre plate, to which 1251-11 of the provided enzyme reagent was added and 
mixed. The plate was then placed in an oven at 37°C for 5 mins for the reaction to 
occur. The absorbance was read at 500nm with the quantity [I-Ig] of TG in each 
sample (in duplicate) being calculated from a linear regression curve of the 
standards. 
Volume of TG Standard (1-11) Volume of 0.9% NaCI (1-11) 
o 500 - ----T .- --.. ----·--·----+----·---·-····-··---·---4 ·c-
9
=·-9-:--










490 --- ---.-- - · __ ·_-----_·_-------1--·-------_··-·_-_· 
20 
20 




_____________ +-___________ ._.4._:7~O _________ _ 60 --- ---.-~--.------~ ---- _ .. _- .. __ .-
80 - ----------.-~----.-----
450 100 
Precinorm® U, a commercially provided standard with a TG range of 111-153 mgd/ 1 was 
used as a caJiiJrator 
4.3.7 Bicinchoninic Acid (BCA) Assay of Proteins 
SCA is a water-soluble compound that is a highly specific reagent for cuprous ions 
(Cu+). The biuret reaction of SCA and Cu+ yields an intense purple colour that is very 
stable and displays maximal absorption at 562nm. Protein quantitation by SCA was 
measured according to the method of Smith et al_, (1985). The method of Lowry et 
al., (1951) is more commonly used for measurement of proteins and is very similar in 
context to that of Smith et aI., (1985) as both techniques are dependent on the 
formation of a colour complex produced from a biuret reaction. However the 
quantitative method of Smith et al., (1985) was preferred as it is regarded as being 
simpler, sensitive and more tolerant to interfering substances (Brown et aI., 1989). 
To determine the protein concentration, homogenate was firstly diluted 1 :20 with 
nanopure H20. 101-11 of this diluted mixture was transferred to a microtitre plate and 
brought to a final volume of 1001-11, also using nanopure H20, then shaken for one 
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minute. 100IJI of BCA-IJD (see BCA solution list below) was added and shaken for a 
further minute and repeated again. The addition of BCA-IJD was carried out in two 
stages to ensure thorough mixing of the homogenate and the BCA solution. After the 
addition of BCA-IJD and shaking, the microtitre plate was floated on the surface of a 
waterbath at 60DC for 1 hr for the reaction to occur. The microtitre plate was then 
briefly cooled and shaken for 1 min before the absorbance was read at 560 nm which 
has an optical density between 0.2 and 1.6. The concentration of proteins in each 
experimental sample (in duplicate) was determined from a non-linear regression 
curve of the bovine serum albumin (BSA) standards. Standard reactions were 
prepared by diluting BSA in nanopure H20 as detailed in the table below (4.3.7.1). 
BCA Solutions: BCA-pA (8% Na2C03, 1.6% NaOH, 1.6% Na2 tariate and NaHC03, pH 11.25) 
BCA-pB (4% BCA in nanopure H20) 
BCA-B (4g CUS04 in 100ml nanopure H20) 
BCA-pC (100 paris BCA-pB +4 paris BCA-B), unstable and should be made fresh. 
BCA-pD (equal paris of BCA-pA + BCA-pC), unstable and should be made fresh. 
4.3.7.1 Albumin Standards -=:'::':":'~==':":::'==~----.,------:--::----.-- _. ---
Volume of Stock Concentration of Stock 
Volume of Water (IJI) Quantity of Albumin [1J91 
~ __ .......... _Sc:.::co .. :::1 u::.:.:ti: o::-,n:-'C.:L. _____ t-__ Sol uti 0rlJp g/lJ I) .. .. 
o 1 0 ..... -.. -------2 -----+--.. -.-.--... --=-:.----.-,---.. --..... -.---=.~---.---._+----0-.5"--
f----.. ·---.. -=---·-· .. ·------I·-----..........c~-··--·----+--------....c..-=------.--.-f------..... --.. - .. - .... --.-
. __ .... __ .. _ . .'L_ ... ____ -j ____ .... ___ .. c.:::::·.= __ .. __ . __ ... __ -j---·.·--.--.--.. ---.-f-------.-..... -... ---.... . 
20 0.25 80 .. ----.-.-.------.------- -----.--.---.----.-.-.. ---- .. _-·_-------------+_·_···-_·· __ .. ··---:-:·_ .. ·_-_ .. _·--·--1 
0.25 
... _. _____ 4 ----.... --f--------=-----.. --.-j-...... -.-... ---=-:c----.. --j----_____ -= ... -::_ ... ____ .. _._ .. _1 
8 5 92 40 .-.---- ------------_ .. _.1---._._-_ .. _. __ ._-=:--:-_._-----... _._+._-----.... ------.--. 
15M 00 _____ • ___ ......L..._. __ --'-__ 
4.3.8 Measurement of Aminotransferases 
Aminotransferases are identified as a family of enzymes that operate as catalysts in 
the interconversions of amino acids and a-oxoacids through transfer of amino 
groups. The release of aminotransferases indicates the presence of hepatic injury, 
however, these enzymes may be released before the clinical manifestations of liver 
disease become evident (Tietz, 1987). The measurement of aminotransferases was 
determined as described by Tietz (1987). 
Blood samples were taken at time of termination of the animals and were 
immediately subjected to centrifugation in a Labnet Spectrafuge 16M at 14,000 rpm 
for 10 mins to produce serum. The serum was stored into 301J1 aliqouts at -70DC until 
required for biochemical assessment. 
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4.3.8.1 Alanine aminotransferase (AL T) 
AL T is a liver-specific enzyme which catalyses an amino transfer reaction. Under the 
catalytic influence of AL T, an amino group is transferred from L-alanine to a-
oxoglutarate with the assistance of pyridoxal-5'-phosphate (P-5-P), to generate 
pyruvate and L-glutamate. However, the direct measurement of aminotransferase 
activity is difficult and has resulted in the activity being determined indirectly by 
assessing pyruvate production via lactate, (as displayed below). 
a-oxoglutarate L-alanine Lactate 
\ / 
ALT Lactate Dehydrogenase (LDH) 
\ 
L-glutamate Pyruvate NADH+ + H+ 
Aminotransferase buffer (13.6g KH 2P04 , 3.3g NaOH in 1 litre distilled H20, pH 7.4) 
and oxaloacetic acid (0.73g oxaloacetic acid in 30ml buffer, pH 7.4, adjusted to a 
final volume of 50ml) were prepared and stored at 4°C and -20°C, respectively. 
In addition, a mixture containing 36mg NADH, 19m1 buffer, 501-11 lactate 
dehydrogenase (25mg/2.5ml H20) and L-alanine (7.6g L-alanine in 100rnl buffer, pH 
74) was freshly prepared, of which 6501-11 was added to 501-11 serum and mixed. The 
solution remained at room temperature for 15 mins to permit the NADH-dependent 
reduction of endogenous oxoacids. Finally, 501-11 oxaloacetic acid was added to all 
samples and vortexed for ten seconds. The absorbance was read at 340nm every 30 
secs for 5 mins and the catalytic activity (quantity of enzyme that catalyzes reaction 
of 11-1ml substrate per min) was represented as U/L. 
4.3.8.2 Aspartate aminotransferase (AST) 
Elevated AST activity signifies a disruption in liver cell integrity and the key concept 
for determination of AST levels is similar to that for AL T (Tietz, 1987). The notable 
difference being that, under the catalytic influence of AST, amino groups are 
transferred from L-aspartate to a-oxoglutarate and resultantly generate a-
oxaloacetate and L-glutamate. As mentioned previously, the direct measurement of 
aminotransferase activity is difficult and has also resulted in AST activity being 
determined indirectly by measuring a-oxaloacetate production via L-malate (as 
displayed below). 
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a-oxoglutarate L-aspartate L-malate NAD+ 
""'~ / '\ / 
AST Malate Dehydrogenase (MDH) 
// 
~ ~ '\ 
L-glutamate a-oxaloacetate NADH~ + H+ 
Aspartic acid solution (pH 7.4) was prepared by mixing 2.66mg aspartic acid in 100ml 
aminotransferase buffer. Malate dehydrogenase (MDH) was prepared in distilled 
water to a concentration of 5mgmg·1. Oxaloacetic acid solution was prepared by 
dissolving O.735g oxaloacetic acid in SOml buffer and was stored at -20°C in Sml 
aliquots. 
In addition, a reaction mixture containing 36mg NADH, 19m1 buffer, 4.Sml aspartic 
acid solution and SOI-iI MDH was freshly prepared, of which 6S01-l1 was added to SOI-iI 
serum and mixed. The solution remained at room temperature for 15 mins to permit 
the NADH-dependent reduction of endogenous oxoacids. Finally, SO 1-1 I oxaloacetic 
acid was added to all samples and vortexed for ten seconds. The absorbance was 
read at 340nm every 30 secs for S mins and the catalytic activity was represented as 
U/L. 
4.3.9 Measurement of Blood Alcohol Levels 
Ethanol concentration was measured using a quantitative assay for gauging levels of 
alcohol in mouse serum. A commercial kit (AxSYM REA Ethanol Reagent Pack) (Ref 
3832-20) was based on the enzymatic method described by Shaffar and Stroupe 
(1983) using an Abbot Axsym® Analyser. The oxidation of ethanol is catalysed by 
alcohol dehydrogenase (ADH) which produces acetaldehyde and reduction of the 
coenzyme nicotinamide adenine dinucleotide NAD (Tietz, 1970). The resultant NAD 
reacts with monotetrazolium dye (MTT) in the presence of diaphorase to generate a 
colour change by which ethanol concentration can be determined (see below). 
ADH 
Ethanol + NAD+ Acetaldehyde + NADH + H+ 
Diaphorase 
NAD + H+MTT NAD+ + MT + Formazan 
The assay of ethanol concentration used 2001-11 of mouse serum which was stored 
frozen at 4°C prior to use. The samples, along with ethanol calibrators were loaded 
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onto reaction wells in the Abbot Axsym® Analyser and mixed with the 3 ethanol 
reagents from the commercial kit to determine the concentration of ethanol present. 
Low, medium and high dose calibrators were commercially provided (X Systems® 
REA Ethanol Calibrators) and displayed the range values as described in table 
(4.3.9.1). The reagents supplied included 5% nicotinamide adenine dinucleotide 
(NAD) in sodium citrate buffer, 5% yeast alcohol dehydrogenase and <1 % 
diaphorase in a protein stabiliser solution and <1 % monotetrazolium dye and <0.01 % 
fluorescein in solvent. Once the reactions were complete, values of experimental 
samples were calculated for ethanol concentration using a calibrated curve derived 
from the ethanol calibrators . 
.. ;L}~~·L£fl}J~!!!JL§.!<!!~d.<!!gJj. _ _ ___._______ _ ____________________________________ . 
Dose Level ~ Ethanol Concentration (mmOl/li Range (mmolll) 
-=~--_~_-_=~-:~=[<?~=~_=_-~=:===~=_ =:==~:_:==I()]E:==~=~_==:==~. =:=:-=·=_==_l·_~f~Ji·~~=_-:::::=_: 
Medium 21.71 16.94 - 26.47 ----------... ----"---,--------.~----.-~- - ---_ ... _ .. --.----------~.- .. ---~-.--~~-~--- -------------~---
54.27 43.50 - 65.03 ,----------_._-- --- .-- . __ .. -_ ....... _-------_ .. _------- ..... --_.- -- ... ----.. -.. -------------------. __ .-
AxSYM® system specific for this assay was used to calibrate controls. The values falling below 
the minimum range were calculated using a linear curve. 
4.4 Statistical Analyses 
Statistical analyses were performed using GraphPad Prism 4 Software. Comparisons 
were conducted between 2 treatment groups (e.g. heterozygous mice (db/wt) and 
homozygous mice (db/db)) using non-parametric, two-sided tests. To compare the 
effect of one treatment within groups (e.g. effects of alcohol in (db/wt) or (db/db) 
groups), non-parametric single variable analyses of variance (Kruskall-Wallis test) 
were conducted. Differences achieved statistical significance when p < 0.05. Linear 
regression was available on the same software. 
The majority of values being presented for statistical analyses will be displayed with 3 
decimal places unless more are required. 
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4.5 Animal Studies 
4.5.1 Assessment of the db/db Mouse Model on Regular Chow over 20 Weeks. 
Male and female 20 week old wild type (wt/wt) , heterozygous (db/wt) and 
homozygous (db/db) mice were received from an in-house breeding programme at 
the UCT Animal Facility. However, due to poor littering numbers, this study could not 
be conducted concurrently and as a result the animals were placed on the protocol 
and sacrificed as they became available over a 15 month period. The animal ethics 
approval reference for this study is 03/042. 
The mice were allocated into 3 different groups dependent on their genotype and 
assigned an animal number prior to termination. The resultant 3 groups based on the 
limited number of animals that did become available were made up as follows; 
6 Male and 6 Female wild type mice (wt/wt) 
16 Male, 8 Female heterozygous mice (db/wt) 
10 Male, 14 Female homozygous mice (db/db) 
During the study and prior to termination, the mice were housed by genotype, sex 
and litter parentage to minimise fighting. The animals were fed on a diet of regular 
chow (EPOL mice cubes reg no. V1787) over the 20 week period which consisted of 
the following; protein - 180g/kg, moisture - 120g/kg, fibre - 60g/kg, fat - 25g/kg, 
calcium - 18g/kg and phosphorous - 7g/kg. Sterilised wood shavings were used as 
bedding and suitable nesting material was also provided. The shavings and nesting 
were changed at least once a week. Temperature and humidity conditions were 
constantly controlled and a 12 hour light/dark cycle in operation. The mice were 
housed in Room 132 of the Rodent Accommodation Section at Chris Barnard 
Building, Cape Town South Africa. 
Body weights and glucose concentration were recorded at termination. 
The scheduled terminations occurred when the animals were 20 weeks old. The 
animals were killed by cardiac puncture, followed by exsanguination under a 
combination anaesthetic of ketamine and xylazine. The anaesthetic drugs are 
obtained from the suppliers with the following concentrations; 100mg/ml and 20 
mg/ml respectively. 1.2 ml of ketamine is mixed with 0.8 ml of xylazine and 8 ml of 
saline is added to give a final volume of 10 ml. Each mouse is injected with a dose of 
0.2 ml (i/p). 
Page 92 
Blood was collected in eppendorf tubes for protein and enzyme determination. Livers 
were removed after dissection and weighed before being wrapped in tin foil and 
snap-frozen in liquid nitrogen. The liver samples were stored at -80°C until required 
for biochemical analysis. Another portion of the liver was processed for histological 
examination. 
4.5.2 Impact of Various Oils, Administered via the Diet (4 Weeks) 
Male and female 12 week old heterozygous (db/+) mice were received from an in-
house breeding programme at the UCT Animal Facility on 24 January 2005. The 
animal ethics approval reference for this study is 04/029. 
The mice were randomly allocated into 4 treatment groups, assigned an animal 
number and allowed to acclimatise for a 1 week period prior to commencement of 
treatment. The 4 groups were made up as follows; 
3 Male and 3 Female heterozygous mice (db/wt) = Control; chow only 
3 Male and 3 Female heterozygous mice (db/wt) = Sunflower Oil 
3 Male and 3 Female heterozygous mice (db/wt) = Canola Oil 
3 Male and 3 Female heterozygous mice (db/wt) = Sunflower Oil and Cholesterol 
The mice were housed by sex and dose group. Sterilised wood shavings were used 
as bedding and suitable nesting material was also provided. The shavings and 
nesting were changed at least once a week. Temperature and humidity conditions 
were constantly controlled and a 12 hour light/dark cycle in operation. The study was 
conducted in Room 132 of the Rodent Accommodation Section at Chris Barnard 
Building, Cape Town South Africa. 
The feed used during this study was EPOL mice cubes reg no. V1787 (same 
nutritional contents as described previously 4.5.1) and was mixed with the various 
oils at 5g oil per 100g chow. The cholesterol was added at 60rng per 100g chow in 
addition to sunflower oil for the respective treatment group. The specially formulated 
diets were made available ad libitum to the animals. The diets were analysed for 
early, intermediate and late lipid peroxidation contents in an attempt to gauge the 
differences between the diets being administered to the animals (figure 4.5.2.1). 
Water was also made ad libitum to the mice. 
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The animals were dosed continuously via their diet for 4 consecutive weeks. Body 
weights were recorded weekly and at termination. The scheduled terminations 
occurred after completion of 4 weeks of treatment. The animals were killed by 
cardiac puncture, followed by exsanguination under ketamine and xylazine 
anaesthesia (as described in 4.5.1). Blood was collected in eppendorf tubes for 
protein determination. Livers were dissected and weighed before being wrapped in 
tin foil and snap 'frozen in liquid nitrogen. The liver samples were stored at -80 DC 
until required for biochemical analysis. Another portion of the liver was processed for 
histological examination. 
4.5.3 Study of Short Period of Alcohol Administration (4 Weeks) 
Male and female 14 week old wild type (wt/wt) , heterozygous (db/wt) and 
homozygous (db/db) mice were received "from an in-house breeding programme at 
the UCT Animal Facility. However, due to poor littering numbers, this study could not 
be conducted concurrently and as a result the animals were added as they became 
available over a 7 month period. The animal ethics approval reference for this study 
is 03/042. 
The mice were allocated into 6 treatment groups, assigned an animal number and 
allowed to acclimatise for a 1 week period prior to commencement of treatment. The 
resultant 6 groups based on the limited number of animals that did become available 
were made up as follows; (please note that saccharine was used to disguise the 
taste of alcohol to ensure the mice drunk 'from their water bottles). 
1 M, 1 F wild type mice (wtlwt) = Water and 0.025% (w/v) Saccharine 
1 M, 1 F wild type mice (wt/wt) = 20% Ethanol and 0.025% (w/v) Saccharine 
2M, 2F heterozygous mice (db/wt) = Water and 0.025% (w/v) Saccharine 
2M, 2F heterozygous mice (db/wt) = 20% Ethanol and 0.025% (w/v) Saccharine 
2M, 2F homozygous mice (db/db) = Water and 0.025% (w/v) Saccharine 
1 M, 3F homozygous mice (db/db) = 20% Ethanol and 0.025% (w/v) Saccharine 
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The mice were housed by genotype, dose group and litter parentage to minimise 
fighting. Sterilised wood shavings were used as bedding and suitable nesting 
material was also provided. The shavings and nesting were changed at least twice a 
week. Temperature and humidity conditions were constantly controlled and a 12 hour 
light/dark cycle in operation. The water-ethanol mixes were prepared twice weekly 
and stored under a seal to prevent evaporation of alcohol. The study was conducted 
in Room 132 of the Rodent Accommodation Section at Chris Barnard Building, Cape 
Town South Africa. 
The animals being treated with 20% ethanol and 0.025% (w/v) saacharine, were 
given a 2 week adaptation period to reach the required concentration of ethanol. At 
the start of treatment, the ethanol concentration was 3% and increased by 3% 
intervals every 2 days until the required 20% concentration was achieved. These 
animals were then treated with the desired 20% concentration for 4 weeks. The 
ethanol and water for their respective treatment groups were made available ad 
libitum to the animals. The feed used during this study was EPOL mice cubes and 
was also made ad libitum. 
All animals were dosed continuously via their water bottles for 6 consecutive weeks. 
The animals being treated with ethanol had 2 weeks adaptation and 4 weeks at 20% 
concentration. Body weights were recorded weekly and at termination. 
The scheduled terminations occurred when the animals were 20 weeks old. The 
animals were killed by cardiac puncture, followed by exsanguination under ketamine 
and xylazine anaesthesia (as described in 4.5.1). Blood was collected in eppendorf 
tubes for protein and enzyme determination. Livers were dissected and were 
unfortunately not weighed before being wrapped in tin foil and snap frozen in liquid 
nitrogen due to a technical error. The liver samples were stored at -80°C until 
required for biochemical analysis. Another portion of the liver was processed for 
histological examination. 
4.5.4 Impact of Alcohol Administered over 8 Weeks in db/wt and db/db Mice 
Male 5 week old heterozygous (db/wt) mice and homozygous (db/db) mice were 
received from Jackson Laboratory, Bar Harbour, Maine, USA on 28 January 2005 
and were immediately housed in the UCT Animal Facility for a 4 week acclimatisation 
period prior to commencement of treatment. The animal ethics approval reference for 
this study is 03/042. 
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Following the acclimatisation period, the mice (all male) were randomly allocated into 
4 treatment groups and assigned an animal number. The 4 groups were made up as 
follows; (please note that saccharine was used to disguise the taste of alcohol to 
ensure the mice drunk from their water bottles). 
7 heterozygous mice (db/wt) = Water and 0.025% (w/v) Saccharine 
6 heterozygous mice (db/wt) = 20% Ethanol and 0.025% (w/v) Saccharine 
7 homozygous mice (db/db) = Water and 0.025% (w/v) Saccharine 
5 homozygous mice (db/db) = 20% Ethanol and 0.025% (w/v) Saccharine 
The mice were housed by genotype, dose group and litter parentage to minimise 
fighting. Sterilised wood shavings were used as bedding and suitable nesting 
material was also provided. The shavings and nesting were changed at least twice a 
week. 
Temperature and humidity conditions were constantly controlled and a 12 hour 
light/dark cycle in operation. The water-ethanol mixes were prepared twice weekly 
and stored under a seal to prevent evaporation of alcohol. The study was conducted 
in Room 132 of the Rodent Accommodation Section at Chris Barnard Building, Cape 
Town South Africa. 
The animals being treated with 20% ethanol and 0.025% (w/v) saccharine were given 
a 3 week adaptation period to reach the required concentration of ethanol. At the 
start of treatment, the ethanol concentration was 2% and increased by 2% intervals 
every 2 days until the required 20% concentration was achieved. These animals 
were then treated with the desired 20% concentration for 8 weeks. The ethanol and 
water for their respective treatment groups were made available ad libitum to the 
animals. The feed used during this study was EPOL mice cubes and was also made 
ad libitum. 
All animals were dosed continuously via their water bottles for 11 consecutive weeks. 
The animals being treated with ethanol had 3 weeks adaptation and 8 weeks at 20% 
concentration. Body weights were recorded weekly and at termination. 
The scheduled terminations occurred when the animals were 20 weeks old. The 
animals were killed by cardiac puncture, followed by exsanguination under ketamine 
and xylazine anaesthesia (as described in 4.5.1). Blood was collected in eppendorf 
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tubes for protein and enzyme determination. Livers were dissected and weighed 
before being wrapped in tin foil and snap frozen in liquid nitrogen. The liver samples 
were stored at -80°C until required for biochemical analysis. Another portion of the 
liver was processed for histological examination. 
4.5.5 Impact of Alcohol Administered over 20 Weeks in db/wt and db/db Mice 
Male 5 week old heterozygous (db/wt) mice and homozygous (db/db) mice were 
received from Jackson Laboratory, Bar Harbour, Maine, USA on 28 January 2005 
and were immediately housed in the UCT Animal Facility for a 4 week acclimatisation 
period prior to commencement of treatment. The animal ethics approval reference for 
this study is 03/042. 
Following the acdimatisation period, the mice (all male) were randomly allocated into 
4 treatment groups and assigned an animal number. The 4 groups were made up as 
follows; (please note that saccharine was used to disguise the taste of alcohol to 
ensure the mice drunk from their water bottles). 
7 heterozygous mice (db/wt) = Water and 0.025% (w/v) Saccharine 
7 heterozygous mice (db/wt) = 20% Ethanol and 0.025% (w/v) Saacharine 
7 homozygous mice (db/db) = Water and 0.025% (w/v) Saccharine 
7 homozygous mice (db/db) = 20% Ethanol and 0.025% (w/v) Saacharine 
The mice were housed by genotype, dose group and litter parentage to minimise 
fighting. Sterilised wood shavings were used as bedding and suitable nesting 
material was also provided. The shavings and nesting were changed at least twice a 
week. Temperature and humidity conditions were constantly controlled and a 12 hour 
light/dark cycle in operation. The water-ethanol mixes were prepared twice weekly 
and stored under a seal to prevent evaporation of alcohol. The study was conducted 
in Room 132 of the Rodent Accommodation Section at Chris Barnard Building, Cape 
Town South Africa. 
The animals being treated with 20% ethanol and 0.025% (w/v) saacharine, were 
given a 3 week adaptation period to reach the required concentration of ethanol. At 
the start of treatment, the ethanol concentration was 2% and increased by 2% 
intervals every 2 days until the required 20% concentration was achieved. These 
animals were then treated with the desired 20% concentration for 20 weeks. The 
ethanol and water for their respective treatment groups were made available ad 
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libitum to the animals. The feed used during this study was EPOL mice cubes and 
was also made ad libitum 
All animals were dosed continuously via their water bottles for 20 consecutive weeks. 
The animals being treated with ethanol had 3 weeks adaptation and 20 weeks at 
20% concentration. Body weights were recorded weekly and at termination. 
The scheduled terminations occurred when the animals were 32 weeks old. The 
animals were killed by cardiac puncture, followed by exsanguination under ketamine 
and xylazine anaesthesia (as described in 4.5.1). Blood was collected in eppendorf 
tubes for protein and enzyme determination. Livers were dissected and weighed 
before being wrapped in tin foil and snap frozen in liquid nitrogen. The liver samples 
were stored at -80°C until required for biochemical analysis. Another portion of the 
liver was processed for histological examination. 
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Chapter 5; Results of Studies 
The results are presented for both biochemical and histological studies. The raw data 
are tabulated and appended (chapters 8&9 respectively) and the process data shall 
be presented in this chapter. The anthropometric data of each study will be 
presented before liver composition and health related parameters (glucose, alcohol 
and transaminases). The lipid peroxidation having to be presented in this context will 
be presented last. Although some comment is made in this chapter, the interpretation 
of the information will take place in the next chapter. The emphasis is to give an 
account of all the data generated in each study. This will take the format mainly of 
histograms. The aim is to examine macroscopic, microscopic and biochemical 
features of the liver as well as morphometric aspects of animal on regular chow for 
20 wks in wt/wt, db/wt and db/db animals. 






Figure 5.1.1: Body mass of wt/wt (n=12), db/wt (n=24) and db/db (n=24) mice on regular 
chow for 20 weeks. The mass in db/db animals was significantly elevated in comparison to 
the wt/wt (,0<0.0001) and db/wt animals (p<O.0001). The db/wt group displayed a slightly 
increased mean body mass when compared to the wt/wt group (p=0.0003). Data represented 












Figure 5.1.2: Liver mass of wtlwt (n=12). db/wt (n=12) and db/db (n=12) mice on regular 
chow for 20 weeks. The increase in liver mass of db/db mice is significant when compared to 
wtlwt and db/wt mice (p<0.0001 for both). The db/wt group revealed a slight increase relative 



















Figure 5.1.3: Liver proportion of body mass of wtlwt (n=12), db/wt (n=12) and db/db (n=12) 
mice on regular chow for 20 weeks . The resultant liver mass/body mass ratios were not 

























Figure 5.1.4: Plasma glucose concentration in livers from wtlwt (n=12), db/wt (n=24) and 
db/db (n=24) mice on regular chow for 20 weeks. Glucose levels were significantly increased 
in db/db animals when compared to the wt/wt and db/wt groups; (J)<0.0001 for both). The 
slight increase in the average glucose db/wt group in contrast to the wtlwt group was not 
statistically significant. Data represented as mean ± SD. 
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Figure 5.1.5: Triglycerides in livers from wt/wt (n=12), db/wt (n=24) and db/db (n=24) mice on 
regular chow for 20 weeks. TG were significantly raised in db/db mice when compared to 
wt/wt mice (p<D.0001) and db/wt mice (p<D.0001), but there was no significant differences 





















Figure 5.1.6: Total cholesterol concentrations in livers from wt/wt (n=12), db/wt (n=24) and 
db/db (n=24) mice on regular chow for 20 weeks. TC was significantly elevated in db/db mice 
in contrast to wt/wt and db/wt mice (p<O.0001 for both). Concentrations for wtlwt and db/wt 
























Figure 5.1.7: Conjugated dienes as early lipid peroxidation products in livers from wt/wt 
(n=12), db/wt (n=24) and db/db (n=24) mice on regular chow for 20 weeks. Conjugated 
Dienes were significantly higher in db/db animals (p<O.0001) in comparison to wt/wt and db/wt 
respectively. A statistically significant increase is also present in the db/wt group when 
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Figure 5.1.8: LOOH as intermediate lipid peroxidation products mean in livers from wtlwt 
(n=12), db/wt (n=24) and db/db (n=24) mice on regular chow for 20 weeks. Statistical 
significance pertained when db/db mice were compared to the wtlwt and db/wt animals 
(p<O.0001 for both). Data represented as mean ± SD. 
* 
c=::I (wt/wt) 












(wtlwt) (db/wt) (db/db) 
Group 
Figure 5.1.9: TTBARS as late lipid peroxidation products in livers from wtlwt (n=12), db/wt 
(n=24) and db/db (n=24) mice on regular chow for 20 weeks. Concentrations of TTBARS in 
db/db mice vs wtlwt mice was not statistically significant (p=0.247) whereas db/db vs db/wt 
did attain statistical significance (p<O.0001). Data represented as mean ± SO. 
Page 103 
5.2 Impact of Various Oils, Administered via the Diet (4 Weeks) 
The aim was to evaluate the impact on lipid and lipid peroxide parameters in the 
livers of db/wt mice fed diets enriched with edible oils and cholesterol over 4 weeks 
subsequent to a 2 wk acciimatisation period. Canola oil provides MUFA and 
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Figure 5.2.1: Body mass in control (chow only) (n=6) and 4 week supplemented sunflower oil 
(n=6), canola oil (n=6) or sunflower oil and cholesterol (n=6) in db/wt mice aged 17 weeks. 
The body mass was recorded for 1 week acclimatisation prior to the 4 week treatment period. 
There is slight variation in body weight gain and loss over the treatment period but the mean 
weight gain of all groups is reasonably comparable, controls; + 1.2g, sunflower oil; + 1.2g; 
canola oil ; +0.8g, sunflower oil and cholesterol; +0.7g. Data represented as mean ± SO. 
Group / Treatment M 
(a) Control 0.252 ± 0.06 
(b) Sunflower Oil 0.301 ± 0.12 
(e) Canola Oil 0.111 ±0.12 
(d) Sunflower Oil/Cholesterol 0.198 ± 0.15 
a v b; (p=0.73) not statistically significant 
a v c; (p=0.31) not statistically significant 
a v d; (p:O.74) not statistically significant 
C (y when x=O) ( 
18.9±0.84 0.8283 
18.3 ± 1.79 0.6019 
21 .6 ± 1.69 0.1875 
21.1 ±2.16 0.3102 
Figure 5.2.2: The gradients of mean weight gain were contrasted for the alcohol-
supplemented and control groups for control (chow only) (n=6) and 4 week supplemented 
sunflower oil (n=6), canola oil (n=6) or sunflower oil and cholesterol (n=6) in db/wt mice aged 
17 weeks. Statistical significance was not attained in either treatment group relative to the 
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Figure 5.2.3: Liver mass in control (chow only) (n==6) and 4 week supplemented sunflower oil 
(n=6), canola oil (n==6) or sunflower oil and cholesterol (n=6) in db/wt mice aged 17 weeks. 
The groups were comparable, no statistically significant change was achieved in any group 
and specific comparison to the controls revealed no differences: sunflower oil; (p=O.82), 
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Figure 5.2.4: Liver proportion of body mass in control (chow only) (n==6) and 4 week 
supplemented sunflower oil (n==6), canola oil (n==6) or sunflower oil and cholesterol (n=6) in 
db/wt mice aged 17 weeks. The canola oil group had a statistically significant difference from 
controls; (p=O.0019), whereas this was not achieved in the other groups, sunflower oil; 
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Figure 5.2.5: Plasma glucose concentration in control (chow only) (n=6) and 4 week 
supplemented sunflower oil (n=6), canola oil (n=6) or sunflower oil and cholesterol (n=6) in 
db/wt mice aged 17 weeks. Statistical significance was not achieved in any treatment group, 
sunflower oil; (p=O.38), canola oil; (p=O.34), sunflower oil and cholesterol; (0.083). Data 
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Figure 5.2.6: Triglycerides in livers from control (chow only) (n=6) and 4 week supplemented 
sunflower oil (n=6), canola oil (n=6) or sunflower oil and cholesterol (n=6) in db/wt mice aged 
17 weeks. Statistical significance was only reached in canola oil treated animals; (p=O.036) 
whereas sunflower oil; (p=O.28) and sunflower oil and cholesterol; (p=0.25) did not differ 
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Figure 5.2.7: Total cholesterol concentrations in livers from control (chow only) (n=6) and 4 
week supplemented sunflower oil (n=6), canola oil (n=6) or sunflower oil and cholesterol (n=6) 
in db/wt mice aged 17 weeks. The levels of total cholesterol were increased in the treatment 
groups in contrast to control animals, reaching statistical significance in mice treated with 
sunflower oil; (p=O.0018) and with sunflower oil and cholesterol; (p=O.007), but not for the 
























c:::::::J Control (chow) 
c::::J Suntower Oil 
Canola Oil 
_ Sunflower Oil / 
Cholesterol 
Figure 5.2.8: Conjugated dienes as early lipid peroxidation products in livers from control 
(chow only) (n=6) and 4 week supplemented sunflower oil (n=6), canola oil (n=6) or sunflower 
oil and cholesterol (n=6) in db/wt mice aged 17 weeks. Statistical significance was achieved in 
the sunflower oil treated mice; (p=O.0019) and the sunflower oil and cholesterol treated mice; 
(p=O.0002). The canola oil treated animals did not reach statistical significance; (p=O.1 01 ). 


























c::::::J Control (chow) 
Sunlower Oil 
_ Canola Oil 
_ Sunflower Oil I 
Cholesterol 
Figure 5.2.9: LOOH as intermediate lipid peroxidation products in livers from control (chow 
only) (n=6) and 4 week supplemented sunflower oil (n=6), canola oil (n=6) or sunflower oil 
and cholesterol (n=6) in db/wt mice aged 17 weeks. In comparison to the control animals, 
statistical significance was not displayed in any group, sunflower oil; (p=O.49), canola oil; 










c::::::J Control (chow) 
Sunlower Oil 
Canola Oil 
_ Sunflower Oil I 
Cholesterol 
Figure 5.2.10: TTBARS as late lipid peroxidation products in livers from control (chow only) 
(n=6) and 4 week supplemented sunflower oil (n=6), canola oil (n=6) or sunflower oil and 
cholesterol (n=6) in db/wt mice aged 17 weeks. No statistical significance was found, 
sunflower oil; (p=O.18), canola oil; (p=O.45) , sunflower oil and cholesterol; (p=O.31). Data 










c::::::::J Control (chow) 
c::::::::J Sunftower Oil 
_ Canola Oil 
_ Sunflower Oil I 
Cholesterol 
Figure 5.2.11: BeA protein in homogenate from control (chow only) (n=6) and 4 week 
supplemented sunflower oil (n=6), canola oil (n=6) or sunflower oil and cholesterol (n=6) in 
db/wt mice aged 17 weeks. No statistically significant difference was found when comparing 
the control group with those consuming: sunflower oil; (p=O.86), canola oil; (p=O.58), 
sunflower oil and cholesterol; (p=O.48). Data represented as mean ± SO. 
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5.3 Study of Short Period of Alcohol Administration (4 Weeks) 
The aim is to examine macroscopic, microscopic and biochemical features of the 
liver as well as morphometric aspects of animal on 20% alcohol for 4 weeks in wtlwt, 
db/wt and db/db animals. 
(wt/wt) Control HP 
ti (wt/wt) 20% Alcohol a 
a a (db/wt) Control H2O 
Q/ D 
3: - (db/wt) 20% Alcohol 
>- - (db/db) Control H2O '1:J 
0 
m a (db/db) 20% Alcohol 
>-




13 14 15 16 17 18 19 20 21 
Age (Weeks) 
Figure 5.3.1: Body mass in control and 4 weeks alcohol·supplemented wtlwt (n=4), db/wt 
(n=8) and db/db (n=8) mice aged 20 weeks. The body mass was recorded for 2 weeks prior 
to the 4 weeks alcohol administration during which the alcohol·treated animals were allowed 
to acclimatise to increasing concentrations of alcohol until the full 20% concentration was 
achieved. The mean weight gain for alcohol vs. control animals in wtlwt, db/wt and db/db 
groups were comparative. Data represented as mean 1: SO. 
Group I Treatment m 
(a) wVwt - Control (H2O) 0.268 ± 0.09 
(b) wVwt - Alcohol (20%) 0.214 ± 0.07 
(c) db/wt- Control (H2O) 0.250 ± 0.03 
(d) db/wt- Alcohol (20%) 0.041 ± 0.04 
(e) db/db- Control (H2O) 0.291 ± 0.09 
(t) db/db - Alcohol (20%) 0.629 ± 0.07 
a v b; (p=0.657) not statistically significant 
c v d; (p=0.002) statistically significant 
e v f; (p=O.014) statistically significant 
C (y when x=O) r2 
14.2±1.61 0.6181 
14.9±1.19 0.6545 
20.7 ± 0.59 0.9119 
21.8 ± 0.65 0.1875 
32.6 ± 1.50 0.6898 
26.0 ± 1.23 0.9392 
Figure 5.3.2: The gradients of mean weight gain were contrasted for the alcohol· 
supplemented and control groups for wtlwt (n=4), db/wt (n=8) and db/db (n=8) mice aged 20 
weeks. The difference between wtlwt animals was not statistically Significant (p=O.66) 
whereas statistical significance was attained when comparing control and alcohol-
supplemented animals for db/wt and db/db groups (p=O.002 and p=O.014 respectively). Data 



















c::::::::J Co n tro I (H 20) 
c::::J 20% Alcohol 
c:::::=:J Conlrol (H 20) 
c::::J 20% Alcohol 
Ic:::::I Co n tro I (H 20) 
_ 20% Alcohol 
Figure 5.3.3: Triglycerides in livers from control and 4 weeks alcohol-supplemented wtlwt 
(n=4), db/wt (n=8) and db/db (n=8) mice aged 20 weeks. Triglyceride concentration was 
increased in alcohol-treated db/db mice relative to the controls (p<D.0001). The triglyceride 
content was also increased in the other groups, although statistical significance could only be 
evaluated in the alcohol-treated and control db/wt animals (p=O.009). Data represented as 



















c::::::::J Co n tro I (H 20) 
c::::J 20% Alcohol 
c::::::::J Control (H 20) 
c::::J 20% Alcohol 
c:::::J Control (H20) 
_ 20% Alcohol 
Figure 5.3.4: Total cholesterol concentration in livers from control and 4 weeks alcohol-
supplemented wtlwt (n=4), db/wt (n=8) and db/db (n=8) mice aged 20 weeks. Alcohol-treated 
mice again exhibited slightly higher values than controls but only the elevation in db/wt 
alcohol-treated mice was of statistical significance against their respective controls (p=O.005). 










c::::J Control (H20) 
c:::::::::J 20% A Ic 0 ho I 
c::::J Control (H20) 
c:::::::::J 20% A Ic 0 ho I 
Control (H20) 
_ 20% Alcohol 
Figure 5.3.5: Conjugated dienes as early lipid peroxidation products in livers from control and 
4 weeks alcohol-supplemented wtlwt (n=4), db/wt (n=8) and db/db (n=8) mice aged 20 
weeks. Conjugated dienes were slightly raised in alcohol-treated animals when compared to 


























c::::J Control (H 20) 
c::::::::J 20% A Ic 0 ho I 
c::::J Control (H~) 
c:::::::::J 20% A Ic 0 ho I 
E::=:J Control (H20) 
_ 20% Alcohol 
Figure 5.3.6: LOOH as intermediate lipid peroxidation products in livers from control and 4 
weeks alcohol-supplemented wtlwt (n=4), db/wt (n=8) and db/db (n=8) mice aged 20 weeks. 
All alcohol-treated groups in comparison with their respective water-treated control animals, 
appeared to have small increases of average LOOH but statistical significance was not 












* ~ Control (H20) 
c::::J 20% Alcohol 
~ Control (H20) 
c::::J 20% Alcohol 
c::::::J Control (H 20) 
20% Alcohol 
Figure 5.3.7: TTBARS as late lipid peroxidation products in livers from control and 4 weeks 
alcohol-supplemented wtlwt (n=4). db/wt (n=8) and db/db (n=8) mice aged 20 weeks. All 
alcohol-treated groups displayed increases when compared to their respective control groups. 
The levels of TTBARS were shown to be statistically significant for db/wt alcohol-treated vs. 
control (p=O.037) and db/db alcohol-treated vs . control (p=O.0003). Data represented as 
mean ± SO. 
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5.4 Impact of Alcohol Administered over 8 Weeks in db/wt and db/db Mice 
The aim is to examine macroscopic, microscopic and biochemical features of the 
liver as well as morphometric aspects of animal on 20% alcohol for 8 weeks in db/wt 
and db/db animals. 
* • • * ....... 
(db/wt) Control H20 
---r- (db/wt) 20% Alcohol 
-.- (db/db) Control H20 
~ (db/db) 20% Alcohol 
~~~~~~~r-,-~-r~~~r-,-~ 
8 9 10 11 12 13 14 15 16 17 18 19 ~ 21 
Age (Weeks) 
Figure 5.4.1: Body mass in control and 8 week alcohol-supplemented db/wt (n=7, n=6 
respectively) and db/db (n=6, n=5) mice aged 20 weeks. The body mass was recorded for 3 
weeks prior to the 8 weeks alcohol administration of 20% ethanol concentration during which 
the alcohol-treated animals were allowed to acclimatise to increasing concentrations of 
alcohol until the full 20% concentration was achieved. The mean body mass of alcohol-
treated db/wt mice was comparable to their respective controls throughout the entire 
treatment period, however the mean weight gain over the same duration was slightly 
decreased for the alcohol-treated group; +4.5g compared with +6.8g for the controls. The 
body mass for the db/db animals were comparable for the first half of the treatment period but 
notable changes became apparent soon after and also resulted in a decreased weight gain 
for the alcohol treated db/db mice; +5.2g compared with + 7.4g for the controls. Data 
represented as mean ± SO. 
Group / Treatment (8wk) m C (y when x=O) r 
(a) db/wt - Control (H2O) 0.655 ± 0.06 20.2 ± 0.83 0.9324 
(b) db/wt - Alcohol (20%) 0.414 ± 0.28 23.6 ± 0.41 0.9577 
(c) db/db - Control (H2O) 0.601 ±0.10 41.1±1.54 0.7728 
(d) db/db - Alcohol (20%) 0.397 ± 0.09 43.1 ± 1.38 0.6480 
a v b; (.0=0.0009) statistically significant 
c v d; (.0=0.155) not statistically significant 
Figure 5.4.2: The gradients of mean weight gain were contrasted for 8 week alcohol-
supplemented db/wt (n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 weeks. The 
difference between db/db animals was not statistically significant (p=O.155) whereas 
statistical significance was attained when comparing control and alcohol-supplemented 








c::::::J Co n tro I (H 20) 
u::::::::::J 20% Alcohol 
_ Control (H20) 
_ 20% Alcohol 
Figure 5.4.3: Liver mass in control and 8 week alcohol-supplemented db/wt (n=7, n=6 
respectively) and db/db (n=6, n=5) mice aged 20 weeks. The increases in alcohol-treated 
db/wt mice compared with the controls was found to be statistically significant (p<O.0001), but 








...J (db/wt) (db/wt) (db/db) (db/db) 
Group 
c:::::J Control (H 20) 
J::::=J 20% Alcohol 
_ Control (H20) 
_ 20% Alcohol 
Figure 5.4.4: Liver proportion of body mass in control and 8 week alcohol-supplemented 
db/wt (n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 weeks. The liver mass/body 
mass ratios demonstrated a significant increase in alcohol-treated db/wt mice when compared 


















(db/wt) (db/wt) (db/db) (db/db) 
Group 
c:::::J Control (H~) 
t=:::lI20% Alcohol 
_ Control (H~) 
_ 20% Alcohol 
Figure 5.4.5: Plasma glucose concentrations in blood from control and 8 week alcohol-
supplemented db/wt (n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 weeks. 
Glucose concentrations were decreased in alcohol-treated animals, attaining statistical 
significance in db/wt mice; (.0=0.006) but not in db/db mice; (,D=0.54). Data represented as 

















c:::::J Control (H20) 
IE::::=:] 20% Alcohol 
_ Control (H~) 
_ 20% Alcohol 
Figure 5.4.6: Alcohol concentrations in blood in serum from control and 8 week alcohol-
supplemented db/wt (n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 weeks . The 
alcohol-treated animals displayed higher levels of ethanol than their respective controls but 
statistical significance was not achieved in either group, db/wt mice; (p=O.055), db/db mice; 










(db/wt) (db/db) (db/db) 
Group 
c::::J Control (H~) 
t::::l20% Alcohol 
_ Control (H 20) 
_ 20% Alcohol 
c::::J Control (H~) 
20% Alcohol 
_ Control (H~) 
_ 20% Alcohol 
Figure 5.4.7: Plasma AST and AL T levels in serum from control and 8 week alcohol-
supplemented db/wt (n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 weeks. (A) 
Mice treated with alcohol displayed no significant increase in AST in either group, db/wt mice; 
(p=O .29), db/db mice (p=0.26). (8) AL T levels were not significantly different between controls 
and alcohol-supplemented groups, db/wt mice (p=O.49), db/db mice (p=O.83). Data 


















c::::::J Control (H 20) 
c:::::::J 20% Alcohol 
_ Control (H~) 
_ 20% Alcohol 
Figure 5.4.8: Triglycerides in livers from control and 8 week alcohol-supplemented db/wt 
(n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 weeks. Triglycerides had a 
statistically significant increase in alcohol-treated groups in contrast to their controls, db/wI 
mice; (p=0.004) and db/db mice; (p=0.008) Furthermore the elevated levels in db/wI alcohol 
treated mice were marginally raised in contrast to the db/db controls but was not statistically 






















c::::::J Control (H 20) 
c:::::::J 20% Alcohol 
_ Control (H~) 
_ 20% Alcohol 
Figure 5.4.9: Mean total cholesterol concentrations in livers from control and 8 week alcohol-
supplemented db/wt (n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 weeks. Total 
cholesterol attained statistically significant increases in alcohol-treated animals when 
compared to their respective controls, db/wt mice; (p=O.008) and db/db mice; (p=O.010). Data 

























c:::::J Control (H 20) 
~ 20% Alcohol 
_ Control (H 20) 
_ 20% Alcohol 
Figure 5.4.10: Conjugated dienes as early lipid peroxidation products in livers from control 
and 8 week alcohol-supplemented db/wt (n=7. n=6 respectively) and db/db (n=6. n=5) mice 
aged 20 weeks . Conjugated dienes were significantly increased in alcohol-treated animals for 



























~ Control (H20) 
.::::::=::JI20% Alcohol 
_ Control (H20) 
_ 20% Alcohol 
Figure 5.4.11: LOOH as intermediate lipid peroxidation products in livers from control and 8 
week alcohol-supplemented db/wt (n=7. n=6 respectively) and db/db (n=6. n=5) mice aged 20 
weeks . The concentrations of lipid hydroperoxides displayed statistically significant increases 
in alcohol-treated groups for db/wt and db/db animals; (p<O.0001 for both groups). Data 







(db/wt) (db/db) (db/db) 
Group 
c::::::::J Control (H~) 
t::=:lI20% Alcohol 
_ Control (H~) 
_ 20% Alcohol 
Figure 5.4.12: TTBARS as late lipid peroxidation products in livers from control and 8 week 
alcohol -supplemented db/wi (n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 
weeks. Increases in TTSARS were statistically significant for alcohol-treated groups in db/wi 
mice; (p<O.0001) and db/db mice; (p<0 .0001) when compared to respective controls . Data 













c::::::::J Control (H~) 
t=::J 20% Alcohol 
_ Control (H 20) 
_ 20% Alcohol 
Figure 5.4.13: BCA protein in livers from control and 8 week alcohol-supplemented db/wt 
(n=7, n=6 respectively) and db/db (n=6, n=5) mice aged 20 weeks . SCA concentrations were 
determined for all groups and despite small increased changes being recorded for alcohol-
treated animals, statistical significance was not attained in dblwt mice; (p=O.26) or db/db mice 
(p=O .35) . Data represented as mean ± SO. 
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5.5 Impact of Alcohol Administered over 20 Weeks in db/wt and db/db Mice 
The aim is to examine macroscopic, microscopic and biochemical features of the 
liver as well as morphometric aspects of animal on 20% alcohol for 20 weeks in db/wt 
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Figure 5.5.1: Body mass in control and 20 week alcohol-supplemented db/wt (n=7, n=4 
respectively) and db/db (n=6, n=6) mice aged 32 weeks. The body mass was recorded for 3 
weeks prior to the 20 weeks alcohol administration of 20% ethanol concentration during which 
the alcohol-treated animals were allowed to acclimatise to increasing concentrations of 
alcohol until the full 20% concentration was achieved. The body mass of alcohol-treated 
animals and their respective controls were comparable at the start of the treatment period for 
db/wt and db/db mice. However after approximately 4-5 weeks of treatment, both sets of 
controls appear to have a slightly increased rate of weight gain when compared to the 
alcohol-treated mice. This lower degree of weight gain is never recovered and is 
demonstrated by the resulting differences between the groups over the treatment period. In 
db/wt mice, the mean weight gain for the controls is +6.4g compared with 1.2g for alcohol-
treated animals whereas the respective gains for db/db mice are + 12.3g and +6.8g. Data 
represented as mean ± SO. 
Group / Treatment (20wk) m 
(a) db/wt- Control (H2O) 0.215 ± 0.04 
(b) db/wt - Alcohol (20%) 0.159 ± 0.02 
(c) db/db - Control (H2O) 0.473 ± 0.07 
(d) db/db - Alcohol (20%) 0.200 ± 0.05 
a v b; (p=0.18) not statistically significant 
c v d; (p=0.003) statistically significant 
C (y when x=O) ~ 
29.9 ± 0.82 0.5942 
26.8 ± 0.32 0.8385 
45.1 ± 1.54 0.6673 
46.5 ± 1.11 0.4093 
Figure 5.5.2: Slope analysis mass in control and 20 week alcohol-supplemented db/wt (n=7, 
n=4 respectively) and db/db (n=6, n=6) mice aged 32 weeks. The body mass was recorded 
for 3 weeks prior to the 20 weeks alcohol administration of 20% ethanol concentration. 
Results from the gradient analysis were contrary to 8wk study as difference between db/wt 
animals was not statistically significant (p=O.18) whereas statistical significance was attained 
when comparing control and alcohol-supplemented animals for db/db groups (p=O.003). Data 











Figure 5.5.3: Liver mass in control and 20 week alcohol-supplemented db/wt (n=7, n=4 
respectively) and db/db (n=6, n=6) mice aged 32 weeks. There was no statistical significance 
reached in db/db mice; (p=O.55). In db/wt mice; statistical significance was achieved; 
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Control (H 20) 
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Figure 5.5.4: Liver proportion of body weight in control and 20 week alcohol supplemented 
db/wt (n=7, n=4 respectively) and db/db (n=6, n=6) mice aged 32 weeks. Liver mass/body 
mass ratios from alcohol-treated animals, the differences between the db/db groups achieved 
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Control (H~) 
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Figure 5.5.5: Plasma glucose concentrations in blood from control and 20 week alcohol-
supplemented db/wt (n=7, n=4 respectively) and db/db (n=6, n=6) mice aged 32 weeks. The 
glucose concentrations were lower for both groups in comparison to the controls, but the 
results did not show statistical significance for either db/wt mice; (p= 0.63) or db/db mice; 




















c::::::J Control (H 20) 
_ 20% Alcohol 
Control (H 20) 
_ 20% Alcohol 
Figure 5.5.6: Alcohol concentrations in blood from control and 20 week alcohol-
supplemented db/wt (n=7, n=4 respectively) and db/db (n=6, n=6) mice aged 32 weeks. The 
increase in db/wt alcohol-treated mice was shown to be statistically significant in comparison 
to the controls; (p=O.0054) but not in alcohol-treated db/db mice; (p=O.31). Data represented 
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c::::J Control (H20) 
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Control (H 20) 
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Figure 5.5.7: AST and AL T levels in serum from control and 20 week alcohol-supplemented 
db/wt (n=7, n=4 respectively) and db/db (n=6, n=6) mice aged 32 weeks. (A) The AST levels 
gained statistical significance for db/wt mice; (p=O.037) but not for db/db mice; (p=O.64). (8) 
The levels of AL T between alcohol-treated and control animals of their respective groups 
were not statistically significantly different for db/wt mice; (p=O.75) and db/db mice; (p=O.62). 



















c::::J Control (H20) 
20% Alcohol 
Control (H 20) 
_ 20% Alcohol 
Figure 5.5.8: Triglycerides in livers from control and 20 week alcohol-supplemented db/wt 
(n=7, n=4 respectively) and db/db (n=6, n=6) mice aged 32 weeks. Triglycerides were 
increased in alcohol-treated groups in contrast to their respective controls for db/wt mice; 























c::::::::J Co n lro I (H 20) 
_ 20% Alcohol 
Conlrol (H 20) 
_20% Alcohol 
Figure 5.5.9: Total cholesterol concentration in livers from control and 20 week alcohol-
supplemented db/wt (n=7, n=4 respectively) and db/db (n=6, n=6) mice aged 32 weeks. The 
increases of total cholesterol detected in alcohol-treated animals were statistically significant 
when compared to the control groups for db/wt mice and db/db mice; (p=0.0010) and 























c:::J Control (H 20) 
_ 20% Alcohol 
Control (H 20) 
- 20% Alcohol 
Figure 5.5.10: Conjugated dienes as early lipid peroxidation products in livers from control 
and 20 week alcohol-supplemented db/wt (n=7, n=4 respectively) and db/db (n=6, n=6) mice 
aged 32 weeks. Conjugated dienes of alcohol-treated animals displayed significantly elevated 
levels in comparison to the control groups, db/wt mice; (,0=0 .031) and db/db mice (p=O.0025). 

























c:::J Control (H20) 
20% Alcohol 
Control (H 20) 
_ 20% Alcohol 
Figure 5.5.11: LOOH as intermediate lipid peroxidation products in livers from control and 20 
week alcohol-supplemented db/wt (n=7, n=4 respectively) and db/db (n=6, n=6) mice aged 32 
weeks. Increased concentrations of lipid hydroperoxides were shown in db/wt and db/db 
alcohol-treated animals when contrasted against the controls, db/wt mice; (p=O.0002) and 












Figure 5.5.12: TTBARS as late lipid peroxidation products in livers from control and 20 week 
alcohol-supplemented db/wt (n=7, n=4 respectively) and db/db (n=6. n=6) mice aged 32 
weeks. The TTBARS concentrations gained statistical significance in db/wt mice; (p=O.0002) 

















c:::::::J Control (H~) 
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Control (H20) 
_ 20% Alcohol 
Figure 5.5.13: BeA protein in homogenate from control and 20 week alcohol-supplemented 
db/wt (n=7, n=4 respectively) and db/db (n=6, n=6) mice aged 32 weeks. No statistical 
significance was attained when compared to respective controls, db/wt mice; (p= 0.24) and 
db/db mice; (p=O.30). Data represented as mean ± SO. 
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5.6.1 Summary of Results for the db/db Mouse Model on Regular Chow for 20 Weeks 
r 
i Wild Type (wtlwt) Heterozygous (db/wt) Homozygous (db/db) 
I 
i 
Sex I M F M F M F 
I 
No. of Animals 6 6 16 8 10 I 14 
I 
Terminal Body Mass 22.4 ± 0.8 17.3±1.6 26.4 ± 2.4 20.8±1.7 44.8 ± 2.4142.2 ± 3.9 (g) 
Liver Mass (g) 0.78 ± 0.06 0.75 ± 0.08 1.27 ± 0.13 0.75 ± 0.09 1.77±0.18 2.09±0.39 
r'l'"Inillnl:ltl'lrl nil'lnl'lCl I 
~~"J~'='-'-- _._ .. _- 2.07 ± 0.21 1.89 ± 0.12 2.58 ± 0.35 2.70 ± 0.34 3.48 ± 0.23 3.63 ± 0.47 
f ___ 1 , I"\I"\U 1_ I: •• _~\ 
\111111.11 L.VVI 1/~.lIvvi} 
I ! I ~ 
1795 ± 87 I 1309 ± 149 
i I I 
I TTBARS (nmol/g.liver) 1264 ± 225 i 1337 ± 127 I 1559 ± 162 I 1731 ± 260 I 
I ............... --1 I II I I 
I Cholesterol 4.47 ± 0.43 I 4.54 ± 0.73 I 6.67 ± 0.80 I 6.68 ± 0.621 4.71 ± 0.391 4.85 ± 0.33 I (mg TC/g.liver) 
I I I 
Triglycerides 
1.81 ± 0.39 11.19 ± 0.22 
I i I 
1.94 ± 0.44 1.41 ± 0.4913.16 ± 1.1314.14 ± 0.81 I (mg TG/g.liver) 
i 
Concentratio~ (mmol/l)! 5.5 ± 1.7 5.1 ± 1.0 9.1 ± 3.4 6.0 ± 1.0 23.0 ± 2.9 20.4 ± 8.0 
I 
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5.6.2 Summary of Results from the Impact of Various Oils, Administered via the 
Diet (4 Weeks) 
-------------------,------------------------------------------
All animals in this study, both male and female were 
Heterozygous (db/wt) 
--------------------- ----------------"-"'-,-----'----'--
Sex I No. Animals 3M + 3F 3M + 3F 3M + 3F 3M +3F 
--------------------------t----------- ---------- ------
Treatment 
Chow Only Sunflower 
(control) Oil 
----- -------------------- ----------+-------------- -
Terminal (~~dY Mass 23.4 ± 3.6 23.6 ± 2.7 
- ---------------------------- --------------------
Mean Mass Gain (g) 
Weeks 12-17 








24.5 ± 5.0 
+ 0.8 + 0.7 




2.00 ± 0.20 2.66 ± 0_33 2.26 ± 0.30 2.46 ± 0.05 
--------------------j----- -------------- ------+---------------
Lipid 
Hyd roperoxides 400 ± 251 561 ± 235 500 ± 90 497 ± 188 
__ J~~9L~_QOH __ /~g'--.li_ve_r_'_) -j-_____________________ _ -----t-------------












20.1 ± 3.5 22.8 ± 4.7 24.4 ± 2.8 22.2 ± 2.4 
71.3 ± 11.9 72.2 ± 4.0 75.0 ± 10.8 75.5 ± 17.7 
--+----------------j------- ---------
6_8 ± 1.9 7.6±1.0 8.0 ± 2.2 4.5 ± 2.2 
-~----.----
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5.6.3 Summary of Results from the Impact of a Short Period of Alcohol Administration (4 Weeks) 
Wild Type (wtlwt) Heterozygous (db/wt) Homozygous (db/db) 
Sex 1 No. of Animals 1M + 1F 1M + 1F 2M + 2F 2M + 2F 2M + 2F 1M + 3F 
Treatment H20 120% alcohol ! H20 ! 20% alcohol I H20 i 20% alcohol I 
I I I 
17.3 ± 1.6 I 26.4 ± 2.4 I 20.8 ± 1,7 
I I Terminal Body Mass I 22.4 ± 0,8 I 44.8 ± 2.4 II 42.2 ± 3.9 I I 
I 
(g) I I 
I 
! Mean Mass Gain (g) I i + 4.2 
I 
+ 2.2 + 1.8 + 1.8 + 0.5 I + 3.5 
Weeks 14-20 I I I 
I i i , I 
con(jugaltjedl.Die)nes 1.81 1.98 1.71 ± 0.31 2.18 ± 0.34 2.90 ± 0.57 3.62 ± 1.04 
J.lmo g.lver 
Lipid 
Hydroperoxides 93 291 158 ± 44 182 ± 49 434 ± 156 654 ± 296 
(nmol LOOH/g.liver) 
TTBARS (nmol/g.liver) 1490 1577 1175 ± 72 1367 ± 125 1307 ± 144 1849 ± 26 
I 








I I I I 
Trialvcerides .. ~~ .. .... . : ... n,.. . f"'\ ""'" j .... "1""'1. • f"'\ ",..... I '" ,,_ • _ __ ! _ ..... _ .. _ t 
I mg g. Iver !! I I ( TGI I') I.O,j I.OL+ I I.UO 1: U.UO I I.LO 1: U.UtI i L.tI,j 1: U.LO I 0,441: U,40 I' 
I ii
Please note that a standard deviation value could not be calculated for wild type (wtlwt) animals as the 
numbers were too small. 
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5.6.4 Summary of Results from the Impact of Alcohol Administered over 8 
Weeks in db/wt and db/db Mice 
Heterozygous (db/wt) Homozygous (db/db) 
.---.-.------.---- 1------- ------.---.- -------- -.--.----.. ---.-
Sex 1 No. Animals 7M 6M 6M 5M 
---------~.--~----.---+-----------.- _.------- ------ -.~.-.------~-
Treatment 20% alcohol 20% alcohol 
----_. __ ._-------------1------- -_._-_._-------_._--------+---
Terminal Body Mass 
( ) 
32.0 ± 2.7 
._-_ .. _-_._._-...]-- . -------_. 
:~1.8±1.1 49.5 ± 8.7 51.8 ± 5.3 
Mean Mass Gain (g) 
Weeks 9-20 
+ 6.8 + 4.5 +7.4 + 5.2 
.. -----------.-.---.-- _._------- ._-_._---- ----j--_._---
Liver Mass (g) 
Conjugated Dienes 
(I-Imol/g.liver) 
1.06 ± 0.06 1.45 ± 0.12 2.83 ± 0.57 2.84 ± 0.42 
1.60 ± 0.31 2.00 ± 0.23 2.66 ± 0.07 3.45 ± 0.16 
..... __ .... _-_._----_. __ . ----_.-
Lipid 
Hydroperoxides 339 ± 54 724 ± 107 1073 ± 92 1486 ± 118 
(nmol LOOH/g.liver) 
. __ .. _-_._--_._--_._------- -.------ -_._-----_._---- ----- ---+------_._-
TTBARS (nmol/g .Iiver) 1762 ± 154 2529 ± 266 1862 ± 230 2962 ± 257 
-. -.- ... -------------.... ---.----. .-----.---.. ---.-- .... ---.-.-.-----.---f---------+---.---------.-. 
Cholesterol 
(mg TC/g.liver) 
3.35 ± 0.95 5.03 ± 0.91 5.91 ± 1.02 8.46 ± 1.58 
-_._._--_ .. _ .. _-_. __ ..... _. __ ._._-_ .. ---- ---_._-------- -_._---_._-_._-----_.- -----_ .. _-----_ ... _-
Triglycerides 
(mg TG/g.liver) 
4.00±1.63 6.61 ±0.78 6.55±1.41 
10.33 ± 
2.25 





55.3 ± 10.5 60.7 ± 3.6 69.4 ± 12.4 76.7 ± 12.2 
----_._--._'---_ .•. _---\--------
32.6±17.3 41.7±11.1 53.8±21.4 77.8±43.4 
____ .. __ . ____ ._._. ___ • __ . __ . __ ._. ___ . ___ .. ___ ._._L._ .. ___ . ___ • 
AL T Levels 
(U/I) 
18.6±10.5 22.3±8.0 65.3±46.9 71.0±33.9 
-_._._._._-_. __ . __ ._--------------------_. -_._--_._--------+-_._--
Blood 1 Alcohol Levels 
(mmol/l) 
0.53 ± 0.46 1.33 ± 0.86 1.12 ± 0.56 4.73 ± 6.0 
----.-.----.--------------t----- ._---_ .. __ .. _- ---.---- .---------
Glucose 
Concentration (mmol/l) 
13.8 ± 3.4 8.6 ± 1.6 31.2 ± 2.0 29.2 ± 2.8 
._. ___ . __ ... _____ . __ . ____ ._---"--_____ .• _. __ • __ ••• _____ . L............... ___ L ______ . __ _ 
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5.6.5 Summary of Results from the Impact of Alcohol Administered over 20 
Weeks in db/wt and db/db Mice 
---"------------~---- ~------.. -.----.--------"--------------
Heterozygous (db/wt) Homozygous (db/db) 
------_._----------- -----------
Sex I No. Animals 7M 4M 6M 6M 
-------~--------- ----~~-- --_._------------1--- ----t.--------
Treatment 20% alcohol 20% alcohol 
---_._---_._-------+----- -.--... ----.-----t------- --------
31.3 ± 2.1 Terminal(~fdY Mass 33.4 ± 2.7 
-.------------ 1-------------- - .. ----.---
Mean Mass Gain (g) 
Weeks 9-32 
+6.4 + 1.2 
-----.--.---------~r___.--~----.-- .-~--------.-
57.4 ± 5.5 50.2 ± 5.7 
+ 12.3 + 6.8 
Liver Mass (g) 1.37 ± 0.05 1.53 ± 0.11 2.84 ± 0.44 2.99 ± 0.38 
Conjugated Dienes 
(~mol/g.liver) 
1.64 ± 0.18 2.19 ± 0.29 2.22 ± 0.15 2.58 ± 0.17 
.---.---.---... -----------t-----------.-- --~----
Lipid 
Hydroperoxides 195 ± 60 452 ± 78 789 ± 10 98 ± 121 
(nmol LOOH/g.liver) 
._._---.-------------------"---I-----~-- .--.-.--.----.------
TTBARS (nmol/g.liver) 1617 ± 30 2816 ± 349 2891 ± 164 3336 ± 399 





3.88 ± 0.50 5.58 ± 0.67 6.14 ± 1.31 9.17 ± 1.58 
3.72 ± 0.54 5.35 ± 0.59 5.74 ± 1.06 7.67 ± 0.60 
------_._----_._--------1-.-._------- .. -.--------.. -----------.-. --.----. 
BCA Protein 
(~g/~g. liver) 
58.6 ± 8.0 64.8 ± 6.0 82.5 ± 10.9 88.5 ± 8.0 
---------.----~--~---------- ---------- ._----- ----_.-
AST Levels 
(U/I) 
23.3 ± 9.2 
-_._----_._._------_ .. 1-----
37.5 ± 9.5 37.3 ± 9.6 43.5 ± 30.3 
AL T Levels 
(U/I) 
15.1 ± 7.8 16.8 ± 7.9 65.2 ± 44.8 76.3 ± 28.6 
.. -_._._._------_._._----- _._----- ----- -----_._._--
Blood I Alcohol Levels 
(mmol/l) 
0.64 ± 0.49 
12.65 ± 
9.09 
0.56 ± 0.27 4.49 ± 9.09 
---.--.-.. ---.----~-- --------.... - -_ ... _---------+-------- ----.-.~ 
Glucose 
Concentration (mmol/l) 
13.6 ± 3.5 12.3 ± 5.2 
____________ ~ ______ L-____ ~ ___ _ 
PagE~ 132 
31.4 ± 0.8 29.2 ± 4.8 
5.7 Histology Findings 
5.7.1 Results for the db/db Mouse Model on Regular Chow for 20 Weeks 
(A) 10x 
Figure 5.7.1; Histological liver sections stained with H&E from (A) heterozygous (db/wt) 
mouse on regular chow for 20wks (8) homozygous (db/db) mouse on regular chow for 20wks. 
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(C) 20x 
Figure 5.7.1; Histological liver sections stained with H&E from (C) heterozygous 
(db/wt) mouse on regular chow for 20wks (D) homozygous (db/db) mouse on regular 
chow for 20 wks. 
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5.7.2 Results from the Impact of Various Oils, Administered via the Diet (4 
Weeks) 
(A) 10x (8) 10x 
(C) 10x (D) 10x 
Figure 5.7.2; Histological liver sections stained with H&E from heterozygous mice 
(db/wt) fed the following diets; (A) Control; regular chow for 4wks (8) regular chow 
supplemented with sunflower oil for 4wks (C) regular chow supplemented with canola 
oil for 4wks (0) regular chow supplemented with sunflower oil and cholesterol for 
4wks. The histology was normal for all groups. 
Page 135 
5.7.3 Results from the Impact of Alcohol Administered over 8 Weeks in db/wt 
and db/db Mice 
(A) 4x 
Figure 5.7.3 Histological liver section stained with H&E from (A) heterozygous 
(db/wt) mouse on 20% alcohol + 0.025% (w/v) saccharine for 8wks. 
Please note that there were slight processing problems with the H&E staining for 
Control; heterozygous (db/wt) mice on water + 0.025% (w/v) saccharine for 8wks 




Figure 5.7.3 Histological liver sections stained with H&E from (8) Control; 
homozygous (db/db) mouse on water + 0.025% (w/v) saccharine for 8wks (C) 
homozygous (db/db) mouse on 20% alcohol + 0.025% (w/v) saccharine for 8wks. 
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(E) 10x 
Figure 5.7.3 Histological liver sections stained with H&E from (0) Control; 
homozygous (db/db) mouse on water + 0.025% (w/v) saccharine for 8wks (E) 
homozygous (db/db) mouse on 20% alcohol + 0.025% (w/v) saccharine for 8wks. 
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Figure 5.7.3 Histological liver sections stained with H&E from (F) Control; 
homozygous (db/db) mouse on water + 0.025% (w/v) saccharine for 8wks (G) 
homozygous (db/db) mouse on 20% alcohol + 0.025% (w/v) saccharine for 8wks. 
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5.7.4 Results from the Impact of Alcohol Administered over 20 Weeks in db/wt 
and db/db Mice 
Figure 5.7.4 Histological liver sections stained with H&E from (A) Control; 
heterozygous (db/wt) mouse on water + 0.025% (w/v) saccharine for 20wks (8) 
heterozygous (db/wt) mouse on 20% alcohol + 0.025% (w/v) saccharine for 20wks. 
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Figure 5.7.4 (C) Control; homozygous (db/db) mouse on water + 0.025% (w/v) 
saccharine for 20wks (0) homozygous (db/db) mouse on 20% alcohol + 0.025% (w/v) 
saccharine for 20wks. 
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Figure 5.7.4 Histological liver section stained with H&E from (E) Control; 
homozygous (db/db) mouse on water + 0.025% (w/v) saccharine for 20wks. 
(F) 10x (G) 10x 
Figure 5.7.4 Histological liver section stained with sirius red for collagen; (F) Control; 
homozygous (db/db) mouse on water + 0.025% (w/v) saccharine for 20wks (G) 
homozygous (db/db) mouse on 20% alcohol + 0.025% (w/v) saccharine for 20wks. 
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Chapter 6; Interpretation of Results 
6.1 Assessment of the db/db Mouse Model on Regular Chow for 20 Weeks 
The db/db mouse was investigated to test its suitability as an appropriate model to 
study the development of fatty liver in the context of NAFLD and NASH. Alcohol was 
used as a possible trigger factor for NASH as it is known to induce enzymes and to 
cause changes similar to NASH in humans. Based on physical appearance alone, it 
was apparent from the outset that there could be considerable biochemical 
differences between the homozygous, heterozygous and wild-type strains of the 
db/db mouse model as the pictures in figure 6.1.1 clearly reveal. The assessment of 
wtlwt, db/wt and db/db animals was undertaken in an attempt to fully characterize the 
model. Furthermore, the graphs display results for combined sexes, male and 
female, to assess each genotype as a single constituent but grouped sexes and 
individual results are presented in the tables and appendix sections respectively. 
Figure 6.1.1: From left to right, the picture displays the size difference between the homozygous 
(db/db), heterozygous (dblwf) and wild·type (wtlwt) strains. 
The analysis of these animals revealed several characteristics that mirror those 
typically witnessed in humans and confirms its usefulness as a model to study 
NAFLD and NASH. Firstly, the db/db mice were obese, laden with visceral fat (see 
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figure 6.1.2) and exhibited body weights which dramatically increased in size in 
comparison to the lean wtlwt and db/wt mice; (43.5g vs. 19.9g and 23.6g 
respectively), and attained statistical significance (p<O.0001 for both). Additionally, 
the mean difference in body mass between the wtlwt and db/wt animals is 3.7g which 
is statistically significant (p=O.0003). Despite this disparity in body mass being small, 
it could possibly be attributed to an effect of the db gene and may influence 
responses, especially in the setting of hyperglycaemia. 
Figure 6.1.2: This clearly depicts the diHerence in fat present in the heterozygous (db/wi) and 
homozygous (db/db) strains. 
The mass of liver was also noticeably increased in db/db mice in contrast to the wtlwt 
and db/wi mice (see figure 6.1.3), achieving statistical significance of p<O.0001 for 
both which reflects the larger body mass of the homozygous mice. Besides this, liver 
mass was slightly elevated in the db/wt animals when compared to the wtlwt animals 
and again reached statistical significance (p=O.011). This information provides further 
evidence that the db gene is possibly causing an effect, and although it is slight, a 
definite trend is beginning to occur. Furthermore, the relative liver weight: body 
weight ratios were assessed for wtlwt, db/wt and db/db animals which resulted in all 
groups being comparative. Therefore, despite the db/db mice having larger livers, 
they do appear to be in appropriate proportion to their body mass. An additional 
observation emerging from the db/db mice is that, although the mean body mass for 
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both sexes is comparable, a marginal decrease in female body mass does exist 
when contrasted against the males; (42.2g vs. 44.8g respectively), yet conversely, 
female liver mass is increased in comparison to the males (2.09g vs. 1.77g 
respectively), although statistical significance is not attained (p=O.103). It is unclear 
whether gender may be affecting the discrepancy in liver mass as previous studies 
have displayed the females to be at higher risk of fatty liver development (Angulo et 
aI., 1999), but there are too few animals in the groups to determine if this is a 'true' 
causative effect. 
Figure 6.1.3: From left to right, the picture displays the variation in liver size of homozygous (db/db) and 
heterozygous (db/wi) mice strains. 
Additionally, the livers of db/db animals were shown to have yellow coloration and 
were significantly enlarged in contrast to the wtlwt and db/wt groups; (p<0.0001 for 
both). Despite the significant increase of liver mass in db/db animals, the liver was 
proportionate to body mass when adjusted for body mass ratios and was found to be 
comparative to that of wtlwt and db/wt groups. However, the extent of fat 
accumulation and the low degree of inflammatory response was not significant 
enough to facilitate I\lASH in these mice. As a result the aptness of this model could 
be slightly restricted, meanwhile posing the question whether some sort of 
contributing factor is missing in the genetic make-up that prevents the progression to 
NASH. Alternatively, the inflammatory response of mice may differ. It is also possible 
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that dietary fat may need to be increased significantly more, possibly with heated fat 
to resemble humans. 
In comparison, histological examination of the lean wtlwt and db/wt groups displayed 
hepatocytes which were normal in structure and function with no aggregations of fat 
droplets present. There were no noteworthy histological differences detected 
between male and female livers in wtlwt, db/wt or db/db groups respectively. 
Although marked steatosis was evident in the db/db mice, the inflammation and 
fibrotic processes of NASH were absent in the control and alcohol groups. These 
findings indicate that histology, though sensitive for qualitative changes such as the 
presence of inflammation and fibrosis is insensitive in detecting more subtle change. 
Biochemical analysis was undertaken to assess early, intermediate and late products 
of lipid peroxidation and all these parameters were found to be elevated in db/db 
mice. Conjugated dienes are considered to be a reliable marker as early products of 
lipid peroxidation. The increase in CD in db/db mice attained statistical Significance 
when compared to the wtlwt and db/wt groups (p<0.0001 for both), highlighting the 
difference in fatty acid metabolism. There was also a slight increase in CDs in db/wt 
mice when compared to the wtlwt group which demonstrated statistical significance 
(p<0.0001) and therefore continues to emphasize the growing trend that the db gene 
may be influential in FA metabolism and consequently the development of fatty liver. 
Furthermore, CD concentrations of male vs. female were analysed for wt/wt, db/wt 
and db/db groups and although they were comparative for wtlwt and db/wt groups; 
(1.81 vs. 1.98 and 1.71 vs. 2.18 IJmol/g. liver respectively), the values were slightly 
elevated in the females. This may show an inherent difference in peroxidation 
activities or susceptibility between the genders. A superior increase was observed in 
females when comparing sexes in the db/db mice; (2.90 vs. 3.62 IJmol/g. liver 
respectively), but this did not achieve statistical significance either (p=0.36). In 
addition, in must be noted that all increases of LOOH occurred in the female gender 
and despite statistical significance not being reached in all groups, a slight effect of 
gender difference could be attributed for the change. A clear effect cannot, however 
be determined due to the small group sizes. 
Lipid hydroperoxides are classified as intermediate products of lipid peroxidation. 
They were found to be significantly increased in db/db animals when evaluated 
against the wtlwt and db/wt animals (p<0.0001 for both). In comparison, there was no 
significant difference between the wtlwt and db/wt groups and therefore the db gene 
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does not appear to display an effect on LOOH concentration. Additionally, no notable 
changes were exhibited when comparing sexes for wtlwt and db/wt groups, but the 
difference proved to be significant in db/db animals (p<0.0001) due to a dramatic 
increase in male mice. This finding contradicts the present trend of female gender 
being influential but a reasonable degree of variation did exist within all groups as 
demonstrated by the standard deviations. 
Late products of lipid peroxidation; total TBARS, were analysed and the increases 
exhibited in db/db mice were found to be statistically significant in comparison to the 
db/wt group; (p=0.0095). The db/db animals also displayed increases of TTBARS 
when contrasted against the wtlwt group but these were only slight and did not attain 
statistical significance (p=0.79 and p=0.25 respectively). The values were 
comparable for wt/wt and db/wt groups, although levels were marginally elevated in 
wtlwt animals. The methods in the numerous published studies are not consistent, 
thus making a comprehensive comparison of experiments difficult, especially for 
products of lipid peroxidation. 
Hepatic triglyceride content was also significantly increased in db/db mice in 
comparison to the lean wtlwt and db/wt groups (p<0.0001 for both). The massive 
difference could be due to abnormal TG synthesis or decreased oxidation and export 
(or all these processes) in the db/db group. The increase of lipid peroxidation 
products could, in part, reflect oxidative stress from enhanced oxidation that does not 
compensate for altered fluxes into the liver of FA or de novo synthesis. Furthermore, 
the db gene did not exert any influence on TG concentration in the heterozygous 
state as the content was slightly higher in wtlwt mice in contrast to the db/wt group, 
although the values were relatively comparable. The TG content was comparable 
between wtlwt male and female mice; (1.81 vs. 1.91 mg TG/g. liver) and db/wt male 
and female mice; (1.19 vs. 1.41 mg TG/g. liver respectively). Despite the fact that no 
statistical significance was reached, values were marginally higher in female animals. 
Additionally, the increases in female mice of db/db group were statistically significant 
in contrast to the males (p=0.019) and provides evidence of a slight effect which 
could be attributed to female gender. 
Concentrations of total cholesterol were examined and again revealed statistically 
significant increases in db/db mice when contrasted against wtlwt and db/wt; 
(p<0.0001 for both). Increases in cholesterol can not be the consequence of the diet 
as all animals were fed regular chow for 20 weeks. Therefore, the significant increase 
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must be attributed as a resulting defect of the db/db model. TC was comparable 
between wtlwt and db/wt groups (4.78 vs. 4.51 mg TC/g. liver respectively), although 
levels were slightly raised in wtlwt animals and therefore demonstrated no influence 
from the db gene. Minor increases were observed in females when compared to 
males in their respective wtlwt, db/wt and db/db groups but the differences were too 
small to be successfully attributed to female gender. 
Glucose concentrations in plasma were shown to continue the growing trend of 
increases in db/db mice being statistically significant when compared to wt/wt and 
db/wt groups (p<O.0001 for both). The prevailing increase in glucose in db/db mice is 
indicative of diabetes being present in this genotype. Slight increases were observed 
in db/wt animals in contrast to the wtlwt group values were comparative and no 
statistical significance was attained. Additionally, glucose concentrations were 
revealed to be increased in males when compared against the females from wtlwt, 
db/wt and db/db groups. The difference was insignificant between sexes of wtlwt and 
db/db animals but did achieve statistical significance in db/wt; (p=O.02). It is possible 
that in the longer term, more striking differences will emerge in db/wt mice as 
diabetes may progress. 
Assessment of the varying genotypes within this mouse model revealed that db/db 
mice were obese in comparison to the lean mice; wtlwt and db/wt, which was 
confirmed by exhibiting mean body mass approximately double in size. Increases in 
liver mass of db/db mice were also statistically significant in comparison to the wtlwt 
and db/wt animals but after adjusting for liver mass: body mass ratios, liver of db/db 
group was found to be in appropriate proportion to body mass resulting in all 3 
groups displaying relatively similar values. CDS, LOOH, TTBARS, TC, and TG were 
all notably higher in db/db mice in comparison to the wtlwt and db/wt and although 
statistical significance was not reached in every parameter investigated, evidence 
does suggest that severely altered fatty acid metabolism is occurring within these 
homozygous mice. The occurrence of obesity and steatosis are prominent 
characteristics of NAFLD and could be attributed to the resulting derangement of FA 
metabolism. The progression from fatty liver to NASH did not transpire in these 
animals and the reasoning remains undefined. In addition, the significant increase of 
plasma glucose is strongly indicative of diabetes which is also strongly associated 
with NAFLD and further enhances the credibility of the db/db mouse as a suitable 
model. Additionally, the presence of the db gene did appear to provoke various 
increases in body mass, liver mass, CDS, LOOH and glucose concentration in 
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comparison to the wt/wl group and potentially may be a slight effect. However, the 
db/wi group displayed slight decreases for TTBARS, TC and TG in comparison to the 
wt/wl animals and resultantly obscures the correct interpretation. The question of 
female gender being attributed as an effect is also debatable, despite displaying 
some statistically significant increases, results were very variable and unpredictable 
and not consistent throughout the groups. Consequently, any small difference cannot 
be attributed to female gender and further studies with larger group sizes would have 
to be undertaken to establish an effect. 
Overall, the db/db mouse mirrors several characteristics often distinguished in 
NAFLD patients such as obesity, diabetes and fatty livers. However, further stress 
must be exerted on this model in an attempt to facilitate the progression to NASH 
and therefore help identify a cause behind this disease. 
6.2 Impact of Various Oils, Administered via the Diet (4 Weeks) 
In society today, various oils are utilized for cooking and preparation of many 
foodstuffs. HUman evolution might not have been on a continuously high 
consumption of TG. The purpose of this study was therefore aimed at determining 
whether the lipids contained within any particular oil were present in significant 
amounts to produce increased levels of fat accumulation. It could also test whether 
PUFA, being more prone to peroxidation, significantly influenced these parameters in 
the short term. In an attempt to provoke hepatic fatty change, lean db/wt mice were 
used as it was thought that any minor change that may occur would be masked in the 
already obese, diabetic db/db mice. Unfortunately, due to limitations with animal 
numbers, all groups only contained 3 males and 3 females which were pooled 
together for statistical reasons. 
The initial observations that were made comprised the weekly recording of body 
weights which were comparable over the treatment period. However, after the first 
week of treatment, the controls were the only group to have an increase in mean 
body mass gain; (+0.3g). The sunflower oil-treated group displayed no change 
whereas the canola oil-treated mice and sunflower oil/cholesterol-treated mice were 
shown to lose weight; (-0.6g and -1.0g respectively). This anomaly can be accredited 
to the diet modification as the oil-treated animals would have possibly taken a dislike 
to the new taste and would therefore not have consumed normal quantities in the 
beginning. This is reflected by all groups displaying an increased mean weight gain in 
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comparison to the controls the following week; (+0.1g vs. +0.3g, +O.2g and +15g 
respectively). As these changes are negligible and values were comparable over the 
treatment period it must be concluded that administration of any oil or combination 
with cholesterol did not have any effect on body weight gain. This is further confirmed 
by contrasting gradients for the treated groups against the control animals as no 
statistical significance was attained; (p=0.73, p=0.31 and p=0.74 respectively). In 
spite of this, there are a small number of individuals who still develop NAFLD and 
NASH without becoming obese so even though an obvious increase in body mass 
did not occur, the possibility of developing fatty liver still remains. 
Liver mass was also comparable for all groups despite the canola oil treated animals 
having a slightly higher mean value than the controls; (1.025g vs. 0.905g 
respectively). However the canola oil group did have a statistically significant 
increase of liver weight: body weight ratio; (p=0.002) and although this change was 
minor, it could be the outcome of fat accumulation attributed to a slight effect of 
treatment with canola oil. Histological examination of the liver sections provided 
conflicting evidence as no significant findings were produced. There was no 
indication of fat accumulation in either treatment group as all hepatocytes appeared 
to be normal in structure without the present of steatosis. The slight increase in liver 
mass of canola oil-treated animals can therefore not be attributed to treatment and 
again signifies that the surplus of ingested lipids from oil administration does not 
appear to have an effect in contrast with the control animals. 
In light of the insignificant histology findings, livers were analysed for products of lipid 
peroxidation to assess whether the oil administration affected the livers at a 
biochemical level. No single treatment group achieved a consistent increase in any of 
the parameters investigated and the control animals even had slightly elevated 
TTBARS when compared to the treatment groups. These findings suggest that under 
near physiologic conditions, dietary fat alone does not stress the liver severely_ 
Conjugated dienes represent one of the early products of lipid peroxidation and were 
found to be slightly raised in all treatment groups in contrast to the controls. Gaining 
statistical significance in the sunflower oil and sunflower oil/cholesterol-treated 
animals; (p=0.0019 and p=0.0002 respectively), and revealing a possible trend for 
the canola oil group; (p=0.1 0) is not surprising as oils contain more CD. 
The concentrations of LOOH were deterrnined to depict the middle products of lipid 
peroxidation. Although the treatment groups maintained slight increases when 
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compared to the control mice, all values were fairly comparable and no statistical 
significance was attained in any group. The increase in CD thus did not promote 
LOOH. This is in accordance with the belief that more than one hit is required. 
TTBARS were marginally raised in the control group in comparison to the treatment 
groups but the values were all comparable nonetheless. The significance of this 
finding is unclear but the low numbers of animals and mixed sex grouping are 
potentially confounding factors. Although many studies correlate fat accumulation 
with TBARS concentrations, it is actually the levels of TG which is a more accurate 
indicator of lipid content. TG levels were increased in all treatment groups in contrast 
to the control group. Despite, canola oil treated animals being the only group to reach 
statistical significance; (p=O.036), it is possible to speculate that the increases in 
triglyceride concentration which were incurred were done so through increased fatty 
acid flux from excess dietary fat in the oils. Bigger differences may be observed on 
higher fat diets and/or more prolonged exposure. 
The concentrations of total cholesterol were also assessed with values being 
considerably increased in all treatment groups in contrast to the control mice. 
Statistical significance was achieved in the sunflower oil; (p=O.002) and sunflower 
oil/cholesterol-treated animals; (p=O.007). The canola oil-treated animals did not 
attain statistical significance but this was because the values were unevenly 
distributed amongst the group which would have possibly been more prominent had 
the group numbers been larger. High cholesterol can be a contributing factor of fatty 
liver development but is considered more damaging in the context of cardiovascular 
problems It is not only TC that is involved in facilitating the development of a fatty 
liver as numerous more steps are involved in the complex process which explains 
why results from TG analysis may be more useful in outlining the underlying causes 
of NAFLD and NASH. 
The levels of circulating protein were shown to be comparable for all treatment 
groups when compared to the control group and consequently displayed no effect of 
oil administration. The results of glucose concentration again highlighted the 
inconsistency of the findings generated form small numbers of study animals. The 
levels of glucose displayed in the sunflower oil and canola 011 groups were slightly 
higher than the controls whereas the values in the sunflower and cholesterol treated 
animals was considerably lower but still comparable resulting in statistical 
significance not being achieved and glucose concentrations not being effected. 
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Overall, there does not appear to be a significant effect of the oil treatment on the 
db/wt mice, but lack of animal numbers and insufficient loading of dietary lipids could 
be at fault for not inciting a more definitive outcome. Another point of significance is 
that humans are the only species that heat food before consumption, so the 
administration of unheated oil to mice involved in this study is not a true 
representation of human dietary activities. Resultantly, any future work carried out 
under the same scope as this experiment should possibly aim at heating oils before 
administration as this promotes further oxidisation of the lipids involved and may be 
the extra influence required to overload biochemical pathways and influence fatty 
liver development. 
6.3 Study of Short Period of Alcohol Administration (4 Weeks) 
NAFLD and NASH by definition asserts that these disorders only develop in patients 
who consume immaterial quantities of alcohol but the actual amount which is 
deemed insignificant has come under great debate as Bacon et a/., (1994) believed 
values of ;?:20g/day to be inappropriate whereas other authors such as Brunt et a/., 
(1999) considered 20g/day to be with in acceptable limits. Investigative work on this 
model has already established the db/db mice to be obese and diabetic with mixed 
steatosis, although liver damage was not severe enough to warrant the diagnosis of 
NASH. Therefore, the purpose of this study was to determine whether alcohol is a 
contributing factor in the facilitation of fatty liver disease in the reputed non-drinker or 
act as a catalyst for the progression to NASH. In addition, due to animal availability 
and restrictions of pilot study agenda, the animal numbers were kept to a minimum 
but were in sufficient quantities to obtain histological, biochemical and statistical 
information in order to gauge whether a main study should occur. Liver mass and 
glucose concentrations were not taken for these animals in error. 
Body mass was recorded over the entire treatment period to monitor whether alcohol 
administration has any notable effects in either of the 3 treatment groups; wtlwt, 
db/wt or db/db when compared to their respective controls. The mean gain for 
alcohol-treated wtlwt mice was comparable to their respective controls; despite being 
marginally decreased; (+2.2g vs. +1.8g). As the difference is too small and there are 
only 2 animals per group, this potential effect cannot be attributed to treatment for 
wtlwt animals. The alcohol-treated animals in the db/wt group displayed a mean gain 
of +0.5g in contrast to +1.8g of their respective controls. The slopes of growth 
generated overtime for alcohol-treated and control db/wt groups were analysed using 
the equation (y = m(x) + c) to determine if there was any differences in the rate of 
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mean body mass gain. The gradient of the db/wt control animals was shown to be 
significantly steeper than that of the respective db/wt alcohol-treated group; 
(p=O.002) and is therefore concluded that alcohol administration results in a 
decreased mean body mass gain in db/wt treated mice over a period of 4 weeks. 
Similarly, the control mice in the db/db group revealed a decrease in mean body 
mass gain when compared to the alcohol-treated animals; (+3.5g vs. +4.2g) and 
when the gradients were contrasted, this difference was also demonstrated to be 
statistically significant; (p=O.014). 
Previous findings generated from assessing this mouse model revealed that a certain 
magnitude of stress pre-exists in the db/db mice by virtue of their metabolic 
deficiency. Results produced from administering alcohol for 4 weeks in db/db animals 
have significantly proven to have a supplementary effect on body mass. Furthermore, 
the effects of alcohol administration also significantly altered the mean body mass 
gain of db/wt animals in contrast to the respective control group and it could therefore 
be argued that the db/wt animals contain various precursors for fatty change which 
alcohol manipulates to impose an effect. Gender could not be investigated in this 
pilot study as both sexes had to be combined to generate sufficient group numbers. 
Histological examination of the fresh liver sections displayed alcohol to have no effect 
in wtlwt, db/wt or db/db groups by comparison with the respective controls. The 
observations confirmed the presence of NAFLD in db/db control mice as confirmed 
earlier through H&E sections displaying grade 2 and 3 micro- and macrovesicular 
steatosis. The db/db alcohol-treated mice revealed no additional signs of hepatic 
injury or fat accumulation resulting in the inability of alcohol to provoke the 
subsequent progression to NASH. Alcohol administration also failed to generate a 
response in wt/wt and db/wt mice in contrast to their respective controls. Livers 
sampled from alcohol-treated mice and controls in wtlwt and db/wt groups were 
found to be comparable as all individuals displayed hepatocytes which were normal 
in structure and function with no steatosis present. Alcohol does not seem to have 
any substantial effect on the histology of these livers, but it must be noted that the 
alcohol was made available to the animals ad libitum and therefore may not have 
been consumed in significant quantities to generate a noteworthy change. The period 
of 4 weeks for which the alcohol was administered may also be insignificant to incur 
any sizeable injury. 
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Investigations into the concentrations of CDs displayed slight increases in the 3 
alcohol-treated groups in contrast to the control animals but this difference was more 
pronounced in the db/db mice. Furthermore, values were unevenly distributed and 
not elevated enough to gain statistical significance in either of the treatment groups 
but does display a trend in that alcohol could be responsible for contributing to an 
increase in early products of lipid peroxidation. In addition, the increase observed in 
db/db controls when contrasted to db/wt control was found to be statistically 
significant (p=O.011) which was expected from previous comparison of the different 
genotypes. However, the alcohol-treated animals from db/wt and db/db groups were 
also compared and although statistical significance was attained (p=O.039) the 
change was more considerable between the controls. Resultantly, despite the stress 
of alcohol acting as a potential exacerbator of early lipid peroxidation products, it 
appears as though the presence of the db gene is causing a more significant effect. 
The results produced from assessment of LOOH revealed increases in the 3 alcohol-
treated groups when contrasted to their respective controls. The difference was only 
minor in the db/wt control vs. alcohol; (158 vs. 182 nmol LOOH/g. liver respectively) 
whereas the increases in the alcohol-treated animals was more definitive in the wt/wt 
and db/db groups; (93 vs. 291 and 434 vs. 654 nmol LOOH/g. liver respectively). The 
discrepancies were not considerable enough to reach statistical significance in either 
group, but provides further evidence of a growing trend that alcohol may be causing 
a slightly increased effect on lipid peroxidation products. The control animals were 
compared from the db/wt and db/db groups and again the increase in the db/db 
animals was established as being statistically significant (p=O.015) as was the 
increase when comparing the alcohol-treated animals from the same groups 
(p=O.21). Although the administration of alcohol is beginning to display a trend in 
contrast to the respective controls, the difference between the controls from db/wt 
and db/db groups attains more pronounced statistical significance and adds scope to 
whether the presence of the db gene causing a more detrimental effect than the 
administration of alcohol. There was also as increase in wtlwt alcohol-treated animals 
when contrasted to the db/wt alcohol-treated group but this can be explained by inter-
group variation and small group numbers. 
TTBARS were shown to be elevated in all alcohol-treated groups in comparison to 
the respective control animals and attained statistical significance for db/wt mice; 
(p=O.038) and db/db mice (p=O.0003). Furthermore, values for wtlwt alcohol-treated 
animals and controls and db/wt alcohol treated animals were all exhibited to be 
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marginally increased in comparison to db/db controls, but no statistical significance 
was achieved. Alcohol could be attributed as an effect but small numbers in the wtlwt 
groups, no accumulation of fat in respective livers and inadequate manifestation of 
significant statistics provides conflicting evidence and therefore any true causative 
effect remains unresolved. 
The concentrations of total cholesterol were examined for all groups and slight 
increases were again observed in wtlwt, db/wt and db/db alcohol-treated mice in 
contrast to the controls. Statistical significance was only reached between the db/wt 
animals; (p=0.005), but adds further support that alcohol may be producing a slight 
effect in these animals. 
TG levels were investigated and demonstrated that the content for db/db alcohol-
treated mice was dramatically increased in comparison with the control group; 
(p<0.0001). Statistical significance was also achieved for an increase in alcohol-
treated db/wt animals (p=0.009) in contrast to the controls. A marginal increase was 
noted in the alcohol-treated animals of the wt/wt group as well and even though 
these differences are being demonstrated to be small, there is a definite trend 
developing which may become more distinctive if further hepatic damage was 
incurred. Triglyceride content is an excellent marker of lipid droplet formation and 
potential problems of fat accumulation which makes this a powerful finding. The more 
sensitive detection of quantative changes gives this biochemistry approach an 
advantage over the histology. The TG content in the db/db controls is significantly 
raised in comparison to the wt/wt and db/wt groups without the addition of alcohol as 
a further stress factor. When alcohol is administered, the db/db treated animals 
display concentrations which are more than double that of the db/db controls; (2.93 
vs. 6.44 mg TG/g. liver). Therefore, despite db/db mice already having disrupted 
metabolic functions, the addition of alcohol may further aggravate the situation. 
Despite the gain in TG, and same increase in lipid peroxidation markers, histological 
examination did not reveal necrosis and inflammatory changes. Alcohol may have a 
preferred route of being incorporated into fatty acids, producing fatty acid palmitate. 
This fatty acid is not subject to the lipid peroxidation products being examined in this 
study. 
In conclusion, although alcohol has not made a statistically significant impact on all 
parameters being investigated, a slight trend is evident. Increasing the period of 
alcohol administration may cause a significant change that would facilitate the 
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progression to NASH or enable a noteworthy change in wtlwt or db/wt mice. If 
alterations in fatty acid synthesis or any other metabolic pathway which is involved in 
development and progression of fatty liver were to become induced by alcohol, it is 
hoped that a main study would be able to highlight when and where the changes 
occur in attempt at alleviating the disease. 
6.4 Impact of Alcohol Administered over 8 and 20 Week Periods in db/wt and 
db/db Mice 
The results obtained from the alcohol pilot study were deemed significant enough to 
proceed to a study over longer periods. The period of alcohol administration 
necessary to cause a more pronounced effect was uncertain so it was decided to 
split the animals into 2 batches; one batch undertaking 8 weeks of alcohol 
administration (short-term) whereas the second batch of animals had a duration of 20 
weeks alcohol administration (long-term). Alcohol-treated animals were compared 
against their respective controls and were assessed in an attempt to identify any 
significant changes that may facilitate or lead to further progression of this disease. 
For the purposes of reporting and clarity, both 8 week and 20 week alcohol 
administration studies will be discussed together. 
Body mass was recorded over a 3wk adaptation period for all animals prior to the 
respective 8wk and 20wk administration of alcohol for treated animals, or water for 
the controls. The 8wk study demonstrated that db/wt alcohol-treated animals had a 
slightly decreased mean body mass gain in contrast to the controls; (+4.5g vs. +6.8g 
respectively). The 8wk db/db alcohol-treated mice also exhibited a decrease when 
compared to the control group; (+5.2g vs. +7.4g respectively). Despite 8wk alcohol-
treated db/wt and db/db groups displaying a decrease in mean body mass gain when 
contrasted against the controls, the differences were only significant in db/wt animals 
upon assessing the gradients; (p=0.0009). In comparison, the body mass of 20wk 
db/wt and db/db alcohol-treated mice was comparable to their respective controls at 
the start of treatment, however, after 4-5 weeks both sets of controls appear to 
increase their rate of mean body mass gain and the resultant reduced gain 
experienced by the db/wt and db/db alcohol-treated animals is not regained by the 
time of termination. This is reflected in the mean body mass gain values of 20wk 
db/wt alcohol-treated animals which was decreased in comparison to the control 
group; (+6.4g vs. +1.2g respectively) as were the db/db alcohol-treated mice from the 
20wk study when compared to the controls; (+12.3g vs. +6.8g respectively). 
Nevertheless, statistical significance is only achieved between the db/db groups 
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which arises from analysing the gradients; (p=0.003). Overall, all 8wk and 20wk 
alcohol-treated db/wt and db/db groups display a reduced mean body mass gain in 
comparison to the controls, but statistical significance is only reached in 8wk db/wt 
and 20wk db/db. This finding is somewhat contradictory, as the trend of alcohol 
inducing a causative effect continues, but the duration of administration and 
susceptibility of genotype is somewhat misleading. The 8wk study gives the 
impression that the db/wt treated mice are more prone to the effects of alcohol 
administration whereas the 20wk study reveals the db/db animals having a higher 
propensity to a reduction in body weight gain. This finding is considered to be 
spurious. Repeat studies with increased group numbers may give a more accurate 
indication of whether this observation is real. 
Observations made from comparing the 8wk and 20wk studies indicate that the 
increased duration of alcohol administration may be a causative factor in reducing 
mean body mass gain. Since food and drink consumption were not specifically 
monitored, it is not known whether the alcohol affected the amount of food taken nor 
the amount of liquid taken in. The mean gain for 8wk db/wt controls revealed an 
increased difference of +2.3g in comparison to the respective alcohol-treated 
animals, whereas the difference in mean gain for 20wk db/wt controls was +5.2g 
when contrasted against the alcohol-treated animals. Similar results were also 
displayed when comparing the db/db mice. The 8wk db/db controls were shown to 
have an elevated mean body mass gain difference of +2.2g in contrast to the 8wk 
db/db alcohol-treated group whilst the difference between 20wk controls and alcohol-
treated mice was +5.5g. As a result, although 8wk alcohol administration certainly 
causes a reduction in weight gain in db/wt and db/db mice, evidence suggests that 
the effect is more definitive in animals who have endured administration for 20 wks. 
Liver mass was recorded for all animals from 8wk and 20wk groups, but 
unfortunately could not be compared with the pilot study as this data was not noted in 
error. Statistically significant increases in mean liver mass were noted for 8wk and 
20wk db/wt alcohol-treated animals in comparison to the controls; (p<0.0001 and 
p=0.0068 respectively). Slight increases were also observed for 8wk and 20wk db/db 
alcohol-treated groups in contrast to the control animals but this was not of 
noteworthy difference to attain statistical significance; (p=0.99 and p=0.55 
respectively). These findings suggest that although alcohol may be eliciting an effect 
in all treated groups, the changes in mean liver mass are more noticeable in the 
db/wt groups from the 8wk and 20wk stUdies in comparison to the db/db animals. 
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This evidence indicates that db/wt animals are possibly more prone to metabolic 
alterations from exposure to alcohol than db/db animals. The changes that are 
causing the liver to increase in size in db/wt mice may have already occurred in 
db/db mice through an alternative mechanism of metabolism and that is why the 
values of db/db animals are comparable regardless of Swk or 20wk alcohol 
administration. It would be of considerable interest to determine how alcohol results 
in an increased liver mass in db/wt but not db/db mice. 
When comparing Swk and 20wk studies, the differing periods of alcohol 
administration did not appear to have made any significant difference to the mean 
liver mass despite marginal increments being noted in the db/wt and db/db 20 wk 
alcohol-treated animals in contrast to the db/wt and db/db S wk alcohol-treated 
groups; (1.53g vs. 1.45g and 2.99g vs. 2.S4g respectively). The Swk db/wt alcohol-
treated mice exhibited a larger increase in liver mass when contrasted against their 
respective controls in comparison to the difference between 20wk db/wt alcohol 
treated mice and the control group; (+0.39g vs. +0.16g). However, this discrepancy 
results from Swk db/wt control mice having a significantly decreased mean liver mass 
in comparison to the 20wk db/db controls; (1.06g vs. 1.37g), but since Swk and 20wk 
db/wt alcohol-treated animals are comparable, this finding was considered to be 
spurious. 
Liver mass / body mass ratios were analysed to determine if liver mass was 
proportional to body mass. The results demonstrated statistically significant 
increases for Swk and 20wk db/wt alcohol-treated animals in comparison to the 
controls; (p<0.0001 and p=0.003 respectively). The liver mass increase from the Swk 
and 20wk db/wt alcohol-treated groups are considered to be out of proportion and 
provides support for that the increases in liver mass are a direct result of alcohol 
consumption. Slight increases were also observed for Swk and 20wk db/db alcohol-
treated groups in contrast to the control animals but did not reach statistical 
significance for Swk administration; (p=0.57) but was achieved for 20wk; (p=0.033). 
Therefore, despite any change in liver mass not being significantly apparent between 
db/db controls and alcohol-treated animals from Swk and 20wk, when adjustments 
are brought about to bring body mass into consideration, the 20wk alcohol-treated 
db/db animals display liver mass which appears slightly out of proportion from the 
body mass. Furthermore as Swk db/db alcohol-treated mice still exhibit proportionate 
liver mass after adjustments, it could again be speculated that the longer duration of 
alcohol administration has had a causative aspect. In addition it could also be argued 
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that db/wt mice are more susceptible to alterations in metabolism as a direct result of 
alcohol than db/db animals. 
Histological examination of the livers did not display any significant differences 
between 8wk animals and their respective counterparts in the 20wk study. As a 
result, administering alcohol for longer periods did not induce additional hepatic 
injury, NASH was not induced and observations were comparable. It appears that the 
biochemistry v. histology are at a variance about the fat content in the liver when the 
results of the 8 and 20 wk studies for db/wt with alcohol and db/db without alcohol 
are compared. The latter group, though displaying frank macrovesicular steatosis do 
not achieve the absolute TG concentration specified for fatty liver to be diagnosed. 
As stated in the review, the TG content should be > 50mg/g. liver. Since calculations 
were checked and spectrophotometric analysis was excluded as technical reasons 
for a low reading in the db/db mice, the only other biochemical explanation is that 
losses may occur in processing very fatty liver samples. The fat noticeably sticks to 
glass tubes and may not be fully suspended by the small amounts of detergent in 
assays. It is also possible that the distribution of the fat is different, i.e. in cytosolic 
droplets in db/db animals and dispersed in membranes and lipoproteins in the other 
animals. 
Results for early lipid peroxidation products were found to be somewhat conflicting. 
Conjugated dienes were shown to be statistically significantly increased for 8wk and 
20wk alcohol-treated db/wt animals when contrasted against the controls; (p=0.027 
and p=0.031 respectively). CDS were also demonstrated to be statistically significant 
for 8wk and 20wk alcohol-treated db/db groups in comparison to the controls; 
(p<0.0001 and p=0.0025 respectively). This adds further evidence to the developing 
trend that alcohol administration affects metabolic pathways and leads to altered 
biochemical functions. However, the inconsistency arises when the 8wk period of 
alcohol administration is weighed against the 20wk study. The db/wt control and 
alcohol-treated animals from the 8wk study exhibit a CDs content which is slightly 
decreased in contrast to the db/wt control and alcohol-treated animals from the 20wk 
study; (1.60 vs. 1.64 and 2.00 vs. 2.19 tJmol/g. liver respectively). On the other hand, 
db/db control and alcohol-treated animals from the 8wk study display statistically 
significant increases when compared to the db/wt control and alcohol-treated animals 
from the 20wk study; (2.66 vs. 2.22 and 3.45 vs. 2.58 tJmol/g. liver respectively). The 
reason behind this is not clear, although it does suggest that despite alcohol 
triggering a causative effect in db/wt and db/db animals, the period of administration 
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does not appear to be relevant. The concentrations of CDs may decrease with age, 
but there is no data to properly confirm this possibility. It is also possible that different 
batches of animals or other incidental factors not recognized at the moment are 
playing a role in the variability of the data. 
Lipid hydroperoxides were assessed to monitor intermediate lipid peroxidation 
products. These were revealed to be dramatically increased in db/wt and db/db 
alcohol-treated animals in comparison to the relative controls for 8wk; (p<0.0001 for 
both) and 20wk studies; (p=0.0002 and p=0.01 09 respectively). In addition, the db/wt 
control and alcohol-treated mice from the 8wk study were shown to have statistically 
significant increases when contrasted against the db/wt control and alcohol-treated 
mice for the 20wk study; (p=0.0007 and p=0.0025 respectively). Increases were 
evident in db/db control and alcohol-treated mice from the 8wk study in comparison 
to the 20wk groups which also attained statistical significance; (p=0.0005 and 
p<0.0001 respectively). Again, alcohol administration demonstrates a causative 
effect by inducing increases in intermediate lipid peroxidation products in db/wt and 
db/db mice for both 8wk and 20k periods. The increases encouraged by alcohol 
administration in the 8wk and 20 wk studies are more definitive than those achieved 
in the 4wk pilot study as no statistical significance was attained over that period. 
Resultantly, it can be concluded that 4 weeks of alcohol administration is not 
sufficient to produce a significant change in LOOH concentration whereas 8 weeks 
duration does inflict a noteworthy effect. Additionally, an increased alcohol 
administration period of 20 weeks does not provoke further change and therefore a 
treatment period of 8 weeks may be optimal to reveal this effect. The inability of 
alcohol to stimulate the development of NASH even after a further 12 weeks of 
alcohol administration means that this process alone is not enough to elicit NASH. 
Histological findings were also comparable for db/wt and db/db mice from 8wk and 
20 wk studies. 
TTBARS also reflected the notable effects of alcohol administration: the increases in 
8wk and 20wk db/wt alcohol-treated animals were statistically significant in contrast 
to the controls; (p<0.0001 and p=0.0002 respectively). The raised values in the 
alcohol-treated groups for 8wk and 20wk db/db animals also achieved statistical 
significance in comparison to the control groups; (p<0.0001 and p=0.03 respectively). 
It is clearly evident that alcohol is altering metabolism in a way that enhances lipid 
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peroxidation in the treated mice from the Bwk and the 20wk studies, but whether the 
longer period of alcohol administration further exacerbates the damage remains 
unclear. The comparison of TTBARS for Bwk and 20wk studies for db/wt and db/db 
alcohol-treated animals does not reveal any differences that are of statistical 
significance; (p=O.1B and p=O.11 respectively). Although TTBARS are significantly 
elevated in the 20wk study for alcohol-treated db/db mice when compared to Bwk 
alcohol-treated db/db mice, there is no other evidence to suggest that longer alcohol 
administration prompts further increases in late lipid peroxidation production. As 
previously mentioned, histology also indicates that as inflammatory infiltrate does not 
occur; nor does fibrosis. 
Triglycerides were again dramatically increased in Bwk and 20wk db/wt animals in 
contrast to the controls and attained statistical significance; (p=O.004 and p=O.001 
respectively. TG was also shown to be significantly elevated in Bwk and 20wk db/db 
animals when compared against the control groups; (p=O.OOB and p=O.003 
respectively). Further evidence of a trend developing in favour of 20wk alcohol 
administration inciting increased damage was noted through statistically significant 
values being exhibited in 20wk treated db/wt and db/db animals in comparison to the 
Bwk groups; (p=O.026 and p=O.02 respectively). Again, the TG content observed in 
the Bwk and 20wk studies was not met through 4wk alcohol administration in the pilot 
study and casts further speculation of a minimal duration of intervention before 
eliciting an effect. Alcohol is definitely aggravating the near-normal metabolic 
functioning of db/wt mice and also enhancing the already existing TG accumulation in 
the db/db mice but neither the db/wt nor the db/db animals are more susceptible to 
NASH over this period. 
The enhanced duration of alcohol administration in the 20wk study also failed to 
make a more significant impact than Bwk groups when investigating total cholesterol 
concentrations. The 8wk and 20wk alcohol-treated db/wt animals were shown to 
display statistically significant increases in TC when contrasted against the controls; 
(p=O.OOB and p=O.001 respectively) as did the db/db groups for Bwk and 20wk 
studies; (p=O.01 and p=O.005 respectively). However, statistical significance was not 
attained when comparing Bwk and 20wk db/wt alcohol-treated mice; (p=O.33) nor 
db/db alcohol-treated mice; (p=0.47). Although the TC increases in 20wk db/wt and 
db/db alcohol-treated animals did not achieve statistical significance over there 
respective Bwk counterparts, a slight trend may exist but the group sizes are 
inadequate to determine a real effect and therefore larger numbers would be required 
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to confirm or disregard this possibility. Furthermore, the levels of TC observed in 
db/wt and db/db animals in the 4wk pilot study did not reach that of db/wt and db/db 
groups in 8wk and 20wk studies. This implies that alcohol administration requires a 
particular time but this point is not known from these studies. It appears as though 
4wk administration is insignificant, whereas the disruption caused at 20wk 
approximates that of the 8wk. Sustained alcohol administration beyond 20wks mayor 
may not further metabolic and liver damage, with the onset of NASH. Further studies 
would be needed to establish when this occurs and whether there is an optimal 
duration of alcohol administration that produces a proportionate hepatic effect. 
Indeed, the human may be prone to NASH on the basis of long term stress. 
Fibrosis may increase the liver protein content. The levels of protein in the liver were 
marginally raised for 8wk alcohol-treated db/wt and db/db animals in comparison to 
the controls but these differences were not deemed significant; (p=O.26 and p=O.35 
respectively). Similar minor increases were observed in 20wk alcohol-treated db/wt 
and db/db groups and again were found to be statistically insignificant in contrast to 
the control animals; (p=O.23 and p=O.30 respectively). Overall, despite the small 
increases, all groups displayed comparable values and therefore, duration of alcohol 
administered or genotype had no effect on protein concentrations. 
Plasma aspartine transaminase (AST) and alanine transaminase (AL T) were 
examined because augmentation of these hepatic enzymes is strongly indicative of 
liver damage. Increases in AST levels were evident in 8wk and 20wk alcohol-treated 
db/wt animals in comparison to the controls, but these differences only attained 
statistical significance in the 20wk group; (p=O.29 and p=O.037 respectively). Minor 
increases were also noted in the 8wk and 20wk alcohol-treated db/db mice when 
contrasted with their controls, however, statistical significance was not reached in 
either group; (p=O.26 and p=O.64 respectively). The AL T levels were found to be 
slightly increased in 8wk and 20wk stUdies for both db/wt and db/db alcohol-treated 
animals in comparison to the control groups, but statistical significance was not 
achieved. Furthermore, the period of alcohol administration did not provoke further 
disruption in AST values or AL T values. Differences between the 8wk and 20wk 
db/wt alcohol-treated animals and 8wk and 20wk db/db alcohol treated animals were 
shown to be insignificant for both parameters; AST (p=O.56 and p=O.16 respectively), 
AL T (p=O.31 and p=O.78 respectively). 
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The previous findings have ilfustrated that alcohol administration alters hepatocyte 
metabolism as many of the db/wt and db/db treated animals have exhibited 
significant increases in lipid peroxidation products in addition to elevated TC and TG 
content. However, the extent of liver damage observed at histology suggests that the 
liver is only in the early stages of fatty development. The progression to 
steatohepatitis and possibly fibrosis did not occur. The results of AST and AL T levels 
suggests that significant hepatocyte damage did not occur. The hepatic injury being 
incurred with alcohol alone has not reached the point of inflammation and fibrosis 
either because of inadequate timing or severity of stress or because the appropriate 
additional hit(s) were not present. 
Blood/alcohol levels were carried out in an attempt to establish that treated animals 
had consumed alcohol, how such consumption affected the plasma and whether it 
reflected the proportionate amount of disruption which was incurred. The alcohol was 
administered ad libitum and it is therefore impossible to guarantee equal intake 
throughout the different groups. Furthermore, as the alcohol was available to the 
treated animals up until termination, it is also possible that some animals would have 
consumed their last drink just before sacrifice whereas others may have had their last 
intake the night before. The high degree of variation between respective alcohol-
treated animals reflected the experimental difficulties with administering the alcohol 
ad libitum. 
The 8wk alcohol-treated db/wt and db/db animals displayed increases in blood 
alcohol in comparison to the relevant controls but these differences did not attain 
statistical significance; (p=O.055 and p=O.17). This suggests that a number of db/wt 
and db/db alcohol-treated animals did not consume any alcohol before termination, 
although db/db alcohol-treated mouse 23 exhibited a concentration 15.33 mmolii. 
This reading is dramatically increased in contrast to the other alcohol-treated animals 
(db/wt and db/db) as evidenced by the mean bar being totally skewed. It could be the 
result of drinking alcohol just before termination. The reason owing to 8wk db/db 
animals displaying a higher blood/alcohol concentration than 8wk db/wt can only be 
explained by the reasons given previously and any future studies should consider 
withdrawing the alcohol from the treated animals 24hr prior to sacrifice. 
Conversely, the 20wk db/wt animals revealed an increased blood/alcohol level in 
contrast to the 20wk db/db animals, although this was not statistically significant due 
to the high degree of variation. This discrepancy can be part explained by the same 
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reasoning as before in that these concentrations only reflect how recently the animal 
in question consumed alcohol. However, it is possible that there is a greater capacity 
to metabolise alcohol in the db/db mice. In addition, db/wt alcohol-treated animals 9 
and 12 and db/db alcohol-treated animal 22 displayed concentrations which were 
radically raised compared with any other animal; (20.89, 19.32 and 23.05 mmol/I 
respectively). This demonstrates the unreliability of random blood/alcohol 
measurements, rather than individual metabolic differences It raises the possibility of 
fluctuating alcohol levels. The 20wk db/wt and db/db alcohol-treated groups did 
exhibit increases in blood/alcohol levels when compared against the controls as 
expected, but only the db/wt mice were shown to be significant; (p=0.005 and p=0.31 
respectively) . 
It is already established that db/db animals have diabetes, thus, the analysis of 
glucose concentrations was undertaken to determine whether alcohol administration 
further exacerbates the metabolic pathways involved or acts as a mechanism 
whereby similar effects insulin deficiency are induced in the non-diabetic db/wt 
animals. Glucose concentrations for 8wk and 20wk, db/wt and db/db alcohol-treated 
animals are actually decreased in comparison to the control groups. These 
differences are not significant for the 20wk study; (p=0.63 and p=0.29 respectively), 
nor 8wk db/db animals; (p=0.54) but does attain statistical significance for 8wk db/wt 
mice; (p=0.006). The reasoning for this finding is unknown but alcohol may have an 
anti-gluconeogenic effect or may have induced starvation. When contrasting 8wk 
db/wt and db/db, control and alcohol-treated animals against the respective 20wk 
groups, the findings were revealed to be comparable and again displays that an 
increased duration of alcohol exposure from 8wks to 20wks does not make a 
significant difference. 
In conclusion, alcohol administration has a definite effect on body and liver mass, 
products of lipid peroxidation, hepatic TC and TG and central markers of hepatic 
injury are altered to a limited extent. The pilot study displayed a trend for these 
changes after only 4 weeks of alcohol administration, whereas the results exhibited 
from the main 8wk and 20wk studies were more pronounced. However, there was no 
significant difference between the 8wk and 20wk duration and therefore the extra 
12wks of alcohol administration had no additional deleterious effect. It remains 
unclear whether db/wt or db/db mice are more susceptible to metabolic stress in 
response to alcohol administration. Although a trend in db/wt mice may be present, 
the changes are small. Gender may still play a role in determining an individual's 
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susceptibility but this aspect could not be assessed as the mice were all male. Any 
future studies should be directed at confirming or rejecting this theory in addition to 
highlighting changes that are associated with facilitation and development of fatty 
liver. 
6.5 Histopathology Analysis 
6.5.1 Results for the db/db Mouse Model on Regular Chow for 20 Weeks 
Analysis of livers from db/wt and db/db mice (figure 5.7.1 (A-O)) revealed 
histopathological differences and further confirmed the diversity between the db 
genotypes. (A) + (C) reveal the liver of heterozygous (db/wt) mice to be normal as 
liver sections showed preservation of normal architecture, with no fibrosis, steatosis, 
inflammation or necrosis. In contrast, livers from homozygous (db/db) mice; (8) + (D) 
showed grade 2 and 3 micro- and macrovesicular steatosis, predominantly present in 
zone 3 and is characteristic of this genotype. Necroinflammation was not observed. 
Despite the presence of significant steatosis, no steatohepatitis was present 
evidenced by a lack of lobular inflammatory foci. This raises the possibility of 
additional contributing factors being required for progression to steatohepatitis in the 
db/db model. 
Similar to heterozygous (db/wt) mice, livers from wild type (wtlwt) animals were 
shown to be normal, displaying hepatocytes which appeared normal over many fields 
with no aggregations of fat droplets present. There were no histological differences 
between male and female livers in wt/wt, db/wt or db/db groups respectively. 
6.5.2 Impact of Various Oils, Administered via the Diet (4 Weeks) 
The histological findings generated from the administration of various oils in db/wt 
mice (figure 5.7.2) uncovered no significant differences in the liver of the control 
group on regular chow for 4wks and the relevant treatment groups; sunflower oil, 
canola oil and sunflower oil and cholesterol respectively. The control animals showed 
normal liver architecture, as expected, with no signs of steatosis. The addition of the 
various oil supplements did not have any notable effect (figure 5.7.2 (A-D)). This 
supports the fact that no major differences were observed from the biochemical 
assessment. Oil supplementation is therefore insufficient for the induction of steatosis 
in heterozygous mice. One concludes that the oil-supplemented diets with modest 
amounts of oils in the short term had no effect. There were no differences between 
male and female mice. 
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6.5.3 Impact of a Short Period of Alcohol Administration (4 Weeks) 
Analysis of liver sections revealed that alcohol administration for 4 wks had no effect 
on liver architecture for wtlwt, db/wt and db/db animals. Unfortunately, the H&E 
stained sections of these livers were misplaced after examination and therefore 
cannot be presented. The wtlwt and db/wt control mice displayed normal hepatic 
structure as expected, without the accumulation of fat or infiltration of inflammatory 
cells. It was anticipated that 4wks of 20% alcohol administration would induce a fatty 
liver or even steatohepatitis in alcohol-treated wt/wt and/or db/wt mice, but no 
significant histological differences were observed between the respective groups. 
In contrast, db/db mice (with and without alcohol) showed mixed micro- and 
macrovesicular steatosis but no inflammation or fibrosis was presented and no 
differences were observed between the db/db mice receiving alcohol and db/db 
animals not receiving alcohol with respect to steatosis, inflammation and fibrosis. It is 
proposed that an increased period of alcohol exposure may still provoke the 
development and possible progression of fatty liver. The duration of 4wks may not be 
significant to trigger an effect, but some encouraging data from the biochemistry 
parameters being investigated was sufficient to proceed to a longer study. 
6.5.4 Impact of Alcohol Administered over 8 Weeks in db/wt and db/db Mice 
The H&E liver sections (figure 5.7.3) from control and alcohol-treated db/wt animals 
(A) were comparable as both groups showed normal liver hepatocytes, no 
inflammatory infiltrate and no steatosis or fibrosis. Control db/db animal (8) showed 
macrovesicular steatosis without inflammatory infiltrate. Moderate macrovesicular 
steatosis was predominantly located in zones 2 and 3, but also located in zone 1 in 
the alcohol-treated db/db mice (C). There is inflammation present in the portal tract 
but this is considered to be non-specific. 
Upon increasing the magnification of control and alcohol-treated db/db animals 
(figure 5.7.3) the differing levels of inflammation become more apparent. (D) and (F) 
reveal no signs of inflammation for the db/db control animals whereas (E) and (G) 
illustrate necroinflammatory foci in the hepatic nodules along with polymorphs and 
lymphocytes in mixed inflammation in alcohol-supplemented db/db mice. Fibrosis is 
not present in the db/db genotype, even after exposure to 20% alcohol for 8wks. This 
raises the possibility that an additional stressor or 'second-hit' is required to promote 
chronic change over time. It appears as though alcohol may have a slight effect on 
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liver of db/db mice, while there is no effect of alcohol on db/wt animals. Longer 
studies are required to evaluate fibrosis with these inflammatory responses. 
The amount of fat present in each liver (table 6.5.4.1) was graded 'blind' by an 
independent pathologist. Unblindly, the analyses revealed that alcohol had no 
significant effect on hepatic structure in db/wt mice. The change in fat was slightly 
elevated for alcohol-treated db/db animals when compared to the respective controls 
but this change was not significant. The levels of inflammatory aggregates were also 
comparable for control and alcohol-treated db/wt animals but this was not the case 
for the db/db mice where the amounts detected are higher for the alcohol-
supplemented group in contrast to the controls (p=O.005), however larger group sizes 
would determine if this was a 'real' effect or not. 
6.5.5 Impact of Alcohol Administered over 20 Weeks in db/wt and db/db Mice 
The administration of alcohol does not appear to affect the histopathology of db/wt 
and db/db mice when compared with their respective controls, despite the animals 
being supplemented for 20wks (an additional exposure of 12wks in comparison to the 
previous study). The findings (figure 5.7.4) showed db/wt mice (with and without 
alcohol, (A) and (8)) to have normal liver histology with no steatosis, inflammation or 
fibrosis. Alcohol also failed to induce additional liver damage in db/db animals, as 
zone 2 and 3 steatosis with minimal inflammation and no fibrosis was evident in 
alcohol-treated db/db mice (D), which was comparative to the respective controls (C). 
Figure 5.7.4 (E) displays unmistakable macrovesicular steatosis in a db/db control 
animals and is also representative of the similar liver morphology observed in the 
alcohol-treated animals. 
Fatty change was also assessed semi quantitatively for the 20wk animals (table 
6.5.5.1). Alcohol had no significant effect on liver architecture in db/wt mice. The 
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change in fat was slightly elevated for alcohol-treated db/db animals but this was not 
statistically significant. Inflammatory aggregate values were unexpected for db/wt 
and db/db animals as control values were higher than the respective alcohol-treated 
groups. This cannot be fully explained as it contradicts all previous histology data. 
Larger group sizes in future studies may be able to prove or disprove this finding. 
Table 6.5.5.1 
Treatment No. Animals Fat Change (0-3) ± SD 
--_ .. _- --------- -. 
0.0 ±O.O 
Inflammatory 
Aggregate~:j: __ ?g __ 
2.86 ± 3.87 
--------- ---------
1.25 ± 1.5 
6 1.83 ± 0.75 3.5 ± 1.64 
6 2.0 ± 0.0 1.5 ± 1.64 
* = Inflammatory aggregates; 20 x objective, 20 fields counted 
The sirius red stain (figure 5.7.4) displays levels of normal collagen present in db/db 
animals, (F) and (G), and again reveals no significant differences between the control 
and alcohol-treated mice. The examination of these findings revealed that db/db mice 
develop simple steatosis coupled with the presence of lobular inflammation, but 
again fibrosis was not evident in these animals. Alcohol is not compounding the 
already present changes, but they are stili there. Though some inflammation is 
attributable to alcohol, it is not significantly changing the histologic picture after 20 
weeks of administration. 
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Chapter 7; Discussion and Conclusion 
This chapter will briefly summarise the studies before considering the model and 
integrating the pathogenesis of fatty liver. 
7.1 Assessment of the db/db Mouse Model on Regular Chow for 20 Weeks 
Compared with the control (wtlwt) animals, the heterozygous (db/wt) animals 
displayed marginal differences in some parameters whereas the homozygous (db/db) 
animals differed greatly in all parameters. 
The db/wt status does influence body mass and liver mass making the obese mouse 
not entirely a 'recessive' condition. The liver remains the same proportion of the body 
as the ratio of liver mass / body mass was not abnormal. Interestingly, the db/wt mice 
liver had high CD concentration, but no increased LOOH or TTBARS, TC, TG and 
glucose. 
The db/db mice were strikingly larger, with larger livers but the same liver mass / 
body mass ratio. In these mice the liver CD and LOOH were prominently higher, as 
were TC, TG and glucose. The TTBARS were increased but not so markedly so. 
From these results it appeared that the db/wt mice could have some increased 
sensitivity towards fatty liver and were preferred as the investigative line along with 
the obviously highly deranged db/db model. These findings also suggest that there 
may be an increase in early peroxidation products with the increase in body and 
proportionally increased liver mass, and that the full obese phenotype is not essential 
for these changes. These changes are also suggestive of early metabolic stress 
without frank diabetes. Whether there is insulin resistance that could provide a similar 
stress to diabetes, can only be resolved with more detailed experiments including 
insulin concentration and glucose disposal studies. Fluxes of fatty acid in plasma, 
hepatocyte TG, PL and VLDL synthesis or oxidation could be investigated further by 
studies in liver slices or whole body. 
7.2 Impact of Various Oils, Administered via the Diet (4 Weeks) 
When the differently enriched diets are compared with the control diet for their effects 
on the parameters studied in this thesis, only minor differences became apparent. 
Note that the background diet was found to comprise of 3.4, 0.26 and 1.87 ~mol/g 
.liver of CD, LOOH and TTBARS respectively. Additionally, the oils were not heated 
in contrast to man's fatty diet. 
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Although small numbers of animals were used, statistical analysis identified some 
interesting observations. Even though mean body mass did not differ, the livers of 
canola oil-fed db/wt mice (diet high in MUFA) appeared heavier but their ratio to body 
mass was the same as for control animals. Sunflower oil-fed db/wt mice (deit high in 
PUFA) consumed more CD and had a higher CD content in their livers, with and 
without additional dietary cholesterol. The LOOH and TTBARS did not differ. 
Interestingly, the hepatic TC was increased by PUFA (+ or - cholesterol) but liver TG 
was minimally increased only by the MUFA oil. Glucose was unaffected. 
Unlike previous studies, this moderately fat-enriched diet did not elicit a significant fat 
accumulation. The PUFA dietary fats did however influence the CD content. It must 
be noted, however, that this supplement did not resemble the human diet because 
the oils were not heated. If this study was to be repeated it is recommended that oils 
should be heated before administration to maximize oxidative products and increase 
stress on the liver in an attempt to induce a noteworthy effect. The period of 
administration should also be increased. 
7.3 Impact of a Short Period of Alcohol Administration (4 Weeks) 
The db/wt mice were larger than the wt/wt, and the db/db were larger again, 
suggesting that there is a gene dose effect on body size even though the db/wt was 
not frankly obese. The administration of 20% alcohol in water to wtlwt, db/wt and 
db/db mice over a short period of 4 weeks revealed some differences in response in 
growth. 
Whereas alcohol administration did not affect the growth rate of the wt/wt mice, it 
appeared to impair the the growth of the db/wt mice. Regrettably, there were too few 
animals in the wtlwt cohort to examine for differences by conventional statistics. The 
starting points of the db/db mice destined to be controls or consumers of alcohol 
were different and could thus influence the response. But the growth rate appeared 
rapid initially and the animals converged on the same mean body mass with no 
apparent deleterious effect of alcohol administration. 
The impact of short term alcohol administration on lipid peroxidation was different for 
the 3 animal variants but the small number of wtlwt mice results in some lack of 
confidence. The apparent increases of CD with alcohol administration were not 
statistically significant, nor were those of LOOH. There was also an increase of 
TTBARS with alcohol administration in each category of animal but TTBARS were 
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not very different in absolute concentration in the db/db model that distinictly has a 
fatty liver. 
In all instances, alcohol administration resulted in an increase in the hepatic TG 
content; for wt/wt, db/wt and db/db animals. The statistical analysis could not be done 
on the wt/wt animals to evaluate the apparent increase of TG but increases in db/wt 
and db/db animals were shown to be statistically significant (p=O.009 and p<O.0001 
respectively). Interestingly, it appears that there may be some increase in hepatic 
cholesterol content with the administration of alcohol. It is not clear whether such an 
increase, if real, reflects a passive phenomenon (storage in same compartment as 
TG) or active phenomenon (in which alcohol influences cholesterol metabolism. 
Taken together, these studies suggest that over a relatively short period (4 weeks), of 
alcohol administration, liver cells accumulate TG and TC and that db/db mice are 
more vulnerable to the TG accumulation than db/wt mice. Despite the fact that there 
is much more TG in the hepatocyte of the db/db mouse on alcohol, the lipid 
peroxidation products did not increase proportionally; indicating that the 2 processes 
are not directly coupled, i.e. the peroxidation products are not proportionally included 
in TG. Indeed, they may even be metabolically quite distinct. This is in accordance 
with publications in the review where liver damage occurred in the absence of TG 
when fatty acid oxidation was promoted. The suggestion is that inadequate fatty acid 
disposal (by oxidation) ± inadequate inhibition of synthesis can be witnessed by TG 
accumulation while TG accumulation per se does not lead to steatohepatitis (even 
when stressed by alcohol in this model). 
7.4 Impact of Alcohol Administered over 8 Weeks in db/wt and db/db Mice 
Contrary to the impression from the 4 wk study, the administration of alcohol, though 
still retarding growth, had a smaller impact over 8 wk than over 4 wk. Although 
alcohol administration increased the liver mass and the proportion of liver / body 
mass in the db/wt mice, the same was not seen for db/db mice. Inspection of figure 
6.4.1 suggests that around the age of 15 weeks both alcohol-fed groups had lower 
growth rates. Such alcohol feeding may thus impose malnutrition on these animals, 
in contrast to the 4 weeks experiment. 
Noting that there was a gene dose effect on liver mass in the standard chow, it would 
have been interesting to see the effect of alcohol in the short term on liver mass but 
regrettably these studies were not done. At the 8 week exposure, alcohol appears to 
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have significantly affected only db/wt animals although a relatively small increase 
may be masked in the variability in the current data set for the db/db mice. 
Liver enzyme release into plasma showed no apparent hepatocyte damage with 
alcohol. Despite no change in plasma enzymes, alcohol increased the early lipid 
peroxidation products (figure 6.4.4) in both db/wt and db/db animals, again 
suggesting an uncoupling of LOOH products and TG storage, or an independent 
effect of alcohol to increase oxidative stress. In contrast to the 4 week study, LOOH 
increased in both gene groups and, like CD, may show an uncoupling of lipid 
peroxidation from storage and suggests that a period of >4 weeks is necessary for 
this effect. The same applies to TBARS. 
Alcohol did not appear to affect the plasma glucose concentration of the db/db mice 
but, if anything, had an 'antidiabetic' effect on the db/wt mice, comparatible with an 
anti-gluconeogenic effect reported for alcohol. 
The biochemical findings of alcohol administration over 8 wks confirm a change in fat 
content and a consistant increase in lipid peroxidation products. 
7.Slmpact of Alcohol Administered over 20 Weeks in db/wt and db/db Mice 
Inspection of figure 6.5.1 reveals that the growth slopes of the animals fed alcohol 
changed soon after the introduction of alcohol and after 20 weeks the alcohol-fed 
animals weighed less than their controls. The graph also suggests that the animals 
reach maturity at 15 and 18 weeks. Alcohol increased the liver mass by a small 
proportion after 20 weeks in the db/wt (figure 6.5.3) but increased the proportion the 
liver makes to the body mass in both db/wt and db/db animals. Glucose 
concentration was not effected whilst alcohol concentration was higher in both 
groups that had alcohol supplemented, possibly more so in the smaller animals 
(db/wt). Whilst AST was mildly increased by alcohol in the db/wt group, no significant 
changes of plasma AL T occurred. Alcohol increased the TG content in both groups 
and affected protein content. Like the 8 week interpretation, alcohol increased the 
hepatic TC content in db/wt and db/db animals. 
As in the 8 week group, CD levels were increased by alcohol, as were the LOOH and 
TTBARS. The concentration of the TTBARS appeared higher in the 32wk db/db 
control mice than 8wk whereas the CD and LOOH content were higher in 8wk db/db 
control mice when compared with the respective 32wk control animals. 
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Overall, the deleterious effects of alcohol administration on health are in evidence 
with a significant reduction in body mass in db/wt and db/db groups. Consistent with 
the previous studies the TG content increased together with cholesterol content but 
protein content changed little. AST increased in the plasma of alcohol-consuming 
db/wt. Plamsa AL T, strikingly higher in db/db mice did not change with alcohol 
consumption. Random plasma alcohol was increased in db/wt mice, but not 
significantly in db/db mice. 
7.6 The Mouse as a Model 
Rodents are good animals to study because they are inexpensive, genetic 
manipulation is possible and interventions can be controlled. However, certain 
disadvantages arise from using mice and rats in medical research. These include 
time scale; a process requiring years in humans may not be suitably studied, 
especially if the process is not equivocally sped up in the rodent model, and, 
adaptations in metabolism with evolution may not make it susceptible to some 
processes in man despite the similarity in basic biochemistry and immune systems. 
Rodents have regulated energy uptake. Though dietary constituents are varied, 
energy intake remains similar day to day. In contrast, obesity associated with fatty 
liver in humans is associated with a decrease in energy expenditure and increase in 
energy intake, often with much fat that is heated. Potentially, such thermally stressed 
oils are predisposed to the putative inflammation inciting products such as HNE. In 
this context insulin resistance, dietary stress and susceptible fatty acids converge on 
a potentially differently primed hepatocyte and immune systems to rodents to elicit 
fatty liver. Humans also have different lipoprotein metabolism and store more TG in 
adipose tissues. 
The db/db model is an extreme one in which obesity, diabetes and fatty liver mimic 
human condition but appears not to promote inflammation and fibrosis until possibly 
the addition of alcohol. More dietary lipid stress together with alcohol may promote a 
steatohepatitis that approaches the histological and possibly clinical outcome to 
cirrhosis. Additional oxidative stressors may be required, although such a complete 
model may not be apt, it could test therapeutic strategies that, if successful, need to 
be tested in human for verification. 
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The db/wt model may be of interest to pursue in the longer term as the animals 
appears to gain TG almost to the biochemical point of fatty liver of db/db mice or with 
alcohol. 
7.7 An Integrated View 
A normal liver contains TG in various locations of the cell, including cytosolic 
droplets, lipoproteins and likely (non polar) membranes. The metabolic processes 
increasing the fat content can be the result of several stressors, and mayor may not 
be coupled with cellular events that elicit cell damage, accumulation of cytosolic 
droplets visible on microscopy and an inflammatory and fibrotic response. The 
diagram (figure 7.7.1) depicts the multiple pathways in the liver that a fatty acid may 
follow to arrive in the liver and be processed. Numerous enzymes are involved in 
these pathways and several errors or stressors may induce TG accumulation and/or 
inflammatory response. 
Absence of apo B and absence of MTP, both causing a !3-lipoproteinaemia will 
disrupt export. Complete disruption of fatty acid oxidation through mitochondria and 
peroxisomes would also dramatically induce fatty liver. If these processes are within 
the normal activity, then excessive FA entry into the cells through lipid peroxidation 
and/or fatty acid transport could lead to TG accumulation if no induction of 13-
oxidation occurs. Increased FA synthesis could further overload the !3-oxidation. 
However, increased !3-oxidation can increase lipid peroxidation, causing cell damage, 
apoptosis and necrosis, eliciting inflammation and fibrosis. Thus for similar metabolic 
stresses, much variation in response can be attributed to the genetic and 
environmental factors pertaining in a given individual. The fatty liver relating to 
alcohol may thus also have a variable contribution from alcohol, especially at lower 
dosage. 
Further studies of fatty liver disease should address the mechanisms involved by 
determining fluxes of FA in plasma, oxidation (even if indirectly by tracer studies of 
CO2 in breath) and lipid peroxidation export. Furthermore, multiple gene micro-array 
studies could declare metabolic and immune responses and variation within these. 
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Figure 7.7.1: Overview of FA metabolism; including dietary assimilation, plasma transport as lipoproteins and albumin bound fatty acids, intracellular 
processes of f3-oxidation, lipid peroxidation, lipoprotein formation and storage of TG droplets. Abbreviations - LCAD; long chain acyl dehydrogenase, LCHAD; 
long chain hydroxyl acyl dehydrogenase, MCAD; medium chain acyl dehydrogenase, SCAD; short chain acyl dehydrogenase, LRP; LDL receptor-related 
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Chapter 8; Tables - Group Mean Values 
8.1 
Table 8.1.1 
Db Mouse Mode/- Group Mean Values: Males and Females 
Terminal Body Mass (g) ± Standard Deviation 
Group Genotype 




Body Weight (g) ± SO 
22.4 ± O.S 
2 Wild Type (wt/wt) 6F 17.3 ± 1.6 
---_ ...... _ .. __ . --_. __ ... _---- ._-_ .. __ . _._._ .. _-_._-_._._----_._----_. 
3 Heterozygous (db/wt) 16M 26.4 ± 2.4 






Homozygous (db/db) 10M 44.8 ± 2.4 
Homozygous (db/db) 14F 42.2 ± 3.9 
._-_. __ .. _--
Db Mouse Mode/- Group Mean Values: Males and Females 
Liver Mass (g) ± Standard Deviation 
·-·---------M~-·-------·-·T.-.-------.----.--- .. ---.----.-. -... --.-
Genotype NO./Asnimals Liver Weights (g) ± SO 
ex 
.-~-~----.- ------_ .. _--- --------------------------
Wild Type (wt/wt) 6M 0.78 ± 0.06 
---_. __ ._----_._ .. _-
Wild Type (wt/wt) 6F 0.75 ± 0.08 
3 Heterozygous (db/wt) 6M 1.27±0.13 
4 Heterozygous (db/wt) 6F 0.75 ± 0.09 
5 Homozygous (db/db) 6M 1.77±0.18 
6 Homozygous (db/db) 6F 2.09 ± 0.39 





Db Mouse Model- Group Mean Values: Males and Females 
Glucose Concentration (mmol/I) ± Standard Deviation 
Wild Type (wt/wt) 6F 5.1 ± 1.0 
Heterozygous (db/wt) 16M 9.1 ± 3.4 
4 Heterozygous (db/wt) BF 6.0 ± 1.0 
--.. - .. --.----....... -- -_._-_ .. __ .. _-1-------_ ... - ..... ----.. .--.------... -.-.. 
5 Homozygous (db/db) 10M 23.0 ± 2.9 
6 
Table 8.1.4 
.. -.-...... ----.-.. --.--- 1-----.--.-.. -- .---.---.------------.--.--.----
Homozygous (db/db) 14F 20.4 ± B.O 
Db Mouse Model- Group Mean Values: Males and Females 
Triglycerides (mg TG/g. liver) ± Standard Deviation 




Genotype Triglycerides (mg TG/g. liver) ± SO 
Wild Type (wt/wt) 6M 1.94 ± 0.44 
2 Wild Type (wt/wt) 6F 1.B1 ± 0.39 
3 Heterozygous (db/wt) 161\11 1.19 ± 0.22 
4 Heterozygous (db/wt) BF 1.41 ±0.49 
5 Homozygous (db/db) 10M 3.16±1.13 
6 Homozygous (db/db) 14F 4.14±0.B1 
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Table 8.1.5 
Db Mouse Model- Group Mean Values: Males and Females 
Cholesterol (mg chollg. liver) ± Standard Deviation 
,---------------~---------,------------ ---------------
Group Genotype 
Wild Type (wUwt) 
-----------------------
2 Wild Type (wt/wt) 
----------------------- --------------
3 Heterozygous (db/wI) 
4 Heterozygous (db/wt) 
----------- ----------------j 
5 Homozygous (db/db) 
------------j--------
6 Homozygous (db/db) 
No. Animals 
/ Sex 
Cholesterol (mg chol/g. liver) ± SO 
--------------
6M 4.71 ± 0.39 
-------- ----------------------
6F 4.85 ± 0.33 
+------------------
16M 4.47±0.43 
8F 4.54 ± 0.73 
10M 6.67 ± 0.80 
---------_._----
14F 6.68 ± 0.62 
Table 8.1.6 
Db Mouse Model- Group Mean Values: Males and Females 





Conjugated Dienes (~mol/g. liver) ± SO 
Wild Type (wt/wt) 6M 2.07 ± 0.21 
-------- r---------------------.-----------
2 Wild Type (wt/wl) 6F 1.89 ± 0.12 
L. ______________ ._______ _ _____________ . __ _ 
3 Heterozygous (db/wt) 16M 2_58 ± 0.35 
--------------- ----- --- ---------- _._- ---------------
4 Heterozygous (db/wt) 8F 2.70 ± 0.34 
------------ -------------------------_._---------------------------_._-- -----
5 Homozygous (db/db) 10M 3.48 ± 0.23 
------------------------------- ---_._---- ------ ----- --_._-------_. __ ._-----
6 Homozygous (db/db) 14F 3.63 ± 0.47 




Db Mouse Model- Group Mean Values: Males and Females 
Lipid Hydroperoxides (nmol LOOH/g. liver) ± Standard 
Deviation 
Genotype 
Wild Type (wtlwt) 6M 217 ± 76 
---------------- --------------+----------- -------------~------------~-----------
2 Wild Type (wt/wt) 6F 137±91 
-------------------------------------------
3 Heterozygous (db/wi) 16M 176 ± 71 
4 Heterozygous (db/wi) 8F 216± 49 
---------- -----------------------t----------------~~---------------------~--
5 Homozygous (db/db) 10M 704±151 
6 Homozygous (db/db) 14F 433 ± 111 
____________ _ _______________ ~ __________ ~~ ____ __L __________________________________ ~ _ _" 
Db Mouse Model- Group Mean Values: Males and Females 





Wild Type (wt/wt) 





FTBARS (nmol/g. liver) ± SD 
1795 ± 87 
------~-----
1309 ± 149 
-------- -- ---t-- ------------- ------------------------------------------------
3 Heterozygous (db/wt) 16M 1264 ± 225 
---------- --------- ----
4 Heterozygous (db/wt) 8F 1337±127 
5 Homozygous (db/db) 10M 1559 ± 162 
----------------------- --------------- --------~ -----------------------------
6 Homozygous (db/db) 14F 1731 ±260 
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8.2 
Impact of Various Oils, Administered via the Diet (4 Weeks)-
Group Mean Values: Males and Females Combined 






________ GroUQi Treillm_e_n __ t___ ,---___ --:-__ 
4 2 3 
Control Sunflower Oil Canola Oil Suncfl~~ertOil ~nd 
__________________ .. __ . ______________ ~o ~~..r:Q __ 
22.2 ± 3.1 22.4 ± 2.9 23.3 ± 3.7 23.8 ± 4.8 
22.0 ± 3.4 22.0:1: 2.2 23.3 ± 3.5 23.8 ± 5.8 
---------------- ---.--------~-+---.--------------+--------.-- ------------








22.4 ± 3.6 
22.8 ± 3.2 
23.4 ± 3.6 
1.2 
----------- ~~-
22.3 ± 2.3 
23.5 ± 2.9 
23.6 ± 2.7 
1.2 
22.9 ± 3.1 24.3 ± 5.7 
23.1 ± 3.5 24.5:t 4.9 
--------------_. 
24.1 ± 3.2 24.5 ± 5.0 
0.8 0.7 
Impact of Various Oils, Administered via the Diet (4 Weeks)-
Group Mean Values: Males and Females Combined 




No. Animals / 
Sex 
---- -----.~---~----~--
Liver Weights (g) ± SO 
--.------.----------- .----.----- f-- -------- -----------------------~------.----- ---------.. --.--- -----.--
1 
(db/wt) 






3M + 3F 0.884 ± 0.13 
----- -------- ---_._----+--._-----_.- -------------------------------------_.-
3 
(db/wt) 
Canola Oil 3M + 3F 1.025 ± 0.13 
----.--------.-- ----------- --r-------------I-- -------------------------------------
4 Sunflower 
3M + 3F 0.889 ± 0.16 Oil and 
(db/wt) 














Impact of Various Oils, Administered via the Diet (4 Weeks)-
Group Mean Values: Males and Females Combined 





Canol a Oil 
Sunflower 
Oil and 
No, Animals / 
Sex 
3M + 3F 
3M + 3F 
3M + 3F 
3M + 3F 
Glucose Concentration (mmolll) ± SO 
6,8 ± 1,9 
7,6 ± 1,0 
8,0:1: 2,2 
4,5 ± 2,2 
Impact of Various Oils, Administered via the Diet (4 Weeks) -
Group Mean Values: Males and Females Combined 















No, Animals / 
Sex 
3M + 3F 
3M + 3F 
3M + 3F 
Triglycerides (mg TG/g, liver) ± SO 





(db/wt) , 011 and 3M + 3F 22,2 ± 2.4 











Impact of Various Oils, Administered via the Diet (4 Weeks)-
Group Mean Values: Males and Females Combined 





Canol a Oil 
No. Animals / 
Sex 
3M + 3F 
3M + 3F 
3M + 3F 
Cholesterol (mg chol/g. liver) ± SO 
2.33 ± 0.52 
4.47± 1.13 


















3M + 3F 
------------'------
3.99 ± 1.08 
Impact of Various Oils, Administered via the Diet (4 Weeks)-
Group Mean Values: Males and Females Combined 
Conjugated Dienes (J1molfg. liver) ± Standard Deviation 
Treatment 
No. Animals 
Conjugated Dienes (I-Imol/g. liver) ± SO 
Sex 
-~-~.----
Control 3M + 3F 2.00 ± 0.20 
---'" 
Sunflower 
3M + 3F 2.66 ± 0.33 
Oil 
Canol a Oil 3M + 3F 2.26 ± 0.30 
Sunflower 










Impact of Various Oils, Administered via the Diet (4 Weeks)-
Group Mean Values: Males and Females Combined 






No. Animals / 
Sex 
3M + 3F 
3M + 3F 
Lipid Hydroperoxides (nmol LOOH/g. liver) ± SD 
400 ± 251 
561 ± 235 






3M + 3F 500 ± 90 
3M + 3F 497 ± 188 
(db/wt) ___________ . Cholest:=er-=-ol'-----L.~ ______ . ___________________ . ___ ._._ 
Impact of Various Oils, Administered via the Diet (4 Weeks)-
Group Mean Values: Males and Females Combined 















(db/wt) Oil and 
Cholesterol ~_~ __ , __ ~ ____ ~ __ .......L ____ ~ ___ _ 
No. Animals / 
Sex 
3M + 3F 
3M + 3F 
3M + 3F 
3M + 3F 
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FTBARS (nmol/g. liver) ± SD 
3532 ± 410 
3173:1:461 
3314 ± 546 












Impact of Various Oils, Administered via the Diet (4 Weeks) -
Group Mean Values: Males and Females Combined 
BCA Protein (pg/pg.liver) ± Standard Deviation 
BeA Protein (~lglrlg. liver) ± SD 
71.3 ± 11.9 
72.2 ± 4.0 
75.0 ± 10.8 
3M+ 75.5± 7.7 
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8.3 
Study of Short Period of Alcohol Administration (4 Weeks)-
Group Mean Values: Males and Females Combined 
Table 8.3.1 Weekly Body Mass (g) ± Standard Deviation 













































24.0 ± 3.1 22.1 ± 3.3 36.4 ± 7.3 34.3 ± 2.1 
24.4 ± 3.8 22.5 ± 3.5 37.3 ± 7.2 35.6 ± 2.1 
24.9±3.1 22.8 ± 3.8 37.8 ± 7.8 36.6 ± 2.1 
25.0 ± 3.8 22.5 ± 3.9 37.3 ± 8.1 36.6 ± 1.7 
25.1 ± 3.7 22.6 ± 3.3 37.4 ± 8.6 37.3 ± 1.8 
18.8 25.1 ±3.7 22.4 ± 3.2 37.8±8.9 37.8±2.1 
19.3 25.8 ± 3.6 22.6 ± 3.3 38.9 ± 9.3 38.5 ± 2.0 
+ 1.8 + 1.8 + 0.5 +3.5 + 4.2 
Please note that a standard deviation value could not be calculated for groups 1 and 2, as the 
number of animals was too small. 
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Table 8.3.2 
Study of Short Period of Alcohol Administration (4 Weeks)-
Group Mean Values: Males and Females Combined 
Triglycerides (mg TG/g. liver) ± Standard Deviation 
----------------- ---------------,------------ ---------------------.--------------------
No. Animals / 
Sex 
Triglycerides (mg TG/g. liver) ± SO Group / Genotype Treatment 
--_._---_.-- -------- ---------------- ------
1 H20 Control 1 M + 1 F 1.53 ______ Jwt~Q ________________ . ____________ . _______________ . 
2 
(wUwt) 20% Alcohol 1 M + 1 F 
-------.------------ --------1-------_._._-
1.84 
__ ___ {9plwt) ___ H20 Control 2M + 2F 1.05 ± 0.08 
______ J9l?1y.rtt ______ + __ 20_0_Yo_A_IC_O_h __ OI_f _____ 2~_~_2_F ______ ._ .. ______ 1_.2_8_~~~_~ ________ _ 
5 
(db/db) H20 Control 2M + 2F 2.93 ± 0.26 
._--------------------1-------------- ------------ -------------------.----------
(db~db) 20% Alcohol 1 M + 3F 6,44 ± 0,48 
------------ -- .. ------.-- ---------------------
Please note that a standard deviation value could not be calculated for groups 1 and 2, as the 
number of animals was too small_ 
Table 8.3.3 
Study of Short Period of Alcohol Administration (4 Weeks)-
Group Mean Values: Males and Females Combined 
Cholesterol (mg chol/g. liver) ± Standard Deviation 
--------_.-------------_. ---------,----------------
No_ Animals / 
Sex 
Group / Genotype Treatment Cholesterol (mg chol/g_ liver) ± SO 
-- -----------------.- ------- -.--------------------- --------- ----------------_.-
1 H20 Control 1 M + 1 F 3.54 ____ L~\AI..!L ________________ ._. _____________________________ _ 
2 20% Alcohol 1 M + 1 F 4.53 
____ ~t{""'!)_____ _ __ ... _____ _ ______ . ________________ . ______ _ 
~ ) H20 Control 2M + 2F 2.62 ± 0.72 ________ ~d_~_\'It___ _ __________ ... __ ._ ... _____ _ .. ____________________ .. _______ _ 
______ idE~\AI.tL ____ ~_~_o~~~~~~~ ___ ~~_~_~~ 4,49 ± 0_51 _________ _ 
______ {9_~~bl __ . H20 c_o_nt_ro_I-+ ___ 2_._M _ +_2_F _________________ 4_-6_5 _±_1 ~~ ________ _ 
6 20% Alcohol ________ {2~~~pl __ _ '1M + 3F 5.15±1,42 ----'---------_ ... --------
Please note that iJ standard deviation value could not be calculated for groups 1 and 2, as the 
number of animals was too small. 
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Study of Short Period of Alcohol Administration (4 Weeks)-
Group Mean Values: Males and Females Combined 
Table 8.3.6 TTBARS (nmollg. liver) ± Standard Deviation 
------r~--:-:--~__:_------ --------------------
No_ Animals / 
Group / Genotype Treatment Sex FTBARS (nmol/g. liver) ± SO 
1 
H20 Control _____ ~~\f\I.!L __ 1M + 1F 1490 
---------+------------- ----------------------.----------
2 20% Alcohol _______ J.~/wtl ________ _ 1M+1F 1577 
3 H20 Control 2M + 2F 1175 ± 72 _____ (db/wt) _________________ 1 ________________________________ _ 
4 20% Alcohol _____ ~~£\f\I!.L__ _ ____ _ 2M+2F 1367±125 
5 H20 Control 
_______ (qlJ~~l _ _+_--- 2M + 2F 1307 ± 144 
6 20% Alcohol 
_~ ____ tqt:l/d~L__ _ _______ _ 
'1M + 3F 1849 ± 26 
--------_ .. ---------------------------------
Please note that a standard deviation value could not be calculated for groups 1 and 2, as the 
number of animals was too small. 
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8.4 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Table 8.4.1 Weekly Body Mass (g) ± Standard Deviation 
--------------,-----_._-----------_.----::--------:-=-,_._--_._---------------------, 






-----'=! 20 CQ.Qtr:9.L 
25.2 ± 1.5 
34 
(db/wt) (db/db) (db/db) 
20°&.6I_gQ.~_~~ _H20 CJ>.Q!r.QL. _____ ~O"l.o...6.~cohol_ 
27.3 ± 1.3 44A ± 3.1 44.3 ± 4.0 
--------+------------ ----------+---
10 26.5 ± 1.7 27.8 ± 1.3 46.9 ± 2A 46.8 ± 4A 
.-.-------- -----_._----_._----_.- --_._------ ------
11 27.3±1.7 28.1 ±1.1 47.6±2.2 48.0±4A 
12 28.1 ± 1.5 28.7 ± 1.0 49.7 ± 2A 48.9 ± 4.2 
13 29.0 ± 1.8 29A ± 1A 49.6 ± 3A 49.0 ± 4.7 
---------1---
14 29.6 ± 2.1 29.8 ± 1.5 49.3 ± 4.8 49.6 ± 5A 
----.------t--------- .----------.----+----
15 31.2 ± 2.3 30.3 ± 1A 50.7 ± 4A 50.0 ± 6.2 
._._-------_._---_._-- ._ .. _----------+-_._-----------_._---
16 30.9 ± 2A 30A ± 1.0 49.9 ± 6A 
17 31.7±2.6 30.9±1.1 52.1 ± 5.1 49.9 ± 7.6 
18 32.3 ± 3.1 31.0 ± 0.8 52A ± 5A 50.5 ± 8.2 





32A ± 2.6 
32.0 ± 2.7 
6.8 
30.9 ± 1.0 
31.8±1.1 
4.5 
50.8 ± 5.3 50.2 ± 8.7 
51.8±5.3 49.5 ± 8.7 
7A 5.2 
_w.._ee_ks.Jl..::~O_ _ _____ .. _._. ___ ._. ____________ ___ L __________ _________________ _ 
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Table 8.4.2 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Liver Mass (g) ± Standard Deviation 
-.-----~.-~ ------------ ------------- -----
Liver Weight (g) ± SO 
1.06 ± 0.06 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Table 8.4.3 Glucose Concentration (mmol/I) ± Standard Deviation 
Table 8.4.4 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Blood/Alcohol Levels (mmol/I) ± Standard Deviation 
(db;db) 20% Alcohol 
_________________________ 1-___ _ 
5 4.73 ± 6.00 
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Table 8.4.5 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
























.-~- .. - ---------_. 
No. Animals AST Levels (U/I) ± SO 
7 32.6 ± 17.3 
6 41.7±11.1 
1-·_· 
6 53.8 ± 21.4 
5 77.8 ± 43.4 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Table 8.4.6 Alanine Transaminase (ALT) Levels (U/I) ± Standard Deviation 
Group / Treatment No. Animals AL T Levels (U/I) ± SO 
_. __ ~e!l0typ~_ _ __ ._._. ___ ._ ..... __ . _ ._._ .. ____ . __ . _____ ~. __ . __ . __ . 
1 H20 Control 7 __ .. _i~bil.'ltl ___ . . __ ... ______ .. _~ ... _______ .. _ ... _._._.~_ .... _ 18.6 ± 10.5 
2 20% Alcohol 6 
__ (db/~L ___ ~ ________ __ .. ___ _ 
22.3 ± 8.0 
3 H20 Control 6 . __ J<!b/9~L __ ._._.~__ _ ___ _ 65.3 ± 46.9 
_ .._.(~1:l;9.~L._ .... _ 2~O/o ~~C_O_h_ol~_.~._5 ___ .~.__ ._. __ ... _ ...... ______ . ___ 71_.0_±_3~~= ___ . __ .... __ ._. __ 
Table 8.4.7 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Triglycerides (mg TG/g. liver) ± Standard Deviation 
__ ~~!fe .. -,~:::~;~, r~~~~i~al' ... ·-:;;i;,Y~~~::~±:~li~~;);~~-
---- ----.. ----- -----... ----.---~.-~--~~--------




.. __ (db/db) 
20% Alcohol 
6 6.55 ± 1.41 




Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Cholesterol (mg chol/g. liver) ± Standard Deviation 
--
eatment No. Animals Cholesterol (mg chol/g. liver) ± SO 
Control 7 3.35 ± 0.95 
o Alcohol 6 5.03 ± 0.91 
----
Control 6 5.91 ± 1.02 
-_. 
o Alcohol 5 8.46 ± 1.58 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 


















No. Animals Conjugated Dienes (IJmol/g. liver) ± SO 
7 1.60 ± 0.31 
6 2.00 ± 0.23 
.---
(db/db). __ _ 
H20 Control 6 2.66 ± 0.07 
-+---_. __ . 
4 
_____ Jc!l:lI_~_b ) 
Table 8.4.10 
Group / 








20% Alcohol 5 3.45±0.16 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Lipid Hydroperoxides (nmol LOOH/g. liver) ± Standard 
Deviation 
--_._------- --------_._-,-_._-_ .. _------------_ .. _------_._--, 
Treatment No. Animals Lipid Hydroperoxides (nmol LOOH/g. liver) ± SO 
--_. __ ._-------
339 ± 54 
20% Alcohol 6 724±107 
6 1073 ± 92 
20% Alcohol 5 1486 ± 118 
--_._------------_._----
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Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Table 8.4.11 TTBARS (nmol/g.liver) ± Standard Deviation 
Group 1 Treatment 
__ ~~~~ty~ _~ _____ _ 
No. Animals FTBARS (nmo/lg. liver) ± SO 
1 H20 Control 7 1762 ± 154 
. ___ (db!~L ______________ j-____ ~ 
2 20% Alcohol 
__ (@/wtL.__ _ ___ _ 
6 2529 ± 266 
3 H20 Control __ i9p/d b) ___ _ _______ . ___ ~ 6 1862±230 
4 20% Alcohol 
tc!.b!~~__ _ ____ _ 5 2962 ± 257 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Table 8.4.12 BCA Protein Assay (Ilg/Ilg. liver) ± Standard Deviation 
Group 1 Treatment 
_~~I:lOtyp~_-+ __ _ 




____ (d~",,!) __ 
3 





H20 Control 7 55.3 ± 10.5 
-~----------- .. --.------------------
20% Alcohol 6 60.7 ± 3.6 
l-bO Control 6 69.4 ± 12.4 
20% Alcohol 5 76.7 ± 12.2 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Fat Change and Inflammation Grading ± Standard Deviation 
Fat Change (0-3) ± SO Inflammatory 
~i1.9!~gates* :!:_~Q. __ _ 
0.0 ± 0.0 
6 0.17 ± 0.41 0.0 ± 0.0 
-----------.-~~-----+------.------. 
6 2.33 ± 0.52 1.33 ± 1.63 
* == Inflammatory aggregates; 20 x objective, 20 fields counted 
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8.5 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 







__ 1i20 Control 
27.0 ± 0.8 
_____ Q!()_u.R / T reatm._e_ n,,_t. ___ ---,-_________ ._ 
234 
(db/wt) (db/db) (db/db) 
20%_Alco!!2!. H20 C?o_n_tr_o __ 1---t_._2_0ol?_~~~J1_o_1 _ 
27.6 ± 0.5 45.1 ± 1.3 43.4 ± 1.8 
----------- ---------------------.-------- -------f------.----------
10 28.1±1.2 27.9±1.0 45.4±0.9 46.3±1.4 
------+-----------
11 28.8 ± 1.1 28.5 ± 0.9 46.2±1.1 47.1±1.0 
12 29.4 ± 1.1 28.2 ± 1.2 50.6 ± 3.1 49.8 ± 1.6 
-.-----.------- --------- f---------.-.-------
13 30.9 ± 1.0 28.7±1.3 51.8 ± 2.2 50.1 ± 2.2 
.------.----------1------ ----------.. --.--------.-----.1---------------... -.--
14 31.4±1.3 29.3 ± 1.2 53.5 ± 2.8 51.0 ± 2.9 
._----------_._---+-- --/------- -------- ------_._-------
15 32.5 ± 2.0 29.8 ± 1.0 54.8 ± 3.6 51.8 ± 2.5 
---------- -_ ... _------_ .. _-----------_._. --------_. __ ._----
16 32.6 ± 1.7 30.4 ± 1.1 56.2 ± 3.6 51.3 ± 2.4 
17 33.1 ± 2.1 30.1 ± 1.3 55.4 ± 3.7 51.5±2.9 
---------.- ------- -------------- -------.. -.----f--------.--------
18 33.5 ± 2.0 30.4 ± 1.2 56.8 ± 4.0 51.8 ± 3.2 
------------ ,-----------_._-
19 33.5 ± 2.2 30.1 ± 1.0 57.4 ± 3.8 51.4 ± 3.5 
_._-------1---------------





Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Weekly Body Mass (g) ± Standard Deviation 
(W~~~S) ~::~wt~~~- --~i:;O"~ ;T,eat::~:;_ r-~~'~b;db)--
_~, ________ ~ Control __ ~QYo AI~Ql!oL!:!z!L.ContrQL __ ,~?Q% AlcohoL 
21 33.4 ± 2.4 30.1 ± 1.3 56.0 ± 3.7 51.3 ± 2.9 
,-,--.~,---+--- ----------
22 32.9 ± 2.6 29.6 ± 1.1 56.3 ± 4.2 50.8 ± 3.2 
~----- .. - ---------'" ------- L.,,,, 
23 33.9 ± 2.8 30.7 ± 0.8 56.3 ± 5.0 50.4 ± 3.6 
---.. ----~- ---_._----- ~---, .-----~--------, 
24 33.3 ± 2.9 30.5 ± 1.0 54.5 ± 4.4 49,9 ± 3.5 
--,,--~ --+-------- '---'-"'-'" -~ ,-,~--.--- --~---~,-"'~, 
25 33.4 ± 2.8 31.0 ± 1.1 56.5 ± 4.4 51.2 ± 3,8 
------~-~--,~-"",-~,,-~--"-, 
26 33.9 ± 3.0 31.6 ± 0.9 57.9 ± 4.8 51,8 ± 4,6 
-'---+--"---'-'-.~-~ 
27 32.7 ± 2.8 31.6±1.4 57.7 ± 4,5 51,8 ± 4,9 
28 32.9 ± 3.2 31.5 ± 1.3 58.6 ± 4,3 52.8 ± 5.0 
29 33.4 ± 2.8 30,9 ± 1.5 59,0 ± 5.0 53.5 ± 5,7 
---j-""--~-,~,~,,,~~,~,- -'-'~--"-'-'-----'---
30 33,8±2.1 31.6±1.7 58.3 ± 4,5 52.7 ± 5.8 
,~,-~~-"-'''~- ,-,~-,----, -"--'---'- ~,,~,----,-,-----~,-,,~"" 
31 33.5 ± 3.3 31.5 ± 2.1 57.4 ± 4.2 51.3±5.7 
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Table 8.5.2 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Liver Mass (g) ± Standard Deviation 
Group / Genotype Treatment No. Animals Liver Weight (g) ± SO 
---------... -----j-----_ .. _------ .. -.------.----.---.--.--~----
______ jd_~}~l ______ H_20_C_on_t_ro_I__+_--.---~--- _______ ~~_±_O_.O=_ _____ . __ _ 
___ .i@~~L___ 20% AICOh_OI___t_---~----. __ .. _________ 1.5~~_0_. ~ 1_._. _____ . __ .. __ 
3 H20 Control ____ {c:J_~~ ________ . 
6 2.84 ± 0.44 
(db;db) J 20% Alcohol 6 2.99 ± 0.38 
----~--~.-----------~-- ------ "._----_._._------ ----------
Table 8.5.3 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Glucose Concentration (mmol/I) ± Standard Deviation 
r--------·---
I Group / Genotype Treatment No. Animals Glucose Concentration (mmol/I) ± SO 
.-._ .. _._-_._-------_. __ .. --.-~---+-----.. --.-.------. -----------_._--------_._._-------
Table 8.5.4 
7 13.6 ± 3.5 
4 12.3 ± 5.2 
6 29.2 ± 4.8 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Blood/Alcohol Levels (mmol/I) ± Standard Deviation 
Group / Treatment No. Animals Blood/Alcohol Levels (mmol/I) ± SO 
___ Qe.'101ype___ _________ ..... __ ---_._-----_ ... _.- ------_._----
1 
_ (db/~l. __ 
7 0.64 ± 0.49 
--_._------------------------.. _---
2 20% Alcohol 4 
---iC!~~-___t_--.---.~ .. ---------- . 
12.65 ± 9.09 
3 
_. __ j@!.<!~L __ 
4 
_____ J~~!d b 1._ 
6 0.56 ± 0.27 
20% Alcohol 6 4.49 ± 9.09 
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Table 8.5.5 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Aspartine Transaminase (AST) Levels (U/I) ± Standard 
Deviation 
---------,-._-------- ------------_._-_._-----------_._-_._-
Group / Genotype Treatment No. Animals AST Levels (U/I) ± SD 
1 
_____ (db/wt) __ 
2 
____ j9b~~L ____ _ 
3 





---j----------- --------.~--------------.-------.----. ---- -- ---.--




37.5 ± 9.5 
----------------------------_._--------_._-_._------------.-
C~~~OI 6 37.3 ± 9.6 
6 43.5 ± 30.3 
20% 
Alcohol _ __ ~ ___________ L_ _________________________________ ~ 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Alanine Transaminase (ALT) Levels (U/I) ± Standard Deviation 
Group / Genotype Treatment No. Animals AL T Levels (U/I) ± SD 
Table 8.5.7 
7 15.1 ±7.8 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Triglycerides (mg TG/g. liver) ± Standard Deviation 
3.72 ± 0.54 
5.35 ± 0.59 
---+-------
20% Alcohol 6 7.67 ± 0.60 
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Table 8.5.8 
Group I ,pnrHV',." 
Table 8.5.9 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Cholesterol (mg chol/g. liver) ± Standard Deviation 
No. Animals rh,."lo .. t"r",1 (mg chol/g. liver) ± SO 
7 3.88 ± 0.50 
4 5.58 ± 0.67 
6 6.14 ± 1.31 
6 9.17 ± 1.58 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Conjugated Dienes (pmol/g. liver) ± Standard Deviation 
Animals IIUU'~lt::U Dienes (I-Imol/g. liver) ± 
7 1.64±0.18 
4 2.19±0.29 
6 2.22 ± 0.15 
6 2.58 ± 0.17 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Table 8.5.10 Lipid Hydroperoxides (nmol LOOH/g. liver) ± Standard 
Deviation 
Group I Genotype Lipid Hydroperoxides (nmol LOOH/g. 
195 ± 60 
452 ± 78 
789 ± 110 
998 ± 121 
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Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Table 8.5.11 TTBARS (nmol/g. liver) ± Standard Deviation 
Group 1 Genotype Treatment No. Animals FTBARS (nmol/g. liver) ± SD 
Table 8.5.12 
2816 ± 349 
2891 ± 164 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
BCA Protein Assay (l1g/l1g. liver) ± Standard Deviation 
·-··········~~-·-.... ·-·-r·--~·.---- .. --·-.... ·-"··-·-·-· 
Group 1 Genotype I Treatment No. Animals Protein Concentration (1J9/IJ9. liver) ± SD 








. ___ jdb/dl~.L 
7 58.6 ± 8.0 
--.-.-.--- -_._---_._ ... __ ... __ . ---
20% Alcohol 4 64.8 ± 6.0 
6 82.5 ± 10.9 
20% Alcohol 6 88.5 ± 8.0 
Impact of Alcohol Administered over 20 Weeks in db/wt and 
db/db Mice - Group Mean Values: Males 
Table 8.5.13 Fat Change and Inflammation Grading ± Standard Deviation 
...... _.-._--_ .. _------_ .... _-_ .. _-..... __ . _._-_._._._------,---_.--._._._--_.-
0.25 ± 0.50 
6 1.83 ± 0.75 
6 2.0 ± 0.0 
Inflammatory 
Aggr,E3.gates~ ± ...§P __ 
2.86 ± 3.87 
1.25 ± 1.5 
3.5 ± 1.64 
1.5 ± 1.64 
-----_._._-----'--------_._._-------
* = Inflammatory aggregates; 20 x objective, 20 fields counted 
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Chapter 9; Appendices -Individual Values 
Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix A 1 Terminal Body Mass (g) 
~----------.-~-----------.--=---:----:-:---c-:-, 
Sex ~rJ!!!l_<!L _____ Body ~~ssJ9L_ 
M 
F 
1 __ 22} __ _ 
1--_--=2'-----_ 22~5 
3 -~---2T2----
4 ~ 22. f-----
-·--------'-5--~-- -----2-3.-5 ~---
----6---- ~ 22.6 







______ ~ _____ __'__ ___ ~_.~ __ _'..:=_ ______ ~~__L~_~ __ . _____ _ 
Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix A2 Liver Mass (g) 
------------ -------~---~~---- --_._---_._----, 





2 0.7377 -----_._-----------------_. __ ._--
3 0.7484 _. __ ._---_ ... _. -_. __ .-- -_._----
4 0~7784 
-------- -------------
5 0.8145 ---------- _. __ ._------_._.-
0~7113 
--t------~~--7c----~-----+---·---O'7-9-79-
•.. _------._-----_._- -----------_ ... _-







Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix A3 Liver Mass / Body Mass x 100 (%) 
Sex Animal Liver Weight I Mass 








5 3.47 ---------- -_._----
____ ~ __ ___j--~-~---~.-~-----+-----~~:UL--





10 4.15 -------- ----------




Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix A4 Glucose Concentration (mmol/I) 





- ---_._----- ----~ -- ~- -_ ... - ---~~--------.---
5 7.0 
-------_._~--_.- - --.-- ----. -----_._----------
6 6.3 
--~- ---------""- ---~.-.-----.----- ---_._--_. ----- ~--.---.-- .. _._---
7 4.2 -----_._---"_._--_._- -. --. . __ ._----- ------ ----_.-
8 6.0 ------ - ._._ .... _------._.-------.- -_ ... _-----------"-
9 6.2 




11 4.9 --_._- --_ .. ------------- -.---------~ .. -
12 5.7 
Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix AS Triglycerides (mg TG/g. liver) 
-- ------Se-x·--------i--·-AnimaT-·-- ----'--'=rriaT1---"--'--" ".------ T riar2-- -----Mean--------
__ ~ ____ ~_ .. _._________ -_. __________ ~~ __ ._._,____ __ - ____ ~ ______ . ·_--,---_.----.-_.---0 ___ ~-. _____ " ____ _ 
2.46 2.56 2.51 
---~-.----.~-. --~--- ~----."-- ._-----_. 
2 2.18 2.49 2.34 
-~.----------.---.- -- .----~~--------.. -. ----------~----- ----- .. "--------------"-~-. 
3 1.94 1.82 1.88 
"--- .----~--... ---- -- ----,--- -.--~"--.- --- - - - ---- ---_."" ----------_ .. _---- ------ -----_. _._"".-.-
4 1.99 2.00 2.00 
M 
---~-------.- .-----------_ .. _. __ ._. --' --.-.-.-.-.~--- --~----.---
1 ___ . ______ = _________ + __ .. _J-'~L___ _ __ 1. ?_~____ __1:~ ___ _ 
6 1.33 1.44 1.39 - --. - ---------~.---- ---"-"--------- --_._------------- - -----~--."--- -----------
7 2.38 2.19 2.29 
- -- .----------.--.-~- ---~~---- .. ------ --- --- -- - --------~------ ------_.-------
8 2.10 2.40 2.25 ------"---_._------._-- --- ... - ---- ---_._--- "---------~-- .--------~----
9 1.98 1.76 1.87 ._----------_ ... _----- - -- ------------_. ----_._-_._------ ------ --------
10 1.38 1.73 1.56 
F 
___ ~ __ "_____ _ _______ ~·_r ".___ __________ _ __________ " 
11 1.17 1.49 1.33 -_._._--_._------ ----'"--- - --------------_._--- --------~~--~------.-
12 1.54 1.59 1.57 
Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix A6 Cholesterol (mg cholfg. liver) 
-----Sex-------- ---An Cmal--- ------TriaIT -·--·····----friai2--- --~-Mea-n-----
------- ------_ .. _-- .-~-- ----.~-.---.-... ~--~. -~-------.-.---~ _ .. - ---"".-----~--- ---.--" .. ---~------.---~ 
1 4.29 4.41 4.35 
-=-= _____ ? ____ .. ·:~:==I:~~ __ .···.=--=:==:_=~~48==-___ =~-=--:'~:~j~=~=~ 
3 5.12 4.96 5.04 --4-----------49T-------·-~-5~07------5-0-2------M 
----~--~------ --~ ---.. --~-------.. -----------~---------- -~------------~----
5 4.15 4.35 4.25 
- ------------------. ---._--------_. _._--._---- -------------- ----. ..-------_._---------
6 5.24 4.99 5.12 
- .--- ------_..... ----_._-------- --.- --- ----- - - ----~.--------.--------------------- ---------.-~-
____ J_________!J-"?L_____ _ ____ 5,1(') __________ ~_,,2..? ___ _ 
8 5.37 4.75 5.06 
------ ---~------.~- --- ---------~---- ._._-----.- --"._-- -------+--~-- -----_ .. -------- "~. -
9 4.18 4.80 4.49 
~--- --- ._------ .~---- - -.-- --- _._ ... "---- "" --- ----~-~ ._" -_.- ---- - -------_._----- ,-_._- ------------ -- -_._--
10 5.25 5.02 5.14 
F 
----.-~-----.---- ---- -~---
11 ______ 1·}2______ _ ____ .'!:f3lt _____ ____ _4_!:iCL __ 
. ______ !.?_ _____ __ ~i!f3____ _ _~:!:iJ____ _ __ !f3~ ___ _ 
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Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix A 7 Conjugated Dienes (Ilmol/g. liver) 
Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix AB Lipid Hydroperoxides (nmol LOOH/g. liver) 
--------------- ------------ ---- --------- ----------------,---c-c-----
Sex Animal Trial 1 Trial 2 Mean 
---,-~-------. ---------.--~ ~---------"~~- --------
1 42 101 72 ------_ .. _-- ~---------.~ -------- ----------
2 232 185 209 -_._--._--------- .----------~.- ------ -------~---
3 283 244 264 M --------- ------- -- ----- --------- ----1 
4 258 216 237 -_._. __ ._---_._-- .----~.-.---.------ ----~------ --~---~---
5 219 245 232 
----.-------~-- ._--_._----_. - ---"----------
6 280 298 289 ------------ ----- --------------_.-.- ------ --------~-
7 255 203 229 ----------_. ~----.------.-.-- -------- ------
8 296 256 276 ---_._-_.- --------- .. ,_ .. ---------_. -----------
9 44 85 65 F ------- ---- ----------- ------- ----------
10 88 59 74 ------------------ -------------_._-._-- -------.--
1 87 109 98 
r------:
1
-2-=-- -----53 --- --11-4- ----- 84----
Wild Type Mice (wtlwt) - Individual Values: Males and Females 
Appendix A9 TTBARS (nmol/g. liver) 
== __ §ex--== =-=~I--=-- ~~ I{~~~ ___ =_-F==Tf~lJ_ -- = ~__ -~~g~ __ ~_ 
2 1920 1828 1874 ---------- -----~.--- --- ----_.- ._---------
3 1883 1810 1847 M ------------ ----------------------------- -----------
4 1682 1755 1719 
-----"~-.- ~--------- ----~- --------
5 1571 1737 1655 
----------.-.---~--.------ - ------_ •.. _-
6 1883 1810 1847 
---.-.---~--.--.--- ----- _._._--- -----------_._------- ----_ ..... _----
7 1243 1426 1335 --------- --.--~.-~ --------- .~--------~--
8 1188 1353 1271 - -----
9 1225 1060 1143 F --------- ----------- -------- ------------
10 1463 1499 481 ------------- -----~----------
11 1517 1426 1472 
--~----.- ----~---------.-- ----- --.. --------" 
12 1079 1225 1152 
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Heterozygous Mice (db/wt) -Individual Values: 
Males and Females 
Appendix B1 Terminal Body Mass (g) 
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Heterozygous Mice (db/wt) -Individual Values: 
Males and Females 
Appendix B2 Liver Mass (g) 
* :::: The liver mass of these animals were not taken in 
error 
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Heterozygous Mice (db/wt) -Individual Values: 
Males and Females 
Appendix B3 Liver Mass / Body Mass x 100 (%) 
----.---.---.~----
Sex Animal Liver Mass I Body 
____ ~____ ______ __~ass~1QQ_._'_'o;(=o --I 
r-______ : _______ 1_·~ __ 4.5_2 __ _ 
2 5.23 
~---------"----- -"--------~~---
1 _____ . __ ..:::.. _____ -1-___ .......:4 .67 
____ 4___ -+-___ ...:5:::.~02 _____ _ 
________ . __ ~_ .~4.:..::..04-'--_ 













_________ 1 _____ ._1:..=.. _____ 1 ___________________ --1 
1 3.18 --------------
1-______ -'--":..... _____ + ____ ..3-63 ___ _ 
19 3.40 - ----_._---------------------
F 
20 3.77 ---------_ ... _ .._.-----------------
21 3.37 
--.-------~--- --- ------------
____ ?_2 _____________ ..1:~6::....--. __ ~ 
23* 
24k ____ . _________ . __ --=-'--__ ---L. ________ _ 
* = The liver mass of these animals were not taken in 
error 
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Heterozygous Mice (dblwt) -Individual Values: 
Males and Females 
Appendix B4 Glucose Concentration (mmolll) 
__ S_e_x __ _ __ ~~~_~ ______ ~~~~~,~~-'L~_nc_-_--I 
M 
F 









f-______ -'--________ + ______________ 7'-'.=-2 ___ --I 
_______ 8 _______ ._________ ____6".::.6 ____ _ 
9 5.3 
~-------~-.- ~------~~.----
_____ lQ_____ _ __ J~,9=___ __ _j 
____ JJ_____ 13.9=-__ -1 
12 9.9 
-~.-------.- - .. -~-----.--------
1 __ -'-~ ______ · __ j_---·----9::::.~5 ___ -j 
_______ ~! _____________ ._. ______ -'..:12=. 7-=---__ ---i 
f ______ ---=-5___ 14.6 





19 7.2 -----------_._._---,- . -~-----------
20 6.6 ------------ --------_.--
21 
----~~------------




Heterozygous Mice (dbl+) -Individual Values: 
Males and Females 
Appendix B5 Triglycerides (mg TGlg. liver) 
-------------
Sex Animal Trial 1 Trial 2 Mean 
1 1.17 1.31 1.24 
'---- 2 -- ---------------
1.06 __ 1.21 1.14 __ ---3---- ------------
1.42 1.44 1.43 
4 1.75 1.56 r----1.6~-
5 1.04 0.99 1,02 ------
6 1.03 1.32 1.18 --------- --- -----
7 0.91 1.00 1--___ g~9_6 ___ 
M 
8 1.10 1.18 1.14 
--
0.94 1.15 1.05 
--






11 0.93 1.01 0.97 ---
12 0.86 1.39 1.13 
13 --1----------1.26 1.16 1.21 ------ -----
14 1.16 1.02 1.09 --
15 ____ --.1.&2 ______ 1.22 1.12 --
16 1.78 1.57 1.68 
17 
-----1.38 ---- 1.41 1.40 -------------------
18 1.31 1.58 1.45 -----19------~-~--~-~-~ 
1.29 1.06 1.18 -------20--- 1.69 1.54 1.62 
F 
21 2.13 1.99 2.06 
--
------ 1------- --
22 0.98 1.27 1.13 ------- --~--.---~-- --
23 1-__ 1.95 ---- -- 1.30 1.18 ------





Heterozygous Mice (db/wt) -Individual Values: 
Males and Females 
Cholesterol (mg chol/g. liver) 
-~~n--] 
f---~--=-~~+-~<--"=~~<~-+-<-__ ~ __ ;·~_-::=-_-_ -__ ~<-«<~<_-_ -~~i~~=~ 
f-------------''+'''----'-:'------.+---'' --:------r-~-4:12----1 
, __ -="=-=~,~-<,--<+--~~~.:::.--,---,+=--"--<.--~--.68==~~] 
4.16 . 
,-------=-.,--f------.= _,. ____ + _____ '-=='-. ____ 1--__ ::;; «:~=I 






Heterozygous Mice (db/wt) -Individual Values: 
Males and Females 
Appendix 87 Conjugated Dienes (/Jmol/g. liver) 
Sex Animal __ Trial 1 Trial 2 Mean f------------
_----.1 2.43 2.59 2.51 
2 2.26 2.31 2.29 ----
3 2.18 2.09 2.14 -
4 ___ ~47 __ 2.58 2.53 ------
-~ 2.42 2.42 2.42 2.18 2.20 2.19 ---
7 3.31 ___ 2.99 ___ 3.15 -- -------
M 
2.31 8 2.57 2.44 --
9 2.46 2.45 2.46 ._--_. __ .- -------_._-
10 2.48 __ 2.36 2.42 
11 2.53 2.50 2.52 
12 2.50 2.50 2.50 --------- ----"-- -----
13 2.03 2.88 2.46 ------- -~--.----- ~~-~-~--~ --
14 3.4L ___ -- 3.00 3.23 ---
15 3.23 3.29 3.26 -- --.--------. 
16 ____ --.1:~§ ____ f-___ bZ6 2.86 
-- 17 3.02 __ 3.07 3.05 ---~--~------
F 
18 ___ ?.:.~L ___ f------- 2.83 2_72 --
19 2.97 3.08 3.03 
------~.-~--
f-- 2.65 20 2.94 2.80 ------- --------"---
-- 21 3.01 __ 2.75 ___ ~Jl3 ___ --------
22 2.72 2.22 2.47 
-~~- -
23 2.71 2.56 2.64 --------- ------------ ------------- ------------
24 2.02 1.98 2.00 
'---- --- ----------------
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Heterozygous Mice (db/wt) -Individual Values: 
Males and Females 
Appendix 88 Lipid Hydroperoxides (nmol LOOH/g. liver) 
---------,-- --- ---,-
Trial 2 Sex Animal Trial 1 Mean 
~-
1 206 195 201 
2 237 237 254 ------------167--1- -3 169 168 -----
4 196 202 199 r-----5 ---- 135 170 1-----153"---
1---




1---- 92 86 80 . ---~ ---------f--------
M 8 78 56 67 
9 
-- ----
81 89 85 
--
f------- 10 -------- --250 254 252 --.-------- ------- -- f---- -262- ----
r---.lL- 279 245 --_._---- --
12 243 281 262 ---------- 1---118
--- "-----"-----
13 193 156 ,-----------j----------------- ---------------
14 248 -~--1--- 235_ ---------
15 t-~?----------~--1----_ 204 ___ 
16 181 173 177 ---------------- .--~.-
17 219 
-- ~~: ~~~ ---- 18 296 -- ---------1----------
19 240 ----?:~--- 1---__ .?:.!'iSL ____ -.-----~----.-
F 
20 246 259 253 
21 235 237 236 ------- 1---------
22 154 154 154 23 --1----178----- -----223 ------1--20-1 ----------- -------::-----------
24 113 178 146 -------- ----------~-------
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Heterozygous Mice (db/wt) -Individual Values: 
Males and Females 
Appendix B9 TTBARS (nmol/g. liver) 
Sex Animal rial 1 - TrialT--' Mean--T 
987 --- -1060-1---10~----------- _._----
M 
----- 1-------~--- ~--,--
969 1115 1042 
1 --------- ----
------------- -----------2 ----3----t--
-------------- -_._-_t097 969 1033 __ 
4 1079 1115 1097 - .'"~.------- -_._-




8 1335 . __ ._----
15~~_ 9 ------------





















1225 1180 - --
1280 I---~-----------
1006 942 
1006 - 960 ------ .----- ---~--. ~ 
17 1444 1335 1390 ------- --_. -- -----------~.-
1335 1371 1353 --




1298 1134 1216 __ 
1371 1316 1344 
20 
----=2--:-1----t------
----- 1463 1645 1554 
1042 ___ 1261 ___ 1152-----_._-- 1-------







Homozygous Mice (db/db) -Individual Values: Males and 
Females 
Appendix C1 Terminal Body Mass (g) 




~- 4 -~'---~-4-2~-,~7---4 
5 45.5 
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Homozygous Mice (db/db) - Individual Values: Males and 
Females 
Appendix C2 Liver Mass (g) 










1--__ 7* _--+ ________ _ 
8* 





12 2.5272 -----------.. -
c-__ ......:1-=..3 __________ 2_.0_88_3 ______ . __ _ 
14 2.1109 -.----.--- ------












* = The liver mass of these animals were not taken in 
error 
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Homozygous Mice (db/db) -Individual Values: Males and 
Females 
Appendix C3 Liver Mass / Body Mass x 100 (%) 
---------~--------.--- ----------
Sex A
· I Liver Mass I Body ntma ____ _~~~~~oo (% 
1 4.37 
f-------,--- -----
1-----_.-:::2'--. _. _______ 3.4~ __ _ 
3 3.85 ---------
4 4.00 --------- "--_._----------
M f---__ 5=---_____ _ _____ ....:..4:...::..0..::...3 __ _ 
6 4.17 
7* ---8*----- ---------1 
9* ---1-0*------ --.---.-------1 
___________ + _____ c':--____ . ____ . ___ .~~--_I 
4.44 
12 5.09 ------- .------.~--




15 -+-_____ 3_._72 _____ _ 










24* L........ ________________ . ________________ _ 
* = The liver mass of these animals were not taken in 
error 
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Homozygous Mice (dbldb) -Individual Values: Males and 
Females 
Appendix C4 Glucose Concentration (mmolll) 
,--~----~- ~--- --------------
~ ________ ~~~m~~___ _ _ ~~~~~~~nc-
___ 'L _______ 20=--:.-=-9~~_1 





M _5 _______________ ._?_~ __ . _ 
____ JL~__ 21.9=--_------1 
7 23.6 -------_._-----_._.--- -.--~----
_~ ____ § _____ ~. _______ ----'2=.9-'----'.5_ 
9 19.9 
------ -.--"-~-----
____ -+-___ 10____ _ ____ -.11.:.:.4 __ ___j 
1 13.6 -- --------=-------1 
12 12.6 ----- -------------~---
1-____ -'--=' ______ + __ ~16=.9 ______ _ 
14 19.5 
~---'--------- -._----------
15 14.9 ----------- -----_._---
16 10.3 
---~------ ----_._-------













Homozygous Mice (db/db) -Individual Values: Males and 
Females 
Appendix C5 Triglycerides (mg TG/g. liver) 
~---~------ - -::--:- -,---:----
Sex Animal Trial 1 Trial 2 Mean 
------- --~--'-'=-_+---~ -=-=-'-----1 
1 2.59 2.83 2.71 ------ --------~---.---------- -----_._--
2 2.29 2.76 2.53 
----::----t----------- ~--=___:_:_-__i-____c::_: 
3 2.12 2.41 2.27 ----=-----1------- ---------- ----
_4'--__ + __ ~;t2__ 2.12 2_.2_2 ____ _ 
3.29 2.95 3.12 r------,:-------t--------- -~-~-
6 5.59 4.68 5.14 
M 
-------- -----_._-_._-_._ .. ----------
7 5.42 4.83 5.13 
--- -----~-- -~---.----
8 2.25 2.90 2.53 r---------- ---~--- -------~-___i_-____=__ 
r--_----'-:c9 __ 3_. 7_5 _ __ ~'_~ti 3._62 ___ _ 
10 1.85 2.62 2.24 
-----.--~--- ---------- ------ ------------
11 4.90 4.53 4.72 -_._-------- -----.~-~-- ----~---
2 2.50 2.76 2.68 1--·--'--='----1---------- --~---- -----
13 3.03 _____ ~1§._ 3=-'-.1:....:.1_ 
14 3.76 3.59 3.68 
---~---- --_ ... _-----
15 4.24 3.79 4.02 
-~-- --------------- ------ ---~ 
16 4.48 4.04 4.26 --------_.. ----- --.--~ 
F ~-_---'-'-7-----+_~--~c~~---- __ 4_.01_ _ 3.78 
18 __ +-____ 1,45_ 4.58 ____ 1:52 
19 5.09 4.67 4.88 .------ --_._ .. ------------ ------- -----
20 5.48 5.45 5.47 -------- --_._------- ---_._-- --------_._--
2'1 5.19 5.32 5.26 _._---------_. ----------~-- ------- -------
22 3.74 4.85 4.30 
--------~ -~---- --- . __ ._-------------
23 3.98 4.39 4.19 
---------___i_---=-==------- ------~- -----.---
24 2.77 3.70 3.24 
~_--L______ _. ___________ ~ 
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Homozygous Mice (db/db) -Individual Values: Males and 
Females 
Appendix C6 Cholesterol (mg chol/g. liver) 
----Sex--- Animal Trial 1 ---- Trial 2 ---Me-an---
------- -- 1 5.41-- -ToS------ill------
2 5.72 5.93 5.83 --
1 ___ 3=-____ 1-~3~ _______ ..2S[L ____ 2,---65 _______ _ 
4 7.3§_______ 7.11 7.24 
5 6.48 7.02 6.75 
------
6 6.44 7.53 6.99 
M 
~~ ____ 1_----~27-- 1--- 7.04 -=-7:.--::6--::-6 __ 1 
8 6.56 --1----- 7.36 __ 6-::-.-'-.96-'--_"" 
___ ..Jl _______ ~_'IL ______ r___.----6=.=22=----_+-----=6'-'--.4.:...:7----
10 5.95 5.98 5.97 
---fi-----r---6J33---I-- 6.63 ____ 6.63 __ _ 
--12---- 7.58 7.14 7.36 
-.---=~--_I_--~~~- ~----~~----~--~-~--_4 
13 6.67 _I-- 6.77 6.72 __ 
14 6.93 7.08 7.01 
15 7.01 6.94 6.98 
=--~f----=~- ~:~~ ~:~~ ----~~--
r-------ul-----'---- 7.28 7.00--- ----r14-
I- 19 7.36 7.18 --I----7.n -
F 
1----2-0 ----- I-- 6.70 6~?"3 6.72 --- ~~-----~----- ~-------.--.-. 
f--__ =2::...:.1 __________ 5.65 ____ 1-____ 1'---19 ___ 1-__ 5.42 ___ _ 
22 7.82 7.15 7.49 
------------------- ---------f--------=~_=_=c______i 
1-_ 23 _____ lL~6 5.35 ___ ~~ __ 
__ -----'. __ 24.. __________ §.~§______ _ 7.06 6.46 ___ _ 
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Homozygous Mice (db/db) -Individual Values: Males and 
Females 
Appendix C7 Conjugated Dienes (J.lmol/g. liver) 
----- -------




1 3.14 303 ----------1----------f-----
2 3.70 3.46 3.53 ---------- -----
3 3.69 f-- 3.71 3.70 ---------_.- r----------
3.51 3.46 4 3.41 - ---
5 3.55 3.93 3.74 -_ .. _--
3.32 
--_._--
6 3.57 3.4!:)_ 
M 
7 4.04 3.95 4.00 1---------------- -- ------.----
8 3.03 3.50 3.27 1----
9
----
3.09 -_._- ____ ,:3.6L __ 1-___ 3.~~ __ 
I- 10 3.45 3.05 3.25 --- ---------
11 3.44 3.22 ,:3,.)_L ____ ----------
12 3.35 3.47 3.41 __ c-------.-----------
3.19 13 3.27 3.23 
.--~-----------------------1--- .-----------
14 4.38 4.26 4.32 --
15 ---~-----1-___ 4.13 1-__ 4.1 !L __ 
16 __ 4.52 ____ I--_....£~- 4.48 ------------ 1---------
17 3.58 3.90 3.74 ,,-- ---
18 3.74 3.56 3.64 
1-- ---.- 1--- --
19 3.93 3.59 3.76 
F 
1--
20 4_03 3.81 3.92 -- ---
21 3.18 3.57 3.38 
1--- -- ---
22 3.44 3.53 3.49 1---------------------
23 ______ =?.29 3.10 3.20 
24 _____ 2.60___ 2.99 2.80 
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Homozygous Mice (db/db) -Individual Values: Males and 
Females 
Appendix CB Lipid Hydroperoxides (nmol LOOH/g. liver) 
Sex 
--:--:--:----,.------------
Animal Trial 1 Trial 2 Mean ------------- --~~.-.-
1 586 502 544 
---- ------- -~-- .--~--."------
2 967 886 927 
.. _---- --~- --~----.------- -------
3 609 704 657 
------ --------
566 623 595 
r----=----+----=-88=-=7 i15----- ----801---
c------=------t------- ----- -- ---------------
6 783 717 750 
M 
4 
----- ---- ------- ------------_._._--
7 686 732 709 --- ---.-~------
8 656 680 668 ------ --.------~--- -_._--------
f----__ 9"---__ _ ___ ~_g~____ _____ §51____ _ ____ §l23 ___ _ 





-----i -~55=0:------ -----41-1-- -----48T-----
---- --.---~.~--------.--------
12 748 627 688 -"-------- ~~.------------- ---.- ----"'----_._-------- -------~-~.--
13 470 538 504 
--~-.----------.-.-- ---------------- ------ ._-------_ .. - -- -- .. ---~-----
14 319 402 361 ------_. --------- -------
15 340 353 347 
----'--"----1------ ------ --- ---
f--------.:.:::'-------+-----;3~L-- ____ }§.~_ __ _ ___ ;357 __ 
17 470 388 429 
18 331 r------=-31c-::3--- ----3-i2-----
1------:-
19
::- -----409----- ---4-07---- ------4-08--
F 
--------------- --~-------- ------~--.---
20 362 329 346 ----- ---~------.-~- -.-"~-~------- --.---
21 __ +--_3§.i..______ __ ;3_~L ....l~_1 __ 
22 333 362 348 
23 --5-48--- 516 -=-53=-=2:-----1 
1----= -------- ----------- -----
______ --' __ ---.::2=-.4'---__ --1. ____ 60L__ 573 587 
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Homozygous Mice (db/db) -Individual Values: Males and 
Females 
Appendix C9 TTBARS (nmol/g. liver) 
__ =- Sex p-A.;;mal T,;al '--:~_,. T,;aI2"'-ean~~ _ 
______ 1______ ~~ _____ I__ 1517 147~ ____ _ 
2 1810 1755 1783 
-------3----- ---1517---- ---f481 1499--
4 - - 1682 -- --1-554-------1618---
1---------------- ----- -----------
5 1316 1206 1261 M 1------- -------1----------- f----------------
6 1828 1719 1774 
7 1481 - ---146-3--1----~72----
1-- - ---------- f--- -----
1---__ 8=----______ L5_7_2 ___ 1444 ______ 1_50_8 ____ _ 
1---___ 9=-____ 1499 1481 1490 
______________ 1--__ 1c-:-0 _____ ___ 1Z~___ 1700 17=10::c------i 





F ~i~~j~:~-=--~f-,-=~~ ~ 
-- ;~ ---+§~------ ---~~~}-----~~:j ~ 
22 2377-- ---2-139--- '------2"258-
----2~- --2-084----- - 1993 ---2039 -
___________ ~__~jJ.§ __ = =-=_Jill~~=_-~_==-}g§l4 -::--
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Appendix D1 
Impact of Various Oils, Administered via the Diet (4 Weeks) - Individual Values: Males and Females 















Age (weeks) Body Mass 
12 13 14 I 15 16 17 Gain I Loss (g) 
I 12-17 weeks 
1 M 25.0 25.0 26.5 26.5 26.5 27.0 +2.0 
2M 25.5 25.5 24.5 24.5 25.0 26.5 +1.0 
Control 13M 24.5 24.5 25.0 25.5 25.5 26.5 +2.0 
(chow only) 4F 19.0 19.0 19.5 18.5 20.0 20.5 +1.5 
5F 20.0 20.0 20.5 21.0 21.0 21.0 +1.0 
~ 6F 19.0 18.0 18.0 18.5 19.0 19.0 0 
I 
I 
I 7M I 23.5 22.5 i 23.5 ! 23.5 I 24.5 I 24.5 r +1.0 
I 8M 24.5 24.0! 24.5 23.5 i 25.0 I 24.5 I 0 I 
I 9M 25.0 24.5 I 25.5 25.0 I 27.0 i 26.5 i +1.5 i 
sun~~wer i 10F 19.0 I 20.0 I 19.5 19.5! 21.5 I 20.5 I +1.5 i 
l 11 F 24.0 I 22.0 i 21.0 , 22.5 1 24.0 1 25.5 I +1.5 
12F 18.5 19.0 18.0 19.5 19.0 20.0 +1.5 
13M 24.5 25.5 24.5 25.0 25.5 26.5 +2.0 
14M 28.0 27.5 26.5 26.0 26.5 27.5 -0.5 
15M 26.0 25.0 25.5 25.0 25.5 26.0 0 
Canola Oil 16F 23.0 23.5 22.0 23.0 23.5 24.0 +1.0 
17F 19.5 19.0 20.0 20.5 19.5 21.0 +1.5 
18F 18.5 19.0 17.5 18.0 18.0 19.5 +1.0 
19M 28.5 29.5 27.5 29.0 29.0 28.0 -0.5 
20M 29.0 30.0 29.0 30.5 29.0 29.5 +0.5 
Sunflower 21M I 27.0 27.5 26.0 I 29.0 I 29.0 t 29.5 +2.5 
Oil and 22F 19.5 20.0 19.0 20.5 I 20.5 21.5 +2.0 I 
Cholesterol 23F 19.5 18.0 17.5 19.0 I 20.0 19.0 -0.5 
24F I 19.5 18.0, 17.5 18.0 I 19.5 19.5 0 
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Impact of Various Oils, Administered via the Diet (4 Weeks) -
Individual Values: Males and Females 















1 1.120 ----_. __ ._--
2 1.031 
-~--------- -----.------





__ 7_ _ ___ Q:..::._8;:,c36=--_--i 






12 0.782 ---------_ .... _-------
13 1.147 





1 0.882 ------.--.. ---









23 0.707 ---_._- ------
24 0_679 
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Impact of Various Oils, Administered via the Diet (4 Weeks)-
Individual Values: Males and Females 
Appendix D3 Liver Mass / Body Mass x 100 (%) 
----------~ -~----- -----,---c------~--
Group / Treatment Animal Liver Mass / Body 












5 3.87 -------- --_ .. _-----------_. 





















11 3.98 ---------._---- ---------
12 3.91 
-~------. 
f--__ --'-c: __ ._~ __ ._+--_. __ 4._33 ___ _I 







___ 19____ __~3~.5~1 ___ ~ 
20 3.60 
f---~------~~-
21 3.40 --22--- -------'-4-.1-=7:----
23 3.72 
.. _--- -.-~---.---
24 3.57 L ______ ~. ___ ~ __ ~ _____ ~ _____ 
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Impact of Various Oils, Administered via the Diet (4 Weeks)-
Individual Values: Males and Females 




















f---_1 OF _~ 6.2 ... 




__ ....1..4..~ ____ ____ 1.!"j __ _ 










20M 5.2 _._-------------_. 
21 M 5.4 
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Impact of Various Oils, Administered via the Diet (4 Weeks)-
Individual Values: Males and Females 












Animal I Sex Trial 1 Trial 2 Mean 
-1-:-:M-:-----t------1-9.6i-- -1-6.48- --18.0-8--
2M --'-'-181)-1 16.82 ·-17.4c...:2----4 ----. --~----- ... --- ------------~ 
3M 18.30 19.06 18.68 _._--- - ----------
4F 21.87 17.47 19.67 
--=5'-'-F=-------1------19-.8-1--- --20.13 -19~7------------ -+-----.~ --------
6F 30.83 22.96 26.90 ---_._" --.~--- ----------- ------.------
7M 20.15 18.22 19.19 1----'--':-' .. ---- -- --------------
8M 19.32 18.39 18.86 
-------~-.-~.- ------_ .. ---"-_._--
9M 18.08 19.97 19.03 ---------- --_._------ --------- -_ .. __ ._-----------
10F 29.23 24.61 26.92 
--------~ -.-------- --~------
11 F 32.30 27.45 29.88 ---------, --- ----_._- ---~-----.--.--
____ . ___________________ ---4 ___ .12£. _ _____ .J5.05 21.33 ___ 2~J_9_ 




------- -~----- ------------ ----~-~---
14M 25.72 23.32 24 .52 
----1-5-M-- ----'2rS-5-- 26.10-----23.--=-83=---1 
______ • ______ 0. ______ , ________ _ 
16F 26.28 29.14 27.71 --_._-- -------_.- ----- ---_ ... _----
17F 25.59 28.29 26.94 
r----:-:18=F-- --'- ------ 21 .63 ----2-1.'5-5 - -------2-1-. 59 ----






_._--- ------------ --~--------- -----~-.-~---
20M 20.89 15.16 18.03 -_._-_._---- ----
21 M 19.92 22.01 20.97 ------,---_._------------------- ------ ~---.----~--"-----~~-----
22F 24.34 22.28 23.31 
----~------------,. -----.----~--~ -- ~--------~---
_____ 2¥~ ___ .. _____ ~4~.9_~_____ _ _____ ~. 90 2.4.4§__ __ _ 
24F 22.74 24.83 23.79 
Page 225 
Impact of Various Oils, Administered via the Diet (4 Weeks)-
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Appendix D6 Cholesterol (mg chol/g. liver) 
--------------- ----------,-----------,---------- ------ --------------, 
Group / 
_____ gerl.Qty~_ 
Treatment Animal/Sex Trial 1 Trial 2 Mean 
1M 1_80 2.17 2.04 ----- -------- ------
2M 1.99 1.90 1.95 --_.- --------
1 Control 3M 1.94 1.88 1.91 
---~~-'-- -~------. -~- --------
(db/wt) (chow only) 4F 2.29 2.34 2.32 ---_.- ---,--_._.- ----- --.---~-
5F 2.89 2.10 2.50 ---------- ----- -------
6F 3.23 3.32 3.28 ._--------_.- _._._---- ~--
7M 5.21 4.72 4.95 
-~--.--- --_._------
8M 5.31 5.30 5.31 ----_._--------
2 Sunflower Oil 
9M 2.37 2.42 2.40 -_._------ ------
(db/wt) 10F 5.30 5.26 5.28 ----- ------~ 
11 F 5.01 4.91 4.96 ------ -_._----- ------~--
12F 4.07 3.76 3.92 
---------- ----- --_._--- ------- ---- ----------_._-
13M 2.69 2.45 2.57 ------------ ----"----_.- ------ -----.--
14M 2.00 2.12 2.06 ------_._-- ----- -------
3 
Canol a Oil 
15M 2.01 1.98 2.00 -------_.- --- --------_.-
(db/wt) 16F 3.63 3.77 3.70 ---- --'-~-------- -------- ------
17F 4.88 4.74 4.81 --- _._--._------_ .... - ----- -------
18F 5_39 5.45 5.42 -----_._------ ----.-- ----- ------~---- -------
19M 3.55 3.61 3.58 
----~---.-.---- ----_._----
Sunflower Oil 
20M 2.75 3.00 2.88 ---_._-_ .. --------- -------- ------
4 21M 3.04 2.26 3.15 and -------- ---_.-_._- -------- ----------
(db/wt) Cholesterol 22F 
5.85 5.82 5.84 ---- ------ -------------
23F 4.90 4.14 4.52 ----- -- -_._----_.-
24F 4.07 3.82 3.94 _h. _______ · ____ ------- --_._---- -_._---------- ------ ----'"--------
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Appendix D7 Conjugated Dienes (J.lmol/g. liver) 




















Animal/Sex Trial 1 Trial 2 Mean 
-TIV1----1--- --
2.26 2.46 2.36 -------- -- --
2M 1.87 1.79 1.83 --
3M 2.11 1.95 2.03 ---- 4F--c----- ------
2.00 2.04 2.02 ------- 1----
_5F 1.82 1.97 1.90 ------------
6F 2.00 1.70 1.85 -----
7M 2.50 2.55 2.53 -----
8M 2.56 2.38 -------------- 2.3~_ 
9M 2.32 2.32 2.32 --------- ----.-~---
~~~ -- 3.05 3.30 3.18 2.84 ---2.62 2.78 --
12F ___ ?1l...L_ 2.83 2.82 
13M 2.28 2.40 2.34 .---------- ---------- ------
_ 14M 2.38 2.41 2.40 ---- --------
15M _~.73 2.78 2.76 
---~ -------~-
16F 2.04 2.07 2.06 --------
17F 1 85 2.17 2.01 ----
1--- 1.89 -----.------~ 18F 2 11 2.00 ------ ----------
19M 2.78 2.02 _. ___ ~,~O ___ ,----- ------ .---.-~--~ 
20M 2.41 2.43 2.42 -------_._- ------
2.50 ___ ..?·1~ _____ 21M 2.39 _._--
22F 2.83 2.20 2.52 
-"--"-~-~ 
23F 2.81 2.24 2.52 
----------------------1---------- ------.--------
24F____ 2.37 __ '--_ 2.48 2.43 
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Impact of Various Oils, Administered via the Diet (4 Weeks)-
Individual Values: Males and Females 
Lipid Hydroperoxides (nmol LOOH/g. liver) 
Group / 
G t Treatment Animal/Sex Trial 1 Trial 2 Mean 
-- en0:Y~ __ f----__________ ----,c:-:-__ t--___ ----::-c:--=-______ -----~--f-------~-------
1 
(db/wt) 
1 M 303 357 330 
____ 2=-cM--'c ___ -+_-~~----'2-7c-=-7---+-- 271 274 
Control ______ 3::c:M~- 394 -----=:3:::7c::2--+-----~3-=-83-::-------
(chow only) 4F 461 449 455 
f-___ - _____ 5=-'-F ___________ + ______ ~_~~ ______ f---______ ..:3::.c1..:=5 __ ---4-_- _-__ - -=3-~7-_=_= 
6F 961 955 958 
-----------+-------1-- 7M 374 386--- 380 
2 
(db/wt) 
---8~--- 351 --f----- 337 344--
-.~-----"--.- ------
Sunflower Oil -- ;o~ --- ~~~ ~;~ -----~~~-----
~=--_lJf~~==-: -=--=--===-i~~~---::--~ 82§ -~====-=1:[~_~=-
12F 699 787 743 
------------- ------__ TiF0 ___ --=_- _..100 === =_=-=-~452---~ ==-__ 4~6 __ -=-= 
3 
(db/wt) 
14M 502 454 483 
Canola Oil -- jQ!'-'1_=~=:... __ =~=8-=-='=_=__ 37Q -_~==:_ -~L9 ==== 
__ ~ _________ ~1L_ 498 523 ___ _ 











Sunflower Oil _ 20M 349 ___ 381 365 __ 
21M 349 405 376 
and 22F 683 --f---- 726 709 
Cholesterol -23F----- -----749---- ---783-------+-766---
--- 24F------ ---372----r----357---- 1----- 408 
-----------'---------
__ -----'---_____________ L __________________ _ 
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Animal I Sex Trial 1 Trial 2 Mean 
r---~----c-.:--.-----t~----=-:::-'-:--------t--- _'---~_t_---~34-6 ----
r-----:::-:--:-c----_+ ___ ~_.=cc_=________ +___=~'-'---____ ._+__--=-=33.Z 4 _____ _ 
r------==----- +-----~--'--':--------+--,--.:.-:'-'--:c__-r__--~----------
3876 ----.. ---~--~~ 
4178 
~~-~~-- ----------
r--__ -:--:--__ -+-_-'-:'~ ______ +------_:-__:_.c.~----_t--~520------
1---___ -:..:.::, __ + __ ..:::.:::=.:..... __ -I _________________ ~.1f)_QL __ _ 
-=:.=...:... __ -+ ___ 3_0_17 ______ _ 
2450 












.--.--~-- .. -- ---~-,--,----~-
3430 
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Impact of Various Oils, Administered via the Diet (4 Weeks)-
Individual Values: Males and Females 
Appendix D11 Animal Cage Assignments 




Study of Shott Period of Alcohol Administration (4 Weeks) - Individual Values: Males and Females 
Weekly Body Mass (g) 
Animal/ Group / Treatment 14 




IV I II I IU : 1;:1 I .<.U I 14-20 weeks 
Age (weeks) Body Mass 
1 &:: 17 1 Q 1 Q "" Gain / Loss (9) 
I 
I 1 H20 Control 
1M 17.5 I 19.5 i 19.5 I 18.5 19.5 I 19.5 I 20.0 +2.5 
I (wt/wt) 2F 
I 17.0 i 18.0 18.5 I 18.5 I 19.0 18.5 19.0 I +2.0 I I 
I 2 
I 3M 19.5 20.5 21.5 I 20.5 21.5 , 21.0 I 21.5 I +2.0 20% Alcohol ' I 
I (wUwt) 4F 15.5 16.5 16.0 I 16.0 16.5 16.5 17.0 I +1.5 
I 5M 25.0 26.5 27.0 I 27.5 28.0 27.5 I 28.0 I +3.0 
I 3 
I H20 Control 
6M 28.0 i 28.5 I 28.0 I 29.0 28.5 29.0 29.5 +1.5 I I (db/wt) 7F 21.5 i 22.0 I 23.0 I 22.0 23.0 i 22.5 23.5 +2.0 I I 
I 8F 21.5 20.5 I 21.5 i 21.5 21.0 I 21.5 22.0 +0.5 
I 9M 24.0 
i 25.0 i 26.0 I 26.0 I 25.5 I 25.0 25.5 I +1.5 
4 10M I 25.0 25.5 25.5 I 25.5 24.5 : 24.5 25 I 0 20% Alcohol I I 
(db/wt) 11 F ! 22.0 
I 
21.5 I 21.5 , 20.5 22.5 i 22.0 I 21.5 I -0.5 I I , I 
1 12F 
I 17.5 18.0 I 18.0 I 18.0 I 18.0 I 18.0 i 18.5 i +1.0 I I 
I i 13M 
I 39.0 40.0 I 41.5 41.0 ! 41.5 I 42.0 I 42.5 +3.5 I I 
5 14M I 45.0 I 45.5 46.0 ! 45.5 i 46.0 I 47.0 I 49.0 +4.0 I H20 Control i I I (db/db) 15F 28.0 28.5 28.0 I 26.5 i 26.0 I 26.5 ! 27.0 -1.0 
I 16F I 33.5 35.0 35.5 I 36.0 36.0 , 35.5 ! 37.0 +3.5 
I I 17M ! 34.0 I 36.0 I 38.0 ! 37.5 38.0 I 39.0 I 40.0 +6.0 I I 
6 20% Alcohol 
18F I 35.0 35.5 i 36.0 ! 35.5 35.5 \ 36.0 36.5 I +1.5 
(db/db) 19F 31.5 33.0 34.0 I 35.0 36.0 I 36.0 37.0 I +5.5 















Study of Short Period of Alcohol Administration (4 Weeks)-
Individual Values: Males and Females 
Triglycerides (mg TG/g. liver) 
Study of Short Period of Alcohol Administration (4 Weeks)-
Individual Values: Males and Females 
Cholesterol (mg chol/g. liver) 











Study of Short Period of Alcohol Administration (4 Weeks) -
Individual Values: Males and Females 
Conjugated Dienes (IimOI/g. liver) 
r~ G~~i~e --r---~-~~--~~~---·~~~-·r'·--~-~~~---f---'~-~~"---i~---.~~-'--l I H20 
._---- (wtJ..~+--~--·--------t---·----=-=-----l--------c:-''::--::'''----I------C~'::::-::----jf-.---~:.:.: __ ~ 
2 20% 
















Study of Short Period of Alcohol Administration (4 Weeks)-
Individual Values: Males and Females 




Study of Shori Period of Alcohol Administration (4 Weeks)-
Individual Values: Males and Females 
Appendix E6 TTBARS (nmol/g. liver) 
-~-.-~.-~-- ---------








72 ----2 20% Alcohol 






















10M 12 ---- ----





12F 13 35 ----------_.- ----------
13M 14 81 ----- --------
14M 14 26 -------------
15F 12 80 ------,-----
16F 1 188 --------
17M 19 01 
----~-----.--~-- -------






20F 18 10 -----
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1645 1627 _____ 
1188 1225 -.------
1261 1234 -------------------"-"-
1097 1079 ---- -----
1188 1161 
1335 ------1298----------
1316 1307 -------.. ---~.-----
1517 1554 -------_. __ ._._-" 
1280 _-.!3_~L __ ------
1517 1499 ---------- -----------
1225 1326 ----------
1207 __ 1244 --------------
1134 1161 __ 
1810 1856 --------- ------------------
1792 1829 -------------1884-1920 
1847 1829 -----
Impact of Alcohol Administered over 8 Weeks in dblwt and db/db Mice - Individual Values: Males 
Appendix F1 Weekly Body Mass (g) 
Gi I Treatment Animal Age (Weeks) Genotype I 9 10 11 i 12 1 13 j 14 15 
1 25.0 25.0 25.5 26.5 t 27.0 i 27.5 29.5 
2 26.0 27.5 28.5 29.5 ; 30.5 I 30.5 I 32.0 
3 I 25.0 27.0 27.5 I 28.0 : 29.0 I 30.0 I 32.0 1 I 
H20 Control , 4 i 26.5 28.0 28.5 I 29.5 30.5 31.5 i 33.0 (db/vvt) I 
5 , 26.0 28.0 29.0 29.5 31.0 32.5 I 34.5 
I 
6 26.0 26.5 I 27.5 I 28.0 28.5 28.5 29.5 ! I 
7 22.0 23.5 , 24.5 26.0 26.5 27.0 28.0 
8 28.5 29.5 29.0 29.5 I 30.0 30.0 I 31.0 
j1 27.5 27.5 29.0 29.5 30.0 31.0 ! 30.5 





11 27.5 27.5 I 28.5! 30.0 --: 30.0 31.0 
12 I 26.0 26.5 26.~ 27.5 27.0 27.5 28.0 
13 I 28.5 29.0 29.0 29.5 31.0 31.5 32.0 
I 14* 43.0 45.5 45.5 47.0 45.5 ! 41.5 fd 
15 43.0 46.5 46.0 48.0 46.5 45.0 43.0 
3 
16 47.0 50.5 50.5 53.0 54.5 54.0 54.0 
H20 Control I 17 I 39.0 44.0 46.0 49.5 50.0 50.0 51:5 
I 18 47.5 49.0 50.5 53.0 53.5 55.0 55.5 
! 19 47.0 48.0 48.0 49.5 i 50.0 ~~:~ 50.5 20 i 44.0 44.5 46.5 48.0 47.5 49.5 
! 21 I 41.5 44.5 45.5 48.0 48.0 51.0 53.0 
I 22 50.0 52.5 53.5 53.5 535 53.0 52.0 4 20% Alcohol i 23 42.0 43.0 44.0 44.0 I 43.0 42.0 41.0 (db/db) 
24 41.0 43.5 45.0 46.0 L 46.5 46.5 47.0 , 
I 25 I 47.0 I 50.5 , 52.0 53.0 I 54.0 55.5 57.0 




Impact of Alcohol Administered over 8 Weeks in db/wt and db/db Mice -Individual Values: Males 
Weekly Body Mass (g) 
Age (Weeks) Body Weight 
Group / I. I i Mass / Loss 
I Genotype I Treatment Animal I 16 I 17 I 18 1 19 20: (9) 9 -20 'I 
I I !! weeks 
I 
1 I 29.0 I 29.5 '29.5 30.0 29.5 +4.5 
i 2 31.5 32.5 36.0 33.0 I 31.5 +5.5 
I 1 H20 3 32.0 33.0 33.5, 34.0 34.0, +9.0 





5 34.0 35.5 35.5 I 36.0 I 35.5 I +9.5 
6 29.0 30.0 30.0 30.5 30.0 +4.0 
f 7 27.5 28.0 28.0 29.0 29.0 + 7.0 
8 30.5 31.5 31.5 31.0 33.0 +4.5 
9 31.0 30.5 31.0 30.5 32.0 +4.5 
10 29.5 30.0 30.0 30.0 31.0 +5.5 
11 31.0 31.5 31.5 31.5 1 32.5 +5.0 
12 29.0 29.5 30.0 30.0 30.0 +4.0 
13 31.5 32.5 32.0 32.5 32.5 +4.0 
I 14*' : T I I ; I - I - - I - I - I -
I 15 45.0 I 45.0 I 45.0 I 43.0 I 45.0 I +2.0 
3 HOi 16 57.0 58.0! 59.0 56.0 i 57.0 ! +10.0 
(db/db) Co~trol I 17 54.5 55.0 I 55.5 55.0 I 56.5 i +17.5 
I 18 56.5 56.5 I 56.5 55.0 56.0 I +8.5 
I!~ 5~.~ I 49.~ : ~O.O ~~.~ 47.~ I +O.~ 
I 21 I 54.0 I 55.0 I 56.5 I 56.5 55.5 i +14.0 
I 
I 
4 20% 22 i 50.5 I 51.0 I, 52.0 ! 51.0 50.0 I 0 
(db/db) Alcohol 23 40.5 i 38.5 I 38.0 I 37.5 36.5 I -5.5 , 
24 47.5 I 47.0 I 47.5 I 46.5 I 46.5 i +5.5 i 
'25 57.0 I 58.0 58.5! 59.5 . 59.0 +12.0 
* = Animal No. 14 was found dead aged 15 weeks 
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Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Individual Values: Males 
Liver Mass (g) 
1 
(db/wt) 
H20 Control ____ ~ ______________ 1.0932 ___ _ 






8 1.3854 -----9---- ----1 A26"3""-
-----"10--- 1.3767 --









.----.--.-.-------+--~=-=-=-=--------I ___ --.J6 __ ____ ~628Z ___ _ 
17 . 2.6939_ 
18 3.6215 
___ ~2 ___ + __ . _ _=2=.9=21-'-'9, ___ _ 




* = Animal No. 14 was found dead aged 15 weeks 
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Appendix F4 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Individual Values: Males 








. __ ._-+-_..J...mmol/I) _. 
1 10.1 
Treatment 
2 13.2 ----_. 
____ 3____ 12.3 
H20 Control I- 45 15·1 .. __ _ 
19.1 
6 9.9 




9 10.2 -_. __ . __ ._-- ----
20% Alcohol -._-- ~ ~.~ --
--·-1-2---- ~--6-:-0-
_____ ._t ____ .~ ___ .. _._~1;} __ . __ .. 7.6 







H20 Control 17 32.9 . -.. ·····--··18---- ----x-· 
.---.. --~-- ... -. 32.6-
----.. - ... ---~.- - .. - ..•. -~--
_ .. _._._ .. _ .._ _ ___ .?.2..______ x 
21 20.1 
• := Animal No. 14 was found dead aged 15 weeks 
x := Animal No. 's 18, 20 and 24 glucose concentration was to high to 
record 
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Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Individual Values: Males 
Appendix F5 Blood/Alcohol Levels (mmol/I) 
---------------,------ ---------~BI-oo-d-/AlcohoT 
Group / Treatment Animal Levels 
__ G_e_n_o~~~e __________ _ _ ~~ 
1 
(db/wt) 
1 0.40 -_._-------- ---
______ .1 ___ -t-_---'O:cc..O::;.cO'--
____ .;L_---jI-______ ·L20 __ _ 
4 0.00 
















9 1.56 ------------ _._--------







15 ----------J-- 0.65 
1.32 16 r---
















------ ----------'---------------------'-- 1.19 
• = Animal No. 14 was found dead aged 15 weeks 
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Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Individual Values: Males 














f _______ ~ ___ ~---2L~-
____~_~~ ___ _+_ __ ~3_=::8 __ 
____ } ___ +--___ 2_0 ___ _ 
33 
----~------














~ ________ ~ ___ _1~_____ _ 40 ___ _ 
14* 
f---------'--=---------I----~~-----
___ ~ __ 1~~ _______ ~ ____ _ 
H20 Control 17 52 .----_._----- --~---
____ t8___ 6:",,3,--_ 
19 40 
.--------~---- -----
____ ~ _________ ~_~ __ 20 _____ ~_ 4~L~ __ 
21 57 
----.--~-. ------
22 32 --------_._----_ .. _- -----._----
20% Alcohol 23 148 
----~------ -
24 70 --------------
____ ~ ______ ~~ __ ~~ __________ ~ ____ ~ ___ ~2 ____ ~~ 
* = Animal No. 14 was found dead aged 15 weeks 
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dbldb Mice - Individual Values: Males 









'::: Animal No. 14 was found dead aged 15 weeks 
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Impact of Alcohol Administered over B Weeks in db/wt and 
db/db Mice - Individual Values: Males 
Appendix FB Trig/ycerides (mg TG/g. liver) 
Alcohol 
.: .. -.. -.+-..... -.----+~-.~~-.- _ ........ . 
+---_....:3::.:..9=9 ___ .. ____ 4.~ __ . ___ ~ 
1-. __ .:..:c. _____ .. +_ ..... _ ... ...::.:.-:.:::. __ -+ __ 5.86 .. __ ........ __ 6.2_5 . __ _ 
5.81 6.28 
-~~""-~------ _ .. ------
.I.--...... :"':'::~~-.--... l--- 8 .34 
Alcohol 
• :::: Animal No. 14 was found dead aged 15 weeks 
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Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Individual Values: Males 
Appendix F9 Cholesterol (mg chol/g. liver) 
G'OU:~b~~~otyp~ ~f~':~::~f~~AT'- --Tff~===f~~~rfi 
5 2.82 2.14 2.48 ------- ~-.~---. -----.... - ---~------
6 1.81 1.71 1.76 _._------- -----~-------- --~---- --.-------~-
7 3.64 3.99 3.82 .----~~-.-------------~ ~------------~---- _._-- -------_.-
8 3.84 3.48 3.66 ----------.- --_._- ---------
9 5.01 4.63 4.82 ----.--- ------- -------- ----~----
2 20% Alcohol __ ..1iL_ .. _ 4.93 ___ 4~__ _~jl_2_ ... _ 
(db/wt) __ 11..._. _____ 5~_. 6.35_~:...?L_ 
12 6.25 6.35 6.30 
----~-~.-- ----------- ----.---.------






----- ._-----+------+-_ .. _ .... -. __ .. 
15 ___ .§.1.6 __ +-_...=:.5.:..=.9-=-5. _______ 5_.6_'1 __ _ 
16 8.21 6.71 7.46 ___________ ~ ___ O~ ____ • ___ • ___ .. _. _____ • __ ~_ 
H20 Control 17 5.46 4.85 5.16 ---- _._- --------~-. 
18 4.52 4.96 4.74 -------_._--- ----_.... ----- -~----------.-
19 7.01 6.56 6.79 
-~-----.- -------_. ----_.-
20 5.69 5.74 5.72 -------------------- ---------- ----_. ._-----
21 7.16 7.29 7.23 
-.~-- -.------- ---.-----.---
22 7.34 8.1 7.75 
----~-----------" -_ ... _._--------------
20% Alcohol 23 704 8.26 7.65 
----~.------ ------- - _._--_. 
24 8.82 8.16 8.49 -----"---- _._--- ---_._------
_ .. _____ . ___ ........ _ ._ .. _. ____ .___ _ __ 25 ______ 10'--.8-'9_----" __ 11.43 ___ 1_1_.1_6_ 
* = Animal No. 14 was found dead aged 15 weeks 
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Appendix F10 Conjugated Dienes (J1mol/g. liver) 
1 
(db/wt) 
-~-~ ------ --~--------- -----
Treatment Animal Trial 1 Trial 2 Mean ----------+--'----------.---I----'c'-'='-'-----+--------. -------
______ L ___ .. __ .. _~--=2.06 _-+_---=2=.2:,:::0 _______ 2._13 ____ _ 
1.61 1.39 1.50 ------------
1.54 1.63 1.59 ------
1.31 1.46 1.39 
5 2.09 1.71 1.90 
--------~ ---------- --"._-
f---__ -=6=---_ __~1_~___ _J_.17 __ ~ ____ 1._20 ___ _ 







1--__ 8____ _.?J_6_ _ __ ?_.1_4 ____ 2_._15 __ _ 
__ !L____ 1.83 -+-__ 1'-'.:.8=-=8,-- _._~-'-?§ ____ _ 
20% Alcohol---~g--- ___ -1~~__ 2.01 _ _ ___ . __ t:?_~ ____ . 
____ 11_____ 1.61 1.85 __ _____ 1J3 __ _ 
12 1.87 2.25 2.04 
------_._- ---------- ----~.-- ---_ .. _--------
___________ ___ .fl ___ ___ 2_.2_6___ __2._45 ___ _ __ 2._3!L_. __ .. 
* = Animal No. 14 was found dead aged 15 weeks 
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Appendix F11 Lipid Hydroperoxides (nmol LOOH/g. liver) 
------------------------ ------------~---_,---__::___:_-__:_-,-----~_,-__=:_:__:_c:_-_,_-----
_G.I<:JLJ_pLc?'ElIlQ!yj>e _-.Ire~l.~e=nt-'----t_ Animal Trial 1 Trial 2 Mean 
1 
(db/wt) 
--1---+--~205 310 258 
---------- - --------
293 298 296 
1------::-----1-----399-- -~-276 ------ ------3-3-8---------'----- ---~- -------
f ____ ~ _____ +------3-8~----- ____ ~~7 ______ _+-------=-~-=------1 
5 394 441 416 ------ ----------- --- -c~~----I 
6 331 335 333 ---.-------- --------_._- ----------------~--









8 614 875 745 
~------- -'- ---------------- -.------------ ---------
542 681 612 
r-----~-~-------------t_-------------------------- ---~--
10 706 803 755 
~------ -----_._- ----~----~---- -----~-.-----.~----
11 824 803 814 ----- -------_._-- ----~--------. ----_ ... _---
12 512 1165 839 ---------.------- ---_ .. __ ._---- ----- -------~~ 
13 542 609 576 
14* 
.-----+----- ------ ------- - -._----,,---. _._---_ .... _-----_._--_. ---------
15 816 1047 932 
r---c1-c-6 - 1149~-- 1191---------1170-----------" .. _- -_._---_ .. _-,,--- --------- -----~.----.-
f _______ C-:. _________ + ____ J9151___ __9_51____ 004 
18 989 1141 1065 -------- . __ . -".--,,-._---------_._ .. -.-------~ -----~~---~--,-.. ---
19 1 068 1157 1113 -----_._-- --.. --~-~~-----"'--- ------------_._-- --~-----~---
20 1250 1056 1153 
~.-----~ --.-------~-- --~--.-~-~-----------~-
21 1473 1326 1400 
------~ .. ----.-.---------~-- ----~ ----------~-----
22 1178 1506 1342 
-.--~----,-----~ -- -- ------_._-
23 1776 1350 1563 
~-~.. ---~----. ---_._-------------- -"--------
24 1587 1679 1633 
---~---~. --_._--""------ ---_.-._------------
_____ 25 __ --L-_ 1772 __ __1_216 11~~ __ 
k = Animal No_ 14 was found dead aged 15 weeks 
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* == Animal No. 14 was found dead aged 15 weeks 
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* = Animal No. 14 was found dead aged 15 weeks 
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Fat Change Inflammatory 





3A 0 0 -- 4A -~----I---.::-O- ----t----O------~-
------
5A 0 0 ---------- --------- --~----~-









9 0 0 
--~--~--~ ------- -~---.-----------
10 0 0 ---------.- -.-------~ 
11 1 0 
20% Alcohol 
------.--- -----~.-- ----_._--
12 0 0 -.---------- ---------- -----.--~-~--
____ 1.l.___ __ __ ~ __ +--____ = ___ ~_I 
14*A X X 
------.~--. ------------------
15A 2 0 ---------- --------_ .. -----------~-
16A 3 0 ---_._--- --- ---~---- -----_._--
H20 Control ___ ~ ______ ~~_~ __ ~ ___ ~ _____ ~ ______ _ 
18 2 -----19--- ~-----2----+~----...c..0---------1 
~---------------- ~----- - -.-------~--
___ +-------20---- ___ ~ ______ 2 ___ ~ ~ _____ 2 __ ~ __ ~ ___ _ 
21 2 8 
--~---- ------- --_._--------"--
22 3 6 
--~--.~."---- ...... _-------- ------~--
20% Alcohol 23 3 3 --------- --------- --------
___ ~4___ _ __ ~ ___ +-----=----__I 
25 3 4 ----- ~-----~----------~---- - ----
* = Animal No. 14 was found dead aged 15 weeks 
~ ~ 20 x objective, 20 fields counted 
" cc Artefact was present in these sections due to a technical problem. 
Assessment predominantly occurred in the periphery sections and is hopefully 
representative of the tissue as a whole. 
X= The quantity of artefact was to severe for this animal to be fairly assessed 
Impact of Alcohol Administered over 8 Weeks in db/wt and 
db/db Mice - Individual Values: Males 
Appendix F15 Animal Cage Assignments 
Please note - the animals were allocated on a 
random basis 
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Appendix G1 Weekly Body Mass (g) 
Group/ -------~~~~~~----------------------~ 
Genotype Treatment Animal Age (Weeks) . . i 
1 26.0 26.0 27.0 28.0 29.5 29.5 
2 27.0 28.0 29.5 29.5 ~ 32.0 32.0 
1 H 0 3 27.0 i 28.5 I 28.5 i 29.5 30.5 32.0 i 
(db/wt) C 2t I i 4 27.0 i 28.0 I 28.5 i 29.5 I 30.5 31.5 I 
on ro I 5 28.5 30.0 I, 30.5 I 31.5 I 32.5 33.5 I 
i 6 27.0 I 28.0 I 29.0 29.0 I 31.0 31.0 
7 26.5 28.5 28.5 29.0 30.5 30.5 
I 8 I 28.5 28.0 28.5 I 28.0 ! 29.5 I 30.0 I 
I 9 28.0 27.0 28.5 I 27.5 I 27.5 I 28.5 I 
2 200/! 10* 27.0 26.0 26.5 I 26.0 I 27.5 i 28.0 1 
(db/wt) Alco~ol. 1t 27.5 28.5 I 29.0 I 28.5 ! 28.0 I 28.0 ! 
i·2 27.0 28.5 29.0 I 29.5 i 30.5 I 31.0 i 
: 13* 27.5 28.5 I 29.0 I 29.0 i 30.0 I 30.0 i 
I 14 i 27.5 I 28.5 1 29.0 i 29.0 I 30.0 ! 30.0 i 
15 I 46.0 I 45.5 I 46.5 I 53.0 ,53.5 56.0. 
I 16 45.5 I 45.0 i 46.5 I 52.5 52.5 I 55.5 I 
i I I! ,- i 3 HOi 17 46.0 46.0 48.0, 54.0 54.5 I 56.5 I 
(db/db) Co~trol I 18* 46.0 I 46.0 i 46.5 1 51.5 52.5 I 53.0 I 
I 19 , 44.0 I 44.0 J 45.5 1 50.5 52.0 I 54.0 
20 42.5 44.5 44.5 46.0 48.5 50.0 
21 45.5 46.5 46.0 47.0 49.0 49.5 
i 22 41.5 I 46.0 i 47.5 50.0 52.5' 48.5 
I I 23* 41.0 I 44.0 ! 46.0 47.0 47.0 fd 
I 20°1< I 24 42.5 46.5 I 48.5 50.0 50.0 47.0 
I Alco;OI I 25 45.5 47.5 i 47.5 51.0 I 53.0 54.5 
L 
I I 26 44.5 47.0 I 47.0 50.5 I 51.5 52.0 i 
I I 27 43.5 45.0 I 45.5 ! 48.5 I 49.5 50.5! 
i i 28 i 45.5 i 48.0 I 47.5 I 51.5 : 53.0 i 53.5 I 
4 
(db/db) 
* = Animal No. 18 was found dead aged 21 weeks 
* = Animal No. 23 was found dead aged 14 weeks 




Impact of Alcohol Administered over 20 Weeks in db/wt and db/db Mice - Individual Values: Males 
Weekly Body Mass (g) 
Group /. Age (Weeks) 
i Genotype Treatment i Animal I 15 16 i 17 ' 18 ,19 20 
i 1 I 29.5 30.5 i 31.0 31.0 I 30.5 29.5 
I 2 31.5 32.5 i 32.5 33.0 I 33.5 32.0 
1 H~O! 3 34.5 34.0 i 35.5 ' 35.0 i 35.5 36.5 
(db/wt) Co~trol I 4 33.0, 32.5 i 33.0 33.5! 33.5 33.5 
I 5 I 35.5 I 35.5 i 36.5 I 37.0 I 37.0 I 37.5 
L 6 32.0 31.5 32.0 32.5 32.5 32.5 7 31.5 ~.O 31.5 ~.5 ~.O ~.5 
8 30.0 31.0 31.0 31.0 29.0 30.0 
9 29.5 30.0 31.0 30.0 30.0 29.5 
2 200/ I 10* 28.5 I 29.0 i 28.0 i 29.0 I 29.5 I 29.5 
! 
(db/wt) Alco;ol! 11 * 29.0 29.0 I 28.5 ! 28.5 ! 29.0 ! 28.5 
I 12 31.0 31.5 30.5 I 31.5 I 31.5 i 30.5 i 
I 13* 31.0 30.5 30.5 i 31.0 I 30.5 I 30.5 
14 I 31.0 i 31.5 31.0 I 31.5 I 31.0 I 29.5 
r 15 I 58.0 I 59.0 i 58.5 T 60.5 I 61.0 I 60.5 
i 16 ! 57.5 I 59.0 I 58.0 I 59.5 I 60.0 60.0 J 
3 HOi 17 59.0 I 60.5 ! 60.0 I 62.0 I 62.5 62.0 
(db/db) Co~trol I 18* 52.5: 55.0 ' 53.5 I 54.5 I 56.0 52.5 
l 19 55.5 I 56~! 55.5 1 56.5 1 56.5 I 57.0 
20 50.5 52.0 51.5 52.5 53.5 52.5 
21 50.5 51.5 50.5 52.0 52.5 51.5 
22 51.0 51.0 52.5 53.5 54.0 53.5 
23* 
2 1' . 4 I 20% 4 48.0 48.0 ~ 47.0 i 47.0 45.0 45.5 
I (db/db) Alcohol I 25 55.0 54.0; 55.0 ! 55.5 54.5 54.0 
I 
I 26 53.0 52.5, 52.5 '53.5 52.5 54.0 
I 
27: 50.5 49.0 I 49.0 i 49.0 I 50.5 I 51.0 . 
I . I 28 ! 53.5 53.5 I 53.0 : 52.5 52.0 i 53.0 I 
* = Animal No. 18 was found dead aged 21 weeks 
• = Animal No. 23 was found dead aged 14 weeks 
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* = Animal No. 23 was found dead 




Impact of Alcohol Administered over 20 Weeks in db/wt and db/db Mice -Individual Values: Males 
Weekly Body Mass (g) 
Group I Age {Weeks} Body Mass 
Treatment Animal I Gain I Loss (9) Genotype 27 1 28 29 30 31 32 I I I I I I 9 - 32 Weeks 
1 30.5 , 30.0 31.0 32.0 29,0 I 30,5 + 4.5 , 
2 I 31.0 31.5 33,5 34.0 I 31,5 I 32.0 + 5.0 I 
3 36.5 37.0 37.5 I 37.0 38,0 1 37.0 + 10.0 H2O I 4 35,0 35.5 35.5 35.0 34,5 33.5 + 6.5 Control - 37.5 38.0 37.5 37.0 380 37.5 + 9.0 
32.0 32.0 32.0 32,5 33.5 32.5 +~ 
32.0 I 31.0 31.5 32.5 32.5 32.0 + 5.5 I 
34.0 34.0 i 33.0 I 34.0 34.5 34.0 + 5.5 
9 ! 30.5 30.5 i 30.5 30.5 31.0 31.0 + 3.0 




18* (db/db) Control 





4 20% I 
24 42.0 42.0 41.0 40.0 39.0 - 3.5 
25 52.5 55.0 55.0 53.5 52.0 + 6.5 (db/db) Alcohol 
26 54.5 57.0 55.0 53.5 52.5 + 8.0 I 
27 54.0 56.5 55.5 54.0 51.5 I +8.0 
28 53.0 54.5 53.5 51.5 50.5T + 5.0 
* = Animal No. 18 was found dead aged 21 weeks 
* = Animal No. 23 was found dead aged 14 weeks 
* = Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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H20 Control 18* ---------
f--- 19 
1--___ 20 ___ 











* ::: Animal No. 18 was found dead aged 21 weeks 
* := Animal No. 23 was found dead aged 14 weeks 
--































* := Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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3 H20 Control 
----,-"------
(db/db) 








20% Alcohol 25 r'---·-'''--·-----
26 1---'---27----
28 
* = Animal No, 18 was found dead aged 21 weeks 
• = Animal No, 23 was found dead aged 14 weeks 
--
Liver Mass / Body 


































* = Animal No's 10, 11 and 13 were found dead aged 29 weeks 
Page 255 
Impact of Alcohol Administered over 20 Weeks in dblwt and 
dbldb Mice - Individual Values: Males 



























































































• == Animal No. 18 was found dead aged 21 weeks 
• = Animal No. 23 was found dead aged 14 weeks 
• = Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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f.~ •. __ ... _._._ .. ::. ___ . ___ -t-_--=-0.51 
1.17 
1.72 
1 __ ." ___ c... __ j--._2_0c~~ ___ _ 
__ 1.:...;.9_.3_2 __ . 
8.68 
r_. ____ ...c:_. __ ~+_---OJil..--~--






l----···----c.-'cc---·--j---·---·-·- .-------- .. -
0.96 
0.87 --------
~-----.. -::..:~--.--.--j ____ iL!:j1 
_____ -'-" ____ + ____ Q:~L __ _ 
0.85 L ______ "'-__ • _____ .• _._ ..• _l_. __ •.. _-=..::c_ ..•.•.•.. ____ L. __ .•. _. ________ _ 
* :: Animal No. 18 was found dead aged 21 weeks 
* Animal No. 23 was found dead aged 14 weeks 
* :: Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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13* ---------_ ....... \--.... _--_.----\ 
f _____ . ___ ._.+--___ . _________ + ______ ._!.4... __ --+-____ ..o:::: __ ~_ ... _.---~ 
15 -----1-6---+-----:::-=-----------1 





_______ l.t:l_ ----+------- =::-------1 
27 
i------c 
* Animal No, 18 was found dead aged 21 weeks 
* Animal No, 23 was found dead aged 14 weeks 
* = Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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Appendix G7 Alanine Transaminase (ALT) Levels (U/I) 
,----------c-- --,-------.--,------ -----. 
Group / Treatment Animal 
















---~-- 8 7 
20% Alcohol 














21 39 -------- ------_._--- ~-~-------
22 113 
23* _ .•.. _-- ---_._._.-
24 68 -_._----
20% Alcohol 25 60 
---"-"----
26. __ -t-__ 5L __ _ 
_ . ___ 2_7_--+ ___ ......:5'-'4---.._--+ 
28 112 
* = Animal No. 18 was found dead aged 21 weeks 
* = Animal No. 23 was found dead aged 14 weeks 
* = Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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Appendix G8 Triglycerides (mg TG/g. liver) 
----------- ------ -----_._--- ------------,-----:::---:-:--=----,----------------
__ C3r~LJPJ_ GeQ..ot e ___ Tr~atmenL __ Ani!!1_al _____ Tri?L!_ _T_ria_I_2 _______ M_e_a~ ____ _ 
1 
(db/wt) 
f---__ 1_. ________ -t---_--=3.19 ._---+--__ ~_.6_7__ __l,~;l __ 
2 2.45 4.04 3.25 ---- ---- _._--_._._--
5.01 4.26 4.64 I------c··-·----+----------- ----.-------- -.--.--------
4 3.33 3.92 3.63 ---.. -----~.--. -------- -- --.--.--------.----. 
5 4.80 3.31 4.06 ------- ----"--._-- -.-~~--- --------------
6 3.39 4.57 3.98 ------ ---- _._------_.-
______________ . ________ + ______ ---: __________ + ______ 2._94 __ .. 3.18 ____ ~:9_7 ____ _ 







6.12 6.39 6.23 
f-------'-c·-------·-I------·------·---I--------- -------
20% Alcohol -11* 
------~- ~---- ---- ----.---_ ... _-----
12 3.77 6.48 5.13 
--------- ----------_.- ---._---- -------~~--
13* 
14 5.56 4.70 5.13 ------ ------~----.---. --------- ----------





f---_---'-1.fL _________ ~JL_. ______ ..?...:_96 ____ _ 
17 5.34 7.05 
18* _._"------ ~---.------
19 6.80 7.49 7.15 
--~-- .-------- ------------ ---_._-- ----------
20 4.89 7.08 5.99 
---.----~- _._--------- ------- .-.----~--------
21 5.13 6.81 5.97 -----_. __ . -_._-------- _._-- ~-.----------
20% Alcohol . -=~=~-f:l~t;-~in-== -=--i~--= 
n--~~_J~--------r--~~- ~:~~ _ --- -~ ~~~_~ __ - __ ~-~~~~~~~ ----_-
* = Animal No. 18 was found dead aged 21 weeks 
* ::: Animal No. 23 was found dead aged 14 weeks 
* == Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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Treatment Animal Trial Trial 2 Mean 
--~-~--~~ _._--- -------- ------------
3,08 4,80 3_94 
---.------
2 2-12 3A8 3_10 
----.----------~----~ -----~ 
3 2,03 4,80 3A2 
----~---- --------- ---.---~.-. 
1 ___ --:: ________ ._+ _____ ~_,3_2_ 5_82 ___ ~:.5_7 __ 
I--_~ ____________ 3_-92__ 4,64 _4,2Jl ____ _ 
3_28 4,20 3-14 --------------- -~--------- -----.. - -----
7 3,96 4,20 4_08 
~----~---.-- ---------------- ------_. .--------
8 5,17 5,73 5A5 
---------- -------- ----------- --------
9 5,09 5.21 5_15 
13* 
20% Alcohol 
10* ---11-*--- --------.. ----T--~-------- -------
----'-'---------+----::---=:c::----- -------~ 
f----------'-==--___ ,_+-_____ ~lL__ __6J3.L ___ ..9_.1_5 _____ _ 
----
14 7.62 5A9 6.56 ------------ '-------+------c-:::---'--- -- ---.---------- ------- ------.. -----





--.-------- ---- -~------ -~--.---
16 7_62 5.13 6.38 --_._ .. _-.---- -------~- --------- _._---_ .. _------
17 2.55 7.05 4.80 
18* ---------- -----_._------- .----~-.----- -----_ ... _----
19 10.07 6.17 8.12 
.----~- --------- ----------_.- -------------_ .. __ ._-
20 5.97 6_69 6.33 
----~-~ ------_. ------- ----- -------_._----_. 
_____ ----i--.------=-:c----+ _____ i3A~____ __ 6.8_1 __________ 6_._6§ ____ _ 
22 10.11 12.68 11AO 
--2=-=3-:-* 
----------.--_._------- .-~~-----.. _----_._-----
24 7.86 7.33 7.60 
-----------~- ~-----~~- -------~-- -------------"---_. 
20% Alcohol 25 6.29 9.02 7_66 
'-=-=---t-----------'~ ~----- ---.. ------,--
26 10.31 7.78 9.05 -----'-- ---~----- -----,-----_.-
27 9A2 7.82 8_62 
-~~----------~~--- -----.-----~ - ------------_._-----
_____ ?§____ _ __ ~Z~____ _ 10_67 10 •. -,-7-,-1 __ , 
*:: Animal No. 18 was found dead aged 21 weeks 
':: Animal No. 23 was found dead aged 14 weeks 
* == Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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Appendix G10 Conjugated Dienes (pmol/g. liver) 
··---··c-:::--c-~-r·---":----~·---------:··--'----:c-7·---:~---'-~~=-;-:--::-----,--------.-.- -.----.--------
Trial 2 Mean ---_. 
1---__ ---'-____ --l_~___'.:_=..:. ___ + ___ 1_.5_8 _ __1&EL __ _ 
I---~-=_ ... ___ ~_1--_--:-:.:::~----.-j-_-1.4.~7-~i----1:.§.6 
1.63 1.66 
I---~.-.-..... --- ... -....... -.-.. -+---..... --~-.--t___-~::_c_ ---~- ..... . 
1---_.---:'-____ + ____ -"-:..:.-=-___ ._+ ___ 1._73~_ __1J2 ___ _ 
1.73 1.76 
Control 
_ ...... _ ... _ ... + ...... _._._-._C-~_. __ ... _+ ___ 1_.8_7 __ __~l89 __ _ 






1--.... ___ --::c:: ____ .--t-_____ ..::c:..::-::;--_t--__ 1_.1 _1 ___ -+-~__=.:..:...._:. __ !
I __ . __ . __ =_~: ____ . ___ ...... + __ --:=-o.::..:.... __ ... -+_.......1·1J ______ ·_
t 
_____ --=--=--= ___ -c 
I.----------~~I-----.--.----.-,---.. ··_·=_'-______ 1·_· __ -=-•• :_-=· ___ -+ __ ?"~8_. __ +__---:--=::-'----
1--.~_ . ..::::_,::... ... _ .. ____ -I-_. ___ -=:.::_.: __ ~+__-. .1~§.--- ---------
4 
'------.. :::--::-----.--+---:::::..::c.:------t-----:;::2.~~-- -----.. --.-.. -... --
2.81 
• = Animal No. 18 was found dead aged 21 weeks 
* = Animal No. 23 was found dead aged 14 weeks 
• = Animal No '.'1 10, 11 and 13 were found dead aged 29 weeks 
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* = Animal No. 18 was found dead aged 21 weeks 
* = Animal No. 23 was found dead aged 14 weeks 
* '" Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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Appendix G12 TTBARS (nmol/g.liverJ 
----------~.-------
Group / Genotyp~ __ Treatme:'-"nt'----jf--. __ 8-_n_im~L. _____ Tr_ia_11____ _T-,-r-:-:iac:::12,----I ____ Me_al'l __ _ 
r ___ 1,- ____ J_5_89__ 1407 ___ H§l~ ___ _ 
1 
(db/wt) 
1--__ --=2 __________ 1 5~L _______ 1_49_8___ _ ____ JJ5JL ____ _ 
3 1754 1151 1453 
--·-4-- ---96S---+----1c-:3c-=5-:-2 ----+----1160---------------- -~----.--.--
5 1845 2119 1982 f-----=------- ------ --------- --------
6 1936 2028 1982 
. ___ .... __ ._._._ .. _. ________ 1 _____ -+-___ -7_--_-_ - .. -_--=_-=.1-=.8-4_5_-=--T_-_-_-_-'c-1 §::-:g=:8=---+ ___ 17~_7 _ 










--~------------- --------~------ --- ---------




12 2338 2667 2503 
13' 
-=-_._-_~i4-_-_-- ----~r_50_3 ~ __ =:===:29~5~9=-_+_ 2731 
15 2064 3690 2877 ._----- -----~------ --_.- -- --------._--._-
16 3160 2393 2777 
-----1 --- --3380----+----3-=-0'51 -----32-1----· 
1-----_-'._._-._-.. _+-----'--'-"--_._ .. -------+-----.. 
18* ___ +--______ . __ +--________ + ____ -,---,_. __ -1 
19 2722 2905 2814 
-~---------.. -----------~-- --------- --_.-





• = Animal No. 18 was found dead aged 21 weeks 
':.: Animal No. 23 was found dead aged 14 weeks 
* = Animal No's 10, 11 and 13 were found dead aged 29 weeks 
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